[go: up one dir, main page]

WO2025064802A1 - INHIBITING HUMAN INTEGRIN α5β1 - Google Patents

INHIBITING HUMAN INTEGRIN α5β1 Download PDF

Info

Publication number
WO2025064802A1
WO2025064802A1 PCT/US2024/047672 US2024047672W WO2025064802A1 WO 2025064802 A1 WO2025064802 A1 WO 2025064802A1 US 2024047672 W US2024047672 W US 2024047672W WO 2025064802 A1 WO2025064802 A1 WO 2025064802A1
Authority
WO
WIPO (PCT)
Prior art keywords
halogen
optionally substituted
alkyl
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/047672
Other languages
French (fr)
Inventor
James E. Dowling
Kerim Babaoglu
Alex BUCKMELTER
Matthew BURSAVICH
Bryce Harrison
Fu-Yang Lin
Blaise Lippa
Thomas Andrew MCTEAGUE
Prolay MONDAL
Meghan MONROY
Qi Qiao
Dawn TROAST
Cheng Zhong
Katherine CHONG
Emelie FLOOD
Aleksey GERASYUTO
Eugene Hickey
Evelyne HOUANG
Mats Svensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphic Therapeutic Inc
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of WO2025064802A1 publication Critical patent/WO2025064802A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • Fibronectin is an extracellular matrix protein that orchestrates complex cell adhesion and signaling through cell surface integrin receptors (Fibronectin-binding integrins (e.g., a5b1)) during tissue development, remodeling, and disease, such as hypertension and heart failure.
  • Heart failure HF is a debilitating disease in which abnormal function of the heart leads to inadequately low perfusion of tissues and organs of the body. Hypertension is a responsible for various deleterious effects and with high morbidity and mortality including heart failure.
  • One form of hypertension is pulmonary arterial hypertension (PAH).
  • Integrins are a family of glycoprotein transmembrane receptors that mediate cell- cell and cell-matrix interactions. Integrins are heterodimers having two different chains, the alpha and beta subunits. In mammals, eighteen alpha and eight beta subunits have been described.
  • the integrin superfamily of cell surface receptors is formed from a number of structurally and functionally related surface glycoproteins, with each receptor existing as a heterodimer of non-covalently linked ⁇ and ⁇ subunits. At least 18 different ⁇ and 8 ⁇ subunits have been identified in mammals, which are known to form more than 24 different receptors.
  • Each integrin interacts specifically with defined extracellular ligands, including extracellular Attorney Docket No. MORF-016WO1 matrix proteins such as, fibronectin, vitronectin, collagen and cell surface molecules such as VCAM, ICAM and PECAM, via linear adhesion motifs.
  • Integrin ⁇ 5ß1 is composed of subunits ITGA5 (integrin ⁇ 5) and integrin ⁇ 1.
  • Integrin ⁇ 5 ⁇ 1 is selective for fibronectin since it requires both the 9 th and 10 th type II repeats of fibronectin (FNIII-9 and FNIII-10) for interaction.
  • Expression of ⁇ 5 ⁇ 1 integrin is mainly in the vasculature and connective tissue. Expression is significantly enhanced in tumor blood vessels, but also in tumor cells itself of many types of cancer, including colon, breast, ovarian, lung and brain tumors. It is further expressed to varying degrees in many cell types including fibroblasts, hematopoietic cell, immune cells, smooth muscle cells, and epithelial cells. High expression of ⁇ 5 ⁇ 1 integrin has also been observed fibrotic tissue such as pulmonary fibrosis.
  • the integrin ⁇ 5 ⁇ l (a5b1or alpha5 beta1) is composed of an ⁇ 5 (a5 or alpha5) and ⁇ l (b1or beta1) subunit.
  • the a5 subunit forms a specific dimer with the beta1 subunit, and is widely expressed in most tissues.
  • Integrin a5b1 almost exclusively mediates cell adhesion through an interaction with fibronectin, binding via the short arginine-glycine-aspartate (RGD) adhesion motif. Endothelial cells and platelets can however bind to fibrin via a5bl.
  • the a5b1interaction with fibronectin plays an important role in physiopathological angiogenesis and vascular integrity.
  • a5b1 is important for survival of endothelial cells on provisional matrix in vitro, suppressing apoptosis and promoting proliferation.
  • a5b1expression is upregulated in tumor vasculature and pulmonary hypertension patients. Consistent with a key functional role for the receptor- ligand pairing, the a5b1 ligand fibronectin is also upregulated in tumor tissue and during wound- healing.
  • Current treatments include vasodilators targeting Ca channels or endothelin receptors. There is a need for new approaches in the treatment of pulmonary hypertension, PAH, heart failure and related diseases.
  • the present invention provides, among other things, methods, and compositions for treating a disease associated with increased expression or activity of integrin ⁇ 5 ⁇ 1.
  • Many normal physiological and disease processes require cells to contact other cells and/or extracellular matrix.
  • Cell-matrix and cell-cell adhesion is mediated through several families of proteins including integrins, selectins, cadherins, and immunoglobulins, and facilitates a variety of normal cellular functions such as proliferation, migration, differentiation, or survival.
  • integrins represent a complex biological area.
  • the invention features a compound of Formula (I), or a pharmaceutically acceptable salt thereof: (I), wherein: a 6- to 12-member aryl ring structure (e.g., a phenyl) or a 3- to 19-member heterocyclyl ring structure (e.g., a 3- to 15-member heterocyclyl ring structure such as a Attorney Docket No.
  • a 6- to 12-member aryl ring structure e.g., a phenyl
  • a 3- to 19-member heterocyclyl ring structure e.g., a 3- to 15-member heterocyclyl ring structure such as a Attorney Docket No.
  • MORF-016WO1 6-member heteroaryl wherein is optionally substituted with halogen, C 1-6 alkyl, C 1- 6 alkyloxy, a 3-8 member heterocyclyl ring structure, an aryl, or a 5- to 6-member heteroaryl, wherein the C 1-6 alkyl, the C 1-6 alkyloxy, the 3-8 member heterocyclyl ring structure, the aryl, or the 5- to 6-member heteroaryl are optionally substituted with one or more halogen, C 1- 4 alkyloxy, or C 1-6 alkyl optionally substituted with one or more halogen; a is 1, 2, 3, 4, 5, 6, 7 or 8; and R a is C 1-6 alkyl.
  • the invention features a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein: a 6- to 12-member aryl ring structure (e.g., a phenyl), wherein is optionally substituted with halogen, C 1-6 alkyl, C 1-6 alkyloxy, a 3-8 member heterocyclyl ring structure, an aryl, or a 5- to 6-member heteroaryl, wherein the C 1-6 alkyl, the C 1-6 alkyloxy, the 3-8 member heterocyclyl ring structure, the aryl, or the 5- to 6-member heteroaryl are optionally substituted with one or more halogen, C 1-4 alkyloxy, or C 1-6 alkyl optionally substituted with one or more halogen; a is 1, 2, 3, 4, 5, 6, 7 or 8; and Ra is C1-6 alkyl.
  • a 6- to 12-member aryl ring structure e.g., a phenyl
  • Ra is C1-6 alkyl.
  • R 5a is H or a C 1-4 alkyl optionally substituted with one or more halogen
  • R 5b is a C 1-4 alkyl or a C 3-6 cycloalkyl, wherein the C 1-4 alkyl or the C 3-6 cycloalkyl is optionally substituted with one or more halogen
  • R 5a and R 5b together form a spirocyclic 3- to 8-member heterocycloalkyl or a spirocyclic C 3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C 3-6 cycloalkyl is optionally substituted with C 1-4 alkyl optionally substituted with one or more halogen, a 4- to 6-member spirocyclic heterocycloalkyl or a C 3-6 spirocyclic cycloalkyl optionally substituted with C 1-4 alkyl optionally substituted with one or more halogen; R 5c is a C 1-4 alkyl optional
  • MORF-016WO1 R 8c is H, C 1-4 alkyl, a 4- to 8-member heterocycloalkyl, or a C 3-6 cycloalkyl, wherein the C 1-4 alkyl, the 4- to 8-member heterocycloalkyl, or the C 3-6 cycloalkyl is optionally substituted with one or more halogen; provided that no two of both X 2 and X 3 . comprise O or N heteroatoms and no two of X 3 and X 4. comprise O or N heteroatoms.
  • X 1 is CR 5a R 5b or NR 5c
  • R 5a is H or a C 1-4 alkyl optionally substituted with one or more halogen
  • R 5b is a C 1-4 alkyl or a C 3-6 cycloalkyl, wherein the C 1-4 alkyl or the C 3-6 cycloalkyl is optionally substituted with one or more halogen;
  • R 5a and R 5b together form a spirocyclic 3- to 8-member heterocycloalkyl or a spirocyclic C 3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C 3-6 cycloalkyl is optionally substituted with C 1-4
  • MORF-016WO1 member heterocycloalkyl is each optionally substituted with one or more halogen or C 1-4 alkyl;
  • R 6c is C 1-4 alkyl optionally substituted with one or more halogen
  • X 3 is a direct bond, CR 7a R 7b , O or NR 7c ;
  • R 7a and R 7b are each independently H or a C 1-4 alkyl optionally substituted with one or more halogen;
  • R 7c is a C 1-4 alkyl optionally substituted with one or more halogen;
  • X 4 is CR 8a R 8b or NR 8c
  • R 8a is H and R 8b is halogen or a C 1-4 alkyl optionally substituted with one or more halogen;
  • R 8a and R 8b together form a spirocyclic 3- to 8-member heterocycloalkyl or a C 3-6 cycloalkyl, wherein the 3- to 8-member heterocycloal
  • R 1 is methoxy; R 2 is fluoro; and R 3 is C 1-4 alkyl optionally substituted with one or more fluoro.
  • R 14 is H; and X 1 is CR 5a R 5b and R 5a is H, and R 5b is methyl or cyclopropyl.
  • R 4 is H, fluoro, or methyl;
  • X 1 is CR 5a R 5b and R 5a is H, and R 5b is methyl;
  • X 2 is O and X 3 is CR 7a R 7b and R 7a and R 7b are each independently H or a C 1-4 alkyl optionally substituted with one or more halogen; or
  • X 3 is O and X 2 is CR 6a R 7b and R 6a and R 6b are each independently H; and
  • X 4 is CR 8a R 8b and R 8a and R 8b are each independently H or a C 1-4 alkyl optionally substituted with one or more halogen, or R 8a and R 8b together form a 4- to 7-member heterocycloalkyl ring or a C 3-7 cycloalkyl ring, wherein the 4- to 7-member heterocycloalkyl or the C 3-7 cycloalkyl is optionally substituted with halogen, C 1-4 alkyl
  • R 10a and R 10b are each independently H or methyl; R 11a and R 11b are each independently H, methyl, or ethyl; R 12a and R 12b are each independently H or methyl; R 13a is methyl, ethyl, or cyclopropyl; R 13b is H; and R 14 is H, fluoro, or methyl.
  • R 4 is H or fluoro; R 13a is methyl, ethyl, or cyclopropyl; and R 14 is H.
  • X 2 is NR 6c and R 6c is C 1-4 alkyl.
  • R 4 is H, fluoro, or methyl; and R 9a and R 9b are each independently H, fluoro, chloro, or methyl optionally substituted with one or more fluoro.
  • X 5 is CR 25a R 25b or NR 25c ;
  • R 25a and R 25b are each independently H or a C 1-4 alkyl optionally substituted with one or more halogen or alkoxy; or
  • R 25a and R 25b together form a C 3-6 cycloalkyl ring or a 4- to 6-member heterocyclyl ring, each optionally substituted with halogen, C 1-4 alkyl, a spirocyclic C 3-6 cycloalkyl, or a spirocyclic 4- to 6-member heterocyclyl ring, wherein the C
  • MORF-016WO1 alkyl, the spirocyclic C 3-6 cycloalkyl, or the spirocyclic 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen or C 1-4 alkyl; and R 27c is H, a C 1-4 alkyl, a C 3-6 cycloalkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, a 5-6 member heteroaryl, or a C 6 aryl, wherein the C 1-4 alkyl, the C 3-6 cycloalkyl, the 4- to 6-member heterocycloalkyl, the 5- to 11-member spirocyclic heterocycloalkyl, the 5-6 member heteroaryl, or the C 6 aryl is optionally substituted with one or more halogen or C 1-4 alkyl optionally substituted with one or more halogen; provided that only one of X 5 and
  • R 20 is H, halogen, a C 1-4 alkyl, or a C 1-4 alkoxy, wherein the C 1-4 alkyl and the C 1-4 alkoxy is optionally substituted with one or more halogen;
  • X 5 is CR 25a R 25b ;
  • R 25a and R 25b are each independently methyl; or
  • R 26a and R 26b are each independently H or a C 1-4 alkyl optionally substituted with one or more halogen or C 1-4 alkyl;
  • X 7 is NR 27c ; and
  • R 27c is a C 1-4 alkyl, a C 3-6 cycloalkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, a 5-6 member heteroaryl, or a C 6 aryl, wherein
  • R 27c is a C 1-4 alkyl. In some embodiments, R 27c is a 5-member heteroaryl. In some embodiments, R 27c is a C 3-6 cycloalkyl optionally substituted with one or more halogen or a C 1-4 alkyl optionally substituted with one or more halogen.
  • R 27c is a C 1-4 alkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, wherein the C 1-4 alkyl, the 4- to 7-member heterocycloalkyl, and the 5- to 11- member spirocyclic heterocycloalkyl is optionally substituted with one or more halogen or C 1-4 alkyl optionally substituted with one or more halogen.
  • the compound of Formula (I) such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein Attorney Docket No.
  • R 20 is H, fluoro, methyl, ethyl, methoxy, -CH 2 -O-CH 3 , or -CF 3 .
  • R 27c is a tetrahydropyan optionally substituted by one or more methyl or fluoro.
  • R 32a , R 32b , R 33a and R 33 b are each independently H, methyl, or fluoro; or one of R 32a and R 32b or R 33a and R33b together form a spirocyclic C3-6 cycloalkyl or a spirocyclic 3- to 6-member heterocyclic ring.
  • R 27c is [00027]
  • the compound is a compound of Formula (I),wherein R 27c is a C 1-4 alkyl.
  • R25c is a C1-4 alkyl
  • R27c is a C1-4 alkyl optionally substituted with one or more halogen or C 1-4 alkoxy, a C 3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C 3-6 cycloalkyl or the 4- to 6-member heterocycloalkyl is optionally substituted with a C 1-4 alkyl optionally substituted with one or more halogen.
  • R 27c is a C 1-4 alkyl; and R 25c is a C 1-4 alkyl optionally substituted with one or more halogen or C 1-4 alkoxy, a C 3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C 3-6 cycloalkyl or the 4- to 6-member heterocycloalkyl is optionally substituted with a C 1-4 alkyl optionally substituted with one or more halogen.
  • R 20 is H or methyl.
  • the compound of Formula (I) is a compound selected from the group consisting of: Attorney Docket No. MORF-016WO1 or a pharmaceutically acceptable salt thereof.
  • Figure 1 is a table of compounds disclosed herein.
  • Compounds of Formula (I) are small ⁇ molecule integrin therapeutics targeting ⁇ 5 ⁇ 1 that can be administered to treat patients with diseases and conditions that are responsive to ⁇ 5 ⁇ 1 integrin inhibition.
  • the present invention provides methods and compositions for treating a disease associated with increased expression or activity of integrin ⁇ 5 ⁇ 1, comprising administering an integrin ⁇ 5 ⁇ 1 inhibitor.
  • the disease is characterized by the World Health Attorney Docket No. MORF-016WO1 Organization (WHO) group.
  • the disease is pulmonary hypertension, WHO Group 1 pulmonary hypertension or pulmonary arterial hypertension (PAH), WHO Group 2 pulmonary hypertension, WHO Group 3 pulmonary hypertension, WHO Group 4 pulmonary hypertension, and WHO Group 5 pulmonary hypertension.
  • the disease is characterized by the World Health Organization (WHO) class system.
  • the disease is characterized by WHO functional class based on cardiac function.
  • the disease is pulmonary hypertension, WHO Class I pulmonary hypertension or pulmonary arterial hypertension (PAH), WHO Class II pulmonary hypertension, WHO Class III pulmonary hypertension, WHO Class IV pulmonary hypertension.
  • the disease associated with increased expression or activity of integrin ⁇ 5 ⁇ 1 is heart failure or right ventricle failure.
  • the inhibition of integrin ⁇ 5 ⁇ 1 by blocking the activity of ⁇ 5 ⁇ 1 or inhibition of ⁇ 5 ⁇ 1 fibronectin binding is effective in preventing and treating pulmonary hypertension, PAH, heart failure and right ventricle failure.
  • the present invention provides a variety of compounds (e.g., small molecule compounds and antibodies) that inhibit that interaction.
  • the compounds are referred to generically herein as “integrin a5b1 inhibitors”.
  • Exemplary Compounds of the Invention This disclosure relates to novel chemical compounds and methods useful for inhibiting ⁇ 5 ⁇ 1 integrin.
  • integrin ⁇ 5 ⁇ 1 inhibitor is a small molecule compound that binds integrin ⁇ 5 ⁇ 1.
  • the integrin ⁇ 5 ⁇ 1 inhibitor is a small molecule compound that specifically binds integrin ⁇ 5. In some embodiments, the integrin ⁇ 5 ⁇ 1 inhibitor is a small molecule compound that specifically binds integrin ⁇ 1. In some Attorney Docket No. MORF-016WO1 embodiments, the integrin ⁇ 5 ⁇ 1 inhibitor is a small molecule compound that specifically binds integrin ⁇ 5 ⁇ 1. In some embodiments, the integrin ⁇ 5 ⁇ 1 inhibitor is a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention features a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein: a 6- to 12-member aryl ring structure (e.g., phenyl) or a 3- to 19-member heterocyclyl ring structure (e.g., a 3- to 15-member heterocyclyl ring structure such as a 6-member heteroaryl), wherein is optionally substituted with halogen, C 1-6 alkyl, C 1- 6 alkyloxy, a 3-8 member heterocyclyl ring structure, an aryl, or a 5- to 6-member heteroaryl, wherein the C 1-6 alkyl, the C 1-6 alkyloxy, the 3-8 member heterocyclyl ring structure, the aryl, or the 5- to 6-member heteroaryl are optionally substituted with one or more halogen, C 1- 4 alkyloxy, or C 1-6 alkyl optionally substituted with one or more halogen; a is 1, 2, 3, 4, 5, 6, 7 or 8; and R
  • the invention features a compound of Formula (I), or a pharmaceutically acceptable salt thereof: Attorney Docket No. MORF-016WO1 wherein: a 6- to 12-member aryl ring structure (e.g., a phenyl), wherein is optionally substituted with halogen, C 1-6 alkyl, C 1-6 alkyloxy, a 3-8 member heterocyclyl ring structure, an aryl, or a 5- to 6-member heteroaryl, wherein the C 1-6 alkyl, the C 1-6 alkyloxy, the 3-8 member heterocyclyl ring structure, the aryl, or the 5- to 6-member heteroaryl are optionally substituted with one or more halogen, C 1-4 alkyloxy, or C 1-6 alkyl optionally substituted with one or more halogen; a is 1, 2, 3, 4, 5, 6, 7 or 8; and R a is C 1-6 alkyl.
  • a 6- to 12-member aryl ring structure e.g., a phenyl
  • the invention features a compound of Formula (I), or a pharmaceutically acceptable salt thereof: (I), wherein: a 3- to 19-member heterocyclyl ring structure (e.g., a 3- to 15-member heterocyclyl ring structure such as a 6-member heteroaryl), wherein is optionally substituted with halogen, C 1-6 alkyl, C 1-6 alkyloxy, a 3-8 member heterocyclyl ring structure, an Attorney Docket No.
  • a 3- to 19-member heterocyclyl ring structure e.g., a 3- to 15-member heterocyclyl ring structure such as a 6-member heteroaryl
  • a is 1, 2, 3, 4, 5, 6, 7 or 8; and R a is C 1-6 alkyl.
  • the compound is a compound of Formula (I-A), or a pharmaceutically acceptable salt thereof.
  • the compound is a compound of Formula (I), wherein phenyl or a 6-member heteroaryl.
  • the compound is a compound of Formula (I), is , wherein R 1 is a C 1-4 alkoxy; and R 2 is a C 1-4 alkyl optionally substituted with one or more halogen; or is a 9- to 19-member heterocyclyl when R 1 and R 2 are taken together to form a fused 5- to 8-member heterocycloalkyl ring, a fused 5- to 6-member heteroaryl ring, Attorney Docket No.
  • MORF-016WO1 or a fused 7- to 15-member spirocyclic heterocycloalkyl ring system, wherein the fused ring is optionally substituted with halogen, C 1-4 alkyl, C 3-6 cycloalkyl, or a 4- to 8-member heterocycloalkyl ring, wherein the C 1-4 alkyl, the C 3-6 cycloalkyl, or the 4- to 8-member heterocycloalkyl ring is optionally substituted with one or more halogen or C 1-4 alkyl optionally substituted with one or more halogen; R 3 is C 1-4 alkyl optionally substituted with one or more halogen.
  • the compound is a compound of Formula (I), wherein R 1 is methoxy; R 2 is fluoro; and R 3 is C 1-4 alkyl optionally substituted with one or more fluoro.
  • the compound is a compound of Formula (I), wherein , wherein R 4 and R 14 are each independently H, halogen or C 1-4 alkyl optionally substituted with one or more halogen;
  • X 1 is CR 5a R 5b or NR 5c ;
  • R 5a is H or C 1-4 alkyl optionally substituted with one or more halogen, and R 5b is C 1-4 alkyl or C 3-6 cycloalkyl, wherein the C 1-4 alkyl or C 3-6 cycloalkyl is optionally substituted with one or more halogen; or
  • R 5a and R 5b together form a spirocyclic 3- to 8-member heterocycloalkyl or a spirocyclic C 3-6 cycl
  • MORF-016WO1 one or more halogen
  • X 4 is CR 8a R 8b or NR 8c
  • R 8a is H and R 8b is halogen or C 1-4 alkyl optionally substituted with one or more halogen
  • R 8a and R 8b together form a spirocyclic 3- to 8-member heterocycloalkyl or a C 3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C 3-6 cycloalkyl is optionally substituted with C 1-4 alkyl optionally substituted with one or more halogen, a 4- to 8-member spirocyclic heterocycloalkyl or a C 3-7 spirocyclic cycloalkyl optionally substituted with C 1-4 alkyl optionally substituted with one or more halogen; and R 8c is H, C 1-4 alkyl, a 4- to 8-member heterocycloalkyl, or C 3-6 cycloalkyl,
  • the compound is a compound of Formula (I), wherein R 10a and R 10b are each independently H or methyl; R 11a and R 11b are each independently H, methyl, or ethyl; R 12a and R 12b are each independently H or methyl; R 13a is methyl, ethyl, or cyclopropyl; R 13b is H; and R 14 is H, fluoro, or methyl.
  • the compound is a compound of Formula (I), wherein R4 is H or fluoro; R 13a is methyl, ethyl, or cyclopropyl; and R 14 is H.
  • the compound is a compound of Formula (I), wherein X 2 is NR 6c and R 6c is C 1-4 alkyl.
  • the compound is a compound of Formula (I), wherein , wherein R 13a is H or methyl, and R 4 is H, F, or methyl.
  • the compound is a compound of Formula (I), Attorney Docket No. MORF-016WO1
  • the compound is a compound of Formula (I), wherein R 10a , R 10b , and R 11a are each H or methyl.
  • the compound is a compound of Formula (I), wherein R 11b is H, methyl, or ethyl.
  • the compound is a compound of Formula (I), wherein methyl optionally substituted with one or more halogen; and R 9a and R 9b are each independently H, halogen, or methyl optionally substituted with one or more halogen.
  • the compound is a compound of Formula (I), wherein R 4 is H, fluoro, or methyl; and R 9a and R 9b are each independently H, fluoro, chloro, or methyl optionally substituted with one or more fluoro.
  • the compound is a compound of Formula (I), wherein Attorney Docket No. MORF-016WO1 halogen, a C 1-4 alkyl, or a C 1-4 alkoxy, wherein the C 1-4 alkyl and the C 1-4 alkoxy are each optionally substituted with one or more halogen;
  • X 5 is CR 25a R 25b or NR 25c ;
  • R 25a and R 25b are each independently H or a C 1-4 alkyl optionally substituted with one or more halogen or alkoxy; or R 25a and R 25b together form a C 3-6 cycloalkyl ring or 4- to 6-member heterocyclyl ring, each optionally substituted with halogen, C 1-4 alkyl, a spirocyclic C 3-6 cycloalkyl or a spirocyclic 4- to 6-member heterocyclyl ring, wherein the C 1-4 alkyl, the spirocyclic C 3-6 cycloal
  • the compound is a compound of Formula (I), wherein R 20 is H, halogen, a C 1-4 alkyl, or a C 1-4 alkoxy, wherein the C 1-4 alkyl and the C 1-4 alkoxy is optionally substituted with one or more halogen;
  • X 5 is CR 25a R 25b ;
  • R 25a and R 25b are each independently methyl; or
  • R 25a and R 25b together form a cyclopropyl;
  • R 26a and R 26b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or C1- Attorney Docket No.
  • MORF-016WO1 4 alkyl; X 7 is NR 27c ; and R 27c is a C 1-4 alkyl, a C 3-6 cycloalkyl, a 4- to 7-member heterocycloalkyl, a 5- to 11-member spirocyclic heterocycloalkyl, a 5-6 member heteroaryl, or a C 6 aryl, wherein the C 1-4 alkyl, the C 3-6 cycloalkyl, the 4- to 6-member heterocycloalkyl, the 5 to 11 member spirocyclic heterocycloalkyl, the 5-6 member heteroaryl, or the C 6 aryl is optionally substituted with one or more halogen or C 1-4 alkyl optionally substituted with one or more halogen.
  • the compound is a compound of Formula (I), R 27c is a C 1-4 alkyl. In some embodiments, the compound is a compound of Formula (I), wherein R 27c is a 5- member heteroaryl. In some embodiments, the compound is a compound of Formula (I), wherein R 27c is a C 3-6 cycloalkyl optionally substituted with one or more halogen or C 1-4 alkyl optionally substituted with one or more halogen.
  • the compound is a compound of Formula (I), wherein R 27c is a C 1-4 alkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, wherein the C 1-4 alkyl, the 4- to 7-member heterocycloalkyl, and the 5- to 11-member spirocyclic heterocycloalkyl is optionally substituted with one or more halogen or C 1-4 alkyl optionally substituted with one or more halogen.
  • R 27c is a C 1-4 alkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, wherein the C 1-4 alkyl, the 4- to 7-member heterocycloalkyl, and the 5- to 11-member spirocyclic heterocycloalkyl is optionally substituted with one or more halogen or C 1-4 alkyl optionally substituted with one or more
  • the compound is a compound of Formula (I), wherein wherein R 20 is H, fluoro, methyl, ethyl, methoxy, -CH 2 -O-CH 3 , or -CF 3 .
  • the compound is a compound of Formula (I), wherein R 27c is a tetrahydropyan optionally substituted by one or more methyl or fluoro.
  • the compound is a compound of Formula (I), wherein R 27c is wherein R 32a , R 32b , R 33a and R 33 b are each independently Attorney Docket No.
  • the compound is a compound of Formula (I), wherein R 27c is .
  • the compound is a compound of Formula (I), wherein R 31a , and R 31b are each independently H, fluoro or methyl; R 20 is H, fluoro, methyl, ethyl, methoxy, -CH 2 -O-CH 3 , or -CF 3 ; R 27c is methyl.
  • the compound is a compound of Formula (I), wherein R 27c is a C 1-4 alkyl.
  • the compound is a compound of Formula (I), wherein some embodiments, the compound is a compound of Formula (I), wherein wherein R 20 is H, halogen, a C 1-4 alkoxy Attorney Docket No. MORF-016WO1 optionally substituted with C 1-4 alkoxy, a C 1-4 alkyl optionally substituted with 4- to 6-member heterocyclyl, or one or more halogen.
  • the compound is a compound of Formula (I), wherein R 25c is a C 1-4 alkyl; and R 27c is a C 1-4 alkyl optionally substituted with one or more halogen or C 1-4 alkoxy, a C 3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C 3-6 cycloalkyl or 4- to 6-member heterocycloalkyl is optionally substituted with a C 1-4 alkyl optionally substituted with one or more halogen.
  • R 25c is a C 1-4 alkyl
  • R 27c is a C 1-4 alkyl optionally substituted with one or more halogen or C 1-4 alkoxy, a C 3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C 3-6 cycloalkyl or 4- to 6-member heterocycloalkyl is optionally substituted with a C 1-4 alkyl optionally substituted with one or more halogen.
  • the compound is a compound of Formula (I), wherein R 27c is C 1-4 alkyl; and R 25c is C 1-4 alkyl optionally substituted with one or more halogen or C 1-4 alkoxy, a C 3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C 3-6 cycloalkyl or the 4- to 6-member heterocycloalkyl is optionally substituted with a C 1-4 alkyl optionally substituted with one or more halogen.
  • the compound is a compound of Formula (I), wherein R 20 is H or methyl.
  • the compound is a compound of Formula (I), wherein ; wherein R 20 is H, halogen, a C 1-4 alkoxy optionally substituted with C 1-4 alkoxy, a C 1-4 alkyl optionally substituted with a 4- to 6- member heterocyclyl, or one or more halogen; R 25c is C 1-4 alkyl; R 27c is a 4- to 6-member heterocyclyl or a C 3-6 cycloalkyl, wherein the 4- to 6-member heterocyclyl or the C 3-6 cycloalkyl is optionally substituted with C 1-4 alkyl.
  • the compound is a compound of the chemical formula pharmaceutically acceptable salt thereof.
  • the compound is a compound of the chemical formula Attorney Docket No. MORF-016WO1 pharmaceutically acceptable salt thereof. In some embodiments, the compound is a compound of the chemical formula pharmaceutically acceptable salt thereof. In some embodiments, the compound is a compound of the chemical formula pharmaceutically acceptable salt thereof. [00070] In some embodiments, the compound is a compound of the chemical formula pharmaceutically acceptable salt thereof. [00071] In some embodiments, the compound is a compound of the chemical formula pharmaceutically acceptable salt thereof. Attorney Docket No. MORF-016WO1 [00072] In some embodiments, the compound is a compound of the chemical formula pharmaceutically acceptable salt thereof. [00073] In some embodiments, the compound is a compound of the chemical formula pharmaceutically acceptable salt thereof.
  • the compound is a compound of the chemical formula pharmaceutically acceptable salt thereof.
  • the compound is a compound of the chemical formula Attorney Docket No. MORF-016WO1
  • the compound is a compound of the chemical formula , or a pharmaceutically acceptable salt thereof.
  • the compound is a compound of the chemical formula , or a pharmaceutically acceptable salt thereof.
  • the compound is a compound of the chemical formula pharmaceutically acceptable salt thereof.
  • the compound is a compound of the chemical formula pharmaceutically acceptable salt thereof.
  • the compound is a compound selected from the group consisting of the compounds in Figure 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is a compound selected from the group consisting of compounds in Table 3, or a pharmaceutically acceptable salt thereof.
  • Attorney Docket No. MORF-016WO1 Definitions [00081] For convenience, before further description of the present invention, certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and understood as by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art.
  • the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
  • This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified.
  • “at least one of A and B” can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
  • compositions of the present invention may exist in particular geometric or stereoisomeric forms.
  • polymers of the present invention may also be optically active.
  • the present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (d)-isomers, (l)- isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of Attorney Docket No. MORF-016WO1 the invention.
  • asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention. [00090] If, for instance, a particular enantiomer of compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
  • diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
  • Structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds produced by the replacement of a hydrogen with deuterium or tritium, or of a carbon with a 13C- or 14C- enriched carbon are within the scope of this invention.
  • phrases “pharmaceutically acceptable excipient” or “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ or portion of the body, to another organ or portion of the body.
  • Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, not injurious to the patient, and substantially non-pyrogenic.
  • materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alg
  • compositions of the present invention are non-pyrogenic, i.e., do not induce significant temperature elevations when administered to a patient.
  • pharmaceutically acceptable salts refers to the relatively non-toxic, inorganic and organic acid addition salts of the compound(s). These salts can be prepared in situ during the final isolation and purification of the compound(s), or by separately reacting a purified compound(s) in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed.
  • Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts, and the like.
  • sulfate bisulfate
  • phosphate nitrate
  • acetate valerate
  • oleate palmitate
  • stearate laurate
  • benzoate lactate
  • phosphate tosylate
  • citrate maleate
  • fumarate succinate
  • tartrate naphthylate
  • mesylate glucoheptonate
  • lactobionate lactobionate
  • laurylsulphonate salts and the like.
  • the compounds useful in the methods of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases.
  • pharmaceutically acceptable salts refers to the relatively non-toxic inorganic and organic base addition salts of a compound(s). These salts can likewise be prepared in situ during the final isolation and purification of the compound(s), or by separately reacting the purified compound(s) in its free acid form with a suitable base, such as the hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, or tertiary amine.
  • Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like.
  • Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like (see, for example, Berge et al., supra).
  • a “therapeutically effective amount” (or “effective amount”) of a compound with respect to use in treatment refers to an amount of the compound in a preparation which, when administered as part of a desired dosage regimen (to a mammal, preferably a human) alleviates a symptom, ameliorates a condition, or slows the onset of disease conditions according to clinically acceptable standards for the disorder or condition to be treated or the cosmetic purpose, e.g., at a reasonable benefit/risk ratio applicable to any medical treatment.
  • the term “prophylactic or therapeutic” treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If it is administered prior Attorney Docket No.
  • MORF-016WO1 to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, (i.e., it protects the host against developing the unwanted condition), whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).
  • the term “patient” refers to a mammal in need of a particular treatment.
  • a patient is a primate, canine, feline, or equine.
  • a patient is a human.
  • a term e.g., alkyl or aryl
  • prefix roots e.g., alk- or ar-
  • affixing the suffix “-ene” to a group indicates the group is a divalent moiety, e.g., arylene is the divalent moiety of aryl
  • heteroarylene is the divalent moiety of heteroaryl
  • heterocycloalkylene is the divalent moiety of heterocycloalkyl.
  • an aliphatic chain comprises the classes of alkyl, alkenyl and alkynyl defined below.
  • a straight aliphatic chain is limited to unbranched carbon chain moieties.
  • the term “aliphatic group” refers to a straight chain, branched-chain, or cyclic aliphatic hydrocarbon group and includes saturated and unsaturated aliphatic groups, such as an alkyl group, an alkenyl group, or an alkynyl group.
  • alkyl refers to a fully saturated cyclic or acyclic, branched or unbranched carbon chain moiety having the number of carbon atoms specified, or 1 up to 30 carbon atoms if no specification is made.
  • alkyl of 1 to 8 carbon atoms refers to moieties such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl, and those moieties which are positional isomers of these moieties.
  • Alkyl of 10 to 30 carbon atoms includes decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, heneicosyl, docosyl, tricosyl and tetracosyl.
  • a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C 1 -C 30 for straight chains, C 3 -C 30 for branched chains), and more preferably 20 or fewer.
  • Alkyl goups may be substituted or unsubstituted.
  • Attorney Docket No. MORF-016WO1 [000101]
  • alkylene refers to an alkyl group having the specified number of carbons, for example from 2 to 12 carbon atoms, that contains two points of attachment to the rest of the compound on its longest carbon chain.
  • Non-limiting examples of alkylene groups include methylene -(CH 2 )-, ethylene -(CH 2 CH 2 )-, n-propylene - (CH 2 CH 2 CH 2 )-, isopropylene -(CH 2 CH(CH 3 ))-, and the like.
  • Alkylene groups can be cyclic or acyclic, branched or unbranched carbon chain moiety, and may be optionally substituted with one or more substituents.
  • "Cycloalkyl” means mono- or bicyclic or bridged or spirocyclic, or polycyclic saturated carbocyclic rings, each having from 3 to 12 carbon atoms. Likewise, preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 3-6 carbons in the ring structure. Cycloalkyl groups may be substituted or unsubstituted.
  • Exemplary cycloalkyl groups include cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cycloheptyl (C7), and cyclooctyl (C8).
  • lower alkyl means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl.
  • lower alkenyl and “lower alkynyl” have similar chain lengths.
  • preferred alkyl groups are lower alkyls.
  • a substituent designated herein as alkyl is a lower alkyl.
  • aryl as used herein includes 3- to 12-membered substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon (i.e., carbocyclic aryl) or where one or more atoms are heteroatoms (i.e., heteroaryl).
  • aryl groups include 5- to 12-membered rings, more preferably 6- to 10-membered rings
  • aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
  • Carbocyclic aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.
  • Heteroaryl groups include substituted or unsubstituted aromatic 3- to 12-membered ring structures, more preferably 5- to 12-membered rings, more preferably 5- to 10-membered rings, whose ring structures include one to four heteroatoms.
  • Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, Attorney Docket No. MORF-016WO1 pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
  • Aryl and heteroaryl can be monocyclic, bicyclic, or polycyclic.
  • halo means halogen and includes, for example, and without being limited thereto, fluoro, chloro, bromo, iodo and the like, in both radioactive and non-radioactive forms. In a preferred embodiment, halo is selected from the group consisting of fluoro, chloro and bromo.
  • heterocyclyl or “heterocyclic group” refer to 3- to 12-membered ring structures, more preferably 5- to 12-membered rings, more preferably 5- to 10-membered rings, whose ring structures include one to four heteroatoms.
  • Heterocycles can be monocyclic, bicyclic, spirocyclic, or polycyclic.
  • Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazin
  • the heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, sulfamoyl, sulfinyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF3, -CN, and the like.
  • substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amid
  • heterocycloalkyl is a non-aromatic heterocyclyl wherein at least one atom is a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus, and the remaining atoms are carbon.
  • heterocycloalkyl groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H- pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithiany
  • the Attorney Docket No. MORF-016WO1 heterocycloalkyl group can be substituted or unsubstituted as recited, e.g., for heterocyclyls as described herein.
  • the term “carbonyl” is art-recognized and includes such moieties as can be represented by the formula: O , wherein X’ is a bond or represents an oxygen or a sulfur, and R 15 represents a hydrogen, an alkyl, an alkenyl, -(CH 2 ) m -R 10 or a pharmaceutically acceptable salt, R16 represents a hydrogen, an alkyl, an alkenyl or -(CH 2 ) m -R 10 , where m and R 10 are as defined above.
  • substituted is contemplated to include all permissible substituents of organic compounds.
  • permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds.
  • Illustrative substituents include, for example, those described herein above, and for example substituted with one or more substituents selected from alkyl, cycloalkyl, heterocyclylakyl, halogen, OH, OMe, C(H)F 2 , C(F)H 2 , CF 3 , C(H) 2 CF 3 , SF 5 , CHFCH 2 amine, CH 2 amine, and CN.
  • the permissible substituents can be one or more and the same or different for appropriate organic compounds.
  • the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
  • substitution or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
  • Attorney Docket No. MORF-016WO1 [000110]
  • nitro means -NO 2
  • halogen designates - F, -Cl, -Br, or -I
  • hydroxyl means -OH
  • cyano means –CN.
  • prodrug encompasses compounds that, under physiological conditions, are converted into therapeutically active agents.
  • a common method for making a prodrug is to include selected moieties that are hydrolyzed under physiological conditions to reveal the desired molecule.
  • the prodrug is converted by an enzymatic activity of the host animal. Accordingly, prodrugs include compounds that are transformed in vivo to yield a disclosed compound or any other pharmaceutically acceptable form of the compound.
  • a prodrug may be inactive when administered to a subject but may be converted in vivo to an active compound, for example, by hydrolysis. See, e.g., Bundgard, H., Design of Prodrugs (1985), pp.7-9, 21-24 (Elsevier, Amsterdam). A discussion of prodrugs is provided in Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” A.C.S. Symposium Series, Vol.14, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein.
  • Prodrugs can typically be prepared using well known methods, such as those described in Burger's Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff ed., 5th ed., 1995), and Design of Prodrugs (H. Bundgaard ed., Elselvier, New York, 1985).
  • the term “prodrug” is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a subject.
  • Prodrugs of compounds described herein may be prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to provide a compound described herein (i.e., the parent active compound).
  • Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of an alcohol or acetamide, formamide and benzamide derivatives of an amine functional group Attorney Docket No.
  • MORF-016WO1 in the active compound and the like.
  • Other examples of prodrugs include compounds that comprise —NO, —NO 2 , —ONO, or —ONO 2 moieties.
  • the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover.
  • the compound is a compound selected from Figure 1, or a pharmaceutically acceptable salt thereof.
  • the compound is a compound selected from Table 3, or a pharmaceutically acceptable salt thereof. Table 3.
  • Exemplary Compounds Attorney Docket No. MORF-016WO1 Attorney Docket No.
  • MORF-016WO1 Therapeutic Uses of a Compound of Formula (I) [000116]
  • normal fibroblasts are present in low population of only 4-5%. However, during fibrosis they proliferate and can occupy up to 80-90% of the organ mass.
  • Myofibroblasts in the fibrotic tissue produce large amounts of extracellular matrix proteins that make the tissue scarred and non-functional. Inhibition of myofibroblasts can counteract these processes. Integrins promote cell proliferation, survival, hypertrophic growth, and fibrosis. As described herein, integrin inhibition can modulate these key elements leading to the progression of pulmonary hypertension (e.g., PAH).
  • PAH pulmonary hypertension
  • the present invention provides methods of treating a disease associated with increased expression or activity of integrin ⁇ 5 ⁇ 1, comprising administering an integrin ⁇ 5 ⁇ 1 inhibitor.
  • the present invention provides an integrin ⁇ 5 ⁇ 1 inhibitor for use in treating a disease associated with increased expression or activity of integrin ⁇ 5 ⁇ 1 in a subject Attorney Docket No. MORF-016WO1 in need of treatment thereof, comprising administering the integrin ⁇ 5 ⁇ 1 inhibitor and a pharmaceutical excipient to the subject.
  • the disease is heart failure or right ventricle failure.
  • the present invention provides a method of treating pulmonary arterial hypertension (PAH) in a subject, comprising administering an integrin ⁇ 5 ⁇ 1 inhibitor.
  • PAH pulmonary arterial hypertension
  • the integrin ⁇ 5 ⁇ 1 inhibitor is administered orally, intravenously, subcutaneously, intranasally, transdermally, intraperitoneally, intramuscularly, or intrapulmonarily.
  • a method for the treatment of a subject suffering from fibrosis or a fibrosis related disorder comprising administering to said subject a therapeutically effective amount of integrin ⁇ 5 ⁇ 1 inhibitor according to the invention.
  • fibrosis refers to a condition characterized by a deposition of extracellular matrix components in the skin or organs, including lungs, kidneys, heart, liver, skin and joints, resulting in scar tissue. The term also refers to the process of formation of scar tissue. [000119]
  • the fibrosis-related disorder is a disorder or condition which may occur as a result of fibrosis, or which is associated with fibrosis.
  • fibrosis and/or a fibrosis-related disorders is a disease or condition selected from the group consisting of kidney fibrosis, liver fibrosis, liver cirrhosis, pulmonary fibrosis, skin fibrosis, biliary fibrosis, peritoneal fibrosis, myocardial fibrosis, pancreatic fibrosis, bone marrow and/or myelofibrosis, reperfusion injury after hepatic or kidney transplantation, Interstitial Lung Disease (ILD), cystic fibrosis (CF), atherosclerosis, systemic sclerosis, osteosclerosis, spinal disc herniation and other spinal cord injuries, fibromatosis, fibromyalgia, arthritis, restenosis.
  • ILD Interstitial Lung Disease
  • CF cystic fibrosis
  • atherosclerosis systemic sclerosis
  • osteosclerosis spinal disc herniation and other spinal cord injuries
  • fibromatosis fibromyalgia, arthritis, reste
  • Pulmonary fibrosis includes idiopathic pulmonary fibrosis and scleroderma lung fibrosis.
  • the methods described herein may be applied to cell populations in vivo or ex vivo.
  • “In vivo” means within a living individual, as within an animal or human. In this context, the methods described herein may be used therapeutically in an individual.
  • “Ex vivo” means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals.
  • Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. The selected compounds may be further characterized to examine the safety or tolerance dosage in human or non-human subjects.
  • compounds described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof may be used to treat subjects who have or are suspected of having disease states, disorders, and conditions (also collectively referred to as “indications”) responsive or believed to be responsive to the inhibition of ⁇ 5 ⁇ 1 integrin activity.
  • the compounds described herein may be used to inhibit the activity of ⁇ 5 ⁇ 1 integrin.
  • the present disclosure provides a compound described herein useful as an inhibitor of ⁇ 5 ⁇ 1 integrin.
  • the present disclosure provides a method of treating or preventing an inflammatory disease or condition comprising administering a compound described herein to a patient.
  • the present disclosure provides a pharmaceutical composition comprising a compound described herein and a pharmaceutically acceptable carrier.
  • Co-administration may also include administering component drugs, e.g., one on more compounds described herein and one or more additional (e.g., a second, third, fourth or fifth) therapeutic agent(s).
  • Such combination of one on more compounds described herein and one or more additional therapeutic agent(s) may be administered simultaneously or in sequence (one after the other) within a reasonable period of time of each administration (e.g., about 1 minute to 24 hours) depending on the pharmacokinetic and/or pharmacodynamics properties of each agent or the combination.
  • Co-administration may also involve treatment with a fixed combination wherein agents of the treatment regimen are combinable in a fixed dosage or combined dosage medium, e.g., solid, liquid or aerosol.
  • Treatment with the second, third, fourth or fifth active agent may be prior to, concomitant with, or following treatment with a compound described herein.
  • a compound described herein is combined with another active agent in a single dosage form.
  • a subject is an adult subject.
  • Dosage Amounts and Frequency compounds of Formula (I) or any pharmaceutically acceptable salt thereof described herein is administered to a human patient in need thereof in an effective amount.
  • Attorney Docket No. MORF-016WO1 the method of treating a disease associated with increased expression or activity of integrin ⁇ 5 ⁇ 1, comprises administering the integrin ⁇ 5 ⁇ 1 inhibitor at a dose of 1 mg/kg to 1000 mg/kg. In some embodiments, the dose is at least 2 mg/kg, at least 4 mg/kg, at least 6 mg/kg, or at least 8 mg/kg.
  • the dose is at least 10 mg/kg, at least 20 mg/kg, at least 30 mg/kg, at least 40 mg/kg, at least 50 mg/kg, at least 60 mg/kg, at least 70 mg/kg, at least 80 mg/kg, at least 90 mg/kg or at least 100 mg/kg. In some embodiments, the dose is at least 200 mg/kg, at least 300 mg/kg, at least 400 mg/kg, at least 500 mg/kg, at least 600 mg/kg, at least 700 mg/kg, at least 800 mg/kg, at least 900 mg/kg, or at least 1000 mg/kg. [000128] In embodiments, a subject receives a dose of a compound of Formula (I) or a pharmaceutically acceptable salt thereof once daily.
  • a subject receives a dose of a compound of Formula (I) or a pharmaceutically acceptable salt thereof twice daily.
  • Cardiac function parameters Various endpoint parameters can be assessed to determine efficacy of a treatment of the present invention, e.g., ⁇ 5 ⁇ 1 level, pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (PAP), cardiac index (CI), mean pulmonary capillary wedge pressure (PCWP), right atrial pressure (RAP), six-minute walk distance (6 MWD), brain natriuretic peptide (BNP) level, diffusion of lung capacity (DLCO), and death or survival.
  • PVR pulmonary vascular resistance
  • PAP mean pulmonary arterial pressure
  • CI cardiac index
  • PCWP mean pulmonary capillary wedge pressure
  • RAP right atrial pressure
  • 6 MWD six-minute walk distance
  • BNP brain natriuretic peptide
  • BNP brain natriuretic peptide
  • DLCO diffusion of lung capacity
  • PVR is commonly used as an endpoint parameter for determination of efficacy of treatment for PAH.
  • a PVR of a subject of >240 dyn ⁇ sec/cm5 is an indication of mild PAH.
  • a PVR of a subject of 600-800 dyn ⁇ sec/cm5 indicates moderate to severe PAH.
  • a decrease in PVR in a subject of 130 dyn ⁇ sec/cm5 or more indicates efficacious treatment.
  • administration of a ⁇ 5 ⁇ 1 inhibitor to a subject with PAH that leads to a decrease in PVR of 180-350 dyn ⁇ sec/cm5 indicates efficacious treatment.
  • Mean pulmonary arterial pressure is also used as an endpoint parameter to determine efficacy of treatment for PAH.
  • a subject without PAH has a mean PAP ranging from about 15-24 mmHg.
  • a subject having mild PAH has a mean PAP of about 25-30 mmHg (e.g., >25 mmHg at rest or 30 mmHg with exercise).
  • a subject having severe PAH has a PAP of greater than 30 mmHg, for e.g., 40-70 mmHg or 60-70 mmHg. After treatment, a decrease in PAP of greater than 1.5 mmHg indicates efficacious treatment.
  • MORF-016WO1 treatment leads to a decrease in PAP of greater than 5, 10, 20, 40, or 50 mmHg, which is indicative of efficacious treatment.
  • Cardiac index (CI) is also used as an endpoint parameter for determining efficacy of treatment for PAH.
  • a low or decreased CI is indicative of heart failure.
  • a CI of 2.5 L/min/m2 or less is indicative of PAH or heart failure.
  • a CI increase of more than 0.3 L/min/m2 is indicative of efficacious treatment.
  • a mean PCWP of less than or equal to 18 mmHg indicates a subject having PAH. After treatment, an increase in mean PCWP of greater than 0.5 mmHg is indicative of efficacious treatment.
  • RVP Right atrial pressure
  • a subject not suffering from PAH has a normal RAP of 0-8 mmHg.
  • a RAP of 8 mmHg or greater is indicative of PAH.
  • a subject suffering from severe PAH has a RAP of about 20 mmHg. After treatment, a decrease of greater than 0.5 mmHg is indicative of efficacious treatment.
  • Six-minute walk distance (6 MWD) is used as an endpoint parameter to determine efficacy of treatment of PAH.
  • the mean 6 MWD of patients with CTD-PAH is about 300 m.
  • an increase in 6 MWD of 25 m or more, or greater than 10% increase indicates efficacious treatment.
  • a 6 MWD of 1000 m or more indicates efficacious treatment.
  • BNP Brain Natriuretic Peptide
  • N-Terminal pro Brain Natriuretic Peptide Reproducible, noninvasive parameters are useful in following patients with PAH.
  • BNP is produced in the cardiac ventricles and is elevated in PPH/IPAH.
  • BNP levels have recently been shown to be Attorney Docket No. MORF-016WO1 closely related to functional impairment in PPH/IPAH patients and parallel the extent of pulmonary hemodynamic changes and right heart failure.
  • BNP levels longitudinally correlate with the functional assessments being made over the course of the study.
  • Plasma NT-pro-BNP are measured by a sandwich immunoassay using polyclonal antibodies that recognize epitopes located in the N-terminal segment (1 to 76) of pro-BNP (1 to 108) (Elecsys analyzer, Roche Diagnostics, Manheim, Germany).
  • DLCO Diffusion of lung capacity
  • CO carbon monoxide
  • a subject not suffering from PAH has a normal DLCO of greater than 80%.
  • a subject suffering from PAH has an abnormal DLC of less than 80%, less than 65%, or less than 45%. After treatment, any increase in % DLCO indicates efficacious treatment.
  • administration of the integrin ⁇ 5 ⁇ 1 inhibitor modulates the level of a biomarker in the subject, wherein the biomarker is selected from the group consisting of survivin, PCNA, Ki67, and annexin V.
  • Pulmonary hypertension is a syndrome characterized by increased pulmonary artery pressure. PH is defined hemodynamically as a systolic pulmonary artery pressure greater than 30 mm Hg or evaluation of mean pulmonary artery pressure greater than 25 mm Hg. See Zaiman et al., Am. J. Respir. Cell Mol. Biol.33:425-31 (2005). Further, PH, as a result of the increased pressure, damages both the large and small pulmonary arteries. The walls of the smallest blood vessels thicken and are no longer able to transfer oxygen and carbon dioxide normally between the blood and the lungs.
  • pulmonary hypertension leads to thickening of the pulmonary arteries and narrowing of the passageways through which blood flows. Once pulmonary hypertension develops, the right side of the heart works harder to compensate; however, the increased effort causes it to become enlarged and thickened. Proliferation of smooth muscle and endothelial cells which normally exist in a quiescent state leads to remodeling of the vessels with obliteration of the lumen of the pulmonary vasculature. This causes a progressive rise in pulmonary pressures as blood is pumped through decreased lumen area. The enlarged right ventricle places a person at risk for pulmonary embolism because blood tends to pool in the ventricle and in the legs.
  • Edema particularly of the legs, may occur because fluid may leak out of the veins and into the tissues, signaling that cor pulmonale has developed.
  • Some people with pulmonary hypertension have connective tissue disorders, especially scleroderma. When people have both conditions, pulmonary hypertension and connective tissue disorders, Raynaud's phenomenon often develops before symptoms of pulmonary hypertension appear, sometimes as long as years earlier. [000143] Treatment of some types of pulmonary hypertension is often directed at the underlying lung disease. Currently, the treatment options available for those suffering from PH target cellular dysfunction that leads to constriction of the vasculature.
  • vasodilators such as calcium channel blockers, nitric oxide, and prostacyclin
  • these drugs have not been proven effective for people with pulmonary hypertension due to an underlying lung disease.
  • vasodilators such as prostacyclin, drastically reduce blood pressure in the pulmonary arteries.
  • the pulmonary hypertension is pulmonary venous hypertension (PVH).
  • PVH pulmonary venous hypertension
  • the PVH is due to left heart failure.
  • the pulmonary hypertension is pulmonary hypertension associated with disorders of the respiratory system and/or hypoxia.
  • the pulmonary hypertension is pulmonary hypertension due to chronic thrombotic and/or embolic disease.
  • the pulmonary hypertension is miscellaneous pulmonary hypertension.
  • the miscellaneous pulmonary hypertension is associated with sarcoidosis, eosinophilic granuloma, histicytosis X, lymphangiolomyiomatosis, or compression of pulmonary vessels (e.g., adenopath, tumor, or fibrosing medianstinitis).
  • the pulmonary hypertension is associated with chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the pulmonary hypertension is associated with pulmonary fibrosis.
  • the pulmonary hypertension is associated with cardiac fibrosis. In some embodiments, the pulmonary hypertension is early-stage pulmonary hypertension or advanced pulmonary hypertension. [000145] In some embodiments, one or more symptoms of the pulmonary hypertension are ameliorated. In some embodiments, the pulmonary hypertension is delayed. In some embodiments, the pulmonary hypertension is prevented. In some embodiments, the methods of treatment provided herein reduce pulmonary pressure. In some embodiments, the methods of treatment provided herein inhibit and/or reduce abnormal cell proliferation in the pulmonary artery. [000146] In some embodiments, the pulmonary hypertension is is characterized by the World Health Organization (WHO) group.
  • WHO World Health Organization
  • the pulmonary hypertension is WHO Group 1 pulmonary hypertension or pulmonary arterial hypertension (PAH), WHO Group 2 pulmonary hypertension, WHO Group 3 pulmonary hypertension, WHO Group 4 pulmonary hypertension, and WHO Group 5 pulmonary hypertension.
  • the pulmonary hypertension is characterized by the World Health Organization (WHO) class system.
  • the pulmonary hypertension is characterized by WHO functional class based on cardiac function.
  • the pulmonary hypertension Attorney Docket No. MORF-016WO1 WHO Class I pulmonary hypertension or pulmonary arterial hypertension (PAH), WHO Class II pulmonary hypertension, WHO Class III pulmonary hypertension, WHO Class IV pulmonary hypertension.
  • the pulmonary hypertension is associated with pulmonary capillary hemangiomatosis.
  • the disease is heart failure or right ventricle failure.
  • the present invention provides a method of treating pulmonary arterial hypertension (PAH) in a subject, comprising administering an integrin ⁇ 5 ⁇ 1 inhibitor.
  • Pulmonary arterial hypertension (PAH) [000148]
  • the present invention provides a method of treating Pulmonary arterial hypertension (PAH), comprising administering an integrin ⁇ 5 ⁇ 1 inhibitor (e.g., small molecule compounds and antibodies disclosed herein).
  • PAH is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular overload and eventually cardiac failure.
  • PAH results in progressive obstruction and decreased compliance of pulmonary arteries (PA), leading to right ventricular (RV) failure and premature death.
  • PA smooth muscle cells (PASMCs) and PAECs) exhibit exaggerated proliferation and resistance to apoptosis in response to increased PA stiffness caused by extracellular matrix (ECM) remodeling.
  • ECM extracellular matrix
  • Integrins signaling could promote PAH- PASMCs and PAH-PAECs proliferation and resistance to apoptosis contributing to PAs vascular remodeling, while in the RV, maladaptive hypertrophy, and fibrosis, leading to RV failure in PAH.
  • PAH is a chronic disorder that involves all layers of the pulmonary vessels.
  • Vasoconstriction, structural changes in the pulmonary vessel wall (vascular remodeling) and thrombosis contribute to the increased pulmonary vascular resistance in PAH.
  • Structural and functional changes of the endothelium lead to endothelial dysfunction.
  • Increased vasoconstrictive factors e.g., endothelin
  • decreased vasodilation capacity e.g., less prostacyclin
  • Vascular remodeling that occurs in PAH is characterized by proliferative and obstructive changes involving many cell types, including endothelial cells, smooth muscle cells and fibroblasts.
  • Vascular remodeling can manifest itself, for example, as medial thickening of pulmonary vessels due to smooth muscle cell hyperplasia and hypertrophy, formation of a neointima made of smooth muscle cells and/or myofibroblasts, and/or formation of plexiform lesions, which consist of localized proliferations of endothelial cells, smooth muscle cells, lymphocytes, and mast cells.
  • Vascular remodeling results in obstruction of the vessel lumen leading to pulmonary hypertension.
  • the pulmonary hypertension is pulmonary arterial hypertension (PAH).
  • PAH idiopathic PAH.
  • the PAH is familial PAH.
  • the PAH is associated with persistent pulmonary hypertension of a newborn. In some variations, the PAH is associated with pulmonary veno- occlusive disease. [000152] In some embodiments, the pulmonary hypertension is assocated with lung diseases. In some embodiments, the lung disease is Idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia (IIP). IPF is a type of idiopathic interstitial pneumonia (IIP), which in turn is a type of interstitial lung disease (also known as diffuse parenchymal lung disease (DPLD)). Interstitial lung disease concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, perivascular and perilymphatic tissues.
  • IPF Idiopathic pulmonary fibrosis
  • IIP interstitial pneumonia
  • Interstitial lung disease concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, perivascular and perilymphatic tissues.
  • idiopathic interstitial pneumonias include non-specific interstitial pneumonia (NSIP), desquamative interstitial pneumonia (DIP) and acute interstitial pneumonia (AIP).
  • NSIP non-specific interstitial pneumonia
  • DIP desquamative interstitial pneumonia
  • AIP acute interstitial pneumonia
  • Examples of known causes of interstitial lung disease include sarcoidosis, hypersensitivity pneumonitis, pulmonary Langerhans cell histiocytosis, asbestosis and collagen vascular diseases such as scleroderma and rheumatoid arthritis.
  • Pulmonary fibrosis is the formation or development of excess fibrous connective tissue in the lungs.
  • the present invention provides a method of treating heart failure (HF), comprising administering an integrin ⁇ 5 ⁇ 1 inhibitor (e.g., small molecule compounds and antibodies disclosed herein).
  • Heart failure refers to any condition characterized by the heart’s inability to pump an adequate supply of blood to the body.
  • the physiological state in Attorney Docket No. MORF-016WO1 which cardiac output is insufficient to meet the needs of the body or to do so only at a higher filing pressure.
  • There are many underlying causes of HF including myocardial infarction, coronary artery disease, valvular disease, hypertension, and myocarditis.
  • Chronic heart failure is associated with neurohormonal activation and alterations in autonomic control.
  • one of the body's main compensatory mechanisms for reduced blood flow in HF is to increase the amount of salt and water retained by the kidneys. Retaining salt and water, instead of excreting it via urine, increases the volume of blood in the bloodstream and helps to maintain blood pressure.
  • the larger volumes of blood also cause the heart muscle, particularly the ventricles, to become enlarged. As the heart chambers become enlarged, the wall thickness decreases and the heart's contractions weaken, causing a downward spiral in cardiac function.
  • a method of treating a disease associated with increased expression or activity of integrin ⁇ 5 ⁇ 1, comprising administering an integrin ⁇ 5 ⁇ 1 inhibitor can include a combination therapy in which a patient in need of treatment is administered an integrin a5b1 inhibitor in combination with one or more drugs approved for the treatment of PH, PAH, heart failure, or right ventricle failure.
  • Approved drugs currently used in the treatment of PH, PAH, heart failure and right ventricle failure in the US or the European Union (EU) include the orally administered PDE-5 inhibitors: sildenafil (Revatio) and tadalafil (Adeirca); the dual endothelin-1A receptor Attorney Docket No. MORF-016WO1 antagonist (ERA): bosentan (Tracleer), ambrisentan (Letairis in US; Volibris internationally).
  • prostacyclins or prostacyclin analogs such as iloprost (Ventavis) or treprostinil (Tyvaso) given as multiple daily inhalations, epoprostenol (Flolan/Veletri) or treprostinil (Remodulin) given as continuous intravenous infusions, or treprostinil also used as a continuous subcutaneous infusion.
  • Intravenous injection of sildenafil is approved for patients who are currently prescribed but are temporarily unable to take oral sildenafil.
  • Inhaled nitric oxide (INOmax) is approved for the neonatal form of PAH— persistent pulmonary hypertension of the newborn (PPHN).
  • combination therapies of any of these drugs and an integrin a5b1 inhibitor are useful in the treatment of PAH or a disorder disclosed herein.
  • the second therapy is selected from the group consisiting of anticoagulants, diuretics, a digitalis glycosideglycosides, calcium channel blockers, endothelin receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, prostanoids, prostanoids receptor agonists, soluble guanylate cyclase stimulators, and/or surgery.
  • the second therapy is oxygen, Warfarin, furosemide, bumetanide, bendroflumethiazide, metolazone, spironolactone, amiloride, Digoxin, nifedipine, diltiazem, nicardipine, amlodipine, ambrisentan, bosentan, macitentan, sildenafil, tadalafil, epoprostenol, iloprost, treprostinil, riociguat, selexipag, surgery, pulmonary endarterectomy, and/or atrial septostomy.
  • the second therapy is macitentan and/or tadalafil.
  • Flolan prostacyclin analog
  • Flolan is an approved therapy for PAH, but is extremely cumbersome and inconvenient to use (intravenous), and has unique safety concerns.
  • Flolan is usually reserved for patients with severe functional status or rapidly progressive PAH. Patients must constitute the drug in sterile conditions several times daily. The drug is available as a freeze-dried preparation that needs to be dissolved in alkaline buffer.
  • Flolan Because of its short half-life (3-5 min) and stability (8 h at room temperature), Flolan must be maintained in a refrigerated state while given by continuous infusion through a central venous catheter via a portable pump that is worn in a bag around the waist (CADD pump, Smith's Medical MD, St. Paul, Minn.).
  • the FDA also approved a new continuous intravenous formulation of epoprostenol that is stable at room temperature for up to 24 h after dilution and may be stored up to 5 days at refrigerator temperature before use (GeneraMedix Inc., Liberty Corner, N.J.).
  • GeneraMedix Inc. sold this formulation to Actelion, which began to market the drug (under the brand name Veletri) in April 2010.
  • an integrin a5b1 inhibitor is administered in combination with epoprostenol, in any of its approved forms, to treat PAH.
  • Remodulin continuous subcutaneous infusion form of prostacyclin analog
  • Remodulin was not generally used as initial therapy because of its expense, route of delivery, and limited efficacy.
  • the FDA and Health Canada approved an intravenous formulation of Remodulin for patients with PAH class II-IV disease who cannot tolerate the subcutaneous form.
  • an integrin a5b1 inhibitor is administered in combination with treprostinil to treat PAH.
  • Ventavis iloprost
  • a prostacyclin analogue administered via inhalation is also marketed in several member countries of the EU as Ilomedine as an intravenous formulation.
  • the label for inhaled iloprost in the EU is restricted to patients with idiopathic PAH and functional class III symptoms.
  • an integrin a5b1 inhibitor is administered in combination with iloprost, in any of its approved forms, to treat PAH.
  • the nonselective ERA Tracleer became the first oral PAH therapy and was available only through a special centralized access program in the US because of its significant risk of (reversible) liver injury, teratogenicity, testicular atrophy, and male sterility.
  • Treatment with Tracleer consists of an initial dosage of 62.5 mg twice daily for 4 weeks, followed by a maintenance dose of 125 mg twice daily. Tracleer was initially indicated for patients with PAH and moderate or severe functional status (WHO class III, IV). In 2008 (EU) and 2009 (US), the label was expanded to patients with mild symptoms (functional class II).
  • an integrin a5b1 inhibitor is administered in combination with bosentan, in any of its approved forms, to treat PAH.
  • Ambrisentan is the oral selective ERA-receptor antagonist marketed by Gilead Sciences in the US (Letairis) and by GlaxoSmithKline in other regions (Volibris) for the once- daily treatment of patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening.
  • ambrisentan has class effects of teratogenicity, testicular injury, reduced male fertility, and anemia.
  • Attorney Docket No. MORF-016WO1 an integrin a5b1 inhibitor is administered in combination with ambrisentan, in any of its approved forms, to treat PAH.
  • the oral PDE-5 inhibitor Revatio (sildenafil) was approved in the US for the treatment of PAH (WHO Group I) to improve exercise ability and delay of clinical worsening at a dose of 20 mg three times daily, regardless of functional class or etiology.
  • the EU label is restricted to improvement of exercise capacity in patients with PAH, which is either idiopathic or associated with collagen vascular disease and with functional class III status.
  • the FDA approved an intravenous form of Revatio given as an injection (10 mg 3-times a day) for a patient unable to take the oral formulation.
  • the EU approved Revatio as an oral suspension (compounded from 20 mg tablets) for the treatment of pediatric patient aged 1 to 17 years with PAH.
  • an integrin a5b1 inhibitor is administered in combination with sildenafil, in any of its approved forms, to treat PAH.
  • the oral PDE-5 Inhibitor Adeirca (tadalafil) 40 mg once daily is indicated in the US to improve exercise ability in patients with PAH (WHO Group I) regardless of etiology or functional class (Packet Insert).
  • the EU label is restricted to patients with functional class II and III status.
  • Tadalafil has a long half-life (35 h) in patients with PAH (US Packet Insert) has also shown benefit in patients with PAH on concomitant bosentan.
  • the method of treating the patient may involve administering at least one additional active agent, i.e., in addition to an integrin a5b1 inhibitor.
  • the additional active agent may be, for example, a vasodilator such as prostacyclin, epoprostenol, and sildenafil; an endothelin receptor antagonist such as bosentan; a calcium channel blocker such as amlodipine, diltiazem, and nifedipine; an anticoagulant such as warfarin; a diuretic, a prostanoid (e.g., prostacyclin or PGI2), drugs for treating diseases associated with overactive B cells or dysfunctional B cells such as Rituximab, and/or a Type V phosphodiesterase (PDE5) inhibitor.
  • a vasodilator such as prostacyclin, epoprostenol, and sildenafil
  • an endothelin receptor antagonist such as bosentan
  • the agents may be administered separately, at the same, or at different times of the day, or they may be administered in a single composition.
  • the present invention provides novel pharmaceutical formulations in which an integrin a5b1 inhibitor is combined with one of the active agents discussed above and unit dose forms of those formulations.
  • each agent can be administered in an “immediate release” manner or in a “controlled release manner.”
  • MORF-016WO1 agent is a vasodilator, for instance, any dosage form containing both active agents i.e., both the integrin a5b1 inhibitor and the vasodilator, can provide for immediate release or controlled release of the vasodilator, and either immediate release or controlled release of the integrin a5b1 inhibitor.
  • a combination dosage form of the invention for once- daily administration might contain in the range of about 1 mg to about 1000 mg of an integrin a5b1 inhibitor of an integrin a5b1 inhibitor, in a controlled release (e.g., sustained release) or immediate release form, and either sildenafil in immediate release form, or in controlled release form, with the additional active agent present in an amount that provides a weight ratio of the an integrin a5b1 inhibitor to sildenafil, or a weight ratio of the an integrin a5b1 inhibitor to sildenafil, specified as above.
  • a controlled release e.g., sustained release
  • sildenafil in immediate release form
  • the additional active agent present in an amount that provides a weight ratio of the an integrin a5b1 inhibitor to sildenafil, or a weight ratio of the an integrin a5b1 inhibitor to sildenafil, specified as above.
  • two or more additional active agents which may or may not be in the same class of drug (e.g., vasodilators) can be present in combination, along with an integrin a5b1 inhibitor.
  • the effective amount of either or each individual additional active agent present will generally be reduced relative to the amount that would be required if only a single added agent were used.
  • the additional active agent may also be, as discussed above, a Type V phosphodiesterase inhibitor, administered with an integrin a5b1 inhibitor, or with both the integrin a5b1 inhibitor and a vasodilator.
  • Type V phosphodiesterase inhibitors include, without limitation, avanafil, sildenafil, tadalafil, zaprinast, dipyridamole, vardenafil and acid addition or other pharmaceutically acceptable salts thereof. Sildenafil is an excellent example.
  • an integrin a5b1 inhibitor is co-administered with a Type V phosphodiesterase inhibitor selected from the group consisting of avanafil, tadalafil, and sildenafil, and the daily dose of a compound of the integrin a5b1 inhibitor is a given above for the monotherapeutic regimen.
  • the vasodilator is selected from sildenafil, avanafil, tadalafil, zaprinast, dipyridamole, vardenafil, bosentan, and pharmaceutically acceptable salts thereof.
  • the additional active agent may also be, as discussed above, an endothelin receptor antagonist, e.g., bosentan, sitaxsentan, or ambrisentan, with bosentan being an exemplary active agent.
  • a pharmaceutical composition of the invention is a pharmaceutical formulation containing an active agent formulated in a manner compatible with its intended route of administration.
  • routes are contemplated, including but not limited to, oral, pulmonary, inhalational, sublingual, intranasal, parenteral, intradermal, transdermal, topical, Attorney Docket No. MORF-016WO1 transmucosal, subcutaneous, intravenous, intramuscular, intraperitoneal, buccal, rectal, and the like.
  • parenteral as used herein is intended to include subcutaneous, intravenous, and intramuscular injection.
  • pharmaceutical formulations of the invention are prepared for oral administration and in an immediate release form suitable for once per day (QD) administration. Certain formulations are suitable for intranasal administration to a patient.
  • Certain pharmaceutical formulations of the invention comprise an integrin a5b1 inhibitor or a salt thereof and one or more pharmaceutically acceptable (approved by a state or federal regulatory agency for use in humans, or is listed in the U.S. Pharmacopia, the European Pharmacopia) excipients or carriers.
  • excipient or carrier as used herein broadly refers to a biologically inactive substance used in combination with the active agents of the formulation.
  • An excipient can be used, for example, as a solubilizing agent, a stabilizing agent, a diluent, an inert carrier, a preservative, a binder, a disintegrant a coating agent, a flavoring agent, or a coloring agent.
  • At least one excipient is chosen to provide one or more beneficial physical properties to the formulation, such as increased stability and/or solubility of the active agent(s).
  • An integrin a5b1 inhibitor or a salt thereof as described herein is an exemplary active agent suitable for use in the formulations of the present invention.
  • excipients include certain inert proteins such as albumins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as aspartic acid (which may alternatively be referred to as aspartate), glutamic acid (which may alternatively be referred to as glutamate), lysine, arginine glycine, and histidine; fatty acids and phospholipids such as alkyl sulfonates and caprylate; surfactants such as sodium dodecyl sulphate and polysorbate; nonionic surfactants such as such as TWEEN®, PLURONICS®, or polyethylene glycol (PEG); carbohydrates such as glucose, sucrose, mannose, maltose, trehalose, and dextrins, including cyclodextrins; polyols such as mannitol and sorbitol; chelating agents such as EDTA; and salt-forming counter-ions such as sodium.
  • inert proteins such as albumins
  • Solutions or suspensions used for the delivery can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol, polysorbate, tocopherol polyethylene glycol succinate (TPGS), or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents Attorney Docket No. MORF-016WO1 for the adjustment of tonicity such as sodium chloride or dextrose.
  • a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol, polysorbate, tocopherol polyethylene glycol succinate (TPGS), or other synthetic solvents
  • the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. These preparations can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • the pharmaceutical formulations of the present invention contain a plurality of liposomes or microparticles comprising the integrin a5b1 inhibitor active agent.
  • the pharmaceutical formulation of the integrin a5b1 inhibitor is a powder comprising solid particles (e.g., liposomes or microparticles) suitable for administration via inhalation.
  • the solid particles comprise the active agent, a carrier, optionally a surfactant, and optionally additional recipients.
  • the powder may be prepared by any convenient method.
  • Suitable liposomes for use in the present formulations of the invention are known in the art.
  • suitable liposomes include cholesterol, 1,2-distearoyl-sn- glycero-3- phosphocholine (DSPC) and PEG-DSPE, with the weight ratio being about 5:10:1.
  • the liposome formulation comprises about 0.1-25%, e.g., 0.1%, 1%, 5%, 10% or 20% (w/w) of a phospholipid, such as dipalmitoylphosphatidylcholine (DPPC) and 1,2- distearoyl-sn-glycero-3-phosphocholine (DSPC).
  • a phospholipid such as dipalmitoylphosphatidylcholine (DPPC) and 1,2- distearoyl-sn-glycero-3-phosphocholine (DSPC).
  • DPPC dipalmitoylphosphatidylcholine
  • DSPC 1,2- distearoyl-sn-glycero-3-phosphocholine
  • the liposome formulation comprises about 0.5-20%, e.g., 1%, 5%, or 10% (w/w) of a hydrophilic polymer, such as polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • microparticles for use in the formulations of the invention are known in the art.
  • microparticles are formed of one or more hydrophilic polymers such as polyvinylpyrrolidone (e.g., PVP-10), polyvinyl alcohol (e.g., PVA-30), polyvinyl acetate, or Poloxamer (e.g., Poloxamer-188).
  • hydrophilic polymers such as polyvinylpyrrolidone (e.g., PVP-10), polyvinyl alcohol (e.g., PVA-30), polyvinyl acetate, or Poloxamer (e.g., Poloxamer-188).
  • the microparticle formulation comprises about 70-85 wt % of polyvinyl alcohol (e.g., PVA-30), about 5-15% PVP (e.g., PVP-10), 1-5% Poloxamer (e.g., Poloxamer-188), 0-10% L-leucine, and about 0.5-10% of an integrin a5b1 inhibitor compound (e.g., 5%).
  • the formulation is suitable for administration via the respiratory tract.
  • the pharmaceutical formulations of an integrin a5b1 inhibitor useful in the methods of the invention can be prepared as a liquid or in a solid form such as a powder, tablet, Attorney Docket No. MORF-016WO1 pill, or capsule for oral administration.
  • Liquid formulations of the invention may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the formulation is an aqueous solution.
  • the final formulation is lyophilized.
  • the integrin a5b1 inhibitor is formulated for inhalation.
  • the formulations of the invention comprise an integrin a5b1 inhibitor at a concentration of from 0.25 wt % to 100 wt %, or from 0.25 wt % in 50 wt %, or from 0.8 wt % to 25 wt %, or from 1 wt % to 10%, or from 1.5 wt % to 5 wt %.
  • an integrin a5b1 inhibitor compound is formulated at a concentration of from about 0.5 wt % to about 5 wt %.
  • an integrin a5b1 inhibitor compound is formulated at a concentration of about 0.25 wt % to about 10 wt %.
  • the present invention also provides a pharmaceutical pack or kit comprising one or more containers filled with a solid or liquid formulation of an integrin a5b1 inhibitor.
  • the formulation is a powder formulation of an integrin a5b1 inhibitor.
  • an integrin a5b1 inhibitor is formulated at a concentration of at least about 0.5 wt % and the formulation is suitable for delivery via inhalation to a human.
  • the present invention also provides for a use of a formulation of an integrin a5b1 inhibitor in the manufacture of a medicament for treating PAH, or a disorder disclosed herein, in a subject in need thereof.
  • the pharmaceutical formulation is sterile.
  • the dosage forms e.g., an inhalable dosage form
  • the pharmaceutical compositions of the invention are preferably formulated for inhalation, e.g., as a solution in saline, as a dry powder, or as an aerosol, other modes of administration are suitable as well.
  • administration may be sublingual, oral, parenteral, transdermal, via an implanted depot, transmucosal, e.g., rectal or vaginal, preferably using a suppository that contains, in addition to the active agent, excipients such as a suppository wax.
  • Transmucosal administration also encompasses transurethral.
  • the pharmaceutical formulation may be a solid, semi-solid or liquid, such as, for example, a tablet, as capsule, a caplet, a liquid, a suspension, an emulsion, a suppository, granules, pellets, beads, a powder, or the like, preferably in unit dosage form suitable for single administration of a precise dosage.
  • suitable pharmaceutical compositions and dosage forms may be prepared using conventional methods known to those in the field of pharmaceutical formulation and described in the pertinent texts and literature, e.g., in Remington: The Science and Practice of Pharmacy (Easton, Pa.: Mack Publishing Co., 1995).
  • oral dosage forms are generally preferred, and include tablets, capsules, caplets, solutions, suspensions and syrups, and may also comprise a plurality of granules, beads, powders, or pellets that may or may not be encapsulated.
  • Preferred oral dosage forms are tablets and capsules.
  • unit dosage forms refers to physically discrete units suited as unitary dosages for the individuals to be treated. That is, the compositions are formulated into discrete dosage units each containing a predetermined, “unit dosage” quantity of an active agent calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • unit dosage forms of the invention are dependent on the unique characteristics of the active agent to be delivered. Dosages can further be determined by reference to the usual dose and manner of administration of the ingredients. It should be noted that, in some cases, two or more individual dosage units in combination provide a therapeutically effective amount of the active agent, e.g., two tablets or capsules taken together may provide a therapeutically effective dosage of an integrin a5b1 inhibitor, such that the unit dosage in each tablet or capsule is approximately 50% of therapeutically effective amount.
  • Attorney Docket No. MORF-016WO1 [000189] Tablets may be manufactured using standard tablet processing procedures and equipment. Direct compression and granulation techniques are preferred.
  • Capsules are another oral dosage forms for those compounds of the current invention, e.g., an integrin a5b1 inhibitors, that are orally active, in which case the active agent-containing composition may be encapsulated in the form of a liquid or solid (including particulates such as granules, beads, powders or pellets).
  • suitable capsules may be either hard or soft, and are generally made of gelatin, starch, or a cellulosic material, with gelatin capsules preferred.
  • Two-piece hard gelatin capsules are preferably sealed, such as with gelatin bands or the like. See, for example, Remington: The Science and Practice of Pharmacy, cited earlier herein, which describes materials and methods for preparing encapsulated pharmaceuticals.
  • Oral dosage forms whether tablets, capsules, caplets, or particulates, if desired, may be formulated so as to provide for controlled release of the compounds of the current invention, for e.g., an integrin a5b1 inhibitors, and in a preferred embodiment, the present formulations are controlled release oral dosage forms.
  • sustained release dosage forms are formulated by dispersing the active agent within a matrix of a gradually hydrolyzable material such as a hydrophilic polymer, or by coating a solid, drug- containing dosage form with such a material.
  • Hydrophilic polymers useful for providing a sustained release coating or matrix include, by way of example: cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, cellulose acetate, and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, preferably formed from acrylic acid, methacrylic acid, acrylic acid alkyl esters, methacrylic acid alkyl esters, and the like, e.g.
  • Preparations according to this invention for parenteral administration include sterile aqueous and nonaqueous solutions, suspensions, and emulsions. Injectable aqueous solutions contain the active agent in water-soluble form. Examples of nonaqueous solvents or Attorney Docket No.
  • MORF-016WO1 vehicles include fatty oils, such as olive oil and corn oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, low molecular weight alcohols such as propylene glycol, synthetic hydrophilic polymers such as polyethylene glycol, liposomes, and the like.
  • Parenteral formulations may also contain adjuvants such as solubilizers, preservatives, wetting agents, emulsifiers, dispersants, and stabilizers, and aqueous suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, and dextran.
  • Injectable formulations are rendered sterile by incorporation of a sterilizing agent, filtration through a bacteria-retaining filter, irradiation, or heat. They can also be manufactured using a sterile injectable medium.
  • the active agent may also be in dried, e.g., lyophilized, form that may be rehydrated with a suitable vehicle immediately prior to administration via injection.
  • the active agent may also be administered through the skin using conventional transdermal drug delivery systems, wherein the active agent is contained within a laminated structure that serves as a drug delivery device to be affixed to the skin. In such a structure, the drug composition is contained in a layer, or “reservoir,” underlying an upper backing layer.
  • the laminated structure may contain a single reservoir, or it may contain multiple reservoirs.
  • the reservoir comprises a polymeric matrix of a pharmaceutically acceptable contact adhesive material that serves to affix the system to the skin during drug delivery.
  • the drug-containing reservoir and skin contact adhesive are present as separate and distinct layers, with the adhesive underlying the reservoir which, in this case, may be either a polymeric matrix as described above, or it may be a liquid or hydrogel reservoir, or may take some other form.
  • Transdermal drug delivery systems may in addition contain a skin permeation enhancer.
  • the active agent may be formulated as a depot preparation for controlled release of the active agent, preferably sustained release over an extended time period.
  • sustained release dosage forms are generally administered by implantation (e.g., subcutaneously or intramuscularly or by intramuscular injection).
  • Certain compounds or active agents of the present invention are capable of further forming salts. All of these forms are also contemplated within the scope of the claimed invention.
  • the compounds of the present invention can also be prepared as esters, for example, pharmaceutically acceptable esters.
  • a carboxylic acid function group in Attorney Docket No. MORF-016WO1 a compound can be converted to its corresponding ester, e.g., a methyl, ethyl or other ester.
  • an alcohol group in a compound can be converted to its corresponding ester, e.g., an acetate, propionate or other ester.
  • Certain compounds of the present invention can also be prepared as prodrugs, for example, pharmaceutically acceptable prodrugs.
  • pro-drug and “prodrug” are used interchangeably herein and refer to any compound which releases an active parent drug in vivo. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.), the compounds of the present invention can be delivered in prodrug form. Thus, the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same. “Prodrugs” are intended to include any covalently bonded carriers that release an active parent drug of the present invention in vivo when such prodrug is administered to a subject.
  • Prodrugs in the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.
  • Prodrugs include compounds of the present invention wherein a hydroxy, amino, sulfhydryl, carboxy or carbonyl group is bonded to any group that may be cleaved in vivo to form a free hydroxyl, free amino, free sulfhydryl, free carboxy or free carbonyl group, respectively.
  • prodrugs include, but are not limited to, esters (e.g., acetate, dialkylaminoacetates, formates, phosphates, sulfates and benzoate derivatives) and carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups, esters (e.g., ethyl esters, morpholinoethanol esters) of carboxyl functional groups, N-acyl derivatives (e.g., N-acetyl) N- Mannich bases, Schiff bases and enaminones of amino functional groups, oximes, acetals, ketals and enol esters of ketone and aldehyde functional groups in compounds of the invention, and the like, See Bundegaard, H., Design of Prodrugs, p 1-92, Elesevier, New York-Oxford (1985).
  • esters e.g., acetate, dialkylaminoacetates, formates,
  • the dosage regimen utilizing the compounds is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed.
  • An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Attorney Docket No. MORF-016WO1 [000200]
  • the composition is suitable for inhalation.
  • the composition is an inhalable formulation used for treating PAH, or a disorder disclosed herein.
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising an integrin a5b1 inhibitor and a plurality of particles, wherein the plurality of particles is a plurality of liposomes comprising 1,2-distearoyl-sn-glycero-3- phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE) or a plurality of microparticles comprising a hydrophilic polymer.
  • the composition is suitable for inhalation, in one embodiment, the composition is an inhalable formulation used for treating PAH, or a disorder disclosed herein.
  • Pharmaceutical Compositions [000202] The pharmaceutical compositions described herein can be administered in a variety of different ways.
  • compositions according to the invention comprise at least one pharmaceutically acceptable carrier, diluent or excipient.
  • suitable carriers for instance comprise keyhole limpet haemocyanin (KLH), serum albumin (e.g. BSA or RSA) and ovalbumin.
  • said suitable carrier is a solution, for example saline.
  • excipients which can be incorporated in tablets, capsules and the like are the following: a binder such as gum tragacanth, acacia, corn starch or gelatine; an excipient such as microcrystalline cellulose; a disintegrating agent such as corn starch, pregelatinized starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; a flavoring agent such as peppermint, oil of wintergreen or cherry.
  • the dosage unit form When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both.
  • a syrup or elixir may contain the active compound, sucrose Attorney Docket No. MORF-016WO1 as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
  • a pharmaceutical composition according to the invention is preferably suitable for human use.
  • compositions for injection can be formulated according to conventional pharmaceutical practice by dissolving or suspending the integrin a5b1 inhibitor of the invention in a vehicle for injection, such as water or a naturally occurring vegetable oil like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or a synthetic fatty vehicle like ethyl oleate or the like. Buffers, preservatives, antioxidants and the like may also be incorporated.
  • Compositions for topical administration can also be formulated according to conventional pharmaceutical practice. “Topical administration” as used herein refers to application to a body surface such as the skin or mucous membranes to locally treat conditions resulting from microbial or parasitic infections.
  • Topical medicaments can be epicutaneous, meaning that they are applied directly to the skin. Topical medicaments can also be inhalational, for instance for application to the mucosal epithelium of the respiratory tract, or applied to the surface of tissues other than the skin, such as eye drops applied to the conjunctiva, or ear drops placed in the ear.
  • Said pharmaceutical composition formulated for topical administration preferably comprises at least one pharmaceutical excipients suitable for topical application, such as an emulsifier, a diluent, a humectant, a preservatives, a pH adjuster and/or water.
  • pharmaceutical excipients suitable for topical application such as an emulsifier, a diluent, a humectant, a preservatives, a pH adjuster and/or water.
  • compositions of the present invention may exist in particular geometric or stereoisomeric forms.
  • polymers of the present invention may also be optically active.
  • the present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)- isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
  • asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention. [000209] If, for instance, a particular enantiomer of compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
  • diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
  • ATU Hexafluorophosphate Azabenzotriazole Tetramethyl U ronium HMDS Hexamethyldisilazane Hz
  • m-CPBA Meta-chloroperbenzoic acid Me methyl MOM methoxymethyl MTBE Methyl tert-butyl ether NBS N-bromosuccinimide NMR Nuclear Magnetic Resonance Ph phenyl Pin pinacolato Piv 2,2-dimethylacetyl prep-HPLC preparative high performance liquid chromatography SFC supercritical fluid chromatography
  • TBAI Tetrabutylammonium Iodide t-Bu tertiary-
  • Step 2 tert-butyl ((1S,3S)-3-hydroxycyclopentyl)(methyl)carbamate [000212] To a solution of (1S,3S)-3-(methylamino)cyclopentan-1-ol (56 g, 486.23 mmol, 1 eq) in THF (600 mL) was added NaHCO3 (81.69 g, 972.45 mmol, 37.82 mL, 2 eq) in H2O (90 mL) and (Boc) 2 O (137.95 g, 632.09 mmol, 145.21 mL, 1.3 eq) at 25 o C under N 2 and the Attorney Docket No.
  • MORF-016WO1 solution was stirred at 25 o C for 16 hrs.
  • H 2 O 200 mL was added to the reaction and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue.
  • Step 3 tert-butyl ((1S,3S)-3-(4-bromobutoxy)cyclopentyl)(methyl)carbamate
  • NaOH (247.09 g, 6.18 mol, 500 mL, 15.65 eq) in toluene (1000 mL)
  • 1,4-dibromobutane 17.9 g, 789.64 mmol, 95.25 mL, 2 eq
  • TBAI 2,18.75 g, 592.23 mmol, 1.5 eq
  • Step 4 tert-butyl ((1S,3S)-3-(but-3-en-1-yloxy)cyclopentyl)(methyl)carbamate
  • tert-butyl ((1S,3S)-3-(4- bromobutoxy)cyclopentyl)(methyl)carbamate 33 g, 94.21 mmol, 1 eq) in THF (400 mL) was added t-BuOK (26.43 g, 235.52 mmol, 2.5 eq) at 0 °C and the mixture was stirred at 20 °C for 16 hrs.
  • Step 5 tert-butyl 7-(4-(((1S,3S)-3-((tert-butoxycarbonyl)(methyl)amino)- cyclopentyl)oxy)butyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate [000215] To a solution of tert-butyl ((1S,3S)-3-(but-3-en-1- yloxy)cyclopentyl)(methyl)carbamate (23 g, 85.38 mmol, 1 eq) in THF (50 mL) was added 9- BBN (0.5 M, 341.53 mL, 2 eq) and the mixture was stirred at 25 °C for 2 hrs.
  • Step 6 (1S,3S)-N-methyl-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentan-1-amine [000216] To a solution of tert-butyl 7-(4-(((1S,3S)-3-((tert-butoxycarbonyl)(methyl)amino)- cyclopentyl)oxy)butyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate (28 g, 55.59 mmol, 1 eq) in DCM (300 mL) was added TFA (153.50 g, 1.35 mol, 100.00 mL, 24.22 eq) at 25 o C under N 2 and the solution was stirred at 25 o C for 16 hrs.
  • TFA 153.50 g, 1.35 mol, 100.00 mL, 24.
  • Step 2 5,5-dimethylcyclopent-2-en-1-one
  • a mixture of 5-bromo-2,2-dimethylcyclopentan-1-one (350 g, 1.83 mol, 1 eq) and DBU (334.65 g, 2.20 mol, 331.34 mL, 1.2 eq) in MTBE (2000 mL) was degassed and purged with nitrogen 3 times. The mixture was allowed to stir at 25 °C for 16 hrs under an atmosphere of N 2 . The mixture was distilled under vacuum (62 o C, -0.08 MPa/water pump).
  • Step 6 rac-tert-butyl ((1S,4R)-4-hydroxy-3,3-dimethylcyclopentyl)(methyl)carbamate [000222] To a solution of tert-butyl (3,3-dimethyl-4-oxocyclopentyl)(methyl)carbamate (130 g, 538.69 mmol, 1 eq) in THF (1000 mL) was added DIBAL-H (1 M, 538.69 mL, 1 eq)) at 0 o C under an atmosphere of N 2 . Then the reaction mixture was warmed up to 20 o C and stirred at 20 o C under an atmosphere of N 2 for 16 hrs.
  • Step 3 4-bromo-1-(tert-butyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one [000228] To a solution of 3-bromo-N 1 -(tert-butyl)benzene-1,2-diamine (20 g, 82.26 mmol, 1 eq) in THF (200 mL) was added TEA (24.97 g, 246.77 mmol, 34.35 mL, 3 eq) and bis(trichloromethyl) carbonate (24.41 g, 82.26 mmol, 1 eq). The mixture was stirred at 20°C Attorney Docket No. MORF-016WO1 for 16 hrs.
  • Step 4 4-bromo-1-(tert-butyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one [000229] To a solution of 4-bromo-1-(tert-butyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (18.6 g, 69.11 mmol, 1 eq) in DMF (190 mL) was added and NaH (5.53 g, 138.22 mmol, 60% purity, 2 eq). The mixture was stirred at 0°C for 0.5 hr.
  • Step 6 tert-butyl 2-bromo-2-(1-(tert-butyl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)acetate
  • tert-butyl 2-(1-(tert-butyl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)acetate 3 g, 9.42 mmol, 1 eq
  • LDA 2 M, 14.13 mL, 3 eq
  • Step 2 tert-butyl 2-(3,6-dimethyl-1-(1-methylcyclopropyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)acetate
  • tert-butyl 2-(3-methyl-1-(1-methylcyclopropyl)-2-oxo-6-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-benzo[d]imidazol-4-yl)acetate 3.5 g, 7.91 mmol, 1 eq.
  • EtOH 14 mL
  • H 2 O 14 mL
  • reaction mixture was heated up to 100 o C and stirred at 100 o C under N 2 for 16 hrs.
  • the reaction mixture was quenched with water (150 mL) at 20 o C and extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (30 mL x 3), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue.
  • Step 3 tert-butyl 2-bromo-2-(3,6-dimethyl-1-(1-methylcyclopropyl)-2-oxo-2,3-dihydro- 1H-benzo[d]imidazol-4-yl)acetate
  • tert-butyl 2-(3,6-dimethyl-1-(1-methylcyclopropyl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-4-yl)acetate 550 mg, 1.66 mmol, 1 eq
  • THF 10 mL
  • LDA 2 M, 2.50 mL, 3 eq
  • Step 5 4-bromo-6-methylindolin-2-one [000241] To a solution of 4'-bromo-1'-(tert-butyl)-6'-methylspiro[cyclopropane-1,3'-indolin]- 2'-one (22 g, 71.38 mmol, 1 eq) in TFA (100 mL) under N 2 and the solution was stirred at 25°C for 0.5 hrs. LCMS showed the starting material was consumed completely and one main peak with desired mass was detected. The reaction was concentrated under reduced pressure to give a residue. The crude product was triturated with MeCN at 20 o C for 30 min.
  • Step 2 2-(2,6-dibromophenyl)propan-1-ol
  • a solution of AlMe 3 (2.0 M, 82.75 mL, 1 eq) in toluene (500 mL) was added drop-wise a solution of 2-(2,6-dibromophenyl)oxirane (46 g, 165.50 mmol, 1 eq) in toluene (300 mL) at -60°C under N 2 .
  • the mixture was stirred at 0°C for 1 hr.
  • TLC petroleum Attorney Docket No.
  • Step 3 1,3-dibromo-2-(1-(methoxymethoxy)propan-2-yl)benzene
  • 2-(2,6-dibromophenyl)propan-1-ol 28 g, 95.24 mmol, 1 eq
  • DIEA 49.24 g, 380.97 mmol, 66.36 mL, 4 eq
  • MOMBr 23.80 g, 190.49 mmol, 15.55 mL, 2 eq
  • Step 4 3-(3-bromo-2-(1-(methoxymethoxy)propan-2-yl)phenyl)tetrahydro-2H-pyran-3-ol
  • 1,3-dibromo-2-(1-(methoxymethoxy)propan-2-yl)benzene 5.2 g, 15.38 mmol, 1 eq
  • TMEDA 1.97 g, 16.92 mmol, 2.55 mL, 1.1 eq
  • THF 60 mL
  • n-BuLi 2.5 M, 6.15 mL, 1 eq
  • Step 5 3-(3-bromo-2-(1-hydroxypropan-2-yl)phenyl)tetrahydro-2H-pyran-3-ol
  • 3-(3-bromo-2-(1-(methoxymethoxy)propan-2- yl)phenyl)tetrahydro-2H-pyran-3-ol 14 g, 38.97 mmol, 1 eq
  • MeCN 50 mL
  • HCl 100 mL
  • Step 6 5-bromo-4-methyl-5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran] [000247] To a solution of 3-(3-bromo-2-(1-hydroxypropan-2-yl)phenyl)tetrahydro-2H- pyran-3-ol (10.7 g, 23.76 mmol, 1 eq) in toluene (100 mL) was added CMBP (8.60 g, 35.64 mmol, 1.5 eq) at 20°C. The mixture was stirred at 80°C for 16 hrs. LCMS showed 3-(3- Attorney Docket No.
  • MORF-016WO1 bromo-2-(1-hydroxypropan-2-yl)phenyl)tetrahydro-2H-pyran-3-ol was consumed and ⁇ 53% of desired compound was detected.
  • the reaction mixture was concentrated under reduced pressure to remove solvent.
  • Step 7 Stereoisomers of 5-bromo-4-methyl-5',6'-dihydro-2'H,4'H-spiro[isochromane- 1,3'-pyran]
  • 5-Bromo-4-methyl-5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran] (4.8 g, 16.15 mmol, 1 eq) was separated by SFC (column: DAICEL CHIRALPAK AD (250mm*30mm, 10um); mobile phase: [CO 2 -MeOH]; B%:15%, isocratic elution mode) to give 4 isomers.
  • Peak 1 arbitrarily assigned as (1S,4S)-5-bromo-4-methyl-5',6'-dihydro-2'H,4'H- spiro[isochromane-1,3'-pyran] (20.83% yield), was obtained as a white solid.
  • LCMS: [M+1] 297.2.
  • SFC: Rt 1.656.
  • Peak 2 arbitrarily assigned as (1S,4R)-5-bromo-4-methyl-5',6'-dihydro-2'H,4'H- spiro[isochromane-1,3'-pyran] (16.88% yield), was obtained as a white solid.
  • LCMS: [M+1] 297.2.
  • SFC: Rt 1.848.
  • Peak 3 arbitrarily assigned as (1R,4R)-5-bromo-4-methyl-5',6'-dihydro-2'H,4'H- spiro[isochromane-1,3'-pyran] (22.92% yield), was obtained as a white solid.
  • LCMS: [M+1] Attorney Docket No. MORF-016WO1 297.2.
  • SFC: Rt 2.441.
  • Peak 4 arbitrarily assigned as (1R,4S)-5-bromo-4-methyl-5',6'-dihydro-2'H,4'H- spiro[isochromane-1,3'-pyran] (22.92% yield), was obtained as a white solid.
  • LCMS: [M+1] 297.2.
  • SFC: Rt 2.441.
  • Peak 1 arbitrarily assigned as (S)-5-bromo-4-methyl-2',3',5',6'-tetrahydrospiro- [isochromane-1,4'-pyran], was obtained as a white solid.
  • SFC R t 1.638 min.
  • Peak 2 arbitrarily assigned as (R)-5-bromo-4-methyl-2',3',5',6'-tetrahydrospiro- [isochromane-1,4'-pyran], was obtained as a white solid.
  • SFC R t 1.873 min.
  • Step 3 methyl (S)-2-(4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]-5- yl)acetate
  • (S)-2-(4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]-5-yl)acetic acid 0.5 g, 904.73 ⁇ mol, 1 eq
  • MeOH 10 mL
  • H 2 SO 4 460.00 mg, 4.69 mmol, 250.00 ⁇ L, 5.18 eq
  • TMSCl (205.79 mg, 1.89 mmol, 240.41 ⁇ L, 2.2 eq) was added at -60 °C and the mixture was allowed to stir at -60 °C for 0.5 hrs.
  • the mixture was allowed to stir at -60 °C for 1 hr.
  • the mixture was diluted with NH 4 Cl (50 mL) and extracted with ethyl acetate (20 mL x 3). The organic solutions were combined, washed with brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • NBS (677.24 mg, 3.81 mmol, 2 eq) in THF (2 mL) was added to the solution at -78 o C and the solution was stirred at -78 o C for 1 hr.
  • LCMS showed the starting material remained and one peak with desired mass was detected.
  • the reaction mixture was quenched by addition aq. NH 4 Cl (10 mL) at 0 o C, extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with brine (5 mL x 3), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue.
  • Step 2 methyl 2-(6'-hydroxy-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane- 1,3'-indolin]-4'-yl)acetate
  • methyl 2-(2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)-6'-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate 2.3 g, 3.65 mmol, 1 eq) in acetone (100 mL) was added Oxone (3.36 g, 5.47 mmol, 1.5 eq) in H 2 O (50 mL) at 0 °C.
  • Step 3 methyl 2-bromo-2-(6'-methoxy-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate Attorney Docket No.
  • Step 4 methyl 2-(6'-methoxy-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane- 1,3'-indolin]-4'-yl)acetate
  • reaction mixture was quenched with H 2 O (400 mL) and extracted with MTBE (200 mL x 4). The combined organic layers were washed with brine (400 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, Eluent of 0 ⁇ 5% ethyl acetate/petroleum ether gradient @ 90 mL/min). 4-Bromo-6-fluoro-3-methyl-1H- indene (97.24% yield) was obtained as a white solid.
  • Step 3 1-(2-bromo-4-fluoro-6-(2-hydroxyethyl)phenyl)ethan-1-ol
  • NaBH4 11.30 g, 298.58 mmol, 3.39 eq
  • Step 4 8-bromo-6-fluoro-1-methylisochromane
  • 1-(2-bromo-4-fluoro-6-(2-hydroxyethyl)phenyl)ethan-1-ol (20 g, 76.02 mmol, 1 eq) in THF (300 mL) was added PPh 3 (29.91 g, 114.02 mmol, 1.5 eq) and DIAD (26.13 g, 129.23 mmol, 25.05 mL, 1.7 eq) at 0 o C and the mixture was stirred at 25 o C for 16 hrs under N 2 atmosphere.
  • Step 5 methyl 2-(6-fluoro-1-methylisochroman-8-yl)acetate
  • Pd(t-Bu 3 P) 2 (1.56 g, 3.06 mmol, 0.1 eq)
  • MeOOCCH 2 ZnBr 1 M, 45.90 mL, 1.5 eq
  • the reaction mixture was quenched with H 2 O (150 mL).
  • the mixture was filtered and the filtrate was extracted with ethyl acetate (100 mL x 3).
  • the combined organic layers were washed with brine (100 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Step 6 methyl (S)-2-(6-fluoro-1-methylisochroman-8-yl)acetate and methyl (R)-2-(6- fluoro-1-methylisochroman-8-yl)acetate
  • Methyl 2-(6-fluoro-1-methylisochroman-8-yl)acetate (7 g) was separated by SFC separation (column: ChiralPak IH, 250 * 50 mm, 10 um; mobile phase: [CO 2 -IPA (0.1% NH 3 H 2 O)]; B%:11%, isocratic elution mode).
  • Peak 1 (44.29% yield) was obtained as a yellow oil and arbitrarily assigned as methyl (S)-2-(6-fluoro-1-methylisochroman-8-yl).
  • 1 H NMR 400 MHz, CHLOROFORM-d
  • Peak 2 arbitrarily assigned as tert-butyl 2-bromo-2-((3S,4R)-3,4,7-trimethylisochroman- 5-yl)acetate was obtained as a yellow oil.
  • SFC separation conditions column: DAICEL CHIRALPAK IC (250 mm * 30 mm, 10 um); mobile phase: [CO 2 -i-PrOH (0.1%NH 3 H 2 O)]; 18% B isocratic elution mode) were prepared two compounds.
  • Peak 1 aribtrarily assigned as methyl 2-bromo-2-((S)-7-fluoro-4-methylisochroman-5-yl)acetate, was obtained as a yellow oil.
  • Peak 2 arbitrarily assigned as methyl 2-bromo-2-((R)-7-fluoro-4-methylisochroman-5- yl)acetate was obtained as a yellow oil.
  • Step 3 2-(3-bromo-2-(1-hydroxyethyl)phenyl)ethan- 1 ) O3 , DCM/MeOH 2) NaBH4 [000297] To a solution of 4-bromo-3-methyl-1H-indene (10 g, 47.83 mmol, 1 eq) in DCM (100 mL) and MeOH (20 mL) was added O 3 (11.48 g, 239.14 mmol, 5 eq) at -70°C. The mixture was stirred at -70°C for 0.5 hrs. NaBH 4 (2.35 g, 62.18 mmol, 1.3 eq) was added at - 70 o C.
  • Step 5 methyl 2-(1-methylisochroman-8-yl)acetate [000299] A mixture of Zn (15.39 g, 235.33 mmol, 1.2 eq) in THF (196.11 mL) was added TMSCl (2.13 g, 19.61 mmol, 2.49 mL, 0.1 eq) at 20°C, and then stirred at 20°C for 0.5 hrs.
  • Step 6 methyl (S)-2-(1-methylisochroman-8-yl)acetate and methyl (R)-2-(1- methylisochroman-8-yl)acetate
  • Peak 1 (40.00% yield) was obtained as a yellow oil and arbitrarily assigned as methyl (S)-2-(1-methylisochroman-8-yl)acetate.
  • 1 H NMR 400 MHz, CHLOROFORM-d
  • Peak 2 (40.00% yield) was obtained as a yellow oil and arbitrarily assigned as methyl (R)-2-(1-methylisochroman-8-yl)acetate.
  • 1 H NMR 400 MHz, CHLOROFORM-d
  • Step 3 2-(3-bromo-5-fluoro-2-(1-hydroxyethyl)phenyl)-N,N-dimethylacetamide
  • 2-(2-acetyl-3-bromo-5-fluorophenyl)-N,N-dimethylacetamide 1.
  • LiBH 4 2 M, 4.63 mL, 2 eq
  • LCMS showed ⁇ 66% desired mass.
  • the mixture was poured into ice water (20 mL), the mixture was extracted with ethyl acetate (20 mL x 2).
  • Step 5 8-bromo-6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]-3- one [000307]
  • DMF dimethyl methoxysulfoxide
  • Step 6 8-bromo-6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]-3- ol
  • 8-bromo-6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]-3-one 1.5 g, 4.56 mmol, 1 eq
  • CH 2 Cl 2 20 mL
  • DIBAL-H DIBAL-H
  • Step 7 8-bromo-6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran] [000309] To a solution of 8-bromo-6-fluoro-1-methyl-2',3',5',6'- tetrahydrospiro[isochromane-4,4'-pyran]-3-ol (700 mg, 2.11 mmol, 1 eq) in DCM (14 mL) was added Et 3 SiH (1.47 g, 12.68 mmol, 2.03 mL, 6 eq) and TFA (2.17 g, 19.02 mmol, 1.41 mL, 9 eq) at 20°C under N 2 .
  • Step 8 methyl 2-(6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]- 8-yl)acetate
  • Peak 2 (15.3% yield) was obtained as a yellow oil and arbitrarily assigned as methyl (R)-2-(6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]-8- yl)acetate.
  • Peak 1 arbitrarily assigned as methyl 2-(6'-methyl-1'-((2S,4S)-2-methyltetrahydro- 2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (13.00% yield), was obtained as a yellow oil.
  • SFC: Rt 2.228 min.
  • Peak 2 arbitrarily assigned as methyl 2-(6'-methyl-1'-((2R,4R)-2- methyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (13.00% yield), was obtained as a yellow oil.
  • SFC: Rt 2.450 min.
  • Peak 3 arbitrarily assigned as methyl 2-(6'-methyl-1'-((2R,4S)-2- methyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (31.7% yield), was obtained as a yellow oil.
  • SFC: Rt 2.794 min.
  • Peak 4 arbitrarily assigned as methyl 2-(6'-methyl-1'-((2S,4R)-2- methyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (33.33% yield), was obtained as a yellow oil.
  • SFC: Rt 3.106 min.
  • Step 2 2-(6-bromo-2,3-difluorophenyl)-2-oxo-N-(tetrahydro-2H-pyran-4-yl)acetamide
  • 2-(6-bromo-2,3-difluorophenyl)-2-oxoacetate 8.7 g, 31.18 mmol, 1 eq
  • MeOH 100 mL
  • tetrahydro-2H-pyran-4-amine 4.73 g, 46.77 mmol, 1.5 eq
  • the reaction mixture was allowed to stir at 25 °C for 16 hrs under an atmosphere of N 2 .
  • the mixture was concentrated under reduced pressure.
  • Step 5 4'-bromo-7'-fluoro-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'- indolin]-2'-one [000322]
  • DMF dimethyl methoxylate
  • Cs 2 CO 3 6.53 g, 20.05 mmol, 3 eq
  • 1,2- dibromoethane 6.28 g, 33.42 mmol, 2.52 mL, 5 eq.
  • Step 6 methyl 2-(7'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'- indolin]-4'-yl)acetate
  • 4'-bromo-7'-fluoro-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-2'-one 1.2 g, 3.53 mmol, 1 eq
  • Pd(t-Bu 3 P) 2 90.14 mg, 176.37 ⁇ mol, 0.05 eq
  • BrZnCH 2 COOMe (1 M, 10.58 mL, 3 eq
  • Step 7 methyl 2-bromo-2-(7'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate
  • methyl 2-(7'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate 180 mg, 539.97 ⁇ mol, 1 eq) in THF (5 mL) was added LDA (2 M, 269.98 ⁇ L, 1 eq) at -70 °C under an atmosphere of N 2 .
  • TMSCl 70.40 mg, 647.96 ⁇ mol, 82.24 ⁇ L, 1.2 eq
  • NBS 288.32 mg, 1.62 mmol, 3 eq
  • the reaction was quenched by the addition of saturated aqueous NH 4 Cl (30 mL) and extracted with ethyl acetate (30 mL x 2). The organic solutions were combined, washed with brine (10 mL), dried over Na 2 SO 4 , filtered and concentrated.
  • Methyl 2-bromo-2-(6'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate was prepared from 4-bromo-6-fluoro-1- (tetrahydro-2H-pyran-4-yl)indoline-2,3-dione following procedures similar to steps 4, 5, 6 and Attorney Docket No.
  • reaction mixture was allowed to stir at -70 °C for 0.5 hrs. Then to the reaction mixture was added a solution of dimethyl oxalate (19.26 g, 163.07 mmol, 2 eq) in toluene (500 mL) at -70 °C. The reaction mixture was allowed to stir at -70 °C for 1 hr. The reaction was quenched by the addition of aq. NH4Cl (400 mL) and the mixture was extracted with ethyl acetate (100 mL x 2). The organic solutions were combined, washed with brine (200 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Step 2 4-bromo-6-fluoro-1-(tetrahydro-2H-pyran-4-yl)indoline-2,3-dione Attorney Docket No. MORF-016WO1 [000327] To a solution of tetrahydro-2H-pyran-4-amine (3.99 g, 39.42 mmol, 1.1 eq) in THF (50 mL) was added n-BuLi (2.5 M, 14.34 mL, 1 eq) at 0 o C under an atmosphere of N 2 . The reaction was allowed to stir at 0 o C for 0.5 hrs.
  • the reaction mixture was added to a solution of methyl 2-(2-bromo-4,6-difluorophenyl)-2-oxoacetate (10 g, 35.84 mmol, 1 eq) in THF (50 mL) at 0 o C under an atmosphere of N 2 .
  • the mixture was allowed to stir at 25 o C for 0.5 hrs.
  • the reaction was quenched with aq.2 M HCl (100 mL) and extracted with ethyl acetate (100 mL x2).
  • the organic solutions were combined, washed with brine (50mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • the crude product was triturated with petroleum ether/ethyl acetate (3/1).
  • MeI (30.98 g, 218.27 mmol, 13.59 mL, 1 eq) was added dropwise at 0 °C under an atmosphere of N 2 . The mixture was allowed to stir at 20 °C for 1 hr. The reaction was quenched by the addition of NH 4 Cl (500 mL) and extracted with ethyl acetate (200 mL x 3). The organic solutions were combined, washed with brine (100 mL x 3), dried over Na 2 SO 4 , filtered and concentrated under Attorney Docket No. MORF-016WO1 reduced pressure. Methyl 2-(2-bromophenyl)propanoate (60 g, crude) was obtained as a yellow oil.
  • Step 3 5-bromo-4-methylisochromane
  • a solution of of 2-(2-bromophenyl)propan-1-ol (17 g, 79.04 mmol, 1 eq) and (HCHO) n (7.83 g, 86.94 mmol, 1.1 eq) in TFA (100 mL) was allowed to stir at 100 °C for 16 hrs.
  • the reaction mixture was concentrated under reduced pressure.
  • the residue was diluted with H 2 O (200 mL) and extracted with ethyl acetate (100 mL x 3). The organic solutions were combined, washed with brine (200 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Step 3 N-(2-bromo-6-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)-4-chlorobutanamide
  • 2-bromo-6-((tetrahydro-2H-pyran-4-yl)oxy)aniline 9 g, 33.07 mmol, 1 eq
  • Na 2 HPO 4 9.39 g, 66.14 mmol, 9.39 mL, 2 eq
  • CHCl 3 90 mL
  • 4-chlorobutanoyl chloride (5.60 g, 39.69 mmol, 4.44 mL, 1.2 eq) at 25 °C and the mixture was allowed to stir at 25 °C for 2 hrs.
  • Step 4 1-(2-bromo-6-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)pyrrolidin-2-one [000339] To a solution of NaH (1.17 g, 29.20 mmol, 60% purity, 1.1 eq) in DMF (50 mL) was added N-(2-bromo-6-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)-4-chlorobutanamide (10 g, 26.55 mmol, 1 eq) in DMF (50 mL) at 0 °C and the mixture was allowed to stir at 25 °C for 12 hrs. The reaction was quenched by the addition of sat.
  • Step 6 2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4-yl)oxy)benzaldehyde [000341] To a solution of 1-(2-((tetrahydro-2H-pyran-4-yl)oxy)-6-vinylphenyl)pyrrolidin-2- one (1.4 g, 4.87 mmol, 1 eq) and 2,6-lutidine (1.04 g, 9.74 mmol, 1.13 mL, 2 eq) in THF (20 mL) and H 2 O (10 mL) was added K 2 OsO 4 .2H 2 O (179.51 mg, 487.21 ⁇ mol, 0.1 eq) and NaIO 4 (4.17 g, 19.49 mmol, 1.08 mL, 4 eq) at 0 °C.
  • Step 7 2-hydroxy-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4- yl)oxy)phenyl)acetonitrile
  • 2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4- yl)oxy)benzaldehyde 950 mg, 3.28 mmol, 1 eq
  • TMSCN 488.62 mg, 4.93 mmol, 616.16 ⁇ L, 1.5 eq
  • ZnCl 2 104.81 mg, 328.35 ⁇ mol, 0.1 eq.
  • Step 8 methyl 2-hydroxy-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4- yl)oxy)phenyl)acetate
  • 2-hydroxy-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4- yl)oxy)phenyl)acetonitrile 1.3 g, 2.01 mmol, 1 eq
  • HCl/MeOH 6 M, 334.59 ⁇ L, 1 eq
  • Step 9 methyl 2-((methylsulfonyl)oxy)-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H- pyran-4-yl)oxy)phenyl)acetate
  • TEA 130.33 mg, 1.29 mmol, 179.27 ⁇ L, 3 eq
  • Ms 2 O 224.37 mg, 1.29 mmol, 3 eq
  • Step 2 7-bromo-1-methyl-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one [000346] Two parallel reactions were carried out. To a solution of 7-bromo-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-2-one (12 g, 42.53 mmol, 1 eq.) in DMF (160 mL) was added NaH (3.40 g, 85.07 mmol, 60% purity, 2 eq.) at 0 o C under an atmosphere of N 2 .
  • reaction mixture was allowed to stir at 0 o C under an atmosphere of N 2 for 0.5 hrs.
  • MeI (12.07 g, 85.07 mmol, 5.30 mL, 2 eq.) was added dropwise to the reaction mixture at 0 o C.
  • the reaction mixture was allowed to warm to 25 o C and stir for 2 hrs.
  • the two reaction mixtures were combined and quenched by the addition of sat. NH 4 Cl (500 mL) at 0 o C.
  • the mixture was extracted with ethyl acetate (50 mL x 3). The organic solutions were combined, washed with brine (50 mL x 3), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • the reaction mixture was warmed to 25 o C and allowed to stir at 25 o C for 2 hrs.
  • reaction mixture was allowed to stir at 0 o C for 2 hrs.
  • the reaction mixture was quenched by the addition of sat. NH 4 Cl (200 mL) at 25 o C and extracted with ethyl acetate (50 mL x 3).
  • the organic solutions were combined, washed with brine (50 mL x 3), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Step 7 tert-butyl 2-(5-(methoxymethyl)-1-methyl-2-oxo-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetate
  • Pd(t-Bu 3 P) 3 721.04 mg, 1.41 mmol, 0.1 eq.
  • ZnBrCH 2 COOt-Bu (1 M, 28.22 mL, 2 eq.
  • the reaction mixture was heated to 80 o C and allowed to stir at 80 o C for 2 hrs.
  • the reaction was quenched by the addition of water (150 mL) at 25 o C and filtered.
  • the filtered cake was washed with ethyl acetate (20 mL x 3) and then with 1 N HCl (500 mL).
  • the filtrate was extracted with ethyl acetate (20 mL x 3).
  • the organic solutions were combined, washed with brine (50 mL x 3), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Step 2 (E)-3-(2-bromo-6-fluorophenyl)but-2-en-1-ol [000354] Two reactions were carried out in parallel. To a solution of methyl (E)-3-(2- bromo-6-fluorophenyl)but-2-enoate (11 g, 40.28 mmol, 1 eq) in THF (120 mL) at 0 °C, under an atmosphere of nitrogen, was added LiAlH 4 (2.5 M, 24.17 mL, 1.5 eq). The reaction mixture was allowed to stir at 20 °C for 2 hrs. To the reaction mixture was added H 2 O (2.5 mL) and NaOH (15%, 2.5ml).
  • Step 4 methyl 2-(4-methyl-2H-chromen-5-yl)acetate
  • a suspension of 5-bromo-4-methyl-2H-chromene (200 mg, 888.57 ⁇ mol, 1 eq), BrZnCH 2 COOMe (1 M, 4.44 mL, 5 eq) and Pd(t-Bu 3 P) 2 (22.71 mg, 44.43 ⁇ mol, 0.05 eq) in THF (250 mL) was allowed to stir at 70 °C for 2 hrs under an atmosphere of N 2 .
  • Water (5 mL) was added and the mixture was filtrated. The filtrate was extracted with ethyl acetate (5 mL x 2).
  • Step 2 2-(1-(2,6-dibromophenyl)ethoxy)acetic acid [000359] To a solution of 1-(2,6-dibromophenyl)ethan-1-ol (36 g, 128.59 mmol, 1 eq) in THF (400 mL)was added NaH (10.29 g, 257.18 mmol, 60% purity, 2 eq) at 0 °C under an atmosphere of N 2 . The mixture was allowed to stir at 0 °C for 0.5 hrs. BrCH 2 COOMe (39.34 Attorney Docket No.
  • MORF-016WO1 g, 257.18 mmol, 24.35 mL, 2 eq was added at 0 o C and the solution was allowed to stir at 20 o C for 1 hr.
  • H 2 O (200 mL) and NaOH (10.29 g, 257.18 mmol, 2 eq) were added into the reaction mixture and the mixture was allowed to stir at 20 °C for 2 hrs.
  • the mixture was extracted with EtOAc (200 mL x 3).
  • Step 3 2-(1-(2,6-dibromophenyl)ethoxy)-N-methoxy-N-methylacetamide
  • Step 5 8-bromo-1-methylisochromane [000362] To a solution of 8-bromo-1-methylisochroman-4-one (38.5 g, 159.70 mmol, 1 eq) in TFA (300 mL) was added Et 3 SiH (92.85 g, 798.49 mmol, 127.54 mL, 5 eq) at 20 °C under an atmosphere of N 2 and the solution was allowed to stir at 50 o C for 16 hrs. The reaction mixture was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (20 mL) and sat. NaHCO 3 (100 mL).
  • Step 2 methyl (S)-2-(1,6-dimethylisochroman-8-yl)acetate
  • EtOH 20 mL
  • H 2 O 20 mL
  • Pd(PPh 3 ) 4 500.64 mg, 433.24 ⁇ mol, 0.05 eq
  • K 2 CO 3 3.59 g, 25.99 mmol, 3 eq
  • MeI 6.15 g, 43.32 mmol, 2.70 mL, 5 eq
  • Step 3 methyl 2-bromo-2-((S)-1,6-dimethylisochroman-8-yl)acetate
  • LDA 2 M, 3.20 mL, 3 eq
  • TMSCl 765.10 mg, 7.04 mmol, 893.81 ⁇ L, 3.3 eq
  • Step 2 7-bromo-1-methyl-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one
  • Step 2 To a solution of 7-bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one (5.4 g, 19.14 mmol, 1 eq) in DMF (55 mL) was added NaH (765.52 mg, 19.14 mmol, 60% purity, 1 eq) at 0 °C.
  • Step 3 tert-butyl 2-(1-methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7- yl)acetate Attorney Docket No.
  • Step 2 2-(2-bromo-6-fluoro-4-methylphenyl)-2-oxo-N-(tetrahydro-2H-pyran-4- yl)acetamide
  • methyl 2-(2-bromo-6-fluoro-4-methylphenyl)-2-oxoacetate (30 g, 109.06 mmol, 1 eq) in MeOH (300 mL) was added tetrahydro-2H-pyran-4-amine (12.13 g, 119.97 mmol, 1.1 eq) dropwise at 0 °C.
  • the mixture was allowed to stir at 25 °C for 16 hrs.
  • the reaction mixture was filtered and concentrated under reduced.
  • Step 3 4-bromo-6-methyl-1-(tetrahydro-2H-pyran-4-yl)indoline-2,3-dione [000372] To a mixture of 2-(2-bromo-6-fluoro-4-methylphenyl)-2-oxo-N-(tetrahydro-2H- pyran-4-yl)acetamide (10 g, 27.76 mmol, 1 eq) in toluene (100 mL) was added dropwise a Attorney Docket No.
  • Step 4 4-bromo-6-methyl-1-(tetrahydro-2H-pyran-4-yl)indoline-2,3- dione (94.44% yield) as a red solid.
  • Step 4 4-bromo-6-methyl-1-(tetrahydro-2H-pyran-4-yl)indolin-2-one [000373] To a solution of 4-bromo-6-methyl-1-(tetrahydro-2H-pyran-4-yl)indoline-2,3-dione (24 g, 74.04 mmol, 1 eq) in glycol (250 mL) was added NH 2 NH 2 .H 2 O (51.60 g, 1.03 mol, 50 mL, 13.92 eq) at 25 °C under an atmosphere of N 2 .
  • Step 5 4'-bromo-6'-methyl-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'- indolin]-2'-one [000374] To a solution of 4-bromo-6-methyl-1-(tetrahydro-2H-pyran-4-yl)indolin-2-one (22.69 g, 73.15 mmol, 1 eq) in DMF (250 mL) was added NaH (14.63 g, 365.75 mmol, 60% purity, 5 eq) at 0 °C under an atompshere of N 2 . The solution was allowed to stir at 0 °C for Attorney Docket No.
  • Step 2 (S)-2-(2-bromo-4-methylphenyl)-1-((3aR,6S,7aS)-8,8-dimethyl-2,2- dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)propan-1-one [000376] Four batches were carried out in parallel.
  • HMPA 79.86 g, 445.63 mmol, 77.98 mL, 5 eq
  • MeI 63.25 g, 445.63 mmol, 27.74 mL, 5 eq
  • the reaction was allowed to stir at -78°C for 2 hrs.
  • the reaction was quenched by aq.NH 4 Cl (800 mL) slowly and extracted with ethyl acetate (300 mL x 3). The organic solutions were combined, washed with brine (300 mL x 3), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Step 3 (S)-2-(2-bromo-4-methylphenyl)propan-1-ol Attorney Docket No. MORF-016WO1 [000377] Three batches were carried out in parallel. To a solution of (S)-2-(2-bromo-4- methylphenyl)-1-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6- methanobenzo[c]isothiazol-1(4H)-yl)propan-1-one (20 g, 45.41 mmol, 1 eq) in THF (150 mL) was added NaBH 4 (3.81 g, 100.65 mmol, 2.22 eq) in H 2 O (12 mL) at 25°C and the mixture was allowed to stir at 25°C for 16 hrs.
  • NaBH 4 3.81 g, 100.65 mmol, 2.22 eq
  • Step 4 (S)-2-(2-bromo-4-methylphenyl)propan-1-ol [000378] To a solution of (S)-2-(2-bromo-4-methylphenyl)propan-1-ol (64 g, 279.34 mmol, 1 eq) in DCM (600 mL) was added DMAP (1.71 g, 13.97 mmol, 0.05 eq), pyridine (38.67 g, 488.84 mmol, 39.46 mL, 1.75 eq) and AcCl (32.89 g, 419.01 mmol, 29.79 mL, 1.5 eq) at 0 o C under an atmosphere of N 2 and the solution was allowed to stir at 20 o C for 2 hrs.
  • DMAP 1.71 g, 13.97 mmol, 0.05 eq
  • pyridine 38.67 g, 488.84 mmol, 39.46 mL, 1.75 eq
  • AcCl
  • the mixture was allowed to stir at 0°C for 1 hr.
  • Step 10 methyl 2-((1S,4S)-4,7-dimethyl-5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'- pyran]-5-yl)acetate and methyl 2-((1R,4S)-4,7-dimethyl-5',6'-dihydro-2'H,4'H- spiro[isochromane-1,3'-pyran]-5-yl)acetate
  • MORF-016WO1 Two batches were carried out in parallel.
  • Peak 2 arbitrarily assigned as methyl 2-((1R,4S)-4,7-dimethyl-5',6'-dihydro- 2'H,4'H-spiro[isochromane-1,3'-pyran]-5-yl)acetate, was obtained (51.88% yield) as a white solid.
  • Step 1 (E)-2-bromo-4-methyl-1-(prop-1-en-1-yl)benzene [000388] To a solution of 2-bromo-4-methylbenzaldehyde (90.0 g, 452.16 mmol, 1.0 eq.) in THF (900 mL) was added EtMgBr (3.0 M, 301.44 mL, 2.0 eq.) at 0°C. The mixture was allowed to stir under an atmosphere of nitrogen at 0°C for 0.5 hrs and then at 25°C for 1 hr. The reaction was quenched by the addition of sat. aq.
  • H 2 O 37.4 g, 196.41 mmol, 3.0 eq.
  • the mixture was heated to 80 o C and allowed to stir at 80°C under an atmosphere of N 2 for 12 hrs.
  • the reaction was quenched by the addition of H 2 O (150 mL) and the mixture was extracted with ethyl acetate (100 mL x 3).
  • Step 2 2-(2-bromo-4-methylphenyl)-3-methyloxirane [000389] To a solution of (E)-2-bromo-4-methyl-1-(prop-1-en-1-yl)benzene (40.0 g, 189.49 mmol, 1.0 eq.) in DCM (400 mL) was added m-CPBA (65.4 g, 322.13 mmol, 85% purity, 1.7 eq.) at 20 o C. The mixture was allowed to stir at 20°C for 6 hrs. The reaction was quenched by the addition of sat. aq.Na 2 SO 3 (400 mL) and then DCM (200 mL) was added.
  • m-CPBA 65.4 g, 322.13 mmol, 85% purity, 1.7 eq.
  • Step 3 (2R,3S)-3-(2-bromo-4-methylphenyl)butan-2-ol and (2S,3S)-3-(2-bromo-4- methylphenyl)butan-2-ol
  • 2-(2-bromo-4-methylphenyl)-3-methyloxirane 36.0 g, 158.52 mmol, 1.0 eq
  • AlMe 3 1.0 M, 317.04 mL, 2.0 eq
  • Step 4 (3R,4S)-5-bromo-3,4,7-trimethylisochromane [000391] To a mixture of (2R,3S)-3-(2-bromo-4-methylphenyl)butan-2-ol and (2S,3S)-3-(2- bromo-4-methylphenyl)butan-2-ol (36.0 g, 148.07 mmol, 1.0 eq.) in TFA (360 mL) was added (HCHO) n (40.0 g, 444.19 mmol, 3.0 eq.) at 20°C. The mixture was allowed to stir at 50 °C for 16 hrs.
  • the mixture was extracted with ethyl acetate (200 mL x 3).
  • Step 2 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((R)-1-methylisochroman-8-yl)acetic acid (Compounds 300 and 299) 299 [000398]
  • the residue was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [NH 4 HCO 3 -ACN]; gradient: 25%-55% B over 8.0 min).
  • the residue was separated by SFC (column: REGIS (s, s) WHELK-O1 (250mm*30mm, 5um); mobile phase: [CO 2 -MeOH (0.1%NH 3 H 2 O)]; B%:50%, isocratic elution mode) to give two peaks.
  • Step 2 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((S)-1-methylisochroman-8-yl)acetic acid (Compounds 300* and 299*) [000399]
  • To a solution of methyl 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((S)-1-methylisochroman-8-yl)acetate 250 mg, 479.21 ⁇ mol, 1 eq) in DCM (3 mL) in dioxane (4 mL) and H 2 O (4 mL) was added LiOH .
  • MORF-016WO1 yl)butoxy)cyclopentyl)amino)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [NH 4 HCO 3 - ACN]; gradient: 25%-65% B over 8.0 min)and separated by SFC (column: REGIS (s, s) WHELK-O1 (250 mm * 30 mm, 5 um); mobile phase: [CO 2 -EtOH (0.1% NH 3 H 2 O)]; B%:50%, isocratic elution mode).
  • MORF-016WO1 2.61 (m, 1H), 2.56 - 2.47 (m, 3H), 2.41 (s, 3H), 2.12 - 1.95 (m, 3H), 1.91 - 1.80 (m, 4H), 1.79 - 1.69 (m, 2H), 1.69 - 1.47 (m, 4H), 1.45 (s, 3H), 1.12 - 1.06 (m, 2H), 1.05 - 0.99 (m, 2H).
  • the isolated 354 was further purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [H 2 O (10mM NH 4 HCO 3 )-ACN]; gradient: 25%-75% B over 8.0 min) to afford 354 (25.2 mg).
  • 64 was further purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150 * 40 mm * 10um; Attorney Docket No. MORF-016WO1 mobile phase: [H 2 O (10mM NH 4 HCO 3 )-ACN]; gradient: 25%-75% B over 8.0 min) to afford 64 (24.1 mg).
  • racemate was further separated by SFC (column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 um); mobile phase: [CO 2 - EtOH (0.1% NH 3 H 2 O)]; B%:50%, isocratic elution mode).
  • Peak 2 was purified by prep- HPLC (column: Phenomenex Luna C1875*30mm*3um; mobile phase: [H 2 O (0.1%TFA)- ACN]; gradient: 15%-35% B over 8.0 min).
  • Compound 359 (peak 1) arbitrarily assigned as (S)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-(2-(2-oxopyrrolidin-1- yl)-3-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)acetic acid, was obtained as a white solid (60.4 mg, 94.38 ⁇ mol, 39.94%).
  • This solid was further separated by chiral SFC Attorney Docket No. MORF-016WO1 (column: Daicel ChiralPak IG (250 * 30 mm, 10 um); mobile phase: [CO 2 -IPA (0.1% NH 3 H 2 O)]; B%: 50%, isocratic elution mode) to give peak 1, a mixture of peak 2 & peak 3, and peak 4.
  • the mixture of peak 2 & peak 3 was further separated by SFC (column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 um); mobile phase: [CO 2 -MeOH (0.1%NH 3 H 2 O)]; B%: 50%, isocratic elution mode).
  • Compound 280 (peak 2), arbitrarily assigned as (S)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methylisochroman-5-yl)acetic acid, was obtained as a white solid (138.4 mg, 258.35 umol, 15.78%).
  • Compound 365 (peak 1), arbitrarily assigned as (S)-2-(6'-fluoro-2'-oxo-1'- (tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid, was obtained as a white solid.
  • the resulting solid was further purified by SFC (column: DAICEL CHIRALPAK IG (250mm*30mm, 10um); mobile phase: [CO 2 -IPA (0.1%NH 3 H 2 O)]; B%:55%, isocratic elution mode).
  • Compound 210 (peak 2), arbitrarily assigned as (R)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]-5-yl)acetic acid, was obtained as a white solid.
  • MORF-016WO1 tetrahydro-2H-pyran-4-ylspiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid
  • Isomers of arbitrarily assigned 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-(6'-methyl-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, and were purified by prep-HPLC (column: Phenomenex luna C18250*150mm*15um; mobile phase: [H 2 O (0.2%FA)-A
  • Compound 156 (peak 1), arbitrarily assigned as (S)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-(6'-methyl-2'-oxo-1'- (tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid was obtained as a white solid.
  • Step 2 2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid [000477] To a solution of (S)-2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H-indazol-7-yl)-2- (methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid (0.4 g, 629.09 ⁇ mol, 1 eq) in DCM (3 mL) was added TFA (1.54 g, 13.46 mmol, 1 mL, 21.
  • MORF-016WO1 2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (0.3 g, 517.48 umol) was separated by SFC (column: ChiralPak IH, 250*30mm, 10um; mobile phase: [CO 2 - EtOH (0.1% NH 3 H 2 O)]; B%:27%, isocratic elution mode).
  • 381 (Peak 1), arbitrarily assigned as (S)-2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H- indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid, was obtained as a white solid (68 mg, 117.30 ⁇ mol).
  • LCMS [M+1] 580.3.
  • Peak 1 was further purified by prep-HPLC (column: REGIS(s, s) WHELK-O1 (250 mm * 30 mm, 5 um); mobile phase: [CO 2 -EtOH (0.1% NH 3 H 2 O)]; B%: 50%, isocratic elution mode).
  • Peak 2 was further purified by prep-HPLC (column: REGIS (s, s) WHELK-O1 (250 mm * 30 mm, 5 um); mobile phase: [CO 2 - EtOH (0.1% NH 3 H 2 O)]; B%:50%, isocratic elution mode).
  • Peak 1 Compound 379, arbitrarily assigned as (S)-2-(1,3-dimethyl-1H-indazol-7- yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)- amino)acetic acid (16.33% yield), was obtained as a white solid.
  • LCMS: [M+1] 506.3.
  • Peak 2 Compound 380, arbitrarily assigned as (R)-2-(1,3-dimethyl-1H-indazol-7- yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)- amino)acetic acid (23.9 mg, 47.27 umol, 15.93%), was obtained as a white solid.
  • LCMS: [M+1] 506.3.
  • MORF-016WO1 Compounds 383 and 384 were prepared starting from the appropriate starting material using procedures similar to those described for the preparation of compounds 381 and 382. The final compounds were purified by prep-HPLC column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [H 2 O (0.05% NH 3 H 2 O + 10 mM NH 4 HCO 3 )-ACN]; gradient: 10%-40% B over 8.0 min) by prep-HPLC column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [H 2 O (0.05% NH 3 H 2 O + 10 mM NH 4 HCO 3 )-ACN]; gradient: 10%-40% B over 8.0 min).
  • Peak 1 Compound 383, arbitrarily assigned as (S)-2-(5-methoxy-1,3-dimethyl-1H- indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid, was obtained (63.8 mg, 119.10 ⁇ mol) as a white solid.
  • LCMS [M+1] 536.2.
  • Peak 2 Compound 384, arbitrarily assigned as (R)-2-(5-methoxy-1,3-dimethyl-1H- indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid, was obtained (65.1 mg, 121.53 ⁇ mol) as a white solid.
  • LCMS [M+1] 536.3.
  • the final compounds were purified by prep-HPLC (column: Phenomenex Luna 80 * 30 mm * 3 um; mobile phase: [water (TFA)-ACN]; B%: 5%-35%, 8 min) and separated by SFC (column: Daicel Chiral Pak IG (250 * 30 mm, 10 um); mobile phase: [CO 2 -MeOH (0.1%NH 3 H 2 O)]; 45%% B isocratic elution mode).
  • Peak 1 Compound 385, arbitrarily assigned as (R)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((3R,4S)-3,4,7- trimethylisochroman-5-yl)acetic acid, was obtained (43.5 mg, 80.50 ⁇ mol) as a white solid.
  • LCMS [M+1] 536.3.
  • Peak 2 Compound 386, arbitrarily assigned as (S)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((3R,4S)-3,4,7- trimethylisochroman-5-yl)acetic acid, was obtained (108.5 mg, 202.11 ⁇ mol) as a white solid.
  • LCMS [M+1] 536.3.
  • Peak 1 arbitrarily assigned as tert-butyl 2-(((1S,4R)-3,3-dimethyl-4-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-(5-(methoxymethyl)-1- methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetate, was obtained as yellow oil.
  • Peak 2 arbitrarily assigned as tert-butyl 2-(((1R,4S)-3,3-dimethyl-4-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-(5-(methoxymethyl)-1- methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetate, was obtained as a yellow oil.
  • MORF-016WO1 (methoxymethyl)-1-methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetic acid (Compounds 248 and 363) + 363 [000492]
  • MORF-016WO1 purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150*40mm*10um; mobile phase: [H 2 O (10mM NH 4 HCO 3 )-ACN]; gradient: 30%-60% B over 8.0 min) and separated by SFC (column: REGIS (s, s) WHELK-O1 (250mm*30mm, 5um); mobile phase: [CO 2 -EtOH (0.1%NH 3 H 2 O)]; B%:50%, isocratic elution mode) to give two compounds.
  • the intermediates after alkylation were purified by SFC (column: REGIS(S, S) WHELK-O1 (250 mm*25 mm, 10 um); mobile phase: [CO 2 -IPA (0.1%NH 3 H 2 O)]; B%:43%, isocratic elution mode to give 2 product mixtures.
  • SFC column: REGIS(S, S) WHELK-O1 (250 mm*25 mm, 10 um); mobile phase: [CO 2 -IPA (0.1%NH 3 H 2 O)]; B%:43%, isocratic elution mode to give 2 product mixtures.
  • Each product following SFC separation was separately subjected to hydrolysis and purified by prep-HPLC (column: Waters Xbridge BEH C18100*30 mm*10 um; mobile phase: [H 2 O (10mM NH 4 HCO 3 )-ACN]; gradient: 30%-60% B over 8.0 min) to give two products.
  • MORF-016WO1 The product of hydrolysis of alkylation SFC peak 2, arbitrarily assigned as (S)-2- (((1RS,4SR)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4-methylchroman-5-yl)acetic acid, was purified by prep-HPLC (column: Waters Xbridge BEH C18100*30 mm*10 um; mobile phase: [H 2 O (10mM NH 4 HCO 3 )-ACN]; gradient: 30%-60% B over 8.0 min) and separated by SFC (column: REGIS (s,s) WHELK-O1 (250 mm*30 mm, 5 um); mobile phase: [CO 2 - IPA(0.1%NH 3 H 2 O)]; B%:50%, isocratic e
  • the intermediates after alkylation were purified by by column chromatography (SiO 2 , 12g Sepa Flash ® Silica Flash Column, Eluent of 0 ⁇ 80% Petroleum ethergradient/ Ethyl acetate@ 120 mL/min) and then separated by SFC (column: DAICEL CHIRALPAK IC (250 mm * 30 mm, 10 um); mobile phase: [CO 2 -IPA (0.1%NH 3 H 2 O)]; B%:60%, isocratic elution mode) to give 2 product mixtures. Each product following SFC separation was separately subjected to hydrolysis to give two products.
  • MORF-016WO1 hydrolysis and purified by by prep-HPLC columnumn: Phenomenex Luna C1875*30mm*3um; mobile phase: [H 2 O (0.1%TFA)-ACN]; gradient: 20%-45% B over 8.0 min).
  • MORF-016WO1 separated by SFC (column: REGIS (s,s) WHELK-O1 (250mm*30mm,5um);mobile phase: [CO 2 -MeOH(0.1%NH 3 H 2 O)];B%:50%, isocratic elution mode) to give two compounds.
  • Fluorescence Polarization (FP) assays with the fluorescein-labeled, disulfide- cyclized peptide ACRGDGWCG.
  • FP Fluorescence Polarization
  • IC50 values were determined by nonlinear regression, 4-parameter curve fitting. [000533] IC 50 values of Tables 1 and 2 as determined by the fluorescence polarization assay are categorized as: A: ⁇ 5 nM; B: 5-500 nM; and C: >500 nM. Table 1. Potency Data Table Attorney Docket No. MORF-016WO1 Attorney Docket No. MORF-016WO1 Attorney Docket No.
  • the invention features a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein: a 3- to 15-member heterocyclyl ring structure optionally substituted with halogen, C 1-6 alkyl, C 1-6 alkyloxy, a 3-8 member heterocyclyl ring structure, an aryl, or a 5- to 6- member heteroaryl, wherein the C 1-6 alkyl, the C 1-6 alkyloxy, the 3-8 member heterocyclyl ring structure, the aryl, or the 5- to 6-member heteroaryl are optionally substituted with one or more halogen, C 1-4 alkyloxy, or C 1-6 alkyl optionally substituted with one or more halogen; a is 1, 2, 3, 4, 5, 6, 7 or 8; and R a is C 1-6 alkyl.
  • Embodiment 2 The compound of Embodiment 1, wherein the compound is a compound of Formula (I-A), or a pharmaceutically acceptable salt thereof.
  • Embodiment 3 The compound of any one of Embodiments 1-2, wherein phenyl or a 6-member heteroaryl.
  • Embodiment 4 The compound of Embodiment 3, wherein R 1 is C 1-4 alkoxy; and R 2 is C 1-4 alkyl optionally substituted with one or more halogen; or R 1 and R 2 together form a fused 5- to 8-member heterocycloalkyl ring, a fused 5- to 6-member heteroaryl ring, a fused 7- to 15-member spirocyclic heterocycloalkyl ring system, wherein the fused ring is optionally substituted with halogen, C 1-4 alkyl, C 3-6 cycloalkyl, or a 4- to 8-member heterocycloalkyl ring, wherein the C 1-4 alkyl, the C 3-6 cycloalkyl, or the 4- to 8-member heterocycloalkyl ring is optionally substituted with one or more halogen or C 1-4 alkyl optionally substituted with one or more halogen; R 3 is C 1-4 alkyl optionally substituted with one or more halogen; Embod
  • Embodiment 6 The compound of Embodiment 4, wherein Attorney Docket No. MORF-016WO1 wherein R 4 and R 14 are each independently H, halogen or C 1-4 alkyl optionally substituted with one or more halogen;
  • X 1 is CR 5a R 5b or NR 5c
  • R 5a is H or a C 1-4 alkyl optionally substituted with one or more halogen
  • R 5b is a C 1-4 alkyl or a C 3-6 cycloalkyl, wherein the C 1-4 alkyl or the C 3-6 cycloalkyl is optionally substituted with one or more halogen; or
  • R 5a and R 5b together form a spirocyclic 3- to 8-member heterocycloalkyl or a spirocyclic C 3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C 3-6 cycloalkyl is optionally substituted with C 1-4 alkyl optional
  • R 7c is a C 1-4 alkyl optionally substituted with one or more halogen
  • X 4 is CR 8a R 8b or NR 8c
  • R 8a is H and R 8b is halogen or a C 1-4 alkyl optionally substituted with one or more halogen
  • R 8a and R 8b together form a spirocyclic 3- to 8-member heterocycloalkyl or a C 3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C 3-6 cycloalkyl is optionally substituted with C 1-4 alkyl optionally substituted with one or more halogen, a 4- to 8-member spirocyclic heterocycloalkyl or a C 3-7 spirocyclic cycloalkyl optionally substituted with C 1-4 alkyl optionally substituted with one or more halogen; and R 8c is H, C 1-4 alkyl, a 4- to 8-member heterocycloalky
  • Embodiment 7 The compound of Embodiment 6, wherein R 14 is H; and X 1 is CR 5a R 5b and R 5a is H, and R 5b is methyl or cyclopropyl.
  • MORF-016WO1 halogen a 4- to 7-member spirocyclic heterocycloalkyl, or a C 3-7 spirocyclic cycloalkyl, optionally substituted with C 1-4 alkyl optionally substituted with one or more halogen.
  • Embodiment 9 The comopound of Embodiment 6, wherein wherein R 10a and R 10b are each independently H, halogen, or a C 1-4 alkyl optionally substituted with one or more halogen; or R 10a and R 10b together form a spirocyclic C 3-6 cycloalkyl or a spirocyclic 6-member heterocycloalkyl; R 11a and R 11b are each independently H, halogen or a C 1-4 alkyl optionally substituted with one or more halogen; R 12a and R 12b are each independently H, halogen or a C 1-4 alkyl optionally substituted with one or more halogen; R13a is methy, ethyl, or cyclopropyl; R 13b is H; R 14 is H, halogen, or a C 1-4 alkyl optionally substituted with one or more halogen.
  • Embodiment 10 The compound of Embodiment 9, wherein R 10a and R 10b are each independently H or methyl; R 11a and R 11b are each independently H, methyl, or ethyl; R 12a and R 12b are each independently H or methyl; R 13a is methyl, ethyl, or cyclopropyl; R 13b is H; R14 is H, fluoro, or methyl.
  • R 4 is H or fluoro
  • R 13a is methyl, ethyl, or cyclopropyl
  • R 14 is H.
  • Embodiment 12 The compound of Embodiment 6, wherein X 2 is NR 6c and R 6c is C 1-4 alkyl.
  • Embodiment 13 The compound of Embodiment 6, wherein wherein R 13a is H or methyl, and R 4 is H, F, or methyl.
  • Embodiment 14 The compound of Embodiment 6, wherein Embodiment 15: The compound of Embodiment 14, wherein R 10a , R 10b , and R 11a are each H or methyl.
  • Embodiment 16 The compound of Embodiment 14, wherein R 11b is H, methyl, or ethyl.
  • Embodiment 17 The compound of Embodiment 6, wherein , wherein R 4 is H, halogen, or methyl optionally substituted with one or more halogen; and Attorney Docket No. MORF-016WO1 R 9a and R 9b are each independently H, halogen, or methyl optionally substituted with one or more halogen.
  • Embodiment 18 The compound of Embodiment 17, wherein R 4 is H, fluoro, or methyl; and R 9a and R 9b are each independently H, fluoro, chloro, or methyl optionally substituted with one or more fluoro.
  • Embodiment 19 The compound of Embodiment 4, wherein R 20 is H, halogen, a C 1-4 alkyl or a C 1-4 alkoxy, wherein the C 1-4 alkyl and the C 1-4 alkoxy are each optionally substituted with one or more halogen;
  • X 5 is CR 25a R 25b or NR 25c
  • R 25a and R 25b are each independently H or a C 1-4 alkyl optionally substituted with one or more halogen or alkoxy; or R 25a and R 25b together form a C 3-6 cycloalkyl ring or a 4- to 6-member heterocyclyl ring, each optionally substituted with halogen, C1-4 alkyl, a spirocyclic C3-6 cycloalkyl, or a spirocyclic 4- to 6-member heterocyclyl ring, wherein the C 1-4 alkyl, the spirocyclic C 3-6 cycloalkyl or the spirocyclic 4-
  • R 27a and R 27b are each independently H or a C 1-4 alkyl optionally substituted with one or more halogen or alkoxy; R 27a and R 27b together form a C 3-6 cycloalkyl ring or a 4- to 6-member heterocyclyl ring, wherein the C 3-6 cycloalkyl ring or the 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen, one or more C 1-4 alkyl, a spirocyclic C 3-6 cycloalkyl or a spirocyclic 4 to 6 member heterocyclyl ring, wherein the C 1-4 alkyl, the spirocyclic C 3-6 cycloalkyl, or the spirocyclic 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen or C 1-4 alkyl; and R 27c is H, a C 1-4 alkyl, a C 3-6 cycloalkyl
  • Embodiment 20 The compound of Embodiment 19, wherein R 20 is H, halogen, a C 1-4 alkyl, or a C 1-4 alkoxy, wherein the C 1-4 alkyl and the C 1-4 alkoxy is optionally substituted with one or more halogen;
  • X 5 is CR 25a R 25b R 25a and R 25b are each independently methyl; or R 25a and R 25b together form a cyclopropyl;
  • R 26a and R 26b are each independently H or a C 1-4 alkyl optionally substituted with one or more halogen or C 1-4 alkyl;
  • X 7 is NR 27c ; and R 27c is a C 1-4 alkyl, a C 3-6 cycloalkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, a 5-6 member heteroaryl, or a
  • MORF-016WO1 optionally substituted with one or more halogen or C 1-4 alkyl optionally substituted with one or more halogen;
  • Embodiment 21 The compound of Embodiment 20, wherein R 27c is a C 1-4 alkyl.
  • Embodiment 22 The compound of Embodiment 20, wherein R 27c is a 5-member heteroaryl.
  • Embodiment 23 The compound of Embodiment 20, wherein R 27c is a C 3-6 cycloalkyl optionally substituted with one or more halogen or a C 1-4 alkyl optionally substituted with one or more halogen.
  • Embodiment 24 The compound of Embodiment 20, wherein R 27c is a C 1-4 alkyl, a 4- to 7- member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, wherein the C 1-4 alkyl, the 4- to 7-member heterocycloalkyl, and the 5- to 11-member spirocyclic heterocycloalkyl is optionally substituted with one or more halogen or C 1-4 alkyl optionally substituted with one or more halogen.
  • Embodiment 25 The compound of Embodiment 24, wherein wherein R 20 is H, fluoro, methyl, ethyl, methoxy, -CH 2 -O-CH 3 , or -CF 3 .
  • Embodiment 26 The compound of Embodiment 25, wherein R 27c is a tetrahydropyan optionally substituted by one or more methyl or fluoro.
  • Embodiment 27 The compound of Embodiment 25, wherein , wherein R 32a , R 32b , R 33a and R 33 b are each independently H, methyl, or fluoro; or Attorney Docket No.
  • MORF-016WO1 one of R 32a and R 32b or R 33a and R 33b together form a spirocyclic C 3-6 cycloalkyl or a spirocyclic 3- to 6-member heterocyclic ring.
  • Embodiment 28 The compound of Embodiment 25, wherein R 27c is .
  • Embodiment 29 The compound of Embodiment 19, wherein R 30a , R 30b , R 31a , and R 31b are each independently H, fluoro, or methyl; R 20 is H, fluoro, methyl, ethyl, methoxy, -CH 2 -O-CH 3 , or -CF 3 ; and R 27c is methyl.
  • Embodiment 30 The compound of Embodiment 25, wherein R 27c is a C 1-4 alkyl.
  • Embodiment 31 The compound of Embodiment 19, wherein Embodiment 32: The compound of Embodiment 4, wherein Attorney Docket No. MORF-016WO1 wherein R 20 is H, halogen, a C 1-4 alkoxy optionally substituted with C 1-4 alkoxy, a C 1-4 alkyl optionally substituted with a 4- to 6-member heterocyclyl or one or more halogen.
  • Embodiment 33 The compound of Embodiment 32, wherein R 25c is a C 1-4 alkyl; and R 27c is a C 1-4 alkyl optionally substituted with one or more halogen or C 1-4 alkoxy, a C 3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C 3-6 cycloalkyl or the 4- to 6-member heterocycloalkyl is optionally substituted with a C1-4 alkyl optionally substituted with one or more halogen.
  • Embodiment 34 The compound of Embodiment 32, wherein R 27c is a C 1-4 alkyl; and R 25c is a C 1-4 alkyl optionally substituted with one or more halogen or C 1-4 alkoxy, a C 3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C 3-6 cycloalkyl or the 4- to 6-member heterocycloalkyl is optionally substituted with a C 1-4 alkyl optionally substituted with one or more halogen.
  • Embodiment 35 The compound of any one of Embodiments 32-34, wherein R 20 is H or methyl.
  • Embodiment 36 The compound of Embodiment 19, wherein Attorney Docket No.
  • MORF-016WO1 R 20 is H, halogen, a C 1-4 alkoxy optionally substituted with C 1-4 alkoxy, C 1-4 alkyl optionally substituted with a 4- to 6-member heterocyclyl or one or more halogen; R 25c is a C 1-4 alkyl; and R 27c is a 4- to 6-member heterocyclyl or a C 3-6 cycloalkyl, wherein the 4- to 6- member heterocyclyl or the C 3-6 cycloalkyl is optionally substituted with C 1-4 alkyl.
  • Embodiment 37 A compound of the chemical formula pharmaceutically acceptable salt thereof.
  • Embodiment 38 A compound of the chemical formula pharmaceutically acceptable salt thereof.
  • Embodiment 39 A compound of the chemical formula pharmaceutically acceptable salt thereof.
  • Embodiment 40 A compound of the chemical formula pharmaceutically acceptable salt thereof.
  • Embodiment 41 A compound selected from the group consisting of the compounds in Figure 1, or a pharmaceutically acceptable salt thereof.
  • Equivalents and Scope [000538] The invention is not to be limited in scope by the specific embodiments disclosed in the examples that are intended as illustrations of a few aspects of the invention and any embodiments that are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims. A number of references have been cited, the entire disclosures of which are incorporated herein by reference for all purposes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are compounds of Formula (I) which may be used in the methods of treating or preventing a disease or condition responsive to inhibition of human α5β1 integrin by administering to a patient in need thereof a compound of Formula (I). Many diseases and conditions can be treated by administration of the compound of Formula (I).

Description

Attorney Docket No. MORF-016WO1 INHIBITING HUMAN INTEGRIN α5β1 CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to, and the benefit of, U.S. provisional application No.63/687,186, filed August 26, 2024, and U.S. provisional application No.63/584,383, filed September 21, 2023, the contents of each of which are hereby incorporated by reference in their entireties. FIELD OF THE INVENTION [0002] This application discloses methods of treating diseases and conditions by inhibiting α5β1 integrin. Diseases and conditions responsive to α5β1 integrin inhibition include, for example, hypertension such as pulmonary arterial hypertension (PAH). BACKGROUND [0003] Fibronectin (Fn) is an extracellular matrix protein that orchestrates complex cell adhesion and signaling through cell surface integrin receptors (Fibronectin-binding integrins (e.g., a5b1)) during tissue development, remodeling, and disease, such as hypertension and heart failure. Heart failure (HF) is a debilitating disease in which abnormal function of the heart leads to inadequately low perfusion of tissues and organs of the body. Hypertension is a responsible for various deleterious effects and with high morbidity and mortality including heart failure. One form of hypertension is pulmonary arterial hypertension (PAH). PAH is a rare but devastating disease, in which the normally low pulmonary arterial pressure becomes elevated due to vasoconstriction and remodeling of pulmonary vessels. Vasoconstriction and vascular remodeling increases workload on the right side of the heart, causing right heart hypertrophy, fibrosis and ultimately heart failure. [0004] Integrins are a family of glycoprotein transmembrane receptors that mediate cell- cell and cell-matrix interactions. Integrins are heterodimers having two different chains, the alpha and beta subunits. In mammals, eighteen alpha and eight beta subunits have been described. The integrin superfamily of cell surface receptors is formed from a number of structurally and functionally related surface glycoproteins, with each receptor existing as a heterodimer of non-covalently linked α and β subunits. At least 18 different α and 8 β subunits have been identified in mammals, which are known to form more than 24 different receptors. Each integrin interacts specifically with defined extracellular ligands, including extracellular Attorney Docket No. MORF-016WO1 matrix proteins such as, fibronectin, vitronectin, collagen and cell surface molecules such as VCAM, ICAM and PECAM, via linear adhesion motifs. [0005] Integrin α5ß1 is composed of subunits ITGA5 (integrin α5) and integrin β1. Several integrins bind to fibronectin. Integrin α5β1 is selective for fibronectin since it requires both the 9 th and 10 th type II repeats of fibronectin (FNIII-9 and FNIII-10) for interaction. Expression of α5β1 integrin is mainly in the vasculature and connective tissue. Expression is significantly enhanced in tumor blood vessels, but also in tumor cells itself of many types of cancer, including colon, breast, ovarian, lung and brain tumors. It is further expressed to varying degrees in many cell types including fibroblasts, hematopoietic cell, immune cells, smooth muscle cells, and epithelial cells. High expression of α5β1 integrin has also been observed fibrotic tissue such as pulmonary fibrosis. [0006] The integrin α5βl (a5b1or alpha5 beta1) is composed of an α5 (a5 or alpha5) and βl (b1or beta1) subunit. The a5 subunit forms a specific dimer with the beta1 subunit, and is widely expressed in most tissues. Integrin a5b1 almost exclusively mediates cell adhesion through an interaction with fibronectin, binding via the short arginine-glycine-aspartate (RGD) adhesion motif. Endothelial cells and platelets can however bind to fibrin via a5bl. The a5b1interaction with fibronectin plays an important role in physiopathological angiogenesis and vascular integrity. Although endothelial cells express a variety of integrins, a5b1 is important for survival of endothelial cells on provisional matrix in vitro, suppressing apoptosis and promoting proliferation. a5b1expression is upregulated in tumor vasculature and pulmonary hypertension patients. Consistent with a key functional role for the receptor- ligand pairing, the a5b1 ligand fibronectin is also upregulated in tumor tissue and during wound- healing. [0007] Current treatments include vasodilators targeting Ca channels or endothelin receptors. There is a need for new approaches in the treatment of pulmonary hypertension, PAH, heart failure and related diseases. Due to the limitations of current treatments for pulmonary hypertension, there remains a significant interest in and need for additional or alternative therapies for treating, stabilizing, preventing, and/or delaying pulmonary hypertension. Various processes have been developed in order to obtain more efficient and/or less toxic drugs for the treatment of pulmonary hypertension. However, these processes still present serious side effects, and the resulting drugs often exhibit short half-life and low bioavailability. Attorney Docket No. MORF-016WO1 [0008] There remains a medical need for an effective and safe oral α5β1 integrin inhibitor as an important addition to the therapeutic armamentarium for α5β1 integrin-mediated conditions. In particular, there remains an unmet need for a small molecule designed to inhibit integrin α 5 β 1 including a need for such a small molecule for administration orally, avoiding the need for periodic therapeutic infusions and the complications associated with this form of drug administration. SUMMARY [0009] The present invention provides, among other things, methods, and compositions for treating a disease associated with increased expression or activity of integrin α5β1. Many normal physiological and disease processes require cells to contact other cells and/or extracellular matrix. Cell-matrix and cell-cell adhesion is mediated through several families of proteins including integrins, selectins, cadherins, and immunoglobulins, and facilitates a variety of normal cellular functions such as proliferation, migration, differentiation, or survival. Cell adhesion is also key to a range of pathologies, and so pharmacological disruption of cell adhesion interactions can provide a mechanism for therapeutic intervention. Members of the integrin superfamily adhesion molecules play an important role in acute and chronic disease states such as cancer, inflammatory diseases, stroke, and neurodegenerative disorders. Thus, integrins represent a complex biological area. [00010] In one aspect, the invention features a compound of Formula (I), or a pharmaceutically acceptable salt thereof:
Figure imgf000005_0001
(I), wherein:
Figure imgf000005_0002
a 6- to 12-member aryl ring structure (e.g., a phenyl) or a 3- to 19-member heterocyclyl ring structure (e.g., a 3- to 15-member heterocyclyl ring structure such as a Attorney Docket No. MORF-016WO1 6-member heteroaryl), wherein
Figure imgf000006_0001
is optionally substituted with halogen, C1-6 alkyl, C1- 6alkyloxy, a 3-8 member heterocyclyl ring structure, an aryl, or a 5- to 6-member heteroaryl, wherein the C1-6 alkyl, the C1-6alkyloxy, the 3-8 member heterocyclyl ring structure, the aryl, or the 5- to 6-member heteroaryl are optionally substituted with one or more halogen, C1- 4alkyloxy, or C1-6 alkyl optionally substituted with one or more halogen; a is 1, 2, 3, 4, 5, 6, 7 or 8; and Ra is C1-6 alkyl. [00011] In some embodiments, the invention features a compound of Formula (I), or a pharmaceutically acceptable salt thereof:
Figure imgf000006_0002
wherein:
Figure imgf000006_0004
a 6- to 12-member aryl ring structure (e.g., a phenyl), wherein
Figure imgf000006_0003
is optionally substituted with halogen, C1-6 alkyl, C1-6alkyloxy, a 3-8 member heterocyclyl ring structure, an aryl, or a 5- to 6-member heteroaryl, wherein the C1-6 alkyl, the C1-6alkyloxy, the 3-8 member heterocyclyl ring structure, the aryl, or the 5- to 6-member heteroaryl are optionally substituted with one or more halogen, C1-4alkyloxy, or C1-6 alkyl optionally substituted with one or more halogen; a is 1, 2, 3, 4, 5, 6, 7 or 8; and Ra is C1-6 alkyl. [00012] In some embodiments, the invention features a compound of Formula (I), or a pharmaceutically acceptable salt thereof: Attorney Docket No. MORF-016WO1
Figure imgf000007_0001
wherein:
Figure imgf000007_0002
a 3- to 19-member heterocyclyl ring structure (e.g., a 3- to 15-member heterocyclyl ring structure such as a 6-member heteroaryl), wherein
Figure imgf000007_0003
is optionally substituted with halogen, C1-6 alkyl, C1-6alkyloxy, a 3-8 member heterocyclyl ring structure, an aryl, or a 5- to 6-member heteroaryl, wherein the C1-6 alkyl, the C1-6alkyloxy, the 3-8 member heterocyclyl ring structure, the aryl, or the 5- to 6-member heteroaryl are optionally substituted with one or more halogen, C1-4alkyloxy, or C1-6 alkyl optionally substituted with one or more halogen; a is 1, 2, 3, 4, 5, 6, 7 or 8; and Ra is C1-6 alkyl. [00013] In some embodiments, the compound of Formula (I) is a compound of Formula (IA), or a pharmaceutically acceptable salt thereof:
Figure imgf000007_0004
[00014] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000007_0005
phenyl or a 6- member heteroaryl. Attorney Docket No. MORF-016WO1 [00015] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000008_0001
wherein R1 is C1-4 alkoxy; and R2 is C1-4 alkyl optionally substituted with one or more halogen; or
Figure imgf000008_0002
a 9- to 19-member heterocyclyl when R1 and R2 are taken together to form a fused 5- to 8-member heterocycloalkyl ring, a fused 5- to 6-member heteroaryl ring, a fused 7- to 15-member spirocyclic heterocycloalkyl ring system, wherein the fused ring is optionally substituted with halogen, C1-4 alkyl, C3-6 cycloalkyl, or a 4- to 8-member heterocycloalkyl ring, wherein the C1-4 alkyl, the C3-6 cycloalkyl, or the 4- to 8-member heterocycloalkyl ring is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen; and R3 is C1-4 alkyl optionally substituted with one or more halogen. In some embodiments, R1 is methoxy; R2 is fluoro; and R3 is C1-4 alkyl optionally substituted with one or more fluoro. [00016] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000008_0003
Figure imgf000008_0004
, wherein R4 and R14 are each independently H, halogen or C1-4 alkyl optionally substituted with one or more halogen; X1 is CR5aR5b or NR5c Attorney Docket No. MORF-016WO1 R5a is H or a C1-4 alkyl optionally substituted with one or more halogen, and R5b is a C1-4 alkyl or a C3-6 cycloalkyl, wherein the C1-4 alkyl or the C3-6 cycloalkyl is optionally substituted with one or more halogen; or R5a and R5b together form a spirocyclic 3- to 8-member heterocycloalkyl or a spirocyclic C3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl optionally substituted with one or more halogen, a 4- to 6-member spirocyclic heterocycloalkyl or a C3-6 spirocyclic cycloalkyl optionally substituted with C1-4 alkyl optionally substituted with one or more halogen; R5c is a C1-4 alkyl or a C3-6 cycloalkyl, wherein the C1-4 alkyl or the C3-6 cycloalkyl is optionally substituted with one or more halogen; X2 is CR6aR6b, -CH2CR6aR6b, C=O, O or NR6c; R6a and R6b are each independently H, a C1-4 alkyl, a 5- to 6-member heteroaryl, a 6-member aryl, a C3-7 cycloalky, or a 4- to 7-member heterocycloalkyl, wherein the C1-4 alkyl, the 5- to 6-member heteroaryl, the 6-member aryl, the C3-8 cycloalky, or the 4- to 7- member heterocycloalkyl is each optionally substituted with one or more halogen or C1-4 alkyl; R6c is C1-4 alkyl optionally substituted with one or more halogen X3 is a direct bond, CR7aR7b, O or NR7c; R7a and R7b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen; R7c is a C1-4 alkyl optionally substituted with one or more halogen; X4 is CR8aR8b or NR8c R8a is H and R8b is halogen or a C1-4 alkyl optionally substituted with one or more halogen; R8a and R8b together form a spirocyclic 3- to 8-member heterocycloalkyl or a C3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl optionally substituted with one or more halogen, a 4- to 8- member spirocyclic heterocycloalkyl or a C3-7 spirocyclic cycloalkyl optionally substituted with C1-4 alkyl optionally substituted with one or more halogen; and Attorney Docket No. MORF-016WO1 R8c is H, C1-4 alkyl, a 4- to 8-member heterocycloalkyl, or a C3-6 cycloalkyl, wherein the C1-4 alkyl, the 4- to 8-member heterocycloalkyl, or the C3-6 cycloalkyl is optionally substituted with one or more halogen; provided that no two of both X2 and X3 .comprise O or N heteroatoms and no two of X3 and X4. comprise O or N heteroatoms. [00017] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000010_0001
Figure imgf000010_0002
, R4 and R14 are each independently H, halogen or C1-4 alkyl optionally substituted with one or more halogen; X1 is CR5aR5b or NR5c R5a is H or a C1-4 alkyl optionally substituted with one or more halogen, and R5b is a C1-4 alkyl or a C3-6 cycloalkyl, wherein the C1-4 alkyl or the C3-6 cycloalkyl is optionally substituted with one or more halogen; or R5a and R5b together form a spirocyclic 3- to 8-member heterocycloalkyl or a spirocyclic C3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl optionally substituted with one or more halogen, a 4- to 6-member spirocyclic heterocycloalkyl or a C3-6 spirocyclic cycloalkyl optionally substituted with C1-4 alkyl optionally substituted with one or more halogen; R5c is a C1-4 alkyl or a C3-6 cycloalkyl, wherein the C1-4 alkyl or the C3-6 cycloalkyl is optionally substituted with one or more halogen; X2 is CR6aR6b, -CH2CR6aR6b, C=O, O or NR6c; R6a and R6b are each independently H, a C1-4 alkyl, a 5- to 6-member heteroaryl, a 6-member aryl, a C3-7 cycloalky, or a 4- to 7-member heterocycloalkyl, wherein the C1-4 alkyl, the 5- to 6-member heteroaryl, the 6-member aryl, the C3-8 cycloalky, or the 4- to 7- Attorney Docket No. MORF-016WO1 member heterocycloalkyl is each optionally substituted with one or more halogen or C1-4 alkyl; R6c is C1-4 alkyl optionally substituted with one or more halogen X3 is a direct bond, CR7aR7b, O or NR7c; R7a and R7b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen; R7c is a C1-4 alkyl optionally substituted with one or more halogen; X4 is CR8aR8b or NR8c R8a is H and R8b is halogen or a C1-4 alkyl optionally substituted with one or more halogen; R8a and R8b together form a spirocyclic 3- to 8-member heterocycloalkyl or a C3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl optionally substituted with one or more halogen, a 4- to 8- member spirocyclic heterocycloalkyl or a C3-7 spirocyclic cycloalkyl optionally substituted with C1-4 alkyl optionally substituted with one or more halogen; and R8c is H, C1-4 alkyl, a 4- to 8-member heterocycloalkyl, or a C3-6 cycloalkyl, wherein the C1-4 alkyl, the 4- to 8-member heterocycloalkyl, or the C3-6 cycloalkyl is optionally substituted with one or more halogen; provided that no two of both X2 and X3 .comprise O or N heteroatoms and no two of X3 and X4. comprise O or N heteroatoms. [00018] In some embodiments, R1 is methoxy; R2 is fluoro; and R3 is C1-4 alkyl optionally substituted with one or more fluoro. In some embodiments, R14 is H; and X1 is CR5aR5b and R5a is H, and R5b is methyl or cyclopropyl. In some embodiments, R4 is H, fluoro, or methyl; X1 is CR5aR5b and R5a is H, and R5b is methyl; X2 is O and X3 is CR7aR7b and R7a and R7b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen; or X3 is O and X2 is CR6aR7b and R6a and R6b are each independently H; and X4 is CR8aR8b and R8a and R8b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen, or R8a and R8b together form a 4- to 7-member heterocycloalkyl ring or a C3-7 cycloalkyl ring, wherein the 4- to 7-member heterocycloalkyl or the C3-7 cycloalkyl is optionally substituted with halogen, C1-4 alkyl optionally substituted with one or more halogen, a 4- to 7-member Attorney Docket No. MORF-016WO1 spirocyclic heterocycloalkyl, or a C3-7 spirocyclic cycloalkyl, optionally substituted with C1-4 alkyl optionally substituted with one or more halogen. [00019] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000012_0001
Figure imgf000012_0002
wherein R10a and R10b are each independently H, halogen, or a C1-4 alkyl optionally substituted with one or more halogen; or R10a and R10b together form a spirocyclic C3-6 cycloalkyl or a spirocyclic 6-member heterocycloalkyl; R11a and R11b are each independently H, halogen or a C1-4 alkyl optionally substituted with one or more halogen; R12a and R12b are each independently H, halogen or a C1-4 alkyl optionally substituted with one or more halogen; R13a is methy, ethyl, or cyclopropyl; R13b is H; and R14 is H, halogen, or a C1-4 alkyl optionally substituted with one or more halogen. [00020] In some embodiments, R10a and R10b are each independently H or methyl; R11a and R11b are each independently H, methyl, or ethyl; R12a and R12b are each independently H or methyl; R13a is methyl, ethyl, or cyclopropyl; R13b is H; and R14 is H, fluoro, or methyl. In some embodiments, R4 is H or fluoro; R13a is methyl, ethyl, or cyclopropyl; and R14 is H. In some embodiments, X2 is NR6c and R6c is C1-4 alkyl. Attorney Docket No. MORF-016WO1 [00021] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000013_0001
Figure imgf000013_0002
, wherein R13a is H or methyl, and R4 is H, F, or methyl. [00022] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000013_0003
Figure imgf000013_0004
In some embodiments, wherein R10a, R10b, and R11a are each H or methyl. In some embodiments, wherein R11b is H, methyl, or ethyl. [00023] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000013_0005
Figure imgf000013_0006
, wherein R4 is H, halogen, or methyl optionally substituted with one or more halogen; and R9a and R9b are each independently H, halogen, or methyl optionally substituted with one or more halogen. In some embodiments, R4 is H, fluoro, or methyl; and R9a and R9b are each independently H, fluoro, chloro, or methyl optionally substituted with one or more fluoro. Attorney Docket No. MORF-016WO1 [00024] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000014_0001
Figure imgf000014_0002
wherein R20 is H, halogen, a C1-4 alkyl or a C1-4 alkoxy, wherein the C1-4 alkyl and the C1-4 alkoxy are each optionally substituted with one or more halogen; X5 is CR25aR25b or NR25c; R25a and R25b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or alkoxy; or R25a and R25b together form a C3-6 cycloalkyl ring or a 4- to 6-member heterocyclyl ring, each optionally substituted with halogen, C1-4 alkyl, a spirocyclic C3-6 cycloalkyl, or a spirocyclic 4- to 6-member heterocyclyl ring, wherein the C1-4 alkyl, the spirocyclic C3-6 cycloalkyl or the spirocyclic 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen or C1-4 alkyl; R25c is C1-4 alkyl, a 5-6 member heteroaryl, or a C6 aryl, wherein the C1-4 alkyl, the 5-6 member heteroaryl, or the C6 aryl is optionally substituted with one or more halogen or C1-4 alkoxy; X6 is CR26aR26b or C=O; R26a and R26b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkyl; X7 is CR27aR27b or NR27c; R27a and R27b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or alkoxy; or R27a and R27b together form a C3-6 cycloalkyl ring or a 4- to 6-member heterocyclyl ring, wherein the C3-6 cycloalkyl ring or the 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen, one or more C1-4 alkyl, a spirocyclic C3-6 cycloalkyl or a spirocyclic 4 to 6 member heterocyclyl ring, wherein the C1-4 Attorney Docket No. MORF-016WO1 alkyl, the spirocyclic C3-6 cycloalkyl, or the spirocyclic 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen or C1-4 alkyl; and R27c is H, a C1-4 alkyl, a C3-6 cycloalkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, a 5-6 member heteroaryl, or a C6 aryl, wherein the C1-4 alkyl, the C3-6 cycloalkyl, the 4- to 6-member heterocycloalkyl, the 5- to 11-member spirocyclic heterocycloalkyl, the 5-6 member heteroaryl, or the C6 aryl is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen; provided that only one of X5 and X7 comprise a N heteroatom. [00025] In some embodiments, R20 is H, halogen, a C1-4 alkyl, or a C1-4 alkoxy, wherein the C1-4 alkyl and the C1-4 alkoxy is optionally substituted with one or more halogen; X5 is CR25aR25b; R25a and R25b are each independently methyl; or R25a and R25b together form a cyclopropyl; X6 is C=O; R26a and R26b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkyl; X7 is NR27c; and R27c is a C1-4 alkyl, a C3-6 cycloalkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, a 5-6 member heteroaryl, or a C6 aryl, wherein the C1-4 alkyl, the C3-6 cycloalkyl, the 4- to 6-member heterocycloalkyl, the 5- to 11-member spirocyclic heterocycloalkyl, the 5-6 member heteroaryl, or the C6 aryl is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen. In some embodiments, R27c is a C1-4 alkyl. In some embodiments, R27c is a 5-member heteroaryl. In some embodiments, R27c is a C3-6 cycloalkyl optionally substituted with one or more halogen or a C1-4 alkyl optionally substituted with one or more halogen. In some embodiments, R27c is a C1-4 alkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, wherein the C1-4 alkyl, the 4- to 7-member heterocycloalkyl, and the 5- to 11- member spirocyclic heterocycloalkyl is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen. [00026] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000015_0001
Attorney Docket No. MORF-016WO1
Figure imgf000016_0001
wherein R20 is H, fluoro, methyl, ethyl, methoxy, -CH2-O-CH3, or -CF3. In some embodiments, R27c is a tetrahydropyan optionally substituted by one or more methyl or fluoro. In some embodiments,
Figure imgf000016_0002
wherein R32a, R32b, R33a and R33b are each independently H, methyl, or fluoro; or one of R32a and R32b or R33a and R33b together form a spirocyclic C3-6 cycloalkyl or a spirocyclic 3- to 6-member heterocyclic ring. In some embodiments, R27c is
Figure imgf000016_0003
[00027] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000016_0004
Figure imgf000016_0005
wherein R30a, R30b, R31a, and R31b are each independently H, fluoro, or methyl; Attorney Docket No. MORF-016WO1 R20 is H, fluoro, methyl, ethyl, methoxy, -CH2-O-CH3, or -CF3; and R27c is methyl. In some embodiments, the compound is a compound of Formula (I),wherein R27c is a C1-4 alkyl. [00028] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000017_0001
Figure imgf000017_0002
. [00029] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000017_0003
Figure imgf000017_0004
, wherein R20 is H, halogen, a C1-4 alkoxy optionally substituted with C1-4 alkoxy, a C1-4 alkyl optionally substituted with a 4- to 6-member heterocyclyl or one or more halogen. In some embodiments, R25c is a C1-4 alkyl; and R27c is a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkoxy, a C3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C3-6 cycloalkyl or the 4- to 6-member heterocycloalkyl is optionally substituted with a C1-4 alkyl optionally substituted with one or more halogen. In some embodiments, R27c is a C1-4 alkyl; and R25c is a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkoxy, a C3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C3-6 cycloalkyl or the 4- to 6-member heterocycloalkyl is optionally substituted with a C1-4 alkyl optionally substituted with one or more halogen. In some embodiments, R20 is H or methyl. Attorney Docket No. MORF-016WO1 [00030] In some embodiments, the compound of Formula (I), such as a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000018_0001
Figure imgf000018_0002
; wherein R20 is H, halogen, a C1-4 alkoxy optionally substituted with C1-4 alkoxy, C1-4 alkyl optionally substituted with a 4- to 6-member heterocyclyl or one or more halogen; R25c is a C1-4 alkyl; and R27c is a 4- to 6-member heterocyclyl or a C3-6 cycloalkyl, wherein the 4- to 6-member heterocyclyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl. [00031] In some embodiments, the compound of Formula (I), is a compound selected from the group consisting of:
Figure imgf000018_0003
Attorney Docket No. MORF-016WO1
Figure imgf000019_0001
or a pharmaceutically acceptable salt thereof. BRIEF DESCRIPTION OF THE FIGURES [00032] Figure 1 is a table of compounds disclosed herein. DETAILED DESCRIPTION [00033] Compounds of Formula (I) are small‑molecule integrin therapeutics targeting α5β1 that can be administered to treat patients with diseases and conditions that are responsive to α5β1 integrin inhibition. [00034] The present invention provides methods and compositions for treating a disease associated with increased expression or activity of integrin α5β1, comprising administering an integrin α5β1 inhibitor. In some embodiments, the disease is characterized by the World Health Attorney Docket No. MORF-016WO1 Organization (WHO) group. In some embodiments, the disease is pulmonary hypertension, WHO Group 1 pulmonary hypertension or pulmonary arterial hypertension (PAH), WHO Group 2 pulmonary hypertension, WHO Group 3 pulmonary hypertension, WHO Group 4 pulmonary hypertension, and WHO Group 5 pulmonary hypertension. In some embodiments, the disease is characterized by the World Health Organization (WHO) class system. In some embodiments, the disease is characterized by WHO functional class based on cardiac function. In some embodiments, the disease is pulmonary hypertension, WHO Class I pulmonary hypertension or pulmonary arterial hypertension (PAH), WHO Class II pulmonary hypertension, WHO Class III pulmonary hypertension, WHO Class IV pulmonary hypertension. In some embodiments, the disease associated with increased expression or activity of integrin α5β1 is heart failure or right ventricle failure. [00035] The inhibition of integrin α5β1 by blocking the activity of α5β1 or inhibition of α5β1 fibronectin binding is effective in preventing and treating pulmonary hypertension, PAH, heart failure and right ventricle failure. The present invention provides a variety of compounds (e.g., small molecule compounds and antibodies) that inhibit that interaction. The compounds are referred to generically herein as “integrin a5b1 inhibitors”. Exemplary Compounds of the Invention [00036] This disclosure relates to novel chemical compounds and methods useful for inhibiting α5β1 integrin. [00037] Exemplary formulas and compounds are described herein. Also provided herein are exemplary embodiments of structural features which may be present in any formula described herein. Any exemplary embodiment of a structural feature may occur in combination with any other exemplary structural feature described herein. Further, and unless otherwise indicated herein, any description of a formula or compound also includes any pharmaceutically acceptable forms of the compound, including but not limited to any pharmaceutically acceptable salts, hydrates, solvates, isomers, polymorphs, prodrugs, and isotopically labeled derivatives of disclosed formulas and compounds. Compounds of Formula (I) [00038] In some embodiments, the integrin α5β1 inhibitor is a small molecule compound that binds integrin α5β1. In some embodiments, the integrin α5β1 inhibitor is a small molecule compound that specifically binds integrin α5. In some embodiments, the integrin α5β1 inhibitor is a small molecule compound that specifically binds integrin β1. In some Attorney Docket No. MORF-016WO1 embodiments, the integrin α5β1 inhibitor is a small molecule compound that specifically binds integrin α5β1. In some embodiments, the integrin α5β1 inhibitor is a compound of Formula (I) or a pharmaceutically acceptable salt thereof. [00039] In one aspect, the invention features a compound of Formula (I), or a pharmaceutically acceptable salt thereof:
Figure imgf000021_0001
wherein:
Figure imgf000021_0002
a 6- to 12-member aryl ring structure (e.g., phenyl) or a 3- to 19-member heterocyclyl ring structure (e.g., a 3- to 15-member heterocyclyl ring structure such as a 6-member heteroaryl), wherein
Figure imgf000021_0003
is optionally substituted with halogen, C1-6 alkyl, C1- 6alkyloxy, a 3-8 member heterocyclyl ring structure, an aryl, or a 5- to 6-member heteroaryl, wherein the C1-6 alkyl, the C1-6alkyloxy, the 3-8 member heterocyclyl ring structure, the aryl, or the 5- to 6-member heteroaryl are optionally substituted with one or more halogen, C1- 4alkyloxy, or C1-6 alkyl optionally substituted with one or more halogen; a is 1, 2, 3, 4, 5, 6, 7 or 8; and Ra is C1-6 alkyl. [00040] In some embodiments, the invention features a compound of Formula (I), or a pharmaceutically acceptable salt thereof: Attorney Docket No. MORF-016WO1
Figure imgf000022_0001
wherein:
Figure imgf000022_0003
a 6- to 12-member aryl ring structure (e.g., a phenyl), wherein
Figure imgf000022_0002
is optionally substituted with halogen, C1-6 alkyl, C1-6alkyloxy, a 3-8 member heterocyclyl ring structure, an aryl, or a 5- to 6-member heteroaryl, wherein the C1-6 alkyl, the C1-6alkyloxy, the 3-8 member heterocyclyl ring structure, the aryl, or the 5- to 6-member heteroaryl are optionally substituted with one or more halogen, C1-4alkyloxy, or C1-6 alkyl optionally substituted with one or more halogen; a is 1, 2, 3, 4, 5, 6, 7 or 8; and Ra is C1-6 alkyl. [00041] In some embodiments, the invention features a compound of Formula (I), or a pharmaceutically acceptable salt thereof:
Figure imgf000022_0004
(I), wherein:
Figure imgf000022_0005
a 3- to 19-member heterocyclyl ring structure (e.g., a 3- to 15-member heterocyclyl ring structure such as a 6-member heteroaryl), wherein
Figure imgf000022_0006
is optionally substituted with halogen, C1-6 alkyl, C1-6alkyloxy, a 3-8 member heterocyclyl ring structure, an Attorney Docket No. MORF-016WO1 aryl, or a 5- to 6-member heteroaryl, wherein the C1-6 alkyl, the C1-6alkyloxy, the 3-8 member heterocyclyl ring structure, the aryl, or the 5- to 6-member heteroaryl are optionally substituted with one or more halogen, C1-4alkyloxy, or C1-6 alkyl optionally substituted with one or more halogen; a is 1, 2, 3, 4, 5, 6, 7 or 8; and Ra is C1-6 alkyl. [00042] In some embodiments,
Figure imgf000023_0001
is a 3- to 15-member heterocycle ring structure. [00043] In some embodiments, the compound is a compound of Formula (I-A), or a pharmaceutically acceptable salt thereof.
Figure imgf000023_0002
[00044] In some embodiments, the compound is a compound of Formula (I), wherein
Figure imgf000023_0003
phenyl or a 6-member heteroaryl. [00045] In some embodiments, the compound is a compound of Formula (I),
Figure imgf000023_0004
is
Figure imgf000023_0005
, wherein R1 is a C1-4 alkoxy; and R2 is a C1-4 alkyl optionally substituted with one or more halogen; or
Figure imgf000023_0006
is a 9- to 19-member heterocyclyl when R1 and R2 are taken together to form a fused 5- to 8-member heterocycloalkyl ring, a fused 5- to 6-member heteroaryl ring, Attorney Docket No. MORF-016WO1 or a fused 7- to 15-member spirocyclic heterocycloalkyl ring system, wherein the fused ring is optionally substituted with halogen, C1-4 alkyl, C3-6 cycloalkyl, or a 4- to 8-member heterocycloalkyl ring, wherein the C1-4 alkyl, the C3-6 cycloalkyl, or the 4- to 8-member heterocycloalkyl ring is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen; R3 is C1-4 alkyl optionally substituted with one or more halogen. [00046] In some embodiments, the compound is a compound of Formula (I), wherein R1 is methoxy; R2 is fluoro; and R3 is C1-4 alkyl optionally substituted with one or more fluoro. [00047] In some embodiments, the compound is a compound of Formula (I), wherein
Figure imgf000024_0001
, wherein R4 and R14 are each independently H, halogen or C1-4 alkyl optionally substituted with one or more halogen; X1 is CR5aR5b or NR5c; R5a is H or C1-4 alkyl optionally substituted with one or more halogen, and R5b is C1-4 alkyl or C3-6 cycloalkyl, wherein the C1-4 alkyl or C3-6 cycloalkyl is optionally substituted with one or more halogen; or R5a and R5b together form a spirocyclic 3- to 8-member heterocycloalkyl or a spirocyclic C3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl optionally substituted with one or more halogen, a 4- to 6-member spirocyclic heterocycloalkyl, or a C3-6 spirocyclic cycloalkyl optionally substituted with C1-4 alkyl optionally substituted with one or more halogen; R5c is C1-4 alkyl or C3-6 cycloalkyl, wherein the C1-4 alkyl or C3-6 cycloalkyl is optionally substituted with one or more halogen; X2 is CR6aR6b, -CH2CR6aR6b, C=O, O or NR6c; R6a and R6b are each independently H, C1-4 alkyl, a 5- to 6-member heteroaryl, a 6-member aryl, a C3-7 cycloalky, or a 4- to 7-member heterocycloalkyl, wherein the C1-4 alkyl, the 5- to 6-member heteroaryl, the 6-member aryl, the C3-8 cycloalky, or the 4- to 7-member heterocycloalkyl is each optionally substituted with one or more halogen or C1-4 alkyl; R6c is C1-4 alkyl optionally substituted with one or more halogen; X3 is a direct bond, CR7aR7b, O, or NR7c; R7a and R7b are each independently H or C1-4 alkyl optionally substituted with one or more halogen; R7c is C1-4 alkyl optionally substituted with Attorney Docket No. MORF-016WO1 one or more halogen; X4 is CR8aR8b or NR8c; R8a is H and R8b is halogen or C1-4 alkyl optionally substituted with one or more halogen; R8a and R8b together form a spirocyclic 3- to 8-member heterocycloalkyl or a C3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl optionally substituted with one or more halogen, a 4- to 8-member spirocyclic heterocycloalkyl or a C3-7 spirocyclic cycloalkyl optionally substituted with C1-4 alkyl optionally substituted with one or more halogen; and R8c is H, C1-4 alkyl, a 4- to 8-member heterocycloalkyl, or C3-6 cycloalkyl, wherein the C1-4 alkyl, the 4- to 8-member heterocycloalkyl, or the C3-6 cycloalkyl is optionally substituted with one or more halogen; provided that no two of both X2 and X3 comprise O or N heteroatoms and no two of X3 and X4 comprise O or N heteroatoms. [00048] In some embodiments, the compound is a compound of Formula (I), wherein R14 is H; X1 is CR5aR5b; R5a is H, and R5b is methyl or cyclopropyl. [00049] In some embodiments, the compound is a compound of Formula (I), wherein R4 is H, fluoro, or methyl; X1 is CR5aR5b; R5a is H, R5b is methyl; X2 is O and X3 is CR7aR7b and R7a and R7b are each independently H or C1-4 alkyl optionally substituted with one or more halogen; or X3 is O and X2 is CR6aR7b and R6a and R6b are each independently H; and X4 is CR8aR8b and R8a and R8b are each independently H or C1-4 alkyl optionally substituted with one or more halogen, or R8a and R8b together form a 4- to 7-member heterocycloalkyl ring or a C3-7 cycloalkyl ring, wherein the 4- to 7-member heterocycloalkyl or the C3-7 cycloalkyl is optionally substituted with halogen, C1-4 alkyl optionally substituted with one or more halogen, a 4- to 7-member spirocyclic heterocycloalkyl or a C3-7 spirocyclic cycloalkyl optionally substituted with C1-4 alkyl optionally substituted with one or more halogen. [00050] In some embodiments, the compound is a compound of Formula (I), wherein
Figure imgf000025_0001
Attorney Docket No. MORF-016WO1
Figure imgf000026_0001
are each independently H, halogen, or C1-4 alkyl optionally substituted with one or more halogen; or R10a and R10b together form a spirocyclic C3-6 cycloalkyl or a spirocyclic 6-member heterocycloalkyl; R11a and R11b are each independently H, halogen, or C1-4 alkyl optionally substituted with one or more halogen; R12a and R12b are each independently H, halogen, or C1-4 alkyl optionally substituted with one or more halogen; R13a is methy, ethyl, or cyclopropyl; R13b is H; and R14 is H, halogen, or a C1-4 alkyl optionally substituted with one or more halogen. [00051] In some embodiments, the compound is a compound of Formula (I), wherein R10a and R10b are each independently H or methyl; R11a and R11b are each independently H, methyl, or ethyl; R12a and R12b are each independently H or methyl; R13a is methyl, ethyl, or cyclopropyl; R13b is H; and R14 is H, fluoro, or methyl. [00052] In some embodiments, the compound is a compound of Formula (I), wherein R4 is H or fluoro; R13a is methyl, ethyl, or cyclopropyl; and R14 is H. [00053] In some embodiments, the compound is a compound of Formula (I), wherein X2 is NR6c and R6c is C1-4 alkyl. [00054] In some embodiments, the compound is a compound of Formula (I), wherein
Figure imgf000026_0002
, wherein R13a is H or methyl, and R4 is H, F, or methyl. [00055] In some embodiments, the compound is a compound of Formula (I),
Figure imgf000026_0003
Attorney Docket No. MORF-016WO1
Figure imgf000027_0001
[00056] In some embodiments, the compound is a compound of Formula (I), wherein R10a, R10b, and R11a are each H or methyl. [00057] In some embodiments, the compound is a compound of Formula (I), wherein R11b is H, methyl, or ethyl. [00058] In some embodiments, the compound is a compound of Formula (I), wherein
Figure imgf000027_0002
methyl optionally substituted with one or more halogen; and R9a and R9b are each independently H, halogen, or methyl optionally substituted with one or more halogen. [00059] In some embodiments, the compound is a compound of Formula (I), wherein R4 is H, fluoro, or methyl; and R9a and R9b are each independently H, fluoro, chloro, or methyl optionally substituted with one or more fluoro. [00060] In some embodiments, the compound is a compound of Formula (I), wherein
Figure imgf000027_0003
Attorney Docket No. MORF-016WO1
Figure imgf000028_0001
halogen, a C1-4 alkyl, or a C1-4 alkoxy, wherein the C1-4 alkyl and the C1-4 alkoxy are each optionally substituted with one or more halogen; X5 is CR25aR25b or NR25c; R25a and R25b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or alkoxy; or R25a and R25b together form a C3-6 cycloalkyl ring or 4- to 6-member heterocyclyl ring, each optionally substituted with halogen, C1-4 alkyl, a spirocyclic C3-6 cycloalkyl or a spirocyclic 4- to 6-member heterocyclyl ring, wherein the C1-4 alkyl, the spirocyclic C3-6 cycloalkyl, or the spirocyclic 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen or C1-4 alkyl; R25c is C1-4 alkyl, a 5-6 member heteroaryl, or a C6 aryl, wherein the C1-4 alkyl, the 5-6 member heteroaryl, or the C6 aryl is optionally substituted with one or more halogen or C1-4 alkoxy; X6 is CR26aR26b or C=O; R26a and R26b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkyl; X7 is CR27aR27b or NR27c; R27a and R27b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or alkoxy; R27a and R27b together form a C3-6 cycloalkyl ring or 4- to 6-member heterocyclyl ring, wherein the C3-6 cycloalkyl ring or the 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen, one or more C1-4 alkyl, a spirocyclic C3-6 cycloalkyl, or a spirocyclic 4- to 6-member heterocyclyl ring, wherein the C1-4 alkyl, the spirocyclic C3-6 cycloalkyl, or the spirocyclic 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen or C1-4 alkyl; and R27c is H, C1-4 alkyl, a C3-6 cycloalkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, a 5-6 member heteroaryl, or a C6 aryl, wherein the C1-4 alkyl, the C3-6 cycloalkyl, the 4 to 6 member heterocycloalkyl, the 5 to 11 member spirocyclic heterocycloalkyl, the 5-6 member heteroaryl, or the C6 aryl is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen; provided that only one of X5 and X7.comprise a N heteroatom. [00061] In some embodiments, the compound is a compound of Formula (I), wherein R20 is H, halogen, a C1-4 alkyl, or a C1-4 alkoxy, wherein the C1-4 alkyl and the C1-4 alkoxy is optionally substituted with one or more halogen; X5 is CR25aR25b; R25a and R25b are each independently methyl; or R25a and R25b together form a cyclopropyl; X6 is C=O; R26a and R26b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or C1- Attorney Docket No. MORF-016WO1 4 alkyl; X7 is NR27c; and R27c is a C1-4 alkyl, a C3-6 cycloalkyl, a 4- to 7-member heterocycloalkyl, a 5- to 11-member spirocyclic heterocycloalkyl, a 5-6 member heteroaryl, or a C6 aryl, wherein the C1-4 alkyl, the C3-6 cycloalkyl, the 4- to 6-member heterocycloalkyl, the 5 to 11 member spirocyclic heterocycloalkyl, the 5-6 member heteroaryl, or the C6 aryl is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen. [00062] In some embodiments, the compound is a compound of Formula (I), R27c is a C1-4 alkyl. In some embodiments, the compound is a compound of Formula (I), wherein R27c is a 5- member heteroaryl. In some embodiments, the compound is a compound of Formula (I), wherein R27c is a C3-6 cycloalkyl optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen. In some embodiments, the compound is a compound of Formula (I), wherein R27c is a C1-4 alkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, wherein the C1-4 alkyl, the 4- to 7-member heterocycloalkyl, and the 5- to 11-member spirocyclic heterocycloalkyl is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen. [00063] In some embodiments, the compound is a compound of Formula (I), wherein
Figure imgf000029_0001
wherein R20 is H, fluoro, methyl, ethyl, methoxy, -CH2-O-CH3, or -CF3. In some embodiments, the compound is a compound of Formula (I), wherein R27c is a tetrahydropyan optionally substituted by one or more methyl or fluoro. In some embodiments, the compound is a compound of Formula (I), wherein R27c is
Figure imgf000029_0002
wherein R32a, R32b, R33a and R33b are each independently Attorney Docket No. MORF-016WO1 H, methyl, or fluoro; or one of R32a and R32b or R33a and R33b together form a spirocyclic C3-6 cycloalkyl or a spirocyclic 3- to 6-member heterocyclic ring. [00064] In some embodiments, the compound is a compound of Formula (I), wherein R27c is
Figure imgf000030_0001
. In some embodiments, the compound is a compound of Formula (I), wherein
Figure imgf000030_0002
R31a, and R31b are each independently H, fluoro or methyl; R20 is H, fluoro, methyl, ethyl, methoxy, -CH2-O-CH3, or -CF3; R27c is methyl. In some embodiments, the compound is a compound of Formula (I), wherein R27c is a C1-4 alkyl. [00065] In some embodiments, the compound is a compound of Formula (I), wherein
Figure imgf000030_0003
some embodiments, the compound is a compound of Formula (I), wherein
Figure imgf000030_0004
wherein R20 is H, halogen, a C1-4 alkoxy Attorney Docket No. MORF-016WO1 optionally substituted with C1-4 alkoxy, a C1-4 alkyl optionally substituted with 4- to 6-member heterocyclyl, or one or more halogen. [00066] In some embodiments, the compound is a compound of Formula (I), wherein R25c is a C1-4 alkyl; and R27c is a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkoxy, a C3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C3-6 cycloalkyl or 4- to 6-member heterocycloalkyl is optionally substituted with a C1-4 alkyl optionally substituted with one or more halogen. [00067] In some embodiments, the compound is a compound of Formula (I), wherein R27c is C1-4 alkyl; and R25c is C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkoxy, a C3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C3-6 cycloalkyl or the 4- to 6-member heterocycloalkyl is optionally substituted with a C1-4 alkyl optionally substituted with one or more halogen. [00068] In some embodiments, the compound is a compound of Formula (I), wherein R20 is H or methyl. In some embodiments, the compound is a compound of Formula (I), wherein
Figure imgf000031_0001
; wherein R20 is H, halogen, a C1-4 alkoxy optionally substituted with C1-4 alkoxy, a C1-4 alkyl optionally substituted with a 4- to 6- member heterocyclyl, or one or more halogen; R25c is C1-4 alkyl; R27c is a 4- to 6-member heterocyclyl or a C3-6 cycloalkyl, wherein the 4- to 6-member heterocyclyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl. [00069] In some embodiments, the compound is a compound of the chemical formula
Figure imgf000031_0002
pharmaceutically acceptable salt thereof. In some embodiments, the compound is a compound of the chemical formula Attorney Docket No. MORF-016WO1
Figure imgf000032_0001
pharmaceutically acceptable salt thereof. In some embodiments, the compound is a compound of the chemical formula
Figure imgf000032_0002
pharmaceutically acceptable salt thereof. In some embodiments, the compound is a compound of the chemical formula
Figure imgf000032_0003
pharmaceutically acceptable salt thereof. [00070] In some embodiments, the compound is a compound of the chemical formula
Figure imgf000032_0004
pharmaceutically acceptable salt thereof. [00071] In some embodiments, the compound is a compound of the chemical formula
Figure imgf000032_0005
pharmaceutically acceptable salt thereof. Attorney Docket No. MORF-016WO1 [00072] In some embodiments, the compound is a compound of the chemical formula
Figure imgf000033_0001
pharmaceutically acceptable salt thereof. [00073] In some embodiments, the compound is a compound of the chemical formula
Figure imgf000033_0002
pharmaceutically acceptable salt thereof. [00074] In some embodiments, the compound is a compound of the chemical formula
Figure imgf000033_0003
pharmaceutically acceptable salt thereof. [00075] In some embodiments, the compound is a compound of the chemical formula
Figure imgf000033_0004
Attorney Docket No. MORF-016WO1 [00076] In some embodiments, the compound is a compound of the chemical formula
Figure imgf000034_0001
, or a pharmaceutically acceptable salt thereof. [00077] In some embodiments, the compound is a compound of the chemical formula
Figure imgf000034_0002
, or a pharmaceutically acceptable salt thereof. [00078] In some embodiments, the compound is a compound of the chemical formula
Figure imgf000034_0003
pharmaceutically acceptable salt thereof. [00079] In some embodiments, the compound is a compound of the chemical formula
Figure imgf000034_0004
pharmaceutically acceptable salt thereof. [00080] In some embodiments, the compound is a compound selected from the group consisting of the compounds in Figure 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is a compound selected from the group consisting of compounds in Table 3, or a pharmaceutically acceptable salt thereof. Attorney Docket No. MORF-016WO1 Definitions [00081] For convenience, before further description of the present invention, certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure and understood as by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art. [00082] In order for the present invention to be more readily understood, certain terms and phrases are defined below and throughout the specification. [00083] The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element. [00084] The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc. [00085] As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” Attorney Docket No. MORF-016WO1 “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law. [00086] As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and/or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc. [00087] It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited. [00088] In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03. [00089] Certain compounds contained in compositions of the present invention may exist in particular geometric or stereoisomeric forms. In addition, polymers of the present invention may also be optically active. The present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (d)-isomers, (l)- isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of Attorney Docket No. MORF-016WO1 the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention. [00090] If, for instance, a particular enantiomer of compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers. [00091] Structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds produced by the replacement of a hydrogen with deuterium or tritium, or of a carbon with a 13C- or 14C- enriched carbon are within the scope of this invention. [00092] The phrase “pharmaceutically acceptable excipient” or “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ or portion of the body, to another organ or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, not injurious to the patient, and substantially non-pyrogenic. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer’s solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations. In Attorney Docket No. MORF-016WO1 certain embodiments, pharmaceutical compositions of the present invention are non-pyrogenic, i.e., do not induce significant temperature elevations when administered to a patient. [00093] The term “pharmaceutically acceptable salts” refers to the relatively non-toxic, inorganic and organic acid addition salts of the compound(s). These salts can be prepared in situ during the final isolation and purification of the compound(s), or by separately reacting a purified compound(s) in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts, and the like. (See, for example, Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci.66:1-19.) [00094] In other cases, the compounds useful in the methods of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term “pharmaceutically acceptable salts” in these instances refers to the relatively non-toxic inorganic and organic base addition salts of a compound(s). These salts can likewise be prepared in situ during the final isolation and purification of the compound(s), or by separately reacting the purified compound(s) in its free acid form with a suitable base, such as the hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like (see, for example, Berge et al., supra). [00095] A “therapeutically effective amount” (or “effective amount”) of a compound with respect to use in treatment, refers to an amount of the compound in a preparation which, when administered as part of a desired dosage regimen (to a mammal, preferably a human) alleviates a symptom, ameliorates a condition, or slows the onset of disease conditions according to clinically acceptable standards for the disorder or condition to be treated or the cosmetic purpose, e.g., at a reasonable benefit/risk ratio applicable to any medical treatment. [00096] The term “prophylactic or therapeutic” treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If it is administered prior Attorney Docket No. MORF-016WO1 to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, (i.e., it protects the host against developing the unwanted condition), whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof). [00097] The term “patient” refers to a mammal in need of a particular treatment. In certain embodiments, a patient is a primate, canine, feline, or equine. In certain embodiments, a patient is a human. [00098] Whenever a term (e.g., alkyl or aryl) or either of their prefix roots (e.g., alk- or ar-) appear in a name of a substituent the name is to be interpreted as including those limitations provided herein. For example, affixing the suffix “-ene” to a group indicates the group is a divalent moiety, e.g., arylene is the divalent moiety of aryl, heteroarylene is the divalent moiety of heteroaryl, and heterocycloalkylene is the divalent moiety of heterocycloalkyl. Similarly, affixing the suffix “-oxy” to a group indicates the group is attached to the parent molecular structure through an oxygen atom (-O-) such as “alkyloxy,” “alkoxy” or “cycloalkoxy” as used herein. [00099] An aliphatic chain comprises the classes of alkyl, alkenyl and alkynyl defined below. A straight aliphatic chain is limited to unbranched carbon chain moieties. As used herein, the term “aliphatic group” refers to a straight chain, branched-chain, or cyclic aliphatic hydrocarbon group and includes saturated and unsaturated aliphatic groups, such as an alkyl group, an alkenyl group, or an alkynyl group. [000100] “Alkyl” refers to a fully saturated cyclic or acyclic, branched or unbranched carbon chain moiety having the number of carbon atoms specified, or 1 up to 30 carbon atoms if no specification is made. For example, alkyl of 1 to 8 carbon atoms refers to moieties such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl, and those moieties which are positional isomers of these moieties. Alkyl of 10 to 30 carbon atoms includes decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, heneicosyl, docosyl, tricosyl and tetracosyl. In certain embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chains, C3-C30 for branched chains), and more preferably 20 or fewer. Alkyl goups may be substituted or unsubstituted. As used herein, “Me” and –CH3 both refer to methyl. Attorney Docket No. MORF-016WO1 [000101] As used herein, the term “alkylene” refers to an alkyl group having the specified number of carbons, for example from 2 to 12 carbon atoms, that contains two points of attachment to the rest of the compound on its longest carbon chain. Non-limiting examples of alkylene groups include methylene -(CH2)-, ethylene -(CH2CH2)-, n-propylene - (CH2CH2CH2)-, isopropylene -(CH2CH(CH3))-, and the like. Alkylene groups can be cyclic or acyclic, branched or unbranched carbon chain moiety, and may be optionally substituted with one or more substituents. [000102] "Cycloalkyl" means mono- or bicyclic or bridged or spirocyclic, or polycyclic saturated carbocyclic rings, each having from 3 to 12 carbon atoms. Likewise, preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 3-6 carbons in the ring structure. Cycloalkyl groups may be substituted or unsubstituted. Exemplary cycloalkyl groups include cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cycloheptyl (C7), and cyclooctyl (C8). [000103] Unless the number of carbons is otherwise specified, “lower alkyl,” as used herein, means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl. Likewise, “lower alkenyl” and “lower alkynyl” have similar chain lengths. Throughout the application, preferred alkyl groups are lower alkyls. In certain embodiments, a substituent designated herein as alkyl is a lower alkyl. [000104] The term “aryl” as used herein includes 3- to 12-membered substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon (i.e., carbocyclic aryl) or where one or more atoms are heteroatoms (i.e., heteroaryl). Preferably, aryl groups include 5- to 12-membered rings, more preferably 6- to 10-membered rings The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Carbocyclic aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like. Heteroaryl groups include substituted or unsubstituted aromatic 3- to 12-membered ring structures, more preferably 5- to 12-membered rings, more preferably 5- to 10-membered rings, whose ring structures include one to four heteroatoms. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, Attorney Docket No. MORF-016WO1 pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Aryl and heteroaryl can be monocyclic, bicyclic, or polycyclic. [000105] The term “halo”, “halide”, or “halogen” as used herein means halogen and includes, for example, and without being limited thereto, fluoro, chloro, bromo, iodo and the like, in both radioactive and non-radioactive forms. In a preferred embodiment, halo is selected from the group consisting of fluoro, chloro and bromo. [000106] The terms “heterocyclyl” or “heterocyclic group” refer to 3- to 12-membered ring structures, more preferably 5- to 12-membered rings, more preferably 5- to 10-membered rings, whose ring structures include one to four heteroatoms. Heterocycles can be monocyclic, bicyclic, spirocyclic, or polycyclic. Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, oxolane, thiolane, oxazole, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like. The heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, sulfamoyl, sulfinyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF3, -CN, and the like. [000107] The term “heterocycloalkyl” as used herein, is a non-aromatic heterocyclyl wherein at least one atom is a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus, and the remaining atoms are carbon. Examples of heterocycloalkyl groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H- pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3- azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolizinyl. The Attorney Docket No. MORF-016WO1 heterocycloalkyl group can be substituted or unsubstituted as recited, e.g., for heterocyclyls as described herein. [000108] The term “carbonyl” is art-recognized and includes such moieties as can be represented by the formula: O
Figure imgf000042_0001
, wherein X’ is a bond or represents an oxygen or a sulfur, and R15 represents a hydrogen, an alkyl, an alkenyl, -(CH2)m-R10 or a pharmaceutically acceptable salt, R16 represents a hydrogen, an alkyl, an alkenyl or -(CH2)m-R10, where m and R10 are as defined above. Where X’ is an oxygen and R15 or R16 is not hydrogen, the formula represents an “ester.” Where X’ is an oxygen, and R15 is as defined above, the moiety is referred to herein as a carboxyl group, and particularly when R15 is a hydrogen, the formula represents a “carboxylic acid”. Where X’ is an oxygen, and R16 is a hydrogen, the formula represents a “formate.” On the other hand, where X’ is a bond, and R15 is not hydrogen, the above formula represents a “ketone” group. Where X’ is a bond, and R15 is a hydrogen, the above formula represents an “aldehyde” group. [000109] As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described herein above, and for example substituted with one or more substituents selected from alkyl, cycloalkyl, heterocyclylakyl, halogen, OH, OMe, C(H)F2, C(F)H2, CF3, C(H)2CF3, SF5, CHFCH2amine, CH2amine, and CN. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. Attorney Docket No. MORF-016WO1 [000110] As used herein, the term “nitro” means -NO2; the term “halogen” designates - F, -Cl, -Br, or -I; the term “hydroxyl” means -OH; and the term “cyano” means –CN. [000111] As used herein, the definition of each expression, e.g., alkyl, m, n, etc., when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure. [000112] The term “prodrug” as used herein encompasses compounds that, under physiological conditions, are converted into therapeutically active agents. A common method for making a prodrug is to include selected moieties that are hydrolyzed under physiological conditions to reveal the desired molecule. In other embodiments, the prodrug is converted by an enzymatic activity of the host animal. Accordingly, prodrugs include compounds that are transformed in vivo to yield a disclosed compound or any other pharmaceutically acceptable form of the compound. In embodiments, a prodrug may be inactive when administered to a subject but may be converted in vivo to an active compound, for example, by hydrolysis. See, e.g., Bundgard, H., Design of Prodrugs (1985), pp.7-9, 21-24 (Elsevier, Amsterdam). A discussion of prodrugs is provided in Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” A.C.S. Symposium Series, Vol.14, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein. Prodrugs can typically be prepared using well known methods, such as those described in Burger's Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff ed., 5th ed., 1995), and Design of Prodrugs (H. Bundgaard ed., Elselvier, New York, 1985). The term “prodrug” is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a subject. [000113] Prodrugs of compounds described herein may be prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to provide a compound described herein (i.e., the parent active compound). Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of an alcohol or acetamide, formamide and benzamide derivatives of an amine functional group Attorney Docket No. MORF-016WO1 in the active compound and the like. Other examples of prodrugs include compounds that comprise —NO, —NO2, —ONO, or —ONO2 moieties. [000114] For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover. [000115] In some embodiments, the compound is a compound selected from Figure 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is a compound selected from Table 3, or a pharmaceutically acceptable salt thereof. Table 3. Exemplary Compounds
Figure imgf000044_0001
Attorney Docket No. MORF-016WO1
Figure imgf000045_0001
Attorney Docket No. MORF-016WO1
Figure imgf000046_0001
Therapeutic Uses of a Compound of Formula (I) [000116] In tissues, normal fibroblasts are present in low population of only 4-5%. However, during fibrosis they proliferate and can occupy up to 80-90% of the organ mass. Myofibroblasts in the fibrotic tissue produce large amounts of extracellular matrix proteins that make the tissue scarred and non-functional. Inhibition of myofibroblasts can counteract these processes. Integrins promote cell proliferation, survival, hypertrophic growth, and fibrosis. As described herein, integrin inhibition can modulate these key elements leading to the progression of pulmonary hypertension (e.g., PAH). [000117] The present invention provides methods of treating a disease associated with increased expression or activity of integrin α5β1, comprising administering an integrin α5β1 inhibitor. In one aspect, the present invention provides an integrin α5β1 inhibitor for use in treating a disease associated with increased expression or activity of integrin α5β1 in a subject Attorney Docket No. MORF-016WO1 in need of treatment thereof, comprising administering the integrin α5β1 inhibitor and a pharmaceutical excipient to the subject. [000118] In some embodiments, the disease is heart failure or right ventricle failure. In one aspect, the present invention provides a method of treating pulmonary arterial hypertension (PAH) in a subject, comprising administering an integrin α5β1 inhibitor. In some embodiments, the integrin α5β1 inhibitor is administered orally, intravenously, subcutaneously, intranasally, transdermally, intraperitoneally, intramuscularly, or intrapulmonarily. Also provided is a method for the treatment of a subject suffering from fibrosis or a fibrosis related disorder, comprising administering to said subject a therapeutically effective amount of integrin α5β1 inhibitor according to the invention. The term “fibrosis” as used herein refers to a condition characterized by a deposition of extracellular matrix components in the skin or organs, including lungs, kidneys, heart, liver, skin and joints, resulting in scar tissue. The term also refers to the process of formation of scar tissue. [000119] In some embodiments, the fibrosis-related disorder is a disorder or condition which may occur as a result of fibrosis, or which is associated with fibrosis. In some embodiments, fibrosis and/or a fibrosis-related disorders is a disease or condition selected from the group consisting of kidney fibrosis, liver fibrosis, liver cirrhosis, pulmonary fibrosis, skin fibrosis, biliary fibrosis, peritoneal fibrosis, myocardial fibrosis, pancreatic fibrosis, bone marrow and/or myelofibrosis, reperfusion injury after hepatic or kidney transplantation, Interstitial Lung Disease (ILD), cystic fibrosis (CF), atherosclerosis, systemic sclerosis, osteosclerosis, spinal disc herniation and other spinal cord injuries, fibromatosis, fibromyalgia, arthritis, restenosis. Pulmonary fibrosis includes idiopathic pulmonary fibrosis and scleroderma lung fibrosis. [000120] The methods described herein may be applied to cell populations in vivo or ex vivo. “In vivo” means within a living individual, as within an animal or human. In this context, the methods described herein may be used therapeutically in an individual. “Ex vivo” means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. [000121] Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. The selected compounds may be further characterized to examine the safety or tolerance dosage in human or non-human subjects. Such properties may be examined using commonly known methods to those skilled in the art. Attorney Docket No. MORF-016WO1 [000122] In some embodiments, compounds described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof, may be used to treat subjects who have or are suspected of having disease states, disorders, and conditions (also collectively referred to as “indications”) responsive or believed to be responsive to the inhibition of α5β1 integrin activity. In some embodiments, the compounds described herein may be used to inhibit the activity of α5β1 integrin. In some embodiments, the present disclosure provides a compound described herein useful as an inhibitor of α5β1 integrin. In some embodiments, the present disclosure provides a method of treating or preventing an inflammatory disease or condition comprising administering a compound described herein to a patient. In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound described herein and a pharmaceutically acceptable carrier. In some embodiments, provided is a compound described herein useful for the treatment of an inflammatory disease or condition in a patient that is mediated, at least in part, by α5β1 integrin. [000123] Co-administration may also include administering component drugs, e.g., one on more compounds described herein and one or more additional (e.g., a second, third, fourth or fifth) therapeutic agent(s). Such combination of one on more compounds described herein and one or more additional therapeutic agent(s) may be administered simultaneously or in sequence (one after the other) within a reasonable period of time of each administration (e.g., about 1 minute to 24 hours) depending on the pharmacokinetic and/or pharmacodynamics properties of each agent or the combination. Co-administration may also involve treatment with a fixed combination wherein agents of the treatment regimen are combinable in a fixed dosage or combined dosage medium, e.g., solid, liquid or aerosol. [000124] Treatment with the second, third, fourth or fifth active agent may be prior to, concomitant with, or following treatment with a compound described herein. In some embodiments, a compound described herein is combined with another active agent in a single dosage form. [000125] In embodiments, a subject is an adult subject. Dosage Amounts and Frequency [000126] In some embodiments, compounds of Formula (I) or any pharmaceutically acceptable salt thereof described herein is administered to a human patient in need thereof in an effective amount. Attorney Docket No. MORF-016WO1 [000127] In some embodiments, the method of treating a disease associated with increased expression or activity of integrin α5β1, comprises administering the integrin α5β1 inhibitor at a dose of 1 mg/kg to 1000 mg/kg. In some embodiments, the dose is at least 2 mg/kg, at least 4 mg/kg, at least 6 mg/kg, or at least 8 mg/kg. In some embodiments, the dose is at least 10 mg/kg, at least 20 mg/kg, at least 30 mg/kg, at least 40 mg/kg, at least 50 mg/kg, at least 60 mg/kg, at least 70 mg/kg, at least 80 mg/kg, at least 90 mg/kg or at least 100 mg/kg. In some embodiments, the dose is at least 200 mg/kg, at least 300 mg/kg, at least 400 mg/kg, at least 500 mg/kg, at least 600 mg/kg, at least 700 mg/kg, at least 800 mg/kg, at least 900 mg/kg, or at least 1000 mg/kg. [000128] In embodiments, a subject receives a dose of a compound of Formula (I) or a pharmaceutically acceptable salt thereof once daily. In embodiments, a subject receives a dose of a compound of Formula (I) or a pharmaceutically acceptable salt thereof twice daily. Cardiac function parameters [000129] Various endpoint parameters can be assessed to determine efficacy of a treatment of the present invention, e.g., α5β1 level, pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (PAP), cardiac index (CI), mean pulmonary capillary wedge pressure (PCWP), right atrial pressure (RAP), six-minute walk distance (6 MWD), brain natriuretic peptide (BNP) level, diffusion of lung capacity (DLCO), and death or survival. See, Chung et al. Chest (2010), 138(6):1383-1394. [000130] PVR is commonly used as an endpoint parameter for determination of efficacy of treatment for PAH. A PVR of a subject of >240 dyn·sec/cm5 is an indication of mild PAH. A PVR of a subject of 600-800 dyn·sec/cm5 indicates moderate to severe PAH. After treatment using the methods and compositions of the invention, a decrease in PVR in a subject of 130 dyn·sec/cm5 or more indicates efficacious treatment. For example, administration of a Α5Β1 inhibitor to a subject with PAH that leads to a decrease in PVR of 180-350 dyn·sec/cm5 indicates efficacious treatment. [000131] Mean pulmonary arterial pressure (PAP) is also used as an endpoint parameter to determine efficacy of treatment for PAH. A subject without PAH has a mean PAP ranging from about 15-24 mmHg. A subject having mild PAH has a mean PAP of about 25-30 mmHg (e.g., >25 mmHg at rest or 30 mmHg with exercise). A subject having severe PAH has a PAP of greater than 30 mmHg, for e.g., 40-70 mmHg or 60-70 mmHg. After treatment, a decrease in PAP of greater than 1.5 mmHg indicates efficacious treatment. In some embodiments, Attorney Docket No. MORF-016WO1 treatment leads to a decrease in PAP of greater than 5, 10, 20, 40, or 50 mmHg, which is indicative of efficacious treatment. [000132] Cardiac index (CI) is also used as an endpoint parameter for determining efficacy of treatment for PAH. A low or decreased CI is indicative of heart failure. For e.g., a CI of 2.5 L/min/m2 or less is indicative of PAH or heart failure. After treatment, a CI increase of more than 0.3 L/min/m2 is indicative of efficacious treatment. [000133] Mean pulmonary capillary wedge pressure (PCWP) can be used as an endpoint parameter for determining efficacy of treatment for PAH. A mean PCWP of less than or equal to 18 mmHg (e.g., less than or equal to 10 mmHg) indicates a subject having PAH. After treatment, an increase in mean PCWP of greater than 0.5 mmHg is indicative of efficacious treatment. [000134] Right atrial pressure (RAP) is also used as an endpoint parameter to determine efficacy of treatment for PAH. A subject not suffering from PAH has a normal RAP of 0-8 mmHg. A RAP of 8 mmHg or greater is indicative of PAH. A subject suffering from severe PAH has a RAP of about 20 mmHg. After treatment, a decrease of greater than 0.5 mmHg is indicative of efficacious treatment. [000135] Six-minute walk distance (6 MWD) is used as an endpoint parameter to determine efficacy of treatment of PAH. The mean 6 MWD of patients with CTD-PAH is about 300 m. After treatment, an increase in 6 MWD of 25 m or more, or greater than 10% increase indicates efficacious treatment. For example, after treatment, a 6 MWD of 1000 m or more indicates efficacious treatment. [000136] Brain Natriuretic Peptide (BNP) is used as an endpoint parameter to determine efficacy of treatment of PAH. BNP is a sensitive marker for the worsening of heart failure and is a predictor of mortality in PAH patients. Normal levels of BNP are <100 pg/mL, e.g., 30-90 pg/mL. Higher levels of BNP indicate worsening of heart failure. A BNP level of about 100- 200 pg/mL, e.g., 160 pg/mL or higher, indicates early heart failure. A BNP level of about 200- 1000 pg/mL indicates real heart failure. The mean BNP level of CTD- PAH patients is about 430 pg/mL. After treatment, any reduction in BNP level indicates efficacious treatment. [000137] N-Terminal pro Brain Natriuretic Peptide (NT-proBNP): Reproducible, noninvasive parameters are useful in following patients with PAH. BNP is produced in the cardiac ventricles and is elevated in PPH/IPAH. BNP levels have recently been shown to be Attorney Docket No. MORF-016WO1 closely related to functional impairment in PPH/IPAH patients and parallel the extent of pulmonary hemodynamic changes and right heart failure. BNP levels longitudinally correlate with the functional assessments being made over the course of the study. Plasma NT-pro-BNP are measured by a sandwich immunoassay using polyclonal antibodies that recognize epitopes located in the N-terminal segment (1 to 76) of pro-BNP (1 to 108) (Elecsys analyzer, Roche Diagnostics, Manheim, Germany). [000138] Diffusion of lung capacity (DLCO), or diffusion capacity of CO, is also used as an endpoint parameter to determine efficacy of treatment of PAH. DLCO measures the ability of carbon monoxide (CO) to diffuse across membranes. A subject not suffering from PAH has a normal DLCO of greater than 80%. A subject suffering from PAH has an abnormal DLC of less than 80%, less than 65%, or less than 45%. After treatment, any increase in % DLCO indicates efficacious treatment. [000139] In some embodiments, administration of the integrin α5β1 inhibitor modulates the level of a biomarker in the subject, wherein the biomarker is selected from the group consisting of survivin, PCNA, Ki67, and annexin V. Pulmonary Hypertension [000140] Pulmonary hypertension (PH) is a syndrome characterized by increased pulmonary artery pressure. PH is defined hemodynamically as a systolic pulmonary artery pressure greater than 30 mm Hg or evaluation of mean pulmonary artery pressure greater than 25 mm Hg. See Zaiman et al., Am. J. Respir. Cell Mol. Biol.33:425-31 (2005). Further, PH, as a result of the increased pressure, damages both the large and small pulmonary arteries. The walls of the smallest blood vessels thicken and are no longer able to transfer oxygen and carbon dioxide normally between the blood and the lungs. In time, pulmonary hypertension leads to thickening of the pulmonary arteries and narrowing of the passageways through which blood flows. Once pulmonary hypertension develops, the right side of the heart works harder to compensate; however, the increased effort causes it to become enlarged and thickened. Proliferation of smooth muscle and endothelial cells which normally exist in a quiescent state leads to remodeling of the vessels with obliteration of the lumen of the pulmonary vasculature. This causes a progressive rise in pulmonary pressures as blood is pumped through decreased lumen area. The enlarged right ventricle places a person at risk for pulmonary embolism because blood tends to pool in the ventricle and in the legs. If clots form in the pooled blood, they may eventually travel and lodge in the lungs. The progressive rise in pressure also places an Attorney Docket No. MORF-016WO1 additional workload on the right ventricle which eventually fails and leads to premature death in these patients. [000141] Various pathologic changes occur in pulmonary arteries as a result of PH. Persistent vasoconstriction and structural remodeling of the pulmonary vessels are cardinal features of PH. Pulmonary vascular smooth muscle cells undergo a phenotypic switch from contractile normal phenotype to a synthetic phenotype leading to cell growth and matrix deposition. Histological examination of tissue samples from patients with pulmonary hypertension shows intimal thickening, as well as smooth muscle cell hypertrophy, especially for those vessels <100 m diameter. Further, abnormal smooth muscle cells often overexpress endothelin and serotonin transporters, which likely play a role in the development of PH. [000142] The most common symptom of pulmonary hypertension initially is shortness of breath upon exertion. Some people feel light-headed or fatigued upon exertion, and an angina- like chest pain is common. Because body tissues are not receiving enough oxygen, general weakness is another problem. Other symptoms, such as coughing and wheezing, may be caused by an underlying lung disease. Edema, particularly of the legs, may occur because fluid may leak out of the veins and into the tissues, signaling that cor pulmonale has developed. Some people with pulmonary hypertension have connective tissue disorders, especially scleroderma. When people have both conditions, pulmonary hypertension and connective tissue disorders, Raynaud's phenomenon often develops before symptoms of pulmonary hypertension appear, sometimes as long as years earlier. [000143] Treatment of some types of pulmonary hypertension is often directed at the underlying lung disease. Currently, the treatment options available for those suffering from PH target cellular dysfunction that leads to constriction of the vasculature. Therapies such as prostanoids, phosphodiesterase-5 inhibitors and endothelin receptor antagonists primarily work by causing dilation of the pulmonary vessels. Vasodilators, such as calcium channel blockers, nitric oxide, and prostacyclin, are often helpful for pulmonary hypertension associated with scleroderma, chronic liver disease, and HIV infection. In contrast, these drugs have not been proven effective for people with pulmonary hypertension due to an underlying lung disease. For most people with pulmonary hypertension due to an unknown cause, vasodilators, such as prostacyclin, drastically reduce blood pressure in the pulmonary arteries. Prostacyclin given intravenously through a catheter surgically implanted in the skin improves the quality of life, increases survival, and reduces the urgency of lung transplantation. Unfortunately, many Attorney Docket No. MORF-016WO1 patients respond poorly to these therapies or stop responding to them over time. The only remaining option at that point in time is a single or double lung transplantation to treat PH. Although there is some evidence that available therapies have secondary effects on vascular remodeling, there are currently no therapies that target abnormal cell proliferation in PAH. [000144] In some embodiments, the pulmonary hypertension is pulmonary venous hypertension (PVH). In some embodiments, the PVH is due to left heart failure. In some embodiments, the pulmonary hypertension is pulmonary hypertension associated with disorders of the respiratory system and/or hypoxia. In some embodiments, the pulmonary hypertension is pulmonary hypertension due to chronic thrombotic and/or embolic disease. In some embodiments, the pulmonary hypertension is miscellaneous pulmonary hypertension. In some embodiments, the miscellaneous pulmonary hypertension is associated with sarcoidosis, eosinophilic granuloma, histicytosis X, lymphangiolomyiomatosis, or compression of pulmonary vessels (e.g., adenopath, tumor, or fibrosing medianstinitis). In some embodiments, the pulmonary hypertension is associated with chronic obstructive pulmonary disease (COPD). In some embodiments, the pulmonary hypertension is associated with pulmonary fibrosis. In some embodiments, the pulmonary hypertension is associated with cardiac fibrosis. In some embodiments, the pulmonary hypertension is early-stage pulmonary hypertension or advanced pulmonary hypertension. [000145] In some embodiments, one or more symptoms of the pulmonary hypertension are ameliorated. In some embodiments, the pulmonary hypertension is delayed. In some embodiments, the pulmonary hypertension is prevented. In some embodiments, the methods of treatment provided herein reduce pulmonary pressure. In some embodiments, the methods of treatment provided herein inhibit and/or reduce abnormal cell proliferation in the pulmonary artery. [000146] In some embodiments, the pulmonary hypertension is is characterized by the World Health Organization (WHO) group. In some embodiments, the pulmonary hypertension is WHO Group 1 pulmonary hypertension or pulmonary arterial hypertension (PAH), WHO Group 2 pulmonary hypertension, WHO Group 3 pulmonary hypertension, WHO Group 4 pulmonary hypertension, and WHO Group 5 pulmonary hypertension. In some embodiments, the pulmonary hypertension is characterized by the World Health Organization (WHO) class system. In some embodiments, the pulmonary hypertension is characterized by WHO functional class based on cardiac function. In some embodiments, the pulmonary hypertension, Attorney Docket No. MORF-016WO1 WHO Class I pulmonary hypertension or pulmonary arterial hypertension (PAH), WHO Class II pulmonary hypertension, WHO Class III pulmonary hypertension, WHO Class IV pulmonary hypertension. [000147] In some embodiments, the pulmonary hypertension is associated with pulmonary capillary hemangiomatosis. In some embodiments, the disease is heart failure or right ventricle failure. In one aspect, the present invention provides a method of treating pulmonary arterial hypertension (PAH) in a subject, comprising administering an integrin α5β1 inhibitor. Pulmonary arterial hypertension (PAH) [000148] In one aspect, the present invention provides a method of treating Pulmonary arterial hypertension (PAH), comprising administering an integrin α5β1 inhibitor (e.g., small molecule compounds and antibodies disclosed herein). PAH is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular overload and eventually cardiac failure. PAH results in progressive obstruction and decreased compliance of pulmonary arteries (PA), leading to right ventricular (RV) failure and premature death. Like cancer cells, PA smooth muscle cells (PASMCs) and endothelial cells (PAECs) exhibit exaggerated proliferation and resistance to apoptosis in response to increased PA stiffness caused by extracellular matrix (ECM) remodeling. Integrins signaling could promote PAH- PASMCs and PAH-PAECs proliferation and resistance to apoptosis contributing to PAs vascular remodeling, while in the RV, maladaptive hypertrophy, and fibrosis, leading to RV failure in PAH. The present invention is based, in part, on the discovery that a5b1 integrin inhibition could reverse PAs vascular remodeling and prevent RV dysfunction in PAH. [000149] PAH is a chronic disorder that involves all layers of the pulmonary vessels. Vasoconstriction, structural changes in the pulmonary vessel wall (vascular remodeling) and thrombosis contribute to the increased pulmonary vascular resistance in PAH. Structural and functional changes of the endothelium lead to endothelial dysfunction. Increased vasoconstrictive factors (e.g., endothelin) and decreased vasodilation capacity (e.g., less prostacyclin) result in vasoconstriction and increased pulmonary vascular resistance. Current treatments that seek to address vasoconstriction may slow the progression of PAH or ameliorate the clinical symptoms for a limited time, but they have not proven to substantially reduce overall PAH morbidity and mortality rates. Underlying structural changes to the pulmonary vessels - vascular remodeling - are not affected by these treatments. Attorney Docket No. MORF-016WO1 [000150] Vascular remodeling that occurs in PAH is characterized by proliferative and obstructive changes involving many cell types, including endothelial cells, smooth muscle cells and fibroblasts. Vascular remodeling can manifest itself, for example, as medial thickening of pulmonary vessels due to smooth muscle cell hyperplasia and hypertrophy, formation of a neointima made of smooth muscle cells and/or myofibroblasts, and/or formation of plexiform lesions, which consist of localized proliferations of endothelial cells, smooth muscle cells, lymphocytes, and mast cells. Vascular remodeling results in obstruction of the vessel lumen leading to pulmonary hypertension. There is a need for therapies that address the proliferative aspect of PAH. [000151] In some embodiments, the pulmonary hypertension is pulmonary arterial hypertension (PAH). In some variations, the PAH is idiopathic PAH. In some variations, the PAH is familial PAH. In some variations, the PAH is associated with persistent pulmonary hypertension of a newborn. In some variations, the PAH is associated with pulmonary veno- occlusive disease. [000152] In some embodiments, the pulmonary hypertension is assocated with lung diseases. In some embodiments, the lung disease is Idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia (IIP). IPF is a type of idiopathic interstitial pneumonia (IIP), which in turn is a type of interstitial lung disease (also known as diffuse parenchymal lung disease (DPLD)). Interstitial lung disease concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, perivascular and perilymphatic tissues. Other forms of idiopathic interstitial pneumonias include non-specific interstitial pneumonia (NSIP), desquamative interstitial pneumonia (DIP) and acute interstitial pneumonia (AIP). Examples of known causes of interstitial lung disease include sarcoidosis, hypersensitivity pneumonitis, pulmonary Langerhans cell histiocytosis, asbestosis and collagen vascular diseases such as scleroderma and rheumatoid arthritis. [000153] Pulmonary fibrosis is the formation or development of excess fibrous connective tissue in the lungs. Heart Failure (HF) [000154] In one aspect, the present invention provides a method of treating heart failure (HF), comprising administering an integrin α5β1 inhibitor (e.g., small molecule compounds and antibodies disclosed herein). Heart failure refers to any condition characterized by the heart’s inability to pump an adequate supply of blood to the body. The physiological state in Attorney Docket No. MORF-016WO1 which cardiac output is insufficient to meet the needs of the body or to do so only at a higher filing pressure. There are many underlying causes of HF, including myocardial infarction, coronary artery disease, valvular disease, hypertension, and myocarditis. Chronic heart failure is associated with neurohormonal activation and alterations in autonomic control. Although these compensatory neurohormonal mechanisms provide valuable support for the heart under normal physiological circumstances, they also play a fundamental role in the development and subsequent progression of HF. [000155] For example, one of the body's main compensatory mechanisms for reduced blood flow in HF is to increase the amount of salt and water retained by the kidneys. Retaining salt and water, instead of excreting it via urine, increases the volume of blood in the bloodstream and helps to maintain blood pressure. However, the larger volumes of blood also cause the heart muscle, particularly the ventricles, to become enlarged. As the heart chambers become enlarged, the wall thickness decreases and the heart's contractions weaken, causing a downward spiral in cardiac function. Another compensatory mechanism is vasoconstriction of the arterial system, which raises the blood pressure to help maintain adequate perfusion, thus increasing the load that the heart must pump against. [000156] In low ejection fraction (EF) heart failure, high pressures in the heart result from the body's attempt to maintain the high pressures needed for adequate peripheral perfusion. However, as the heart weakens because of such high pressures, the disorder becomes exacerbated. Pressure in the left atrium may exceed 25 mm Hg, at which stage, fluids from the blood flowing through the pulmonary circulatory system transudate or flow out of the pulmonary capillaries into the pulmonary interstitial spaces and into the alveoli, causing lung congestion and if untreated the syndrome of acute pulmonary edema and death. Standard of Care (SoC) and Combination Therapy [000157] As described herein, a method of treating a disease associated with increased expression or activity of integrin α5β1, comprising administering an integrin α5β1 inhibitor can include a combination therapy in which a patient in need of treatment is administered an integrin a5b1 inhibitor in combination with one or more drugs approved for the treatment of PH, PAH, heart failure, or right ventricle failure. [000158] Approved drugs currently used in the treatment of PH, PAH, heart failure and right ventricle failure in the US or the European Union (EU) include the orally administered PDE-5 inhibitors: sildenafil (Revatio) and tadalafil (Adeirca); the dual endothelin-1A receptor Attorney Docket No. MORF-016WO1 antagonist (ERA): bosentan (Tracleer), ambrisentan (Letairis in US; Volibris internationally). Patients with more advanced disease are often treated with prostacyclins or prostacyclin analogs such as iloprost (Ventavis) or treprostinil (Tyvaso) given as multiple daily inhalations, epoprostenol (Flolan/Veletri) or treprostinil (Remodulin) given as continuous intravenous infusions, or treprostinil also used as a continuous subcutaneous infusion. Intravenous injection of sildenafil is approved for patients who are currently prescribed but are temporarily unable to take oral sildenafil. Inhaled nitric oxide (INOmax) is approved for the neonatal form of PAH— persistent pulmonary hypertension of the newborn (PPHN). Thus, in accordance with the invention, combination therapies of any of these drugs and an integrin a5b1 inhibitor are useful in the treatment of PAH or a disorder disclosed herein. [000159] In some embodiments, the second therapy is selected from the group consisiting of anticoagulants, diuretics, a digitalis glycosideglycosides, calcium channel blockers, endothelin receptor antagonists, phosphodiesterase 5 (PDE5) inhibitors, prostanoids, prostanoids receptor agonists, soluble guanylate cyclase stimulators, and/or surgery. [000160] In some embodiments, the second therapy is oxygen, Warfarin, furosemide, bumetanide, bendroflumethiazide, metolazone, spironolactone, amiloride, Digoxin, nifedipine, diltiazem, nicardipine, amlodipine, ambrisentan, bosentan, macitentan, sildenafil, tadalafil, epoprostenol, iloprost, treprostinil, riociguat, selexipag, surgery, pulmonary endarterectomy, and/or atrial septostomy. In some embodiments, the second therapy is macitentan and/or tadalafil. Flolan (prostacyclin analog) is an approved therapy for PAH, but is extremely cumbersome and inconvenient to use (intravenous), and has unique safety concerns. As a result, Flolan is usually reserved for patients with severe functional status or rapidly progressive PAH. Patients must constitute the drug in sterile conditions several times daily. The drug is available as a freeze-dried preparation that needs to be dissolved in alkaline buffer. Because of its short half-life (3-5 min) and stability (8 h at room temperature), Flolan must be maintained in a refrigerated state while given by continuous infusion through a central venous catheter via a portable pump that is worn in a bag around the waist (CADD pump, Smith's Medical MD, St. Paul, Minn.). In 2008, the FDA also approved a new continuous intravenous formulation of epoprostenol that is stable at room temperature for up to 24 h after dilution and may be stored up to 5 days at refrigerator temperature before use (GeneraMedix Inc., Liberty Corner, N.J.). In 2009, GeneraMedix Inc. sold this formulation to Actelion, which began to market the drug (under the brand name Veletri) in April 2010. In late 2010, the Veletri label was expanded to allow preparation of medication up to 7 days at refrigerator temperature or up Attorney Docket No. MORF-016WO1 to 48 h at room temperature in advance of use. Thus, in one embodiment of the invention, an integrin a5b1 inhibitor is administered in combination with epoprostenol, in any of its approved forms, to treat PAH. [000161] Remodulin (continuous subcutaneous infusion form of prostacyclin analog) was not generally used as initial therapy because of its expense, route of delivery, and limited efficacy. In 2004, the FDA and Health Canada approved an intravenous formulation of Remodulin for patients with PAH class II-IV disease who cannot tolerate the subcutaneous form. In early 2006, the FDA expanded the Remodulin label to include patients requiring transition from Flolan. In 2009, United Therapeutics received FDA approval for an inhaled formulation of treprostinil (Tyvaso). Thus, in one embodiment of the invention, an integrin a5b1 inhibitor is administered in combination with treprostinil to treat PAH. [000162] Ventavis (iloprost), a prostacyclin analogue administered via inhalation is also marketed in several member countries of the EU as Ilomedine as an intravenous formulation. The label for inhaled iloprost in the EU is restricted to patients with idiopathic PAH and functional class III symptoms. In contrast, the label in the US is broader: patients with PAH (regardless of etiology) and class III or IV symptoms. It is required 6 to 9 times a day administration. Thus, in one embodiment of the invention, an integrin a5b1 inhibitor is administered in combination with iloprost, in any of its approved forms, to treat PAH. [000163] In 2001, the nonselective ERA Tracleer (bosentan) became the first oral PAH therapy and was available only through a special centralized access program in the US because of its significant risk of (reversible) liver injury, teratogenicity, testicular atrophy, and male sterility. Treatment with Tracleer consists of an initial dosage of 62.5 mg twice daily for 4 weeks, followed by a maintenance dose of 125 mg twice daily. Tracleer was initially indicated for patients with PAH and moderate or severe functional status (WHO class III, IV). In 2008 (EU) and 2009 (US), the label was expanded to patients with mild symptoms (functional class II). Thus, in one embodiment of the invention, an integrin a5b1 inhibitor is administered in combination with bosentan, in any of its approved forms, to treat PAH. [000164] Ambrisentan is the oral selective ERA-receptor antagonist marketed by Gilead Sciences in the US (Letairis) and by GlaxoSmithKline in other regions (Volibris) for the once- daily treatment of patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening. As with bosentan, ambrisentan has class effects of teratogenicity, testicular injury, reduced male fertility, and anemia. Thus, in one embodiment of the invention, Attorney Docket No. MORF-016WO1 an integrin a5b1 inhibitor is administered in combination with ambrisentan, in any of its approved forms, to treat PAH. [000165] The oral PDE-5 inhibitor Revatio (sildenafil) was approved in the US for the treatment of PAH (WHO Group I) to improve exercise ability and delay of clinical worsening at a dose of 20 mg three times daily, regardless of functional class or etiology. The EU label is restricted to improvement of exercise capacity in patients with PAH, which is either idiopathic or associated with collagen vascular disease and with functional class III status. In 2009, the FDA approved an intravenous form of Revatio given as an injection (10 mg 3-times a day) for a patient unable to take the oral formulation. In May 2010, the EU approved Revatio as an oral suspension (compounded from 20 mg tablets) for the treatment of pediatric patient aged 1 to 17 years with PAH. Thus, in one embodiment of the invention, an integrin a5b1 inhibitor is administered in combination with sildenafil, in any of its approved forms, to treat PAH. [000166] The oral PDE-5 Inhibitor Adeirca (tadalafil) 40 mg once daily is indicated in the US to improve exercise ability in patients with PAH (WHO Group I) regardless of etiology or functional class (Packet Insert). The EU label is restricted to patients with functional class II and III status. Tadalafil has a long half-life (35 h) in patients with PAH (US Packet Insert) has also shown benefit in patients with PAH on concomitant bosentan. [000167] Thus, the method of treating the patient may involve administering at least one additional active agent, i.e., in addition to an integrin a5b1 inhibitor. The additional active agent may be, for example, a vasodilator such as prostacyclin, epoprostenol, and sildenafil; an endothelin receptor antagonist such as bosentan; a calcium channel blocker such as amlodipine, diltiazem, and nifedipine; an anticoagulant such as warfarin; a diuretic, a prostanoid (e.g., prostacyclin or PGI2), drugs for treating diseases associated with overactive B cells or dysfunctional B cells such as Rituximab, and/or a Type V phosphodiesterase (PDE5) inhibitor. [000168] When the method of the invention involves combination therapy, i.e., wherein a secondary agent such as a vasodilator is co-administered with an integrin a5b1 inhibitor, the agents may be administered separately, at the same, or at different times of the day, or they may be administered in a single composition. Thus, the present invention provides novel pharmaceutical formulations in which an integrin a5b1 inhibitor is combined with one of the active agents discussed above and unit dose forms of those formulations. [000169] In the combination therapies of the invention, each agent can be administered in an “immediate release” manner or in a “controlled release manner.” When the additional active Attorney Docket No. MORF-016WO1 agent is a vasodilator, for instance, any dosage form containing both active agents i.e., both the integrin a5b1 inhibitor and the vasodilator, can provide for immediate release or controlled release of the vasodilator, and either immediate release or controlled release of the integrin a5b1 inhibitor. [000170] As a general example, a combination dosage form of the invention for once- daily administration might contain in the range of about 1 mg to about 1000 mg of an integrin a5b1 inhibitor of an integrin a5b1 inhibitor, in a controlled release (e.g., sustained release) or immediate release form, and either sildenafil in immediate release form, or in controlled release form, with the additional active agent present in an amount that provides a weight ratio of the an integrin a5b1 inhibitor to sildenafil, or a weight ratio of the an integrin a5b1 inhibitor to sildenafil, specified as above. In other formulations of the invention, two or more additional active agents, which may or may not be in the same class of drug (e.g., vasodilators), can be present in combination, along with an integrin a5b1 inhibitor. In such a case, the effective amount of either or each individual additional active agent present will generally be reduced relative to the amount that would be required if only a single added agent were used. [000171] The additional active agent may also be, as discussed above, a Type V phosphodiesterase inhibitor, administered with an integrin a5b1 inhibitor, or with both the integrin a5b1 inhibitor and a vasodilator. Examples of Type V phosphodiesterase inhibitors include, without limitation, avanafil, sildenafil, tadalafil, zaprinast, dipyridamole, vardenafil and acid addition or other pharmaceutically acceptable salts thereof. Sildenafil is an excellent example. In an exemplary embodiment, an integrin a5b1 inhibitor is co-administered with a Type V phosphodiesterase inhibitor selected from the group consisting of avanafil, tadalafil, and sildenafil, and the daily dose of a compound of the integrin a5b1 inhibitor is a given above for the monotherapeutic regimen. [000172] In one embodiment, the vasodilator is selected from sildenafil, avanafil, tadalafil, zaprinast, dipyridamole, vardenafil, bosentan, and pharmaceutically acceptable salts thereof. The additional active agent may also be, as discussed above, an endothelin receptor antagonist, e.g., bosentan, sitaxsentan, or ambrisentan, with bosentan being an exemplary active agent. [000173] A pharmaceutical composition of the invention is a pharmaceutical formulation containing an active agent formulated in a manner compatible with its intended route of administration. A variety of routes are contemplated, including but not limited to, oral, pulmonary, inhalational, sublingual, intranasal, parenteral, intradermal, transdermal, topical, Attorney Docket No. MORF-016WO1 transmucosal, subcutaneous, intravenous, intramuscular, intraperitoneal, buccal, rectal, and the like. The term “parenteral” as used herein is intended to include subcutaneous, intravenous, and intramuscular injection. [000174] Generally, pharmaceutical formulations of the invention are prepared for oral administration and in an immediate release form suitable for once per day (QD) administration. Certain formulations are suitable for intranasal administration to a patient. [000175] Certain pharmaceutical formulations of the invention comprise an integrin a5b1 inhibitor or a salt thereof and one or more pharmaceutically acceptable (approved by a state or federal regulatory agency for use in humans, or is listed in the U.S. Pharmacopia, the European Pharmacopia) excipients or carriers. The term excipient or carrier as used herein broadly refers to a biologically inactive substance used in combination with the active agents of the formulation. An excipient can be used, for example, as a solubilizing agent, a stabilizing agent, a diluent, an inert carrier, a preservative, a binder, a disintegrant a coating agent, a flavoring agent, or a coloring agent. Preferably, at least one excipient is chosen to provide one or more beneficial physical properties to the formulation, such as increased stability and/or solubility of the active agent(s). An integrin a5b1 inhibitor or a salt thereof as described herein is an exemplary active agent suitable for use in the formulations of the present invention. [000176] Examples of suitable excipients include certain inert proteins such as albumins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as aspartic acid (which may alternatively be referred to as aspartate), glutamic acid (which may alternatively be referred to as glutamate), lysine, arginine glycine, and histidine; fatty acids and phospholipids such as alkyl sulfonates and caprylate; surfactants such as sodium dodecyl sulphate and polysorbate; nonionic surfactants such as such as TWEEN®, PLURONICS®, or polyethylene glycol (PEG); carbohydrates such as glucose, sucrose, mannose, maltose, trehalose, and dextrins, including cyclodextrins; polyols such as mannitol and sorbitol; chelating agents such as EDTA; and salt-forming counter-ions such as sodium. [000177] Solutions or suspensions used for the delivery can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol, polysorbate, tocopherol polyethylene glycol succinate (TPGS), or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents Attorney Docket No. MORF-016WO1 for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. These preparations can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. [000178] In some embodiments, the pharmaceutical formulations of the present invention contain a plurality of liposomes or microparticles comprising the integrin a5b1 inhibitor active agent. In various embodiments, the pharmaceutical formulation of the integrin a5b1 inhibitor is a powder comprising solid particles (e.g., liposomes or microparticles) suitable for administration via inhalation. The solid particles comprise the active agent, a carrier, optionally a surfactant, and optionally additional recipients. The powder may be prepared by any convenient method. An example of a preparatory method is spray drying a solution containing the active agent (and other components) onto a powder comprising the carrier compound. Another example is freeze drying a solution comprising all of the components of the final powder. [000179] Suitable liposomes for use in the present formulations of the invention are known in the art. For example, suitable liposomes include cholesterol, 1,2-distearoyl-sn- glycero-3- phosphocholine (DSPC) and PEG-DSPE, with the weight ratio being about 5:10:1. In some embodiments, the liposome formulation comprises about 0.1-25%, e.g., 0.1%, 1%, 5%, 10% or 20% (w/w) of a phospholipid, such as dipalmitoylphosphatidylcholine (DPPC) and 1,2- distearoyl-sn-glycero-3-phosphocholine (DSPC). In some embodiments, the liposome formulation comprises about 0.5-20%, e.g., 1%, 5%, or 10% (w/w) of a hydrophilic polymer, such as polyvinylpyrrolidone (PVP). In some embodiments, the liposome formulation comprises about 10-35% of an amino acid, such L-leucine. [000180] Suitable microparticles for use in the formulations of the invention are known in the art. For example, microparticles are formed of one or more hydrophilic polymers such as polyvinylpyrrolidone (e.g., PVP-10), polyvinyl alcohol (e.g., PVA-30), polyvinyl acetate, or Poloxamer (e.g., Poloxamer-188). In some embodiments, the microparticle formulation comprises about 70-85 wt % of polyvinyl alcohol (e.g., PVA-30), about 5-15% PVP (e.g., PVP-10), 1-5% Poloxamer (e.g., Poloxamer-188), 0-10% L-leucine, and about 0.5-10% of an integrin a5b1 inhibitor compound (e.g., 5%). In some embodiments, the formulation is suitable for administration via the respiratory tract. [000181] The pharmaceutical formulations of an integrin a5b1 inhibitor useful in the methods of the invention can be prepared as a liquid or in a solid form such as a powder, tablet, Attorney Docket No. MORF-016WO1 pill, or capsule for oral administration. Liquid formulations of the invention may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. In one embodiment, the formulation is an aqueous solution. In another embodiment, the final formulation is lyophilized. In some embodiments, the integrin a5b1 inhibitor is formulated for inhalation. [000182] In various embodiments, the formulations of the invention comprise an integrin a5b1 inhibitor at a concentration of from 0.25 wt % to 100 wt %, or from 0.25 wt % in 50 wt %, or from 0.8 wt % to 25 wt %, or from 1 wt % to 10%, or from 1.5 wt % to 5 wt %. In certain embodiments, an integrin a5b1 inhibitor compound is formulated at a concentration of from about 0.5 wt % to about 5 wt %. In certain embodiments, an integrin a5b1 inhibitor compound is formulated at a concentration of about 0.25 wt % to about 10 wt %. [000183] The present invention also provides a pharmaceutical pack or kit comprising one or more containers filled with a solid or liquid formulation of an integrin a5b1 inhibitor. In a particular embodiment, the formulation is a powder formulation of an integrin a5b1 inhibitor. In various embodiments, an integrin a5b1 inhibitor is formulated at a concentration of at least about 0.5 wt % and the formulation is suitable for delivery via inhalation to a human. [000184] The present invention also provides for a use of a formulation of an integrin a5b1 inhibitor in the manufacture of a medicament for treating PAH, or a disorder disclosed herein, in a subject in need thereof. Generally, the pharmaceutical formulation is sterile. [000185] Generally, the dosage forms, e.g., an inhalable dosage form, provide for sustained release, i.e., gradual, release of a compound of the current invention, for e.g., an integrin a5b1 inhibitor, from the dosage form to the patient's body over an extended time period, typically providing for a substantially constant blood level of the agent over a time period in the range of about 4 to about 12 hours, typically in the range of about 6 to about 10 hours. In a particularly preferred embodiment, there is a very gradual increase in blood level of the drug following nasal administration of the dosage form containing a compound of the current invention, for e.g., an integrin a5b1 inhibitor, such that peak blood level is not reached until at least 4-6 hours have elapsed, with the rate of increase of blood level drug approximately linear. In addition, in the preferred embodiment, there is an equally gradual decrease in blood level at the end of the sustained release period. Attorney Docket No. MORF-016WO1 [000186] Although the pharmaceutical compositions of the invention are preferably formulated for inhalation, e.g., as a solution in saline, as a dry powder, or as an aerosol, other modes of administration are suitable as well. For example, administration may be sublingual, oral, parenteral, transdermal, via an implanted depot, transmucosal, e.g., rectal or vaginal, preferably using a suppository that contains, in addition to the active agent, excipients such as a suppository wax. Transmucosal administration also encompasses transurethral. [000187] Depending on the intended mode of administration, the pharmaceutical formulation may be a solid, semi-solid or liquid, such as, for example, a tablet, as capsule, a caplet, a liquid, a suspension, an emulsion, a suppository, granules, pellets, beads, a powder, or the like, preferably in unit dosage form suitable for single administration of a precise dosage. Suitable pharmaceutical compositions and dosage forms may be prepared using conventional methods known to those in the field of pharmaceutical formulation and described in the pertinent texts and literature, e.g., in Remington: The Science and Practice of Pharmacy (Easton, Pa.: Mack Publishing Co., 1995). For those compounds that are orally active, oral dosage forms are generally preferred, and include tablets, capsules, caplets, solutions, suspensions and syrups, and may also comprise a plurality of granules, beads, powders, or pellets that may or may not be encapsulated. Preferred oral dosage forms are tablets and capsules. [000188] In embodiments, it may be especially advantageous to formulate compositions of the invention in unit dosage form for ease of administration and uniformity of dosage. The term “unit dosage forms” as used herein refers to physically discrete units suited as unitary dosages for the individuals to be treated. That is, the compositions are formulated into discrete dosage units each containing a predetermined, “unit dosage” quantity of an active agent calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specifications of unit dosage forms of the invention are dependent on the unique characteristics of the active agent to be delivered. Dosages can further be determined by reference to the usual dose and manner of administration of the ingredients. It should be noted that, in some cases, two or more individual dosage units in combination provide a therapeutically effective amount of the active agent, e.g., two tablets or capsules taken together may provide a therapeutically effective dosage of an integrin a5b1 inhibitor, such that the unit dosage in each tablet or capsule is approximately 50% of therapeutically effective amount. Attorney Docket No. MORF-016WO1 [000189] Tablets may be manufactured using standard tablet processing procedures and equipment. Direct compression and granulation techniques are preferred. In addition to the active agent, tablets will generally contain inactive, pharmaceutically acceptable carrier materials such as binders, lubricants, disintegrants, fillers, stabilizers, surfactants, coloring agents, and the like. [000190] Capsules are another oral dosage forms for those compounds of the current invention, e.g., an integrin a5b1 inhibitors, that are orally active, in which case the active agent-containing composition may be encapsulated in the form of a liquid or solid (including particulates such as granules, beads, powders or pellets). Suitable capsules may be either hard or soft, and are generally made of gelatin, starch, or a cellulosic material, with gelatin capsules preferred. Two-piece hard gelatin capsules are preferably sealed, such as with gelatin bands or the like. See, for example, Remington: The Science and Practice of Pharmacy, cited earlier herein, which describes materials and methods for preparing encapsulated pharmaceuticals. [000191] Oral dosage forms, whether tablets, capsules, caplets, or particulates, if desired, may be formulated so as to provide for controlled release of the compounds of the current invention, for e.g., an integrin a5b1 inhibitors, and in a preferred embodiment, the present formulations are controlled release oral dosage forms. [000192] Generally, as will be appreciated by those of ordinary skill in the art, sustained release dosage forms are formulated by dispersing the active agent within a matrix of a gradually hydrolyzable material such as a hydrophilic polymer, or by coating a solid, drug- containing dosage form with such a material. Hydrophilic polymers useful for providing a sustained release coating or matrix include, by way of example: cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, cellulose acetate, and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, preferably formed from acrylic acid, methacrylic acid, acrylic acid alkyl esters, methacrylic acid alkyl esters, and the like, e.g. copolymers of acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate; and vinyl polymers and copolymers such as polyvinyl pyrrolidone, polyvinyl acetate, and ethylene-vinyl acetate copolymer. [000193] Preparations according to this invention for parenteral administration include sterile aqueous and nonaqueous solutions, suspensions, and emulsions. Injectable aqueous solutions contain the active agent in water-soluble form. Examples of nonaqueous solvents or Attorney Docket No. MORF-016WO1 vehicles include fatty oils, such as olive oil and corn oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, low molecular weight alcohols such as propylene glycol, synthetic hydrophilic polymers such as polyethylene glycol, liposomes, and the like. Parenteral formulations may also contain adjuvants such as solubilizers, preservatives, wetting agents, emulsifiers, dispersants, and stabilizers, and aqueous suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, and dextran. Injectable formulations are rendered sterile by incorporation of a sterilizing agent, filtration through a bacteria-retaining filter, irradiation, or heat. They can also be manufactured using a sterile injectable medium. The active agent may also be in dried, e.g., lyophilized, form that may be rehydrated with a suitable vehicle immediately prior to administration via injection. [000194] The active agent may also be administered through the skin using conventional transdermal drug delivery systems, wherein the active agent is contained within a laminated structure that serves as a drug delivery device to be affixed to the skin. In such a structure, the drug composition is contained in a layer, or “reservoir,” underlying an upper backing layer. The laminated structure may contain a single reservoir, or it may contain multiple reservoirs. In one embodiment, the reservoir comprises a polymeric matrix of a pharmaceutically acceptable contact adhesive material that serves to affix the system to the skin during drug delivery. Alternatively, the drug-containing reservoir and skin contact adhesive are present as separate and distinct layers, with the adhesive underlying the reservoir which, in this case, may be either a polymeric matrix as described above, or it may be a liquid or hydrogel reservoir, or may take some other form. Transdermal drug delivery systems may in addition contain a skin permeation enhancer. [000195] In addition to the formulations described previously, the active agent may be formulated as a depot preparation for controlled release of the active agent, preferably sustained release over an extended time period. These sustained release dosage forms are generally administered by implantation (e.g., subcutaneously or intramuscularly or by intramuscular injection). [000196] Certain compounds or active agents of the present invention are capable of further forming salts. All of these forms are also contemplated within the scope of the claimed invention. The compounds of the present invention can also be prepared as esters, for example, pharmaceutically acceptable esters. For example, a carboxylic acid function group in Attorney Docket No. MORF-016WO1 a compound can be converted to its corresponding ester, e.g., a methyl, ethyl or other ester. Also, an alcohol group in a compound can be converted to its corresponding ester, e.g., an acetate, propionate or other ester. [000197] Certain compounds of the present invention can also be prepared as prodrugs, for example, pharmaceutically acceptable prodrugs. The terms “pro-drug” and “prodrug” are used interchangeably herein and refer to any compound which releases an active parent drug in vivo. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.), the compounds of the present invention can be delivered in prodrug form. Thus, the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same. “Prodrugs” are intended to include any covalently bonded carriers that release an active parent drug of the present invention in vivo when such prodrug is administered to a subject. Prodrugs in the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of the present invention wherein a hydroxy, amino, sulfhydryl, carboxy or carbonyl group is bonded to any group that may be cleaved in vivo to form a free hydroxyl, free amino, free sulfhydryl, free carboxy or free carbonyl group, respectively. [000198] Examples of prodrugs include, but are not limited to, esters (e.g., acetate, dialkylaminoacetates, formates, phosphates, sulfates and benzoate derivatives) and carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups, esters (e.g., ethyl esters, morpholinoethanol esters) of carboxyl functional groups, N-acyl derivatives (e.g., N-acetyl) N- Mannich bases, Schiff bases and enaminones of amino functional groups, oximes, acetals, ketals and enol esters of ketone and aldehyde functional groups in compounds of the invention, and the like, See Bundegaard, H., Design of Prodrugs, p 1-92, Elesevier, New York-Oxford (1985). [000199] The dosage regimen utilizing the compounds is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition. Attorney Docket No. MORF-016WO1 [000200] In some embodiments, the composition is suitable for inhalation. In one embodiment, the composition is an inhalable formulation used for treating PAH, or a disorder disclosed herein. [000201] In still another aspect, the present disclosure provides a pharmaceutical composition comprising an integrin a5b1 inhibitor and a plurality of particles, wherein the plurality of particles is a plurality of liposomes comprising 1,2-distearoyl-sn-glycero-3- phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE) or a plurality of microparticles comprising a hydrophilic polymer. In one embodiment, the composition is suitable for inhalation, in one embodiment, the composition is an inhalable formulation used for treating PAH, or a disorder disclosed herein. Pharmaceutical Compositions [000202] The pharmaceutical compositions described herein can be administered in a variety of different ways. Examples include administering a pharmaceutical composition comprising a peptide according to the invention or multimeric, preferably peptide according to the invention and containing a pharmaceutically acceptable carrier via oral, intranasal, rectal, topical, intraperitoneal, intravenous, intramuscular, subcutaneous, subdermal, transdermal, intrathecal, and intracranial methods. For oral administration, the active ingredient can be administered in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. [000203] Pharmaceutical compositions according to the invention comprise at least one pharmaceutically acceptable carrier, diluent or excipient. Examples of suitable carriers for instance comprise keyhole limpet haemocyanin (KLH), serum albumin (e.g. BSA or RSA) and ovalbumin. In some embodiments said suitable carrier is a solution, for example saline. Examples of excipients which can be incorporated in tablets, capsules and the like are the following: a binder such as gum tragacanth, acacia, corn starch or gelatine; an excipient such as microcrystalline cellulose; a disintegrating agent such as corn starch, pregelatinized starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; a flavoring agent such as peppermint, oil of wintergreen or cherry. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose Attorney Docket No. MORF-016WO1 as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor. A pharmaceutical composition according to the invention is preferably suitable for human use. [000204] Sterile compositions for injection can be formulated according to conventional pharmaceutical practice by dissolving or suspending the integrin a5b1 inhibitor of the invention in a vehicle for injection, such as water or a naturally occurring vegetable oil like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or a synthetic fatty vehicle like ethyl oleate or the like. Buffers, preservatives, antioxidants and the like may also be incorporated. [000205] Compositions for topical administration can also be formulated according to conventional pharmaceutical practice. “Topical administration” as used herein refers to application to a body surface such as the skin or mucous membranes to locally treat conditions resulting from microbial or parasitic infections. Examples of formulations suitable for topical administration include, but are not limited to a cream, gel, ointment, lotion, foam, suspension, spray, aerosol, powder aerosol. Topical medicaments can be epicutaneous, meaning that they are applied directly to the skin. Topical medicaments can also be inhalational, for instance for application to the mucosal epithelium of the respiratory tract, or applied to the surface of tissues other than the skin, such as eye drops applied to the conjunctiva, or ear drops placed in the ear. Said pharmaceutical composition formulated for topical administration preferably comprises at least one pharmaceutical excipients suitable for topical application, such as an emulsifier, a diluent, a humectant, a preservatives, a pH adjuster and/or water. Exemplary Embodiments [000206] The following examples are set forth to assist in understanding the invention and should not be construed as specifically limiting the invention described and claimed herein. Such variations of the invention, including the substitution of all equivalents now known or later developed, that would be within the purview of those skilled in the art, and changes in formulation or changes in experimental design, are to be considered to fall within the scope of the invention incorporated herein. [000207] Certain examples below relate to methods for treating or preventing a disease responsive to an α5β1 integrin inhibitor by administering a compound of formula (I) to a human in need of such treatment. Attorney Docket No. MORF-016WO1 EXAMPLES [000208] Certain compounds contained in compositions of the present invention may exist in particular geometric or stereoisomeric forms. In addition, polymers of the present invention may also be optically active. The present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)- isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention. [000209] If, for instance, a particular enantiomer of compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers. Examples Abbreviations Abbreviation Chemical Name 9-BBN 9-Borabicyclo[3.3.1]nonane dimer Ac acetyl ACN acetonitrile (4- (N,N-Dimethylamino)phenyl)di-tert-butylphosphine, [4- APhos Pd G3 (Di-tert-butylphosphino)-N,N-dimethylaniline-2- (2′- aminobiphenyl)]palladium (II) methanesulfonate Boc tert-butyloxycarbonyl Bu butyl CMBP 4-Chlorine-4′-Maleimide Benzophenone cod cyclooctadiene Cp cyclopentadienyl dba dibenzylideneacetone DCM dichloromethane DIAD Diisopropyl azodicarboxylate DIBAL Diisobutylaluminium DIEA N,N-diisopropylethylamine DMF dimethyl formamide DMSO dimethyl sulfoxide Attorney Docket No. MORF-016WO1 dppf 1,1-bis(diphenylphosphino)ferrocene dtbpy 4,4′-Di-tert-butyl-2,2′-dipyridyl Et ethyl HATU Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium HMDS Hexamethyldisilazane Hz Hertz iPr isopropyl LDA lithium diisopropyl amide m-CPBA Meta-chloroperbenzoic acid Me methyl MOM methoxymethyl MTBE Methyl tert-butyl ether NBS N-bromosuccinimide NMR Nuclear Magnetic Resonance Ph phenyl Pin pinacolato Piv 2,2-dimethylacetyl prep-HPLC preparative high performance liquid chromatography SFC supercritical fluid chromatography TBAI Tetrabutylammonium Iodide t-Bu tertiary-butyl TEA triethylamine Tf trifluoromethanesulfonyl TFA trifluoroacetic acid THF tetrahydrofuran TLC Thin layer chromatography TMEDA Tetramethylethylenediamine TMS trimethylsilyl Ts p-toluenesulfonyl Analytical Methods, Materials, and Instrumentation [000210] Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. Left-Side Intermediates Attorney Docket No. MORF-016WO1 Preparation of (1S,3S)-N-methyl-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentan-1-amine
Figure imgf000072_0001
[000211] To a solution of LiAlH4 (18.86 g, 496.86 mmol, 2 eq) in THF (500 mL) was added dropwise 1/3 solution of tert-butyl ((1S,3S)-3-hydroxycyclopentyl)carbamate (50 g, 248.43 mmol, 1 eq) in THF (500 mL) slowly at 20 oC under N2 and the solution was stirred at 80 oC, then the 2/3 solution of tert-butyl ((1S,3S)-3-hydroxycyclopentyl)carbamate was added to the solution slowly at 80 oC under N2 and the solution was stirred at 80 oC for 2 hrs. TLC (Petroleum ether/Ethyl acetate = 1/1) indicated the starting material was consumed completely and one new spot formed. The reaction mixture was quenched by H2O (20 mL), aq NaOH (15%, 20 mL) and H2O (60 mL) dropwise slowly at 10 °C under N2. The mixture was dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. (1S,3S)-3-(methylamino)cyclopentan-1-ol (28.61 g, crude) was obtained as yellow oil. The residue was used directly without further purification. Step 2: tert-butyl ((1S,3S)-3-hydroxycyclopentyl)(methyl)carbamate
Figure imgf000072_0002
[000212] To a solution of (1S,3S)-3-(methylamino)cyclopentan-1-ol (56 g, 486.23 mmol, 1 eq) in THF (600 mL) was added NaHCO3 (81.69 g, 972.45 mmol, 37.82 mL, 2 eq) in H2O (90 mL) and (Boc)2O (137.95 g, 632.09 mmol, 145.21 mL, 1.3 eq) at 25 oC under N2 and the Attorney Docket No. MORF-016WO1 solution was stirred at 25 oC for 16 hrs. TLC (Petroleum ether/Ethyl acetate = 1/1, Rf = 0.4) indicated the starting material was consumed completely and one new spot formed. H2O (200 mL) was added to the reaction and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 1/1). tert-butyl ((1S,3S)-3- hydroxycyclopentyl)(methyl)carbamate (82.16% yield) was obtained as a yellow oil. 1H NMR (400 MHz, CHLOROFORM-d) δ = 4.74 (br s, 1H), 4.39 (br s, 1H), 2.73 (s, 3H), 2.03 - 1.97 (m, 2H), 1.88 - 1.72 (m, 2H), 1.66 - 1.54 (m, 2H), 1.47 (s, 9H). Step 3: tert-butyl ((1S,3S)-3-(4-bromobutoxy)cyclopentyl)(methyl)carbamate
Figure imgf000073_0001
[000213] To To a solution of tert-butyl ((1S,3S)-3-hydroxycyclopentyl)(methyl)carbamate (85 g, 394.82 mmol, 1 eq), NaOH (247.09 g, 6.18 mol, 500 mL, 15.65 eq) in toluene (1000 mL) was added 1,4-dibromobutane (170.49 g, 789.64 mmol, 95.25 mL, 2 eq) and TBAI (218.75 g, 592.23 mmol, 1.5 eq) at 25 °C and the solution was stirred at 50 oC for 16 hrs. TLC (Petroleum ether/Ethyl acetate = 5/1, Rf = 0.6) indicated the starting material remained and one new spot formed. The reaction mixture was quenched by addition H2O (1000mL) at 0 oC, extracted with ethyl acetate (300 mL x 3). The combined organic layers were washed with brine (300 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 5/1). tert-butyl ((1S,3S)-3-(4- bromobutoxy)cyclopentyl)(methyl)carbamate (28.92% yield) was obtained as a yellow oil. 1H NMR (400 MHz, CHLOROFORM-d) δ = 4.61 (br s, 1H), 3.91 (br d, J = 2.9 Hz, 1H), 3.47 - 3.37 (m, 4H), 2.72 (s, 3H), 2.00 - 1.82 (m, 6H), 1.72 - 1.62 (m, 4H), 1.46 (s, 9H). Step 4: tert-butyl ((1S,3S)-3-(but-3-en-1-yloxy)cyclopentyl)(methyl)carbamate
Figure imgf000073_0002
[000214] To a solution of tert-butyl ((1S,3S)-3-(4- bromobutoxy)cyclopentyl)(methyl)carbamate (33 g, 94.21 mmol, 1 eq) in THF (400 mL) was added t-BuOK (26.43 g, 235.52 mmol, 2.5 eq) at 0 °C and the mixture was stirred at 20 °C for 16 hrs. TLC (Petroleum ether/Ethyl acetate = 5/1, Rf = 0.61) indicated the starting material Attorney Docket No. MORF-016WO1 was consumed completely and one new spot formed. The reaction mixture was quenched by addition H2O (100 mL) at 0oC, extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 5/1). tert-butyl ((1S,3S)-3- (but-3-en-1-yloxy)cyclopentyl)(methyl)carbamate (90.63% yield) was obtained as a yellow oil. 1H NMR (400 MHz, CHLOROFORM-d) δ = 5.82 (tdd, J = 6.7, 10.3, 17.1 Hz, 1H), 5.14 - 4.99 (m, 2H), 4.61 (br s, 1H), 3.94 - 3.89 (m, 1H), 3.43 - 3.37 (m, 2H), 2.72 (s, 3H), 2.32 - 2.27 (m, 2H), 1.99 - 1.84 (m, 4H), 1.69 - 1.61 (m, 2H), 1.46 (s, 9H). Step 5: tert-butyl 7-(4-(((1S,3S)-3-((tert-butoxycarbonyl)(methyl)amino)- cyclopentyl)oxy)butyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate
Figure imgf000074_0001
[000215] To a solution of tert-butyl ((1S,3S)-3-(but-3-en-1- yloxy)cyclopentyl)(methyl)carbamate (23 g, 85.38 mmol, 1 eq) in THF (50 mL) was added 9- BBN (0.5 M, 341.53 mL, 2 eq) and the mixture was stirred at 25 °C for 2 hrs. TLC (Petroleum ether/Ethyl acetate = 5/1, Rf = 0.53) indicated the starting material was consumed completely and one new spot formed. The above solution (34.87 g, 89.09 mmol, 1 eq) in tAmylOH (400 mL) was added tert-butyl 7-chloro-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate (21.55 g, 80.18 mmol, 0.9 eq), APhos Pd G3 (5.66 g, 8.91 mmol, 0.1 eq) and Cs2CO3 (58.06 g, 178.18 mmol, 2 eq) at 25 °C. The mixture was stirred under N2 at 80°C for another 14 hrs. LCMS showed the starting material was consumed completely and one main peak with desired mass was detected. The reaction mixture was quenched by addition H2O (500mL) at 0 oC, extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (200 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 1/1). tert-butyl 7-(4-(((1S,3S)-3-((tert-butoxycarbonyl)(methyl)amino)- cyclopentyl)oxy)butyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate (62.40% yield) was obtained as red oil.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.23 (br d, J = 7.6 Hz, 1H), Attorney Docket No. MORF-016WO1 6.75 (d, J = 7.6 Hz, 1H), 3.90 - 3.77 (m, 1H), 3.70 - 3.66 (m, 2H), 3.31 (t, J = 6.6 Hz, 2H), 2.65 (br s, 3H), 2.64 (s, 3H), 1.92 - 1.74 (m, 6H), 1.73 - 1.50 (m, 8H), 1.45 (s, 9H), 1.38 (s, 9H). Step 6: (1S,3S)-N-methyl-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentan-1-amine
Figure imgf000075_0001
[000216] To a solution of tert-butyl 7-(4-(((1S,3S)-3-((tert-butoxycarbonyl)(methyl)amino)- cyclopentyl)oxy)butyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate (28 g, 55.59 mmol, 1 eq) in DCM (300 mL) was added TFA (153.50 g, 1.35 mol, 100.00 mL, 24.22 eq) at 25 oC under N2 and the solution was stirred at 25 oC for 16 hrs. LCMS showed the starting material was consumed completely and one main peak with desired mass was detected. The residue was adjusted to pH ~7 by aq. NaHCO3 solution, extracted with DCM (100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Welch Xtimate C18250 x 100 mm x 10 um; mobile phase: [water (NH3H2O+NH4HCO3)-ACN];B%: 0%-50%,35min) to give (1S,3S)-N-methyl-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentan-1-amine (54.54% yield) as a yellow oil. [000217] LCMS: [M+1] = 304.2; SFC: Rt = 2.070 min; 1H NMR (400 MHz, METHANOL- d4) δ = 7.11 (d, J = 7.4 Hz, 1H), 6.35 (d, J = 7.4 Hz, 1H), 4.07 - 3.82 (m, 1H), 3.41 - 3.34 (m, 4H), 3.10 (quin, J = 7.1 Hz, 1H), 2.68 (t, J = 6.3 Hz, 2H), 2.51 (t, J = 7.6 Hz, 2H), 2.32 (s, 3H), 2.03 - 1.91 (m, 3H), 1.90 - 1.83 (m, 2H), 1.71 - 1.59 (m, 3H), 1.57 - 1.46 (m, 3H), 1.38 - 1.28 (m, 1H). Preparation of rac-(1S,4R)-N,3,3-trimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-
Figure imgf000075_0002
Step 1: 5-bromo-2,2-dimethylcyclopentan-1-one Attorney Docket No. MORF-016WO1
Figure imgf000076_0001
[000218] To a solution of 2,2-dimethylcyclopentan-1-one (250 g, 2.23 mol, 279.64 mL, 1 eq) in DCM (2000 mL) was added a solution of Br2 (391.8 g, 2.45 mol, 126.31 mL, 1.1 eq) in DCM (500 mL) at 0 oC. The mixture was allowed to stir at 20 oC for 16 hrs. The reaction was quenched by the addition of H2O (2000 mL) and sat. NaS2O3 was added at 25 oC until the solution turned colorless. The pH of the solution was adjusted to pH = 7 by the addition of sat. NaHCO3. The mixture was diluted with DCM (2000 mL) and extracted with DCM (1000 mL x 3). The organic solutions were combined, washed with brine (1000 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give 5-bromo-2,2-dimethylcyclopentan-1- one (350 g, crude) as a brown solid. Step 2: 5,5-dimethylcyclopent-2-en-1-one
Figure imgf000076_0002
[000219] A mixture of 5-bromo-2,2-dimethylcyclopentan-1-one (350 g, 1.83 mol, 1 eq) and DBU (334.65 g, 2.20 mol, 331.34 mL, 1.2 eq) in MTBE (2000 mL) was degassed and purged with nitrogen 3 times. The mixture was allowed to stir at 25 °C for 16 hrs under an atmosphere of N2. The mixture was distilled under vacuum (62 oC, -0.08 MPa/water pump). 5,5- dimethylcyclopent-2-en-1-one (110 g, 798.89 mmol, 44.81% yield over 2 steps) was obtained as a light yellow oil. Step 3: 4-(benzyl(methyl)amino)-2,2-dimethylcyclopentan-1-one
Figure imgf000076_0003
[000220] BnMeNH (114.96 g, 948.68 mmol, 122.43 mL, 0.95 eq) was added to 5,5- dimethylcyclopent-2-en-1-one (110 g, 998.61 mmol, 1 eq) dropwise at 25 oC and the mixture was allowed to stir at 50 oC for 2 hrs. The reaction mixture was cooled to 0 oC and solids were formed. The mixture was filtered and the filter cake was dried under vacuum. 4- (benzyl(methyl)amino)-2,2-dimethylcyclopentan-1-one (51.95% yield) was obtained as a yellow solid. Attorney Docket No. MORF-016WO1 Step 4: tert-butyl (3,3-dimethyl-4-oxocyclopentyl)(methyl)carbamate
Figure imgf000077_0001
[000221] To a solution of Pd/C (5 g, 10% purity) in MeOH (1000 mL) was added Boc2O (84.91 g, 389.05 mmol, 89.38 mL, 1.5 eq) and 4-(benzyl(methyl)amino)-2,2- dimethylcyclopentan-1-one (60 g, 259.37, 1 eq) under Ar at 25 oC. The suspension was degassed under vacuum and purged with H2 three times. The mixture was allowed to stir under H2 (30 psi) at 25 oC for 12 hrs. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=1/0 to 3/1). tert-butyl (3,3-dimethyl-4- oxocyclopentyl)(methyl)carbamate (51.92% yield) was obtained as light yellow oil. 1H NMR (400 MHz, CDCl3) δ = 4.81 (br d, J = 1.0 Hz, 1H), 2.77 (s, 3H), 2.61 - 2.48 (m, 1H), 2.39 - 2.25 (m, 1H), 2.02 - 1.93 (m, 1H), 1.89 - 1.77 (m, 1H), 1.47 (s, 9H), 1.13 (s, 3H), 1.06 (s, 3H). Step 6: rac-tert-butyl ((1S,4R)-4-hydroxy-3,3-dimethylcyclopentyl)(methyl)carbamate
Figure imgf000077_0002
[000222] To a solution of tert-butyl (3,3-dimethyl-4-oxocyclopentyl)(methyl)carbamate (130 g, 538.69 mmol, 1 eq) in THF (1000 mL) was added DIBAL-H (1 M, 538.69 mL, 1 eq)) at 0 oC under an atmosphere of N2. Then the reaction mixture was warmed up to 20 oC and stirred at 20 oC under an atmosphere of N2 for 16 hrs. The mixture was quenched by the addition of Na2SO4.10 H2O (100 g). Then the mixture was dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=1/0 to 3/1). Rac-tert-butyl ((1S,4R)-4-hydroxy-3,3- dimethylcyclopentyl)(methyl)carbamate (41.96% yield) was obtained as colorless oil. 1H NMR (400 MHz, CDCl3) δ = 4.72 (m, 1H), 3.83 (t, J = 7.8 Hz, 1H), 2.73 (s, 3H), 2.06 - 1.96 (m, 2H), 1.88 (br dd, J = 7.7, 10.4 Hz, 1H), 1.75 (dd, J = 8.6, 12.9 Hz, 1H), 1.46 (s, 9H), 1.06 (s, 3H), 0.94 (s, 3H). Final Steps: rac-(1S,4R)-N,3,3-trimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentan-1-amine hydrochloride Attorney Docket No. MORF-016WO1
Figure imgf000078_0001
[000223] Rac-tert-butyl ((1S,4R)-4-hydroxy-3,3-dimethylcyclopentyl)(methyl)carbamate was converted to rac-(1S,4R)-N,3,3-trimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentan-1-amine hydrochloride by methods similar to those described above in Steps 3-6 for the synthesis of rac-(1S,3S)-N-methyl-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin- 2-yl)butoxy)cyclopentan-1-amine. LCMS [M + 1] = 332.2, 96.78% 1H NMR (400 MHz, CD3OD) δ = 7.58 (d, J = 7.3 Hz, 1H), 6.60 (d, J = 7.4 Hz, 1H), 3.64 (br dd, J = 6.8, 8.5 Hz, 1H), 3.57 (s, 5H), 2.82 (t, J = 6.1 Hz, 2H), 2.73 (t, J = 7.7 Hz, 2H), 2.65 (s, 3H), 2.13 - 1.93 (m, 5H), 1.82 - 1.73 (m, 2H), 1.62 (br dd, J = 6.2, 8.7 Hz, 2H), 1.45 (dd, J = 8.8, 13.1 Hz, 1H), 1.11 (s, 3H), 0.94 (s, 3H). Right-Side Intermediates Preparation of 1-bromo-3-fluoro-4-methyl-2-nitrobenzene
Figure imgf000078_0002
Step 1: 3-fluoro-4-methyl-2-nitroaniline [000224] Two reactions were carried out in parallel. To a mixture of 4-bromo-3-fluoro-2- nitroaniline (25 g, 106.38 mmol, 1 eq) and methylboronic acid (31.84 g, 531.89 mmol, 5 eq) in dioxane (250 mL) and H2O (62.5 mL) were added Pd(dppf)Cl2 (3.89 g, 5.32 mmol, 0.05 eq) and K2CO3 (44.11 g, 319.13 mmol, 3 eq) at 25°C. The mixture was allowed to stir at 90°C for 16 hrs under an atmosphere of N2. The mixture was quenched by the addition of H2O (300 mL) and filtered. The filtrate was extracted with ethyl acetate (200 mL x 3). The organic solutions were combined, washed with brine (150 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography (SiO2, petroleumether/ethylacetate = 100/1 to 5/1). 3-fluoro-4-methyl-2-nitroaniline (55.25% yield) was obtained as a yellow oil. LCMS: Rt = 0.557 min, [M+1] = 171.1, 55.30%. 1H NMR (400 MHz, CDCl3) δ = 7.11 (t, J = 8.1 Hz, 1H), 6.50 (dd, J = 1.6, 8.6 Hz, 1H), 2.19 (d, J = 2.5 Hz, 3H). Attorney Docket No. MORF-016WO1 Step 2: 1-bromo-3-fluoro-4-methyl-2-nitrobenzene [000225] To a solution of HBr (111.75 g, 455.77 mmol, 75.00 mL, 33% purity, 15.51 eq) in H2O (500 mL) was added 3-fluoro-4-methyl-2-nitroaniline and the mixture was allowed to stir at 70°C for 30 min. The mixture is cooled to -5 °C and NaNO2 (12.57 g, 182.20 mmol, 6.2 eq) dissolved in H2O (62.5 mL) was added slowly. The mixture was allowed to stir at -5°C for 30 min. A solution of CuBr (52.70 g, 367.34 mmol, 11.19 mL, 12.5 eq) in aqueous HBr (260.75 g, 1.06 mol, 175.00 mL, 33% purity, 36.19 eq) was added dropwise at 0 °C. The mixture was allowed to stir at 70 °C for 30 min. The reaction was quenched by the addition of water (200 mL) and extracted with DCM (200 mL x 3). The organic solutions were combined, washed with aq. NaOH (4 M, 150 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 5/1). 1-bromo-3-fluoro-4-methyl-2-nitrobenzene (79.97% yield) was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.36 (dd, J = 1.4, 8.3 Hz, 1H), 7.26 - 7.20 (m, 1H), 2.33 (d, J = 2.1 Hz, 3H). Preparation of tert-butyl 2-bromo-2-(1-(tert-butyl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)acetate
Figure imgf000079_0003
Figure imgf000079_0001
Figure imgf000079_0004
Step 1: 3-bromo-N-(tert-butyl)-2-nitroaniline
Figure imgf000079_0002
[000226] To a solution of 1-bromo-3-fluoro-2-nitrobenzene (50 g, 227.28 mmol, 1 eq) in DMSO (100 mL) was added Cs2CO3 (148.10 g, 454.55 mmol, 2 eq) and t-BuNH2 (16.62 g, 227.28 mmol, 23.88 mL, 1 eq) at 25°C. The mixture was stirred at 60°C for 12 hrs. TLC (Petroleum ether: Ethyl acetate = 5:1, Rf = 0.63) showed starting material was consumed Attorney Docket No. MORF-016WO1 completely, and a new spot with lower polarity was detected. The mixture was quenched by H2O (300 mL) and ethyl acetate (150 mL) was added to the mixture. The layers were separated and the aqueous phase was extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with brine (300 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give 3-bromo-N-(tert-butyl)-2-nitroaniline (64.4% yield) as red oil. 1H NMR (400 MHz, METHANOL-d4) δ = 7.21 - 7.16 (m, 2H), 6.98 (dd, J = 2.4, 6.5 Hz, 1H), 1.39 (s, 9H) Step 2: 3-bromo-N1-(tert-butyl)benzene-1,2-diamine
Figure imgf000080_0001
[000227] To the solution of 3-bromo-N-(tert-butyl)-2-nitroaniline (30 g, 109.84 mmol, 1 eq) in CH3COOH (75 mL) and EtOAc (225 mL) was added H2O (25 mL) at 25°C. The mixture was heated at 50°C. Then Fe (30.67 g, 549.20 mmol, 5 eq) was added in portions at 50°C and then the mixture was heated to 80°C and then stirred for 16 hrs. TLC (Petroleum ether: Ethyl acetate = 5:1, Rf = 0.61) showed starting material was consumed completely, and some new spots with larger polarity were detected. The reaction mixture was filter at 80°C and then concentrated to give a residue. The residue was dissolved with EtOAc (200 mL) and adjusted pH to 7-8 by sat.NaHCO3. The organic phase was separated and washed by brine (100 mL x 3). The organic phase was dried over Na2SO4, filtered and concentrated to give a crude product. The residue was purified by flash silica gel chromatography (ISCO®; 200 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate/Petroleum gradient @ 150 mL/min). 3-bromo-N1-(tert-butyl)benzene-1,2-diamine (74.9% yield) was obtained as a yellow oil. 1H NMR (400 MHz, METHANOL-d4) δ = 7.00 (dd, J= 1.3, 8.0 Hz, 1H), 6.88 (dd, J = 1.3, 7.9 Hz, 1H), 6.52 (t, J = 7.9 Hz, 1H), 1.27 (s, 9H). Step 3: 4-bromo-1-(tert-butyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
Figure imgf000080_0002
[000228] To a solution of 3-bromo-N1-(tert-butyl)benzene-1,2-diamine (20 g, 82.26 mmol, 1 eq) in THF (200 mL) was added TEA (24.97 g, 246.77 mmol, 34.35 mL, 3 eq) and bis(trichloromethyl) carbonate (24.41 g, 82.26 mmol, 1 eq). The mixture was stirred at 20°C Attorney Docket No. MORF-016WO1 for 16 hrs. LCMS (Rt = 0.675 min) showed the starting material was consumed completely and one main peak with desired mass was detected. The reaction was quenched by ice water (200 mL) slowly, adjusted to pH = 7, extracted with ethyl acetate (100 mL x 2). The combined organic phase was washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (ISCO®; 200 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate/Petroleum gradient @ 150 mL/min). 4-bromo-1-(tert-butyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (84.0% yield) was obtained as a yellow oil. LCMS: [M+1] = 270.9. 1H NMR (400 MHz, METHANOL-d4) δ = 7.45 (d, J = 8.3 Hz, 1H), 7.15 (d, J = 8.2 Hz, 1H), 6.91 (t, J = 8.3 Hz, 1H), 1.77 (s, 9H). Step 4: 4-bromo-1-(tert-butyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one
Figure imgf000081_0001
[000229] To a solution of 4-bromo-1-(tert-butyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (18.6 g, 69.11 mmol, 1 eq) in DMF (190 mL) was added and NaH (5.53 g, 138.22 mmol, 60% purity, 2 eq). The mixture was stirred at 0°C for 0.5 hr. Then MeI (19.62 g, 138.22 mmol, 62.42 mL, 2 eq) was added the above mixture, the mixture was stried at 20°C for 1 hr. LCMS (Rt = 1.661 min) showed the starting material was consumed completely and one main peak with desired mass was detected. The reaction mixture was quenched by addition NH4Cl (200 mL) at 0°C, and extracted with EtOAc (150 mL x 3). The combined organic layers were washed with brine 450 mL, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 200 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate/Petroleum gradient @ 150 mL/min). 4-bromo-1-(tert-butyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol- 2-one (97.09% yield) was obtained as a yellow oil. LCMS: [M+1] = 283.1.1H NMR (400 MHz, METHANOL-d4) δ = 7.52 (d, J = 8.3 Hz, 1H), 7.21 (d, J = 8.1 Hz, 1H), 6.92 (t, J = 8.3 Hz, 1H), 3.70 (s, 3H), 1.77 (s, 9H). Step 5: tert-butyl 2-(1-(tert-butyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4- yl)acetate
Figure imgf000081_0002
Attorney Docket No. MORF-016WO1 [000230] To a solution of 4-bromo-1-(tert-butyl)-3-methyl-1,3-dihydro-2H- benzo[d]imidazol-2-one (19 g, 67.10 mmol, 1 eq) and bromo-(2-tert-butoxy-2-oxo-ethyl)zinc (1M, 167.75 mL, 2.5 eq) in THF (200 mL) was added Pd(t-Bu3P)2 (1.71 g, 6.71 mmol, 0.05 eq). The mixture was stirred at 80°C for 2 hrs. TLC (Petroleum ether: Ethyl acetate = 5:1, Rf = 0.43) showed starting material was consumed completely, and a new spot with larger polarity was detected. The reaction was quenched by ice water (200 mL) slowly, extracted with ethyl acetate (100 mL x 2). The combined organic phase was washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (ISCO®; 200 g SepaFlash® Silica Flash Column, Eluent of 0-50% Ethyl acetate/Petroleum gradient @ 120 mL/min). tert-butyl 2-(1-(tert-butyl)-3-methyl-2-oxo- 2,3-dihydro-1H-benzo[d]imidazol-4-yl)acetate (93.61% yield) was obtained as a yellow oil. 1H NMR (400 MHz, METHANOL-d4) δ = 7.47 (dd, J = 0.7, 8.2 Hz, 1H), 7.02 - 6.94 (m, 1H), 6.89 (d, J = 7.5 Hz, 1H), 3.91 (s, 2H), 3.57 (s, 3H), 1.79 (s, 9H), 1.44 (s, 9H). Step 6: tert-butyl 2-bromo-2-(1-(tert-butyl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)acetate
Figure imgf000082_0001
[000231] To a solution of tert-butyl 2-(1-(tert-butyl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)acetate (3 g, 9.42 mmol, 1 eq) in THF (30 mL) was added LDA (2 M, 14.13 mL, 3 eq) at -70°C and the mixture was stirred at -70°C for 45 min. TMSCl (3.07 g, 28.27 mmol, 3.59 mL, 3 eq) was added. After 15 min, a solution of NBS (5.03 g, 28.27 mmol, 3 eq) in THF (15 mL) was addedand the minture was stirred at -70 °C for 1 hr. TLC (Petroleum ether: Ethyl acetate = 5:1, Rf = 0.69) showed starting material was consumed completely, and a new spot with lower polarity was detected. The reaction was quenched by ice water (30 mL) slowly, extracted with ethyl acetate (15 mL x 2). The combined organic phase was washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate/Petroleum gradient @ 80 mL/min). tert-butyl 2-bromo-2-(1-(tert-butyl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)acetate (90.83% yield) was obtained as a yellow oil. Attorney Docket No. MORF-016WO1 [000232] Intermediates in the table below were prepared according to similar procedures as those described for tert-butyl 2-bromo-2-(1-(tert-butyl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)acetate from the starting materials shown, substituting the appropriate reagents and purified using appropriate conditions:
Figure imgf000083_0001
Attorney Docket No. MORF-016WO1 Preparation of tert-butyl 2-bromo-2-(3,6-dimethyl-1-(1-methylcyclopropyl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-4-yl)acetate
Figure imgf000084_0001
Step 1: tert-butyl 2-(3-methyl-1-(1-methylcyclopropyl)-2-oxo-6-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-2,3-dihydro-1H-benzo[d]imidazol-4-yl)acetate
Figure imgf000084_0002
[000233] To a solution of tert-butyl 2-(3-methyl-1-(1-methylcyclopropyl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-4-yl)acetate (2 g, 6.32 mmol, 1 eq) in dioxane (40 mL) was added dtbpy (101.80 mg, 379.27 umol, 0.06 eq) and [Ir(OMe)(cod)]2 (251.41 mg, 379.27 umol, 0.06 eq) and Pin2B2 (3.21 g, 12.64 mmol, 2 eq) at 20°C under N2. The mixture was heated up to 80oC and stirred at 80°C under N2 for 16 hrs. TLC (Petroleum ether/ethyl acetate = 5/1, Rf = 0.52) indicated the starting material was consumed completely, and one major new spot with lower polarity was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue to give crude product. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 100/1 to 10/1). tert-Butyl 2-(3-methyl- 1-(1-methylcyclopropyl)-2-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro- 1H-benzo[d]imidazol-4-yl)acetate (4.5 g, crude) was obtained as a yellow oil. Step 2: tert-butyl 2-(3,6-dimethyl-1-(1-methylcyclopropyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)acetate
Figure imgf000084_0003
[000234] To a solution of tert-butyl 2-(3-methyl-1-(1-methylcyclopropyl)-2-oxo-6-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-benzo[d]imidazol-4-yl)acetate (3.5 g, 7.91 mmol, 1 eq.) in toluene (35 mL), EtOH (14 mL) and H2O (14 mL) was added K2CO3 (3.28 g, 23.74 mmol, 3 eq.), Pd(PPh3)4 (457.15 mg, 395.61 umol, 0.05 eq.) and MeI (5.62 g, 39.56 mmol, 2.46 mL, 5 eq.) in turns at 20oC under N2. Then the reaction mixture was heated up to 100oC and stirred at 100oC under N2 for 16 hrs. LCMS (Rt = 0.797, [M+1] = 331.1, Attorney Docket No. MORF-016WO1 56.55%) showed compound 2 was consumed completely, 56.55% of desired MS was detected. The reaction mixture was quenched with water (150 mL) at 20oC and extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (30 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate = 100/0 to 80/20). tert-Butyl 2-(3,6-dimethyl-1-(1-methylcyclopropyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)acetate (42.08% yield) was obtained as a yellow oil. Step 3: tert-butyl 2-bromo-2-(3,6-dimethyl-1-(1-methylcyclopropyl)-2-oxo-2,3-dihydro- 1H-benzo[d]imidazol-4-yl)acetate
Figure imgf000085_0001
[000235] To a solution of tert-butyl 2-(3,6-dimethyl-1-(1-methylcyclopropyl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-4-yl)acetate (550 mg, 1.66 mmol, 1 eq) in THF (10 mL) and then added LDA (2 M, 2.50 mL, 3 eq) at -70°C under N2. Then the mixture was stirred at - 70°C under N2 for 0.5 hrs. Then to the above reaction mixture was added TMSCl (542.52 mg, 4.99 mmol, 633.78 μL, 3 eq) at -70oC under N2. Then the mixture was stirred at -70°C under N2 for 0.5 hrs. Then to the above reaction mixture was added the solution of NBS (888.79 mg, 4.99 mmol, 3 eq) in THF (10 mL) at -70°C under N2. Then the mixture was stirred at -70°C under N2 for 1 hr. LCMS showed the starting material was consumed completely, and 87.45% of the desired MS was detected. The reaction mixture was quenched with saturated aqueous NH4Cl (100 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated to give residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 100/1 to 10/1). tert-Butyl 2-bromo-2-(3,6-dimethyl-1-(1-methylcyclopropyl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-4-yl)acetate (77.79% yield) was obtained as a yellow oil. LCMS: [M+1] =411.1.1H NMR (400 MHz, CDCl3) δ = 7.15 (s, 1H), 6.99 (d, J = 0.8 Hz, 1H), 5.94 (s, 1H), 3.71 (s, 3H), 2.41 (s, 3H), 2.05 (s, 2H), 1.49 (s, 9H), 1.15-1.12 (m, 2H), 1.00-0.96 (m, 2H), 0.21-0.13 (m, 1H). [000236] Intermediates in the table below were prepared according to similar procedures as those described for tert-butyl 2-bromo-2-(3,6-dimethyl-1-(1-methylcyclopropyl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-4-yl)acetate from the starting materials shown, substituting the appropriate reagents and purified using appropriate conditions: Attorney Docket No. MORF-016WO1
Figure imgf000086_0003
Figure imgf000086_0001
Step 1: methyl 2-(2-bromo-6-fluoro-4-methylphenyl)-2-oxoacetate
Figure imgf000086_0002
[000237] To the solution of 1-bromo-3-fluoro-5-methylbenzene (100 g, 529.03 mmol, 1 eq) in THF (500 mL) was added LDA (2 M, 317.42 mL, 1.2 eq) dropwise at -70°C under N2. Then the reaction mixture was stirred at -70°C for 0.5 hrs. Then to the above reaction mixture was added the solution of dimethyl oxalate (81.21 g, 687.74 mmol, 1.3 eq) in THF (500 mL) at -70°C under N2. Then the reaction mixture was stirred at -70°C under N2 for 1 hr. TLC (Petroleum ether/Ethyl acetate = 5/1, Rf = 0.43) indicated the starting material was consumed completely and one new spot formed. The residue was quenched with aq.NH4Cl (1000 mL), extracted with EtOAc (500mL x3). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 5/1). Methyl 2-(2-bromo-6-fluoro-4-methylphenyl)-2-oxoacetate (65.28% yield) was obtained as red oil. 1 H NMR (400 MHz, CHLOROFORM-d) δ = 7.29 (s, 1H), 6.96 (d, J = 10.3 Hz, 1H), 3.95 (s, 3H), 2.40 (s, 3H). Attorney Docket No. MORF-016WO1 Step 2: 4-bromo-1-(tert-butyl)-6-methylindoline-2,3-dione
Figure imgf000087_0001
[000238] To a solution of t-BuNH2 (5.85 g, 79.98 mmol, 8.40 mL, 2.2 eq) in THF (100 mL) was added n-BuLi (2.5 M, 30.54 mL, 2.1 eq) at -70°C under N2. The mixture was stirred at - 70°C for 0.5 hrs. Methyl 2-(2-bromo-6-fluoro-4-methylphenyl)-2-oxoacetate (10 g, 36.35 mmol, 1 eq) in THF (100 mL) was added at -70°C under N2. The mixture was stirred at 20°C for 2 hrs. LCMS showed the starting material was consumed completely and one main peak with desired mass was detected. The reaction mixture was quenched with iced aqueous HCl (200 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with PE: EA = 3:1 at 20oC for 30 min. 4-Bromo-1-(tert-butyl)-6-methylindoline-2,3-dione (63.47% yield) was obtained as a red solid. LCMS: [M+1] = 296.0. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.07 (s, 2H), 2.42 (s, 3H), 1.74 (s, 9H) Step 3: 4-bromo-1-(tert-butyl)-6-methylindolin-2-one
Figure imgf000087_0002
[000239] To a solution of 4-bromo-1-(tert-butyl)-6-methylindoline-2,3-dione (39 g, 131.69 mmol, 1 eq) in glycol (400 mL) was added NH2NH2.H2O (82.56 g, 1.62 mol, 80 mL, 98% purity, 12.27 eq) at 25°C under N2. The mixture was stirred at 130°C for 3 hrs. LCMS showed the starting material was consumed completely and one main peak with desired mass was detected. The reaction mixture was concentrated under reduced pressure and quenched by addition H2O (200 mL), extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was used directly without further purification. 4-Bromo-1-(tert-butyl)-6-methylindolin-2-one (94.19% yield) was obtained as a red solid. LCMS: [M+1] = 284.0. 1 H NMR (400 MHz, CHLOROFORM-d) δ = 6.99 (d, J = 9.7 Hz, 2H), 3.38 (s, 2H), 2.36 (s, 3H), 1.71 (s, 9H) Attorney Docket No. MORF-016WO1 Step 4: 4'-bromo-1'-(tert-butyl)-6'-methylspiro[cyclopropane-1,3'-indolin]-2'-one
Figure imgf000088_0001
[000240] To a solution of 4-bromo-1-(tert-butyl)-6-methylindolin-2-one (42 g, 148.84 mmol, 1 eq) in DMF (400 mL) was added NaH (17.86 g, 446.53 mmol, 60% purity, 3 eq) at 0oC under N2 and the solution was stirred at 0°C for 0.5 hrs, then 1, 2-dibromoethane (83.89 g, 446.53 mmol, 33.69 mL, 3 eq) was added to the solution at 0°C and the solution was stirred at 25°C for 1 hr. LCMS showed the starting material was consumed completely and one main peak with desired mass was detected. The reaction was quenched with sat. NH4Cl (400 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 5/1). 4'-Bromo-1'- (tert-butyl)-6'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (47.96% yield) was obtained as a yellow oil. LCMS: [M+1] = 310.1. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.03 (s, 1H), 6.85 (s, 1H), 2.28 (s, 3H), 2.15 (q, J = 3.7 Hz, 2H), 1.67 (s, 9H), 1.35 (q, J = 3.7 Hz, 2H), 1.31 (s, 3H). Step 5: 4-bromo-6-methylindolin-2-one
Figure imgf000088_0002
[000241] To a solution of 4'-bromo-1'-(tert-butyl)-6'-methylspiro[cyclopropane-1,3'-indolin]- 2'-one (22 g, 71.38 mmol, 1 eq) in TFA (100 mL) under N2 and the solution was stirred at 25°C for 0.5 hrs. LCMS showed the starting material was consumed completely and one main peak with desired mass was detected. The reaction was concentrated under reduced pressure to give a residue. The crude product was triturated with MeCN at 20oC for 30 min. 4-Bromo-6- methylindolin-2-one (77.80% yield) was obtained as a yellow solid. LCMS: [M+1] = 253.9. 1H NMR (400 MHz, CHLOROFORM-d) δ = 6.94 (s, 1H), 6.76 (s, 1H), 2.33 (s, 3H), 2.28 (d, J = 3.9 Hz, 2H), 1.56 (d, J = 3.9 Hz, 2H). Attorney Docket No. MORF-016WO1
Figure imgf000089_0001
Step 1: 2-(2,6-dibromophenyl)oxirane
Figure imgf000089_0002
[000242] To a solution of 2,6-dibromobenzaldehyde (30 g, 113.67 mmol, 1 eq) and Me3S+I- (69.59 g, 341.02 mmol, 3 eq) in THF (500 mL) and DMSO (100 mL) was added NaH (13.64 g, 341.02 mmol, 60% purity, 3 eq) at -10°C under N2. The mixture was stirred at 20°C for 1 hr. TLC (petroleum ether/ethyl acetate = 10/1, Rf = 0.6) indicated 2,6-dibromobenzaldehyde was consumed, and one major new spot with larger polarity was detected. The mixture was quenched by aq. NH4Cl (1.5 L) and extracted with ethyl acetate (500 mL x 3). The combined organic layers were washed with brine (1000 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with EtOH at 20oC for 10 min to get 2-(2,6-dibromophenyl)oxirane (66.47% yield) as a white solid. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.55 (d, J = 8.1 Hz, 2H), 7.06 (t, J = 8.1 Hz, 1H), 3.94-3.85 (m, 1H), 3.33 (dd, J = 4.3, 5.0 Hz, 1H), 2.98 (dd, J = 2.8, 5.1 Hz, 1H). Step 2: 2-(2,6-dibromophenyl)propan-1-ol
Figure imgf000089_0003
[000243] To a solution of AlMe3 (2.0 M, 82.75 mL, 1 eq) in toluene (500 mL) was added drop-wise a solution of 2-(2,6-dibromophenyl)oxirane (46 g, 165.50 mmol, 1 eq) in toluene (300 mL) at -60°C under N2. The mixture was stirred at 0°C for 1 hr. TLC (petroleum Attorney Docket No. MORF-016WO1 ether/ethyl acetate = 3/1, Rf = 0.3) indicated 2-(2,6-dibromophenyl)oxirane was consumed, and one major new spot with larger polarity was detected. The mixture was quenched by adding Na2SO4.10H2O (100 g) and THF (500 mL). The mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 5/1 to 3/1) to get 2-(2,6-dibromophenyl)propan-1-ol (61.66% yield) as colorless oil. Step 3: 1,3-dibromo-2-(1-(methoxymethoxy)propan-2-yl)benzene
Figure imgf000090_0001
[000244] To a solution of 2-(2,6-dibromophenyl)propan-1-ol (28 g, 95.24 mmol, 1 eq) and DIEA (49.24 g, 380.97 mmol, 66.36 mL, 4 eq) in DCM (200 mL) was added MOMBr (23.80 g, 190.49 mmol, 15.55 mL, 2 eq) at 0°C and the mixture was stirred at 20°C for 16 hrs. TLC (petroleum ether/ethyl acetate = 1/1, Rf = 0.59) indicated 2-(2,6-dibromophenyl)propan-1-ol was consumed, and one major new spot with lower polarity was detected. The reaction mixture was quenched by addition aq.NaHCO3 (300 mL), and extracted with DCM (100 mL x 3). The combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10/1 to 5/1) to get 1,3- dibromo-2-(1-(methoxymethoxy)propan-2-yl)benzene (86.97% yield) as colorless oil. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.57 (d, J = 8.0 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 6.90 (t, J = 8.0 Hz, 1H), 4.67-4.56 (m, 2H), 4.17-4.05 (m, 2H), 3.93 (dd, J = 6.8, 8.9 Hz, 1H), 3.31 (s, 3H), 1.44 (d, J = 7.0 Hz, 3H). Step 4: 3-(3-bromo-2-(1-(methoxymethoxy)propan-2-yl)phenyl)tetrahydro-2H-pyran-3-ol
Figure imgf000090_0002
[000245] To a solution of 1,3-dibromo-2-(1-(methoxymethoxy)propan-2-yl)benzene (5.2 g, 15.38 mmol, 1 eq) and TMEDA (1.97 g, 16.92 mmol, 2.55 mL, 1.1 eq) in THF (60 mL) was added drop-wise n-BuLi (2.5 M, 6.15 mL, 1 eq) at -60°C under N2. The mixture was stirred at -60°Cfor 0.5 hr. Then dihydro-2H-pyran-3(4H)-one (4.62 g, 46.15 mmol, 3 eq) was added Attorney Docket No. MORF-016WO1 drop-wise to the system at -60°C and the mixture was stirred at 0°C for 0.5 hr. TLC (petroleum ether/ethyl acetate = 10/1, Rf = 0.4) indicated 1,3-dibromo-2-(1- (methoxymethoxy)propan-2-yl)benzene was consumed, and one major new spot with larger polarity was detected. The mixture was quenched by aqNH4Cl (300 mL) and extracted with ethyl acetate (200 mL x 2). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 3/1 to 2/1) to get 3-(3-bromo-2-(1-(methoxymethoxy)propan-2-yl)phenyl)tetrahydro-2H-pyran-3-ol (37.09% yield) as colorless oil. Step 5: 3-(3-bromo-2-(1-hydroxypropan-2-yl)phenyl)tetrahydro-2H-pyran-3-ol
Figure imgf000091_0001
[000246] To a solution of 3-(3-bromo-2-(1-(methoxymethoxy)propan-2- yl)phenyl)tetrahydro-2H-pyran-3-ol (14 g, 38.97 mmol, 1 eq) in MeCN (50 mL) was added HCl (100 mL) at 20°C and the mixture was stirred at 20°C for 12 hrs. TLC (petroleum ether/ethyl acetate = 3/1, Rf = 0.42) indicated 3-(3-bromo-2-(1-(methoxymethoxy)propan-2- yl)phenyl)tetrahydro-2H-pyran-3-ol was consumed, and one major new spot with larger polarity was detected. The mixture was quenched by H2O (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 3/1 to 1/1) to get 3-(3-bromo-2-(1-hydroxypropan-2-yl)phenyl)tetrahydro-2H-pyran-3-ol (10.7 g, 23.76 mmol, 60.98% yield, 70% purity) as a yellow oil. LCMS: [M+1] = 296.9. Step 6: 5-bromo-4-methyl-5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran]
Figure imgf000091_0002
[000247] To a solution of 3-(3-bromo-2-(1-hydroxypropan-2-yl)phenyl)tetrahydro-2H- pyran-3-ol (10.7 g, 23.76 mmol, 1 eq) in toluene (100 mL) was added CMBP (8.60 g, 35.64 mmol, 1.5 eq) at 20°C. The mixture was stirred at 80°C for 16 hrs. LCMS showed 3-(3- Attorney Docket No. MORF-016WO1 bromo-2-(1-hydroxypropan-2-yl)phenyl)tetrahydro-2H-pyran-3-ol was consumed and ~53% of desired compound was detected. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 10/1) and purified by prep-HPLC (column: Phenomenex luna c18250mm*100mm*10um; mobile phase: [H2O (0.1%TFA)-ACN]; gradient: 30%-65% B over 24.0 min) to get 5-bromo-4-methyl-5',6'-dihydro-2'H,4'H- spiro[isochromane-1,3'-pyran] (67.97% yield) as a yellow oil. Step 7: Stereoisomers of 5-bromo-4-methyl-5',6'-dihydro-2'H,4'H-spiro[isochromane- 1,3'-pyran]
Figure imgf000092_0001
[000248] 5-Bromo-4-methyl-5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran] (4.8 g, 16.15 mmol, 1 eq) was separated by SFC (column: DAICEL CHIRALPAK AD (250mm*30mm, 10um); mobile phase: [CO2-MeOH]; B%:15%, isocratic elution mode) to give 4 isomers. [000249] Peak 1, arbitrarily assigned as (1S,4S)-5-bromo-4-methyl-5',6'-dihydro-2'H,4'H- spiro[isochromane-1,3'-pyran] (20.83% yield), was obtained as a white solid. LCMS: [M+1] = 297.2. SFC: Rt = 1.656. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.46 (d, J = 7.5 Hz, 1H), 7.13-7.06 (m, 2H), 4.08 (br dd, J = 4.2, 11.2 Hz, 1H), 4.01 (br d, J = 12.4 Hz, 1H), 3.96- 3.91 (m, 1H), 3.87-3.82 (m, 1H), 3.56-3.49 (m, 1H), 3.39 (d, J = 12.5 Hz, 1H), 3.00 (q, J = 6.2 Hz, 1H), 2.30-2.19 (m, 1H), 2.06-1.97 (m, 2H), 1.57 (br d, J = 9.3 Hz, 1H), 1.39 (d, J = 6.9 Hz, 3H). [000250] Peak 2, arbitrarily assigned as (1S,4R)-5-bromo-4-methyl-5',6'-dihydro-2'H,4'H- spiro[isochromane-1,3'-pyran] (16.88% yield), was obtained as a white solid. LCMS: [M+1] = 297.2. SFC: Rt = 1.848. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.46 (dd, J = 2.3, 6.6 Hz, 1H), 7.11-7.06 (m, 2H), 4.08 (br dd, J = 3.0, 12.4 Hz, 1H), 3.91-3.85 (m, 2H), 3.76-3.74 (m, 1H), 3.71-3.67 (m, 1H), 3.54 (br t, J = 11.8 Hz, 1H), 3.05-2.98 (m, 1H), 2.24-2.14 (m, 2H), 1.79-1.71 (m, 1H), 1.51 (br d, J = 13.5 Hz, 1H), 1.39 (d, J = 6.9 Hz, 3H). [000251] Peak 3, arbitrarily assigned as (1R,4R)-5-bromo-4-methyl-5',6'-dihydro-2'H,4'H- spiro[isochromane-1,3'-pyran] (22.92% yield), was obtained as a white solid. LCMS: [M+1] = Attorney Docket No. MORF-016WO1 297.2. SFC: Rt = 2.441.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.46 (dd, J = 1.6, 7.4 Hz, 1H), 7.12-7.05 (m, 2H), 4.08 (br dd, J = 4.4, 11.2 Hz, 1H), 4.02 (br d, J = 12.4 Hz, 1H), 3.96-3.92 (m, 1H), 3.87-3.83 (m, 1H), 3.56-3.49 (m, 1H), 3.39 (d, J = 12.4 Hz, 1H), 3.03-2.97 (m, 1H), 2.29-2.19 (m, 1H), 2.06-1.98 (m, 2H), 1.56 (br s, 1H), 1.39 (d, J = 6.9 Hz, 3H). [000252] Peak 4, arbitrarily assigned as (1R,4S)-5-bromo-4-methyl-5',6'-dihydro-2'H,4'H- spiro[isochromane-1,3'-pyran] (22.92% yield), was obtained as a white solid. LCMS: [M+1] = 297.2. SFC: Rt = 2.441. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.46 (dd, J = 2.2, 6.7 Hz, 1H), 7.11-7.06 (m, 2H), 4.11-4.06 (m, 1H), 3.90-3.85 (m, 2H), 3.74 (br d, J = 2.0 Hz, 1H), 3.71-3.67 (m, 1H), 3.57-3.51 (m, 1H), 3.01 (q, J = 6.8 Hz, 1H), 2.24-2.14 (m, 2H), 1.79-1.71 (m, 1H), 1.56-1.49 (m, 1H), 1.39 (d, J = 6.9 Hz, 3H). Preparation of 5-bromo-4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]
Figure imgf000093_0001
[000253] Isomers of 5-bromo-4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran] were prepared using a method similar to that described above for the preparation of 5-bromo-4- methyl-5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran] and separated by SFC (column: DAICEL CHIRALPAK AD (250 mm * 30 mm, 10 um); mobile phase: [CO2-EtOH]; B%: 15%, isocratic elution mode). [000254] Peak 1, arbitrarily assigned as (S)-5-bromo-4-methyl-2',3',5',6'-tetrahydrospiro- [isochromane-1,4'-pyran], was obtained as a white solid. SFC Rt = 1.638 min.1H NMR (400 MHz, CDCl3) δ = 7.44 (dd, J = 1.6, 7.4 Hz, 1H), 7.14 - 7.07 (m, 2H), 3.99 - 3.92 (m, 1H), 3.90 - 3.86 (m, 2H), 3.85 - 3.82 (m, 2H), 3.80 (s, 1H), 3.04 - 2.96 (m, 1H), 2.23 - 2.16 (m, 1H), 1.93 - 1.87 (m, 2H), 1.65 (br d, J = 13.5 Hz, 1H), 1.38 (d, J = 6.9 Hz, 3H). [000255] Peak 2, arbitrarily assigned as (R)-5-bromo-4-methyl-2',3',5',6'-tetrahydrospiro- [isochromane-1,4'-pyran], was obtained as a white solid. SFC Rt = 1.873 min.1H NMR (400 MHz, CDCl3) δ = 7.44 (dd, J = 1.6, 7.4 Hz, 1H), 7.15 - 7.08 (m, 2H), 3.99 - 3.92 (m, 1H), 3.87 (dd, J = 4.7, 7.1 Hz, 2H), 3.85 - 3.83 (m, 2H), 3.80 (s, 1H), 3.02 - 2.96 (m, 1H), 2.25 - 2.17 (m, 1H), 1.92 - 1.87 (m, 2H), 1.65 (br d, J = 13.6 Hz, 1H), 1.38 (d, J = 6.9 Hz, 3H). Attorney Docket No. MORF-016WO1 Preparation of methyl 2-bromo-2-((S)-4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'- pyran]-5-yl)acetate
Figure imgf000094_0001
Step 1: (S)-5-allyl-4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]
Figure imgf000094_0002
[000256] To a solution of (S)-5-bromo-4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'- pyran] (0.7 g, 2.36 mmol, 1 eq) in dioxane (10 mL) was added 2-allyl-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane (791.61 mg, 4.71 mmol, 2 eq), Pd(dppf)Cl2 (172.35 mg, 235.54 μmol, 0.1 eq) and Cs2CO3 (1.53 g, 4.71 mmol, 2 eq) at 20 °C. The mixture was allowed to stir at 80 °C for 16 hrs under an atmosphere of N2. The reaction was quenched by the addition of H2O (50 mL) and extracted with ethyl acetate (10 mL x 3). The organic solutions were combined, washed with brine (20 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 10/1 to 5/1) to give (S)-5-allyl-4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'- pyran] (0.62 g, 1.20 mmol, 50.94% yield, 50% purity) as a white solid. Attorney Docket No. MORF-016WO1 Step 2: (S)-2-(4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]-5-yl)acetic acid
Figure imgf000095_0001
[000257] To a solution of (S)-5-allyl-4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'- pyran] (0.6 g, 1.16 mmol, 1 eq) in MeCN (5 mL), hexane (5 mL) and H2O (10 mL) was added RuCl3 (24.09 mg, 116.12 μmol, 7.74 μL, 0.1 eq) and NaIO4 (993.47 mg, 4.64 mmol, 257.38 μL, 4 eq) in potions at -10 °C. The mixture was allowed to stir at -10 °C for 1 hr. The reaction was quenched by the slow addition of aq.Na2SO3 (100 mL), adjusted to pH = 5 and extracted with ethyl acetate (50 mL x 2). The organic solutions were combined, washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuum to give (S)-2-(4- methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]-5-yl)acetic acid (0.5 g, 904.73 μmol, 77.91% yield, 50% purity) as a white solid. Step 3: methyl (S)-2-(4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]-5- yl)acetate
Figure imgf000095_0002
[000258] To a solution of (S)-2-(4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'- pyran]-5-yl)acetic acid (0.5 g, 904.73 μmol, 1 eq) in MeOH (10 mL) was added H2SO4 (460.00 mg, 4.69 mmol, 250.00 μL, 5.18 eq) at 20 °C. The mixture was allowed to stir at 70 °C for 16 hrs. The reaction was quenched by the addition of NaHCO3 (50 mL) and extracted with ethyl acetate (20 mL x 3). The organic solutions were combined, washed with brine (20 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 10/1 to 5/1) to give methyl (S)-2-(4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]-5-yl)acetate (95.17% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 7.23 - 7.18 (m, 1H), 7.16 - 7.09 (m, 2H), 3.99 - 3.91 (m, 1H), 3.90 - 3.81 (m, 4H), 3.78 (d, J = 8.2 Hz, 1H), 3.76 - 3.72 (m, 1H), 3.71 (s, Attorney Docket No. MORF-016WO1 3H), 3.65 - 3.59 (m, 1H), 2.87 (q, J = 6.6 Hz, 1H), 2.22 (dt, J = 5.3, 13.1 Hz, 1H), 1.95 - 1.89 (m, 2H), 1.66 (br d, J = 13.6 Hz, 1H), 1.33 (d, J = 6.9 Hz, 3H) Step 4: methyl 2-bromo-2-((S)-4-methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'- pyran]-5-yl)acetate
Figure imgf000096_0001
[000259] To a solution of methyl (S)-2-(4-methyl-2',3',5',6'-tetrahydrospiro[isochromane- 1,4'-pyran]-5-yl)acetate (0.25 g, 861.02 μmol, 1 eq) in THF (3 mL) was added LDA (2 M, 861.02 μL, 2 eq) at -60 °C and the mixture was allowed to stir at -60 °C for 30 min. TMSCl (205.79 mg, 1.89 mmol, 240.41 μL, 2.2 eq) was added at -60 °C and the mixture was allowed to stir at -60 °C for 0.5 hrs. A solution of NBS (199.22 mg, 1.12 mmol, 1.3 eq) in THF (3 mL) was added at -60 °C. The mixture was allowed to stir at -60 °C for 1 hr. The mixture was diluted with NH4Cl (50 mL) and extracted with ethyl acetate (20 mL x 3). The organic solutions were combined, washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 10/1 to 5/1) to give methyl 2-bromo-2-((S)-4-methyl- 2',3',5',6'-tetrahydrospiro-[isochromane-1,4'-pyran]-5-yl)acetate (78.63% yield) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ = 7.59 (d, J = 7.8 Hz, 1H), 7.31 - 7.28 (m, 1H), 7.18 (d, J = 8.0 Hz, 1H), 5.69 (s, 1H), 3.94 (br d, J = 12.3 Hz, 1H), 3.86 (br dd, J = 3.0, 10.6 Hz, 4H), 3.83 (s, 3H), 3.80 - 3.78 (m, 1H), 2.93 - 2.87 (m, 1H), 2.19 (dt, J = 5.4, 12.9 Hz, 1H), 1.95 - 1.91 (m, 2H), 1.65 (br d, J = 14.0 Hz, 1H), 1.45 (d, J = 7.0 Hz, 3H). [000260] By similar procedures, methyl 2-bromo-2-((R)-4-methyl-2',3',5',6'- tetrahydrospiro[isochromane-1,4'-pyran]-5-yl)acetate was prepared from (R)-5-bromo-4- methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]. Preparation of methyl 2-bromo-2-(2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane- 1,3'-indolin]-4'-yl)acetate Attorney Docket No. MORF-016WO1
Figure imgf000097_0001
Step 1: 4'-bromospiro[cyclopropane-1,3'-indolin]-2'-one
Figure imgf000097_0002
[000261] To a solution of 4'-bromospiro[cyclopropane-1,3'-indolin]-2'-one (6 g, 28.30 mmol, 1 eq) in DMF (250 mL) was added (2-bromoethyl)diphenylsulfonium trifluoromethanesulfonate (18.82 g, 42.44 mmol, 1.5 eq) at 25oC under N2 and the solution was stirred at 25oC for 6 min, then TEA (8.59 g, 84.89 mmol, 11.82 mL, 3 eq) was added to the solution at 25oC and the solution was stirred at 25oC for 6 hrs. LCMS showed the starting material consumed completely and one peak with desired mass was detected. The reaction mixture was quenched by addition H2O (750 mL) at 0oC, extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (200 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 3/1). 4'- bromospiro[cyclopropane-1,3'-indolin]-2'-one (62.34% yield) was obtained as a yellow oil.1H NMR (400 MHz, METHANOL-d4) δ = 7.12 - 7.06 (m, 2H), 6.96 (dd, J = 2.3, 6.4 Hz, 1H), 2.29 (q, J = 3.9 Hz, 2H), 1.47 (q, J = 3.9 Hz, 2H). Attorney Docket No. MORF-016WO1 Step 2: 4'-bromo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-2'-one
Figure imgf000098_0001
[000262] To a solution of 4'-bromospiro[cyclopropane-1,3'-indolin]-2'-one (3.4 g, 14.28 mmol, 1 eq) in toluene (10 mL) was added CMBP (6.89 g, 28.56 mmol, 2 eq) and tetrahydro- 2H-pyran-4-ol (5.83 g, 57.12 mmol, 5.72 mL, 4 eq) at 25oC under N2 and the solution was stirred at 120oC for 16 hrs. LCMS showed the starting material remained and two peaks with desired mass were detected. The reaction mixture was quenched by addition H2O (50 mL) at 0oC, extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was further purified by prep-HPLC (column: Welch Xtimate C18250 * 70 mm # 10 um; mobile phase: [water (TFA) - ACN]; B%: 25%-55%, 20 min. HPLC: Rt = 3.332 min) to give a product. 4'-bromo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'- indolin]-2'-one (34.77% yield) was obtained as a yellow solid. Step 3: methyl 2-(2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]- 4'-yl)acetate
Figure imgf000098_0002
[000263] To a solution of 4'-bromo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'- indolin]-2'-one (1.6 g, 4.97 mmol, 1 eq) in THF (15 mL) was added Pd(t-Bu3P)2 (126.89 mg, 248.30 umol, 0.05 eq) and BrZnCH2COOMe (1 M, 14.90 mL, 3 eq) at 25oC under N2 and the solution was stirred at 80oC for 2 hrs. LCMS (Rt = 0.602 min) showed the starting material remained and two peaks with desired mass were detected. The reaction mixture was quenched by addition H2O (50 mL) at 0oC, extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (10 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 3/1). Methyl 2-(2'-oxo-1'- Attorney Docket No. MORF-016WO1 (tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (1.6 g, crude) was obtained as a yellow solid. Step 4: methyl 2-bromo-2-(2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'- indolin]-4'-yl)acetate
Figure imgf000099_0001
[000264] To a solution of methyl 2-(2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (600 mg, 1.90 mmol, 1 eq) in THF (4 mL) was added LDA (2 M, 1.71 mL, 1.8 eq) dropwised at -70oC under N2 and the solution was stirred at -78oC for 0.5 hrs, then TMSCl (413.40 mg, 3.81 mmol, 482.94 uL, 2 eq) was added to the solution at -78oC and the solution was stirred at -78oC for 0.5 hrs. Then NBS (677.24 mg, 3.81 mmol, 2 eq) in THF (2 mL) was added to the solution at -78oC and the solution was stirred at -78oC for 1 hr. LCMS showed the starting material remained and one peak with desired mass was detected. The reaction mixture was quenched by addition aq. NH4Cl (10 mL) at 0oC, extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with brine (5 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 3/1). Methyl 2-bromo-2-(2'-oxo-1'-(tetrahydro-2H- pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (79.99% yield) was obtained as a yellow oil. [000265] Intermediates in the table below were prepared according to similar procedures as those described for methyl 2-bromo-2-(2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate from the starting materials shown, substituting the appropriate reagents and purified using appropriate conditions: Attorney Docket No. MORF-016WO1
Figure imgf000100_0001
Attorney Docket No. MORF-016WO1 Preparation of methyl 2-(6'-methoxy-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate
Figure imgf000101_0001
Step 1: methyl 2-(2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)-6'-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate
Figure imgf000101_0002
[000266] To a solution of methyl 2-(2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (300 mg, 951.29 μmol, 1 eq) in dioxane (6 mL) was added Pin2B2 (483.14 mg, 1.90 mmol, 2 eq), [Ir (OMe) (cod)]2 (51.06 mg, 190.26 μmol, 0.2 eq) and dtbpy (50.00 mg, 75.43 μmol, 7.93e-2 eq) at 25°C under N2. The mixture was warmed up to 60 °C and stirred at 60 °C for 2 hrs under N2. LCMS showed the starting material was consumed completely and 77.62% with desired Ms was detected. The reaction mixture was added H2O (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 3/1). Methyl 2-(2'-oxo-1'- (tetrahydro-2H-pyran-4-yl)-6'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (2.3 g, crude) was obtained as a yellow solid. LCMS: [M+1] = 442.3. 1H NMR (400 MHz, METHANOL-d4) δ = 7.47 (s, 1H), 7.34 (s, 1H), 4.47 (ddd, J = 4.2, 8.0, 12.3 Hz, 1H), 4.09 (br dd, J = 4.2, 11.5 Hz, 2H), 3.68 (s, 3H), 3.59 (br t, Attorney Docket No. MORF-016WO1 J = 11.4 Hz, 2H), 3.47 (s, 2H), 2.66 - 2.55 (m, 2H), 2.06 - 1.99 (m, 2H), 1.68 (br dd, J = 2.0, 12.3 Hz, 2H), 1.60 - 1.54 (m, 2H), 1.37 (s, 12H). Step 2: methyl 2-(6'-hydroxy-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane- 1,3'-indolin]-4'-yl)acetate
Figure imgf000102_0001
[000267] To a solution of methyl 2-(2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)-6'-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (2.3 g, 3.65 mmol, 1 eq) in acetone (100 mL) was added Oxone (3.36 g, 5.47 mmol, 1.5 eq) in H2O (50 mL) at 0 °C. The mixture warmed up to 25 °C and was stirred at 25 °C for 1 hr. LCMS showed the starting material was consumed completely and 86.72% with desired Ms was detected. The mixture was quenched with Na2SO3 (100 mL) and ethyl acetate (100 mL) was added to the mixture. The layers were separated and the aqueous phase was extracted with ethyl acetate (100 mL x 3). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 1/1). Methyl 2-(6'- hydroxy-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (64.52% yield) was obtained as a yellow solid. LCMS: [M+1] = 332.1. 1H NMR (400 MHz, CHLOROFORM-d) δ = 6.74 (d, J = 2.1 Hz, 1H), 6.42 (d, J = 2.0 Hz, 1H), 4.56 (tt, J = 4.1, 12.4 Hz, 1H), 4.14 (br dd, J = 4.4, 11.5 Hz, 2H), 3.71 (s, 3H), 3.58 - 3.51 (m, 2H), 3.31 (s, 2H), 2.60 - 2.49 (m, 2H), 1.87 - 1.80 (m, 2H), 1.69 (br dd, J = 2.3, 12.8 Hz, 2H), 1.64 - 1.59 (m, 3H). Step 3: methyl 2-bromo-2-(6'-methoxy-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate
Figure imgf000102_0002
Attorney Docket No. MORF-016WO1 [000268] To a mixture of methyl 2-(6'-hydroxy-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (680 mg, 2.05 mmol, 1 eq) and K2CO3 (425.42 mg, 3.08 mmol, 1.5 eq) in DMF (10 mL) was added MeI (1.75 g, 12.31 mmol, 766.52 μL, 6 eq) at 25°C under N2 in portions. The mixture was stirred 25°C for 2 hrs. LCMS showed ~8% of starting material was remained and 87.09% with desired mass was detected. The reaction mixture was added H2O (20 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (20 mL x 1), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 1/1). Methyl 2- bromo-2-(6'-methoxy-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'- yl)acetate (73.37% yield) was obtained as a yellow solid. LCMS: [M+1] = 346.1. 1H NMR (400 MHz, CHLOROFORM-d) δ = 6.71 (d, J = 2.1 Hz, 1H), 6.46 (d, J = 2.1 Hz, 1H), 4.52 (tt, J = 4.3, 12.4 Hz, 1H), 4.12 (dd, J = 4.6, 11.5 Hz, 2H), 3.83 (s, 3H), 3.71 (s, 3H), 3.53 (dt, J = 1.9, 12.0 Hz, 2H), 3.35 (s, 2H), 2.60 - 2.49 (m, 2H), 1.86 - 1.81 (m, 2H), 1.68 (br dd, J = 2.6, 12.5 Hz, 2H), 1.63 - 1.59 (m, 2H). Step 4: methyl 2-(6'-methoxy-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane- 1,3'-indolin]-4'-yl)acetate
Figure imgf000103_0001
[000269] A mixture of methyl 2-bromo-2-(6'-methoxy-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (570 mg, 1.65 mmol, 1 eq) in THF (20 mL) was allowed to stir at 25°C under N2. The mixture was cooled down to -70°C under N2. Then was added LDA (2 M, 2.48 mL, 3 eq) at -70°C and then the mixture was stirred at -70°C under N2 for 30 min. Then TMSCl (537.88 mg, 4.95 mmol, 628.36 μL, 3 eq) was added and stirred at -70°C under N2 for 30 min. Then a solution of NBS (881.19 mg, 4.95 mmol, 3 eq) in THF (10 mL) was added into the mixture at -70°C and the mixture was stirred at -70°C under N2 for 1 hr. LCMS showed 33.57% of starting material was remained and 62.09% with desired mass was detected. The mixture was quenched with NH4Cl (10 mL) and ethyl acetate (10 x 3 mL) was added to the mixture. The combined organic phases were washed by brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by Attorney Docket No. MORF-016WO1 column chromatography (SiO2, Petroleum ether/ethyl acetate = 100/1 to 3/1). Methyl 2-(6'- methoxy-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (58.55% yield) was obtained as a yellow oil. LCMS: [M+1] = 426.4. 1H NMR (400 MHz, CHLOROFORM-d) δ = 6.88 (d, J = 2.1 Hz, 1H), 6.75 (d, J = 2.1 Hz, 1H), 4.96 (s, 1H), 4.56 - 4.47 (m, 1H), 4.13 (br dd, J = 2.0, 9.4 Hz, 2H), 3.85 (s, 3H), 3.80 (s, 3H), 3.56 - 3.49 (m, 2H), 2.56 - 2.47 (m, 2H), 1.96 - 1.90 (m, 1H), 1.89 - 1.84 (m, 1H), 1.75 - 1.65 (m, 4H). [000270] Using procedures similar to those described above in steps 1, 2 and 3 starting from 7-bromo-1,3-dimethyl-1H-indazole was prepared 7-bromo-5-methoxy-1,3-dimethyl-1H- indazole as a white solid. 1H NMR (400 MHz, CD3OD) δ = 7.24 (d, J = 2.1 Hz, 1H), 7.04 (d, J = 2.1 Hz, 1H), 4.23 (s, 3H), 3.83 (s, 3H), 2.46 (s, 3H). [000271] Using procedures similar to those described above in steps 1, 2 and 3 starting from 7-bromo-1,3-dimethyl-1H-indazole was prepared 7-bromo-5-(2-methoxyethoxy)-1,3-dimethyl- 1H-indazole as a yellow solid. 1H NMR (400 MHz, CDCl3) δ = 7.31 (d, J = 2.1 Hz, 1H), 6.93 (d, J = 2.1 Hz, 1H), 4.29 (s, 3H), 4.18 - 4.12 (m, 2H), 3.82 - 3.74 (m, 2H), 3.48 (s, 3H), 2.49 (s, 3H). Preparation of methyl 2-bromo-2-((S)-6-fluoro-1-methylisochroman-8-yl)acetate and methyl 2-bromo-2-((R)-6-fluoro-1-methylisochroman-8-yl)acetate
Figure imgf000104_0001
Step 1: 7-bromo-5-fluoro-1-methyl-2,3-dihydro-1H-inden-1-ol
Figure imgf000104_0002
[000272] To a solution of MeMgBr (3 M, 145.53 mL, 5 eq) was added 7-bromo-5-fluoro- 2,3-dihydro-1H-inden-1-one (20 g, 87.32 mmol, 1 eq) in THF (200 mL) at 0oC under N2 Attorney Docket No. MORF-016WO1 atmosphere. The mixture was stirred at 0oC for 2 hrs. TLC (petroleum ether/ethyl acetate = 5/1, Rf = 0.47) indicated the starting material was consumed completely and one new spot with lower polarity was formed. The reaction mixture was quenched with aq.NH4Cl (500 mL) and extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give 7- bromo-5-fluoro-1-methyl-2,3-dihydro-1H-inden-1-ol (22.2 g, crude) as a white solid. The crude product was used for next step directly without purification.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.11 (dd, J = 1.9, 8.4 Hz, 1H), 6.87 (dd, J = 0.9, 8.1 Hz, 1H), 2.97 - 2.86 (m, 1H), 2.84 - 2.76 (m, 1H), 2.29 (dd, J = 5.6, 8.6 Hz, 2H), 1.63 (s, 3H). Step 2: 4-bromo-6-fluoro-3-methyl-1H-indene
Figure imgf000105_0001
[000273] To a solution of 7-bromo-5-fluoro-1-methyl-2,3-dihydro-1H-inden-1-ol (22.2 g, 90.58 mmol, 1 eq) in THF (200 mL) was added HCl (12 M, 200 mL, 26.50 eq) at 0oC under N2 atmosphere. The mixture was stirred at 20oC for 2 hrs. TLC (petroleum ether/ethyl acetate = 5/1, Rf = 0.69) indicated the starting material was remained and one new spot with lower polarity was formed. The reaction mixture was quenched with H2O (400 mL) and extracted with MTBE (200 mL x 4). The combined organic layers were washed with brine (400 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, Eluent of 0~5% ethyl acetate/petroleum ether gradient @ 90 mL/min). 4-Bromo-6-fluoro-3-methyl-1H- indene (97.24% yield) was obtained as a white solid. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.19 (dd, J = 2.3, 8.8 Hz, 1H), 7.10 (dd, J = 2.3, 8.0 Hz, 1H), 6.26 - 6.22 (m, 1H), 3.29 (t, J = 2.0 Hz, 2H), 2.40 (q, J = 2.0 Hz, 3H). Step 3: 1-(2-bromo-4-fluoro-6-(2-hydroxyethyl)phenyl)ethan-1-ol
Figure imgf000105_0002
[000274] A solution of 4-bromo-6-fluoro-3-methyl-1H-indene (20 g, 88.08 mmol, 1 eq) in DCM (200 mL) and MeOH (40 mL) was bubbled with O3 (21.14 g, 440.39 mmol, 5 eq) for 2 hrs at -70oC. Then NaBH4 (11.30 g, 298.58 mmol, 3.39 eq) was added at 0oC and the mixture was stirred at 25oC for 16 hrs. TLC (petroleum ether/ethyl acetate = 3/1, Rf = 0.41) indicated the starting material was consumed completely and one new spot with higher polarity was Attorney Docket No. MORF-016WO1 formed. The reaction mixture was quenched with H2O (300 mL) and extracted with DCM (100 mL x 3). The combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give 1-(2-bromo-4-fluoro-6-(2- hydroxyethyl)phenyl)ethan-1-ol (20 g, crude) as a white solid. The crude product was used for next step directly without purification.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.21 (dd, J = 2.6, 7.7 Hz, 1H), 6.95 (dd, J = 2.6, 9.2 Hz, 1H), 5.59 (q, J = 6.7 Hz, 1H), 3.99 (td, J = 5.1, 10.2 Hz, 1H), 3.84 (dt, J = 5.1, 9.7 Hz, 1H), 3.64 - 3.52 (m, 1H), 2.84 (td, J = 4.7, 13.7 Hz, 1H), 1.55 (d, J = 6.8 Hz, 3H). Step 4: 8-bromo-6-fluoro-1-methylisochromane
Figure imgf000106_0001
[000275] To a solution of 1-(2-bromo-4-fluoro-6-(2-hydroxyethyl)phenyl)ethan-1-ol (20 g, 76.02 mmol, 1 eq) in THF (300 mL) was added PPh3 (29.91 g, 114.02 mmol, 1.5 eq) and DIAD (26.13 g, 129.23 mmol, 25.05 mL, 1.7 eq) at 0oC and the mixture was stirred at 25oC for 16 hrs under N2 atmosphere. TLC (petroleum ether/ethyl acetate = 10/1, Rf = 0.57) indicated the starting material was consumed completely and two new spots with lower polarity were formed. The top point was desired. The reaction mixture was quenched with H2O (500 mL) and extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 220 g SepaFlash® Silica Flash Column, Eluent of 0~22% ethyl acetate/petroleum ether gradient @ 80 mL/min). 8- Bromo-6-fluoro-1-methylisochromane (40.79% yield) was obtained as purple oil. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.15 (dd, J = 2.5, 8.1 Hz, 1H), 6.83 (dd, J = 2.5, 8.7 Hz, 1H), 5.02 (q, J = 6.4 Hz, 1H), 4.08 (ddd, J = 4.3, 9.6, 11.7 Hz, 1H), 3.85 (ddd, J = 3.5, 6.0, 11.7 Hz, 1H), 2.97 - 2.85 (m, 1H), 2.78 - 2.67 (m, 1H), 1.57 (d, J = 6.4 Hz, 3H). Step 5: methyl 2-(6-fluoro-1-methylisochroman-8-yl)acetate
Figure imgf000106_0002
[000276] To a solution of 8-bromo-6-fluoro-1-methylisochromane (7.5 g, 30.60 mmol, 1 eq) in THF (80 mL) was added Pd(t-Bu3P)2 (1.56 g, 3.06 mmol, 0.1 eq) and MeOOCCH2ZnBr (1 M, 45.90 mL, 1.5 eq) at 25oC. The mixture was stirred at 80oC for 2 hrs under N2 atmosphere. Attorney Docket No. MORF-016WO1 TLC (petroleum ether/ethyl acetate = 5/1, Rf = 0.36) indicated the starting material was consumed completely and three new spots with lager polarity were formed. The reaction mixture was quenched with H2O (150 mL). The mixture was filtered and the filtrate was extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0~28% ethyl acetate/petroleum ether gradient @ 80 mL/min). Methyl 2-(6-fluoro-1-methylisochroman-8-yl)acetate (96.01% yield) was obtained as a yellow oil. 1H NMR (400 MHz, CHLOROFORM-d) δ = 6.85 (dd, J = 2.6, 9.4 Hz, 1H), 6.77 (dd, J = 2.3, 8.8 Hz, 1H), 5.06 (q, J = 6.5 Hz, 1H), 4.13 - 4.05 (m, 1H), 3.82 (td, J = 5.4, 10.8 Hz, 1H), 3.72 (s, 3H), 3.64 - 3.46 (m, 2H), 2.99 - 2.88 (m, 1H), 2.81 - 2.72 (m, 1H), 1.46 (d, J = 6.5 Hz, 3H). Step 6: methyl (S)-2-(6-fluoro-1-methylisochroman-8-yl)acetate and methyl (R)-2-(6- fluoro-1-methylisochroman-8-yl)acetate
Figure imgf000107_0001
[000277] Methyl 2-(6-fluoro-1-methylisochroman-8-yl)acetate (7 g) was separated by SFC separation (column: ChiralPak IH, 250 * 50 mm, 10 um; mobile phase: [CO2-IPA (0.1% NH3H2O)]; B%:11%, isocratic elution mode). [000278] Peak 1 (44.29% yield) was obtained as a yellow oil and arbitrarily assigned as methyl (S)-2-(6-fluoro-1-methylisochroman-8-yl). 1H NMR (400 MHz, CHLOROFORM-d) δ = 6.85 (dd, J = 2.5, 9.5 Hz, 1H), 6.77 (dd, J = 2.3, 8.9 Hz, 1H), 5.06 (q, J = 6.5 Hz, 1H), 4.08 (ddd, J = 4.4, 8.7, 11.5 Hz, 1H), 3.88 - 3.78 (m, 1H), 3.72 (s, 3H), 3.65 - 3.47 (m, 2H), 2.97 - 2.85 (m, 1H), 2.81 - 2.72 (m, 1H), 1.46 (d, J = 6.5 Hz, 3H) [000279] Peak 2 (45.71% yield) was obtained as a yellow oil and arbitrarily assigned as methyl (R)-2-(6-fluoro-1-methylisochroman-8-yl)acetate. 1H NMR (400 MHz, CHLOROFORM-d) δ = 6.85 (dd, J = 2.5, 9.4 Hz, 1H), 6.77 (dd, J = 2.3, 8.9 Hz, 1H), 5.06 (q, J = 6.5 Hz, 1H), 4.08 (ddd, J = 4.5, 8.8, 11.5 Hz, 1H), 3.87 - 3.78 (m, 1H), 3.72 (s, 3H), 3.65 - 3.45 (m, 2H), 2.99 - 2.87 (m, 1H), 2.82 - 2.70 (m, 1H), 1.46 (d, J = 6.5 Hz, 3H) Attorney Docket No. MORF-016WO1 Step 7: methyl 2-bromo-2-((S)-6-fluoro-1-methylisochroman-8-yl)acetate
Figure imgf000108_0001
[000280] To a solution of arbitrarily assigned methyl (S)-2-(6-fluoro-1-methylisochroman-8- yl) (1 g, 4.20 mmol, 1 eq) in THF (20 mL) was added LDA (2 M, 6.30 mL, 3 eq) at -78oC under N2 atmosphere. The mixture was stirred at -78oC for 30 min. TMSCl (1.37 g, 12.59 mmol, 1.60 mL, 3 eq) was added at -78oC. After the reaction mixture had stirred at -78oC for 30 min, NBS (2.24 g, 12.59 mmol, 3 eq) in THF (40 mL) was added. The mixture was stirred at -78oC for 1 hr. TLC (petroleum ether/ethyl acetate = 5/1, Rf = 0.45, 0.51) indicated the starting material was consumed completely and two new spots with lower polarity were formed. The reaction mixture was quenched by addition aqueous NH4Cl (40 mL), and extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (40 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~22% ethyl acetate/petroleum ether gradient @ 80 mL/min). Arbitrarily assigned methyl 2-bromo-2-((S)-6-fluoro-1-methylisochroman-8-yl)acetate (97.66% yield) was obtained as a yellow oil. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.36 (ddd, J = 2.6, 9.7, 16.4 Hz, 1H), 6.83 (br d, J = 8.6 Hz, 1H), 5.45 - 5.35 (m, 1H), 5.23 - 5.10 (m, 1H), 4.09 - 4.04 (m, 1H), 3.87 - 3.77 (m, 4H), 3.01 - 2.88 (m, 1H), 2.81 - 2.71 (m, 1H), 1.56 (dd, J = 6.6, 12.1 Hz, 3H). [000281] By a similar procedure as described above in Step 7 starting from arbitrarily assigned methyl (R)-2-(6-fluoro-1-methylisochroman-8-yl)acetate was prepared arbitrarily assigned methyl 2-bromo-2-((R)-6-fluoro-1-methylisochroman-8-yl)acetate.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.36 (ddd, J = 2.6, 9.7, 16.3 Hz, 1H), 6.83 (br d, J = 8.6 Hz, 1H), 5.46 - 5.35 (m, 1H), 5.22 - 5.06 (m, 1H), 4.09 - 4.03 (m, 1H), 3.86 - 3.77 (m, 4H), 2.99 - 2.88 (m, 1H), 2.79 - 2.72 (m, 1H), 1.56 (dd, J = 6.6, 12.0 Hz, 3H). [000282] By a similar procedure as described above in Step 7 starting from arbitrarily assigned methyl (R)-2-(1-methylisochroman-8-yl)acetate was prepared arbitrarily assigned methyl 2-bromo-2-((R)-1-methylisochroman-8-yl)acetate.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.68 - 7.51 (m, 1H), 7.26 - 7.20 (m, 1H), 5.66 - 5.34 (m, 1H), 4.18 - 4.05 (m, 2H), 3.76 (s, 3H), 3.05 - 2.87 (m, 2H), 2.87 - 2.64 (m, 2H), 1.57 (s, 3H). Attorney Docket No. MORF-016WO1 [000283] By a similar procedure as described above in Step 7 starting from arbitrarily assigned methyl (S)-2-(6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]-8- yl)acetate was prepared arbitrarily assigned methyl 2-bromo-2-((S)-6-fluoro-1-methyl- 2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]-8-yl)acetate (79.6% yield) as a yellow solid. [000284] By a similar procedure as described above in Step 7 starting from arbitrarily assigned methyl (R)-2-(6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]- 8-yl)acetate was prepared arbitrarily assigned methyl 2-bromo-2-((R)-6-fluoro-1-methyl- 2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]-8-yl)acetate. [000285] By a similar procedure as described above in Step 6, methyl 2-(1'-(2,2- dimethyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetate was separated (SFC (column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 um); mobile phase: [CO2-MeOH]; B%:20%, isocratic elution mode) to give arbitrarily assigned methyl (S)- 2-(1'-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'- yl)acetate and arbitrarily assigned methyl (R)-2-(1'-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-2'- oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetate. [000286] By a similar procedure as described above in Step 7 starting from arbitrarily assigned methyl (R)-2-(1'-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane- 1,3'-indolin]-4'-yl)acetate was prepared arbitrarily assigned methyl 2-bromo-2-(1'-((R)-2,2- dimethyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (78.26% yield) as a yellow oil.1H NMR (400 MHz, CDCl3) δ = 7.38 (d, J = 8.0 Hz, 1H), 7.30 - 7.28 (m, 1H), 7.14 (d, J = 8.1 Hz, 1H), 5.00 (s, 1H), 4.83 - 4.69 (m, 1H), 3.96 - 3.90 (m, 1H), 3.86 - 3.81 (m, 1H), 3.80 (s, 3H), 2.52 - 2.43 (m, 1H), 2.35 - 2.28 (m, 1H), 1.98 - 1.91 (m, 1H), 1.78 (s, 2H), 1.71 - 1.60 (m, 3H), 1.36 (s, 3H), 1.32 (s, 3H). [000287] By a similar procedure as described above in Step 7 starting from arbitrarily assigned methyl (S)-2-(1'-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane- 1,3'-indolin]-4'-yl)acetate was prepared arbitrarily assigned methyl 2-bromo-2-(1'-((S)-2,2- dimethyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetate. [000288] By a similar procedure as described above in Step 6, methyl 2-(4-methylchroman- 5-yl)acetate was separated by SFC (column: DAICEL CHIRALPAK IC(250 mm*30 mm, 10 um);mobile phase: [CO2-IPA(0.1%NH3H2O)];B%:25%, isocratic elution mode) to give 2 compounds. Peak 1, arbitrarily assigned methyl (S)-2-(4-methylchroman-5-yl)acetate, was obtained as a yellow oil. SFC Rt= 0.900 min. 1H NMR (400 MHz, CD3OD) δ = 7.00 (t, J = Attorney Docket No. MORF-016WO1 7.9 Hz, 1H), 6.73 (dd, J = 0.8, 7.4 Hz, 1H), 6.65 (d, J = 8.3 Hz, 1H), 4.23 - 4.15 (m, 2H), 3.75 - 3.57 (m, 5H), 3.14 - 3.01 (m, 1H), 2.16 - 1.94 (m, 1H), 1.75 (qd, J = 2.2, 13.8 Hz, 1H), 1.24 (d, J = 7.0 Hz, 3H). Peak 2, arbitrarily assigned methyl (R)-2-(4-methylchroman-5-yl)acetate, was obtained as a yellow oil. SFC Rt= 1.170 min. 1H NMR (400 MHz, CD3OD) δ = 7.00 (t, J = 7.9 Hz, 1H), 6.73 (dd, J = 0.7, 7.4 Hz, 1H), 6.66 (d, J = 8.3 Hz, 1H), 4.28 - 4.12 (m, 2H), 3.76 - 3.69 (m, 1H), 3.67 (s, 3H), 3.65 - 3.58 (m, 1H), 3.12 - 3.01 (m, 1H), 2.11 - 1.95 (m, 1H), 1.82 - 1.67 (m, 1H), 1.24 (d, J = 7.1 Hz, 3H). [000289] By a similar procedure as described above in Step 7 starting from arbitrarily assigned methyl (S)-2-(4-methylchroman-5-yl)acetate was prepared arbitrarily assigned methyl 2-bromo-2-((S)-4-methylchroman-5-yl)acetate as a yellow oil. LCMS [M+1] = 299.0. 1H NMR (400 MHz, CDCl3) δ = 7.33 - 7.21 (m, 1H), 7.14 (dt, J = 2.7, 8.0 Hz, 1H), 6.80 (ddd, J = 0.8, 3.5, 8.0 Hz, 1H), 5.67 (d, J = 1.8 Hz, 1H), 4.33 - 4.19 (m, 2H), 3.80 (d, J = 19.9 Hz, 3H), 3.26 - 3.10 (m, 1H), 2.21 - 2.08 (m, 1H), 1.78 (qdd, J = 2.2, 4.5, 13.8 Hz, 1H), 1.39 (dd, J = 2.3, 7.1 Hz, 3H). [000290] By a similar procedure as described above in Step 7 starting from arbitrarily assigned methyl (R)-2-(4-methylchroman-5-yl)acetate was prepared arbitrarily assigned methyl 2-bromo-2-((R)-4-methylchroman-5-yl)acetate as a yellow oil. LCMS [M+1] = 219.1. [000291] By a similar procedure as described above in Step 7 starting from arbitrarily assigned methyl (S)-2-(1-methylisochroman-8-yl)acetate was prepared arbitrarily assigned methyl 2-bromo-2-((S)-1-methylisochroman-8-yl)acetate (92.03% yield) as a yellow oil. LCMS [M+1] = 300.9. [000292] By a similar procedure as described above in steps 5 and 6 starting from 8-bromo- 1-methylisochromane (SFC separation conditions: (column: ChiralPak IH, 250 x 50 mm, 10 um; mobile phase: [CO2-Heptane: IPA=1:1(0.1% NH3H2O)]; B%:11%, isocratic elution mode)) were prepared two compounds. Peak 1, aribtrarily assigned as (R)-2-(1- methylisochroman-8-yl)acetate, was obtained as a yellow oil. Peak 2, arbitrarily assigned as methyl (S)-2-(1-methylisochroman-8-yl)acetate was obtained as a yellow oil1H NMR (400 MHz, CDCl3) δ = 7.19 - 7.14 (m, 1H), 7.13 - 7.09 (m, 1H), 7.05 (d, J = 7.2 Hz, 1H), 5.11 (q, J = 6.6 Hz, 1H), 4.13 - 4.06 (m, 1H), 3.86 - 3.80 (m, 1H), 3.71 (s, 3H), 3.67 - 3.60 (m, 1H), 3.58 - 3.51 (m, 1H), 2.97 - 2.90 (m, 1H), 2.84 - 2.76 (m, 1H), 1.49 (d, J = 6.6 Hz, 3H). [000293] By similar procedures as described above in steps 5, 6 and 7 starting from (3R,4S)- 5-bromo-3,4,7-trimethylisochromane (SFC separation conditions: column: DAICEL Attorney Docket No. MORF-016WO1 CHIRALPAK AD (250 mm * 50 mm, 10 um); mobile phase: [CO2-i-PrOH (0.1%NH3·H2O)]; B%: 11%-11%, 2 min) were prepared two compounds. Peak 1, aribtrarily assigned as tert- butyl 2-bromo-2-((3R,4S)-3,4,7-trimethylisochroman-5-yl)acetate, was obtained as a yellow oil. Peak 2, arbitrarily assigned as tert-butyl 2-bromo-2-((3S,4R)-3,4,7-trimethylisochroman- 5-yl)acetate was obtained as a yellow oil. [000294] By similar procedures as described above in steps 5, 6 and 7 starting from 5- bromo-7-fluoro-4-methylisochromane (SFC separation conditions: column: DAICEL CHIRALPAK IC (250 mm * 30 mm, 10 um); mobile phase: [CO2-i-PrOH (0.1%NH3H2O)]; 18% B isocratic elution mode) were prepared two compounds. Peak 1, aribtrarily assigned as methyl 2-bromo-2-((S)-7-fluoro-4-methylisochroman-5-yl)acetate, was obtained as a yellow oil. Peak 2, arbitrarily assigned as methyl 2-bromo-2-((R)-7-fluoro-4-methylisochroman-5- yl)acetate was obtained as a yellow oil. Preparation of methyl (S)-2-(1-methylisochroman-8-yl)acetate and methyl (R)-2-(1- methylisochroman-8-yl)acetate
Figure imgf000111_0001
Step 1: 7-bromo-1-methyl-2,3-dihydro-1H-inden-
Figure imgf000111_0002
Figure imgf000111_0003
[000295] To a solution
Figure imgf000111_0004
M, 157.94 mL, 5 eq) was added 7-bromo-2,3- dihydro-1H-inden-1-one (20 g, 94.76 mmol, 1 eq) in THF (200 mL) at 0°C under N2. The mixture was stirred at 0°C for 2 hrs. TLC (Petroleum ether/ethyl acetate = 5/1, Rf = 0.35) indicated one new spot was formed and 7-bromo-2,3-dihydro-1H-inden-1-one was consumed completely. The reaction mixture was quenched by aq.NH4Cl (500 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (400 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 0/1). 7-Bromo-1-methyl-2,3-dihydro-1H-inden-1-ol (88.29% yield) was obtained as a yellow Attorney Docket No. MORF-016WO1 oil. 1H NMR (400 MHz, CDCl3) δ = 7.35 (d, J = 7.8 Hz, 1H), 7.19 - 7.14 (m, 1H), 7.11 - 7.06 (m, 1H), 2.97 - 2.91 (m, 1H), 2.82 (t, J = 8.8 Hz, 1H), 2.27 (dd, J = 5.4, 8.7 Hz, 2H), 1.64 (s, 3H). Step 2: 4-bromo-3-methyl-1H-indene
Figure imgf000112_0001
[000296] To a solution of 7-bromo-1-methyl-2,3-dihydro-1H-inden-1-ol (19 g, 83.66 mmol, 1 eq) in toluene (150 mL) was added TsOH (288.14 mg, 1.67 mmol, 0.02 eq) at 20°C. The mixture was stirred at 135°C for 2 hrs. TLC (Petroleum ether/ethyl acetate = 3/1, Rf = 0.85) indicated one new spot was formed and 7-bromo-1-methyl-2,3-dihydro-1H-inden-1-ol was consumed completely. The reaction mixture was quenched by H2O (300 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 0/1). 4-Bromo-3-methyl-1H-indene (97.18% yield) was obtained as a colorless solid. 1H NMR (400 MHz, CDCl3) δ = 7.47 - 7.35 (m, 2H), 7.02 (t, J = 7.6 Hz, 1H), 6.33 - 6.20 (m, 1H), 3.30 (t, J = 2.2 Hz, 2H), 2.43 (q, J = 2.2 Hz, 3H). Step 3: 2-(3-bromo-2-(1-hydroxyethyl)phenyl)ethan- 1) O3 , DCM/MeOH 2) NaBH4
Figure imgf000112_0003
Figure imgf000112_0002
[000297] To a solution of 4-bromo-3-methyl-1H-indene (10 g, 47.83 mmol, 1 eq) in DCM (100 mL) and MeOH (20 mL) was added O3 (11.48 g, 239.14 mmol, 5 eq) at -70°C. The mixture was stirred at -70°C for 0.5 hrs. NaBH4 (2.35 g, 62.18 mmol, 1.3 eq) was added at - 70oC. The mixture was stirred at 15°C for 2 hrs. TLC (Petroleum ether/ethyl acetate = 5/1, Rf = 0.25) indicated one new spot was formed and 4-bromo-3-methyl-1H-indene was consumed completely. The reaction mixture was quenched by NH4Cl (200 mL) and extracted with CH2Cl2 (100 mL x 3). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was used for next step and without purification. 2-(3-Bromo-2-(1- hydroxyethyl)phenyl)ethan-1-ol (6.4 g, crude) was obtained as a white solid. Attorney Docket No. MORF-016WO1 Step 4: 8-bromo-1-methylisochromane
Figure imgf000113_0001
[000298] To a solution of 2-(3-bromo-2-(1-hydroxyethyl)phenyl)ethan-1-ol (6.2 g, 25.29 mmol, 1 eq) in CH3CN (60 mL) was added H3PO4 (26.04 g, 265.73 mmol, 15.50 mL, 10.51 eq) at 20°C under N2. The mixture was stirred at 80°C for 12 hrs. TLC (Petroleum ether/ethyl acetate = 3/1, Rf = 0.5) indicated one new spot was formed and 2-(3-bromo-2-(1- hydroxyethyl)phenyl)ethan-1-ol remained. The reaction mixture was quenched by H2O (200 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 0/1). 8-Bromo-1-methylisochromane (52.23% yield) was obtained as colorless oil. Step 5: methyl 2-(1-methylisochroman-8-yl)acetate
Figure imgf000113_0002
[000299] A mixture of Zn (15.39 g, 235.33 mmol, 1.2 eq) in THF (196.11 mL) was added TMSCl (2.13 g, 19.61 mmol, 2.49 mL, 0.1 eq) at 20°C, and then stirred at 20°C for 0.5 hrs. BrCH2COOt-Bu (30 g, 196.11 mmol, 18.52 mL, 1 eq) was dropwise added at 20°C and then stirred at 20°C for 12 hrs. To a solution of 8-bromo-1-methylisochromane (3 g, 13.21 mmol, 1 eq) in THF (25 mL) was added (Pd t-Bu3P)2 (675.11 mg, 1.32 mmol, 0.1 eq) and the above mixture (1 M, 39.63 mL, 3 eq) at 25°C under N2. The mixture was stirred at 80°C for 1 hr. TLC (Petroleum ether/ethyl acetate = 2/1, Rf = 0.26) indicated 8-bromo-1-methylisochromane was consumed completely and one new spot formed. The reaction mixture was filtered and the filter cake was washed with ethyl acetate. Then the reaction mixture was quenched by addition H2O (20 mL) at 20°C, and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 1/0 to 0/1). Methyl 2-(1-methylisochroman-8-yl)acetate (68.73% yield) was obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ = 7.19 - 7.13 (m, 1H), 7.13 - 7.09 (m, 1H), 7.05 (d, J = 7.4 Hz, 1H), 5.11 (q, J = 6.6 Hz, 1H), 4.12 - 4.07 (m, Attorney Docket No. MORF-016WO1 1H), 3.86 - 3.80 (m, 1H), 3.70 (s, 3H), 3.66 - 3.60 (m, 1H), 3.57 - 3.51 (m, 1H), 3.00 - 2.89 (m, 1H), 2.82 - 2.73 (m, 1H), 1.49 (d, J = 6.5 Hz, 3H). Step 6: methyl (S)-2-(1-methylisochroman-8-yl)acetate and methyl (R)-2-(1- methylisochroman-8-yl)acetate
Figure imgf000114_0001
[000300] Methyl 2-(1-methylisochroman-8-yl)acetate was separated by SFC (column: DAICEL CHIRALCEL OJ (250mm*50mm, 10um); mobile phase: [Heptane-EtOH]; B%:20%, isocratic elution mode) to give two peaks (Rt1 = 2.93 min & Rt2 = 3.44 min). [000301] Peak 1 (40.00% yield) was obtained as a yellow oil and arbitrarily assigned as methyl (S)-2-(1-methylisochroman-8-yl)acetate. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.19 - 7.14 (m, 1H), 7.13 - 7.09 (m, 1H), 7.05 (d, J = 7.3 Hz, 1H), 5.11 (q, J = 6.5 Hz, 1H), 4.11 (dd, J = 4.4, 8.6, 11.4 Hz, 1H), 3.87 - 3.80 (m, 1H), 3.71 (s, 3H), 3.66 - 3.60 (m, 1H), 3.58 - 3.51 (m, 1H), 2.99 - 2.90 (m, 1H), 2.83 - 2.75 (m, 1H), 1.49 (d, J = 6.5 Hz, 3H). [000302] Peak 2 (40.00% yield) was obtained as a yellow oil and arbitrarily assigned as methyl (R)-2-(1-methylisochroman-8-yl)acetate. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.19 - 7.14 (m, 1H), 7.13 - 7.08 (m, 1H), 7.05 (d, J = 7.4 Hz, 1H), 5.11 (q, J = 6.5 Hz, 1H), 4.11 (ddd, J = 4.5, 8.6, 11.4 Hz, 1H), 3.83 (td, J = 5.0, 11.3 Hz, 1H), 3.71 (s, 3H), 3.66 - 3.61 (m, 1H), 3.58 - 3.50 (m, 1H), 2.99 - 2.89 (m, 1H), 2.84 - 2.75 (m, 1H), 1.49 (d, J = 6.5 Hz, 3H).
Attorney Docket No. MORF-016WO1 Preparation of methyl 2-(6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-
Figure imgf000115_0001
Step 1: 2-(2-acetyl-3-bromo-5-fluorophenyl)acetic acid
Figure imgf000115_0002
[000303] A mixture of 1-(2-bromo-4-fluorophenyl)ethan-1-one (8.50 g, 39.16 mmol, 1 eq), 5-diazo-2,2-dimethyl-1,3-dioxane-4,6-dione (9.99 g, 58.75 mmol, 1.5 eq), [Ir(Cp)Cl2]2 (315.97 mg, 391.64 μmol, 0.01 eq), AgNTf2(258.33 mg, 665.79 μmol, 0.017 eq), PhB(OH)2 (4.78 g, 39.16 mmol, 1 eq) in H2O (170 mL) was stirred for 16 hrs at 80°C. LCMS showed 66% of starting material was remained and ~16% with desired Mass was detected. Water (10 mL) was added, the mixture was extracted with ethyl acetate (10 mL x 2). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4 and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage®; 40 g SepaFlash® Silica Flash Column, Eluentof 0~10% Ethyl acetate/Petroleum ether gradient @ 80 mL/min) to give 2-(2-acetyl-3-bromo-5-fluorophenyl)acetic acid (9.3% yield) as a white solid. LCMS: [M+1] = 275.0. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.27 (dd, J = 2.3, 7.8 Hz, 1H), 7.00 (dd, J = 2.3, 8.8 Hz, 1H), 3.62 (s, 2H), 2.59 (s, 3H). Attorney Docket No. MORF-016WO1 Step 2: 2-(2-acetyl-3-bromo-5-fluorophenyl)-N,N-dimethylacetamide
Figure imgf000116_0001
[000304] To a solution of 2-(2-acetyl-3-bromo-5-fluorophenyl)acetic acid (1.91 g, 6.96 mmol, 1 eq) in DCM (25 mL) was added N-methylmethanamine;hydrochloride (1.30 g, 16.00 mmol, 2.3 eq), DIEA (3.15 g, 24.35 mmol, 4.24 mL, 3.5 eq), DMAP (1.44 g, 11.83 mmol, 1.7 eq), HATU (4.76 g, 12.52 mmol, 1.8 eq), the mixture was stirred at 25°C for 16 hrs. LCMS showed ~30.9 % desired mass. Water (30 mL) was added, the mixture was extracted with DCM (30 mL x 2). The combined organic layers were washed brine (30 mL x 2), dried over Na2SO4 and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, 20gSepaFlash ® Silica Flash Column,Eluentof 0~30% Petroleum ethergradient /Ethyl acetate @ 120mL/min) to give product 2-(2-acetyl-3-bromo-5- fluorophenyl)-N,N-dimethylacetamide (66.6% yield) as a yellow oil. LCMS: [M+1] = 302.0. Step 3: 2-(3-bromo-5-fluoro-2-(1-hydroxyethyl)phenyl)-N,N-dimethylacetamide
Figure imgf000116_0002
[000305] To a solution of 2-(2-acetyl-3-bromo-5-fluorophenyl)-N,N-dimethylacetamide (1.4 g, 4.63 mmol, 1 eq) in THF (20 mL) was added LiBH4 (2 M, 4.63 mL, 2 eq) in 0°C, the mixture was stirred at 25°C for 12 hrs. LCMS showed ~ 66% desired mass. The mixture was poured into ice water (20 mL), the mixture was extracted with ethyl acetate (20 mL x 2). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4 and concentrated under reduced pressure to give a residue to give 2-(3-bromo-5-fluoro-2-(1- hydroxyethyl)phenyl)-N,N-dimethylacetamide (1.1 g, crude) as a yellow oil. LCMS: [M+1] = 286.0. Step 4: 8-bromo-6-fluoro-1-methylisochroman-3-one Attorney Docket No. MORF-016WO1
Figure imgf000117_0001
[000306] To a solution of 2-(3-bromo-5-fluoro-2-(1-hydroxyethyl)phenyl)-N,N- dimethylacetamide (1.1 g, 3.62 mmol, 1 eq) in THF (12 mL) was added HCl (3 M, 1.21 mL, 1 eq), the mixture was stirred at 90°C for 2 hrs. LCMS showed ~54 % desired mass. Water (15 mL) was added, the mixture was extracted with ethyl acetate (15 mL x2). The combined organic layers were washed with brine (15 mL x 2), dried over Na2SO4 and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, 20g SepaFlash ® Silica Flash Column, Eluent of 0~30%Petroleum ether gradient /Ethyl acetate @ 120mL/min) to give 8-bromo-6-fluoro-1-methylisochroman-3-one (59.7% yield) as a yellow oil. LCMS: [M+1] = 259.0. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.20 - 7.18 (m, 1H), 6.84 (br d, J = 8.1 Hz, 1H), 5.73 (q, J = 6.9 Hz, 1H), 3.71 - 3.61 (m, 2H), 1.55 (d, J = 6.9 Hz, 3H). Step 5: 8-bromo-6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]-3- one
Figure imgf000117_0002
[000307] To a solution of Cs2CO3 (6.41 g, 19.69 mmol, 3 eq) in DMF (10 mL) was added give 8-bromo-6-fluoro-1-methylisochroman-3-one (1.7 g, 6.56 mmol, 1 eq) in DMF (10 mL) at 20°C under N2. The mixture was stirred at 20°C for 0.5 hrs.1-bromo-2-(2- bromoethoxy)ethane (6.09 g, 26.25 mmol, 3.30 mL, 4 eq) was added at 20°C under N2. The mixture was stirred at 20°C for 12 hr. LCMS showed one peak with desired mass was detected. The reaction mixture was quenched by H2O (100 mL) and extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (100 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 0/1) to give 8-bromo-6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro-[isochromane-4,4'-pyran]-3-one Attorney Docket No. MORF-016WO1 (69.4% yield) as colorless oil. LCMS: [M+1] = 329.1. 1H NMR (400 MHz, CHLOROFORM- d) δ = 7.31 (dd, J = 2.4, 7.5 Hz, 1H), 7.24 (dd, J = 2.3, 10.1 Hz, 1H), 5.76 (q, J = 6.6 Hz, 1H), 4.50 (dt, J = 2.5, 11.6 Hz, 1H), 4.05 - 3.86 (m, 3H), 2.34 (ddd, J = 5.6, 11.6, 13.9 Hz, 1H), 2.04 - 1.90 (m, 3H), 1.72 (d, J = 6.8 Hz, 3H). Step 6: 8-bromo-6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]-3- ol
Figure imgf000118_0001
[000308] To a solution of 8-bromo-6-fluoro-1-methyl-2',3',5',6'- tetrahydrospiro[isochromane-4,4'-pyran]-3-one (1.5 g, 4.56 mmol, 1 eq) in CH2Cl2 (20 mL) was added DIBAL-H (1 M, 5.92 mL, 1.3 eq) at 0°C under N2. The mixture was stirred at 0°C for 1 hr. TLC (petroleum ether/ethyl acetate = 3/1, Rf = 0.25) indicated one new spot was formed. The reaction mixture was added aq.HCl (1M, 50 mL), it was stirred for 30 mins, then extracted with DCM (30 mL x 3). The combined organic layers were washed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 0/1) to give 8-bromo-6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]- 3-ol (800 mg, 2.42 mmol, 53.0%) as a white solid. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.25 - 7.15 (m, 2H), 5.77 - 5.46 (m, 1H), 5.11 (q, J = 6.4 Hz, 1H), 4.01 - 3.77 (m, 4H), 2.29 - 2.06 (m, 2H), 1.82 - 1.59 (m, 5H). Step 7: 8-bromo-6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]
Figure imgf000118_0002
[000309] To a solution of 8-bromo-6-fluoro-1-methyl-2',3',5',6'- tetrahydrospiro[isochromane-4,4'-pyran]-3-ol (700 mg, 2.11 mmol, 1 eq) in DCM (14 mL) was added Et3SiH (1.47 g, 12.68 mmol, 2.03 mL, 6 eq) and TFA (2.17 g, 19.02 mmol, 1.41 mL, 9 eq) at 20°C under N2. The mixture was stirred at 50°C for 24 hrs. TLC (Plate 1, petroleum Attorney Docket No. MORF-016WO1 ether/ethyl acetate = 3/1, Rf = 0.5) indicated one new spot was formed. The reaction mixture was quenched by H2O (30 mL) and extracted with DCM (10 mL x 3). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 0/1) to give 8-bromo-6-fluoro-1-methyl-2',3',5',6'- tetrahydrospiro[isochromane-4,4'-pyran] (1.1 g, crude) as a white solid. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.20 - 7.13 (m, 2H), 5.04 (q, J = 6.4 Hz, 1H), 4.10 (d, J = 12.1 Hz, 1H), 3.97 - 3.87 (m, 3H), 3.75 - 3.67 (m, 1H), 3.58 (dt, J = 2.1, 12.4 Hz, 1H), 2.23 (dt, J = 5.1, 13.3 Hz, 1H), 1.90 - 1.81 (m, 1H), 1.77 - 1.70 (m, 1H), 1.60 (d, J = 6.4 Hz, 3H), 1.56 (br d, J = 4.8 Hz, 1H). Step 8: methyl 2-(6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]- 8-yl)acetate
Figure imgf000119_0001
[000310] A mixture of give 8-bromo-6-fluoro-1-methyl-2',3',5',6'- tetrahydrospiro[isochromane-4,4'-pyran] (1.0 g, 3.17 mmol, 1 eq) in THF (5 mL) was added Pd(t-Bu3P)2 (162.15 mg, 317.28 μmol, 0.1 eq) at 25°C. BrZnCH2COOMe (1 M, 6.98 mL, 2.2 eq) was added into the reaction. The reaction was stirred at 80°C for 3 hrs. TLC (Petroleum ether: Ethyl acetate = 2:1) showed the starting material (Rf =0.50) was consumed and a new spot (Rf = 0.30) observed. The mixture was filtered and H2O was added to the filtrate. The mixture was filtered and the layers were separated and the aqueous phase was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Petroleum ether/Ethyl acetate= 2/1). The product was further separated by SFC (condition: column: DAICEL CHIRALPAK AD (250mm*30mm,10um);mobile phase: [CO2-EtOH];B%:15%, isocratic elution mode). [000311] Peak 1 (15.3% yield) was obtained as a yellow oil and arbitrarily assigned as methyl (S)-2-(6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]-8- yl)acetate. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.10 (dd, J = 2.6, 10.3 Hz, 1H), 6.87 Attorney Docket No. MORF-016WO1 (dd, J = 2.6, 9.1 Hz, 1H), 5.07 (q, J = 6.5 Hz, 1H), 4.06 - 3.95 (m, 2H), 3.93 - 3.83 (m, 2H), 3.73 (s, 3H), 3.75 - 3.66 (m, 1H), 3.64 - 3.48 (m, 3H), 2.21 (dt, J = 5.1, 13.3 Hz, 1H), 1.92 (dt, J = 5.1, 13.3 Hz, 1H), 1.76 - 1.50 (m, 4H), 1.49 (d, J = 6.5 Hz, 3H). [000312] Peak 2 (15.3% yield) was obtained as a yellow oil and arbitrarily assigned as methyl (R)-2-(6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]-8- yl)acetate.1H NMR (400 MHz, CHLOROFORM-d) δ = 7.09 (dd, J = 2.6, 10.3 Hz, 1H), 6.87 (dd, J = 2.5, 9.1 Hz, 1H), 5.07 (q, J = 6.5 Hz, 1H), 4.00 (q, J = 12.0 Hz, 2H), 3.95 - 3.84 (m, 2H), 3.80 - 3.67 (m, 4H), 3.64 - 3.47 (m, 3H), 2.21 (dt, J = 5.2, 13.4 Hz, 1H), 1.92 (dt, J = 5.1, 13.2 Hz, 1H), 1.74 - 1.59 (m, 2H), 1.48 (d, J = 6.5 Hz, 3H). Separation of isomers of methyl 2-(6'-methyl-1'-(2-methyltetrahydro-2H-pyran-4-yl)-2'-
Figure imgf000120_0001
[000313] Methyl 2-(6'-methyl-1'-(2-methyltetrahydro-2H-pyran-4-yl)-2'- oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (4.8 g, 16.15 mmol, 1 eq) was separated by SFC (column: DAICEL CHIRALPAK IC (250 mm*50 mm, 10 um); mobile phase: [CO2- MeOH (0.1%NH3H2O)]; B%:35%, isocratic elution mode and column: REGIS (s,s) WHELK- O1 (250 mm*50 mm, 10 um); mobile phase: [CO2-IPA]; B%:25%, isocratic elution mode) to give 4 isomers. [000314] Peak 1, arbitrarily assigned as methyl 2-(6'-methyl-1'-((2S,4S)-2-methyltetrahydro- 2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (13.00% yield), was obtained as a yellow oil. SFC: Rt = 2.228 min. 1H NMR (400 MHz, CHLOROFORM-d) δ = 6.92 (s, 1H), 6.74 (s, 1H), 4.66 - 4.45 (m, 1H), 4.15 (dd, J = 3.8, 11.9 Hz, 1H), 3.71 (s, 3H), 3.65 - 3.52 (m, 2H), 3.35 (s, 2H), 2.50 (dq, J = 4.7, 12.6 Hz, 1H), 2.38 (s, 3H), 2.25 - 2.11 (m, 1H), 1.89 - 1.85 (m, 2H), 1.75 (td, J = 2.0, 12.6 Hz, 1H), 1.68 (br d, J = 2.4 Hz, 1H), 1.61 (br s, 2H), 1.28 (d, J = 6.2 Hz, 3H). [000315] Peak 2, arbitrarily assigned as methyl 2-(6'-methyl-1'-((2R,4R)-2- methyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (13.00% yield), was obtained as a yellow oil. SFC: Rt = 2.450 min. 1H NMR (400 MHz, CHLOROFORM-d) δ = 6.92 (s, 1H), 6.74 (s, 1H), 4.57 (tdd, J = 4.3, 8.3, 12.6 Hz, 1H), 4.15 Attorney Docket No. MORF-016WO1 (dd, J = 4.5, 11.1 Hz, 1H), 3.71 (s, 3H), 3.65 - 3.55 (m, 2H), 3.35 (s, 2H), 2.50 (dq, J = 4.8, 12.6 Hz, 1H), 2.38 (s, 3H), 2.26 - 2.11 (m, 1H), 1.91 - 1.82 (m, 2H), 1.75 (td, J = 2.0, 12.7 Hz, 1H), 1.68 (br d, J = 2.0 Hz, 1H), 1.65 - 1.61 (m, 2H), 1.28 (d, J = 6.2 Hz, 3H). [000316] Peak 3, arbitrarily assigned as methyl 2-(6'-methyl-1'-((2R,4S)-2- methyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (31.7% yield), was obtained as a yellow oil. SFC: Rt = 2.794 min. 1H NMR (400 MHz, CHLOROFORM-d) δ = 6.91 (s, 1H), 6.75 (s, 1H), 4.79 - 4.68 (m, 1H), 4.40 - 4.32 (m, 1H), 3.92 - 3.86 (m, 2H), 3.71 (s, 3H), 3.35 (s, 2H), 2.70 - 2.61 (m, 1H), 2.56 - 2.45 (m, 1H), 2.38 (s, 3H), 1.89 - 1.83 (m, 2H), 1.77 - 1.70 (m, 1H), 1.65 - 1.57 (m, 3H), 1.39 (d, J = 6.9 Hz, 3H). [000317] Peak 4, arbitrarily assigned as methyl 2-(6'-methyl-1'-((2S,4R)-2- methyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (33.33% yield), was obtained as a yellow oil. SFC: Rt = 3.106 min. 1H NMR (400 MHz, CHLOROFORM-d) δ = 6.91 (s, 1H), 6.75 (s, 1H), 4.87 - 4.61 (m, 1H), 4.44 - 4.28 (m, 1H), 3.93 - 3.82 (m, 2H), 3.71 (s, 3H), 3.35 (s, 2H), 2.70 - 2.60 (m, 1H), 2.56 - 2.44 (m, 1H), 2.38 (s, 3H), 1.88 - 1.82 (m, 2H), 1.77 - 1.68 (m, 1H), 1.65 - 1.57 (m, 3H), 1.39 (d, J = 6.8 Hz, 3H). Preparation of methyl 2-bromo-2-(7'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4-
Figure imgf000121_0001
Step 1: methyl 2-(6-bromo-2,3-difluorophenyl)-2-oxoacetate Attorney Docket No. MORF-016WO1
Figure imgf000122_0001
[000318] To a solution of 4-bromo-1,2-difluorobenzene (10 g, 51.82 mmol, 1 eq) in THF (100 mL) was added LDA (2 M, 25.91 mL, 1 eq) dropwise at -70 °C under an atmosphere of N2. The reaction mixture was allowed to stir at -70 °C for 0.5 hrs. To this mixture was added a solution of dimethyl oxalate (6.12 g, 51.82 mmol, 1 eq) in THF (50 mL) at -70 °C. The reaction mixture was allowed to stir at -70°C for 1 hr. The reaction was quenched by the addition of aq. NH4Cl (200 mL) and extracted with ethyl acetate (200 mL x 2). The organic solutions were combined, washed with brine (200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. Methyl 2-(6-bromo-2,3- difluorophenyl)-2-oxoacetate (8.7 g, crude) was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.40 (ddd, J = 1.8, 3.9, 8.9 Hz, 1H), 7.27 - 7.20 (m, 1H), 3.98 (s, 3H). Step 2: 2-(6-bromo-2,3-difluorophenyl)-2-oxo-N-(tetrahydro-2H-pyran-4-yl)acetamide
Figure imgf000122_0002
[000319] To methyl 2-(6-bromo-2,3-difluorophenyl)-2-oxoacetate (8.7 g, 31.18 mmol, 1 eq) in MeOH (100 mL) was added tetrahydro-2H-pyran-4-amine (4.73 g, 46.77 mmol, 1.5 eq) at 25 °C under an atmosphere of N2. The reaction mixture was allowed to stir at 25 °C for 16 hrs under an atmosphere of N2. The mixture was concentrated under reduced pressure. The crude product was triturated with petroleum ether/ethyl acetate (5/1). 2-(6-bromo-2,3- difluorophenyl)-2-oxo-N-(tetrahydro-2H-pyran-4-yl)acetamide (73.70% yield) was obtained as a yellow oil. LCMS [M+1] = 348.0. 1H NMR (400 MHz, CDCl3) δ = 7.36 (ddd, J = 1.8, 3.9, 8.9 Hz, 1H), 7.26 - 7.14 (m, 1H), 6.88 (br d, J = 6.4 Hz, 1H), 4.05 - 3.94 (m, 3H), 3.56 - 3.49 (m, 2H), 2.05 - 1.92 (m, 2H), 1.67 - 1.58 (m, 2H) Step 3: 4-bromo-7-fluoro-1-(tetrahydro-2H-pyran-4-yl)indoline-2,3-dione Attorney Docket No. MORF-016WO1
Figure imgf000123_0001
[000320] To a solution of 2-(6-bromo-2,3-difluorophenyl)-2-oxo-N-(tetrahydro-2H-pyran-4- yl)acetamide (8 g, 22.98 mmol, 1 eq) in toluene (100 mL) was added potassium 2- methylbutan-2-olate (1 M, 34.47 mL, 1.5 eq) at 0 °C under an atmosphere of N2. The mixture was allowed to stir at 25 °C for 1 hr. The reaction was quenched by the addition of cold aq. HCl (1 M, 100 mL) and extracted with ethyl acetate (100 mL x 2). The organic solutions were combined, washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give 4-bromo-7-fluoro-1-(tetrahydro-2H-pyran-4-yl)indoline-2,3-dione (66.31% yield) as a yellow solid. LCMS [M+1] = 328.0. 1H NMR (400 MHz, CDCl3) δ = 7.25 (s, 1H), 7.23 (d, J = 2.5 Hz, 1H), 4.63 - 4.54 (m, 1H), 4.13 (dd, J = 4.8, 11.7 Hz, 2H), 3.54 - 3.49 (m, 2H), 2.55 - 2.46 (m, 2H), 1.75 (br dd, J = 2.4, 12.3 Hz, 2H). Step 4: 4-bromo-7-fluoro-1-(tetrahydro-2H-pyran-4-yl)indolin-2-one
Figure imgf000123_0002
[000321] Two batches were carried out in parallel. To a mixture of Zn (1.4 g, 21.41 mmol, 4.68 eq) in THF (20 mL) was added TiCl4 (2.60 g, 13.71 mmol, 1.5 mL, 3 eq) dropwise at 0 °C under an atmosphere of N2. The mixture was allowed to stir at 80 °C for 2 hrs. A solution of 4-bromo-7-fluoro-1-(tetrahydro-2H-pyran-4-yl)indoline-2,3-dione (1.5 g, 4.57 mmol, 1 eq) in THF (20 mL) was added at 20 °C and the mixture was allowed to stir at 20 °C for 2 hrs. The reaction was quenched by the addition of saturated aq. NaHCO3 (100 mL). The mixture was filtered and the filtrate was extracted with ethyl acetate (100 mL x 3). The organic solutions were combined, washed with brine (100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 3/1). 4-bromo-7-fluoro-1-(tetrahydro-2H-pyran-4-yl)indolin-2-one (69.63% yield) was obtained form the combined batches as a yellow oil. LCMS [M+1] = Attorney Docket No. MORF-016WO1 314.0. 1H NMR (400 MHz, CDCl3) δ = 7.13 (dd, J = 3.7, 8.9 Hz, 1H), 6.97 (dd, J = 8.9, 11.8 Hz, 1H), 4.73 - 4.62 (m, 1H), 4.11 (dd, J = 4.9, 11.6 Hz, 2H), 3.55 - 3.48 (m, 4H), 2.50 - 2.39 (m, 2H), 1.66 (br dd, J = 2.4, 12.3 Hz, 2H). Step 5: 4'-bromo-7'-fluoro-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'- indolin]-2'-one
Figure imgf000124_0001
[000322] To a solution of 4-bromo-7-fluoro-1-(tetrahydro-2H-pyran-4-yl)indolin-2-one (2.1 g, 6.68 mmol, 1 eq) in DMF (30 mL) was added Cs2CO3 (6.53 g, 20.05 mmol, 3 eq) and 1,2- dibromoethane (6.28 g, 33.42 mmol, 2.52 mL, 5 eq). The mixture was allowed to stir at 35°C for 12 hrs. The reaction was quenched by the addition of H2O (100mL) at 0 ℃ and extracted with ethyl acetate (50 mL x 3). The organic solutions were combined, washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 3/1). 4'- bromo-7'-fluoro-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-2'-one (87.95% yield) was obtained as a yellow solid. LCMS [M+1] = 340.0. 1H NMR (400 MHz, CDCl3) δ = 7.07 (dd, J = 4.0, 8.9 Hz, 1H), 6.90 (dd, J = 8.9, 11.8 Hz, 1H), 4.81 - 4.69 (m, 1H), 4.11 (dd, J = 4.8, 11.5 Hz, 2H), 3.52 (br t, J = 11.9 Hz, 2H), 2.58 - 2.46 (m, 2H), 2.41 (q, J = 3.9 Hz, 2H), 1.72 - 1.65 (m, 2H), 1.61 - 1.58 (m, 2H). Step 6: methyl 2-(7'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'- indolin]-4'-yl)acetate
Figure imgf000124_0002
[000323] To a solution of 4'-bromo-7'-fluoro-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-2'-one (1.2 g, 3.53 mmol, 1 eq) in THF (10 mL) was added Pd(t-Bu3P)2 (90.14 mg, 176.37 μmol, 0.05 eq) and BrZnCH2COOMe (1 M, 10.58 mL, 3 eq) at 20 °C and the reaction was allowed to stir at 80 °C for 2 hrs under an atmosphere of N2. The Attorney Docket No. MORF-016WO1 reaction was quenched by the addition of H2O (30 mL) at 0 ℃ and filtered. The filtrate was extracted with ethyl acetate (30 mL x 3). The organic solutions were combined, washed with brine (30 mL x 3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 3/1). Methyl 2-(7'- fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (19.56% yield) was obtained as a yellow oil. LCMS Rt = 0.445 min, [M+1] = 334.3. 1H NMR (400 MHz, CDCl3) δ = 6.99 (dd, J = 8.6, 12.0 Hz, 1H), 6.94 - 6.86 (m, 1H), 4.86 - 4.63 (m, 1H), 4.13 - 4.08 (m, 2H), 3.71 (s, 3H), 3.56 - 3.50 (m, 2H), 3.35 (s, 2H), 2.60 - 2.46 (m, 2H), 2.00 - 1.89 (m, 2H), 1.72 - 1.65 (m, 4H). Step 7: methyl 2-bromo-2-(7'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate
Figure imgf000125_0001
[000324] To a solution of methyl 2-(7'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (180 mg, 539.97 μmol, 1 eq) in THF (5 mL) was added LDA (2 M, 269.98 μL, 1 eq) at -70 °C under an atmosphere of N2. After 0.5 hrs, TMSCl (70.40 mg, 647.96 μmol, 82.24 μL, 1.2 eq) was added and the mixture was allowed to stir at -70 °C for 0.5hrs. NBS (288.32 mg, 1.62 mmol, 3 eq) in THF (5 mL) was added. The mixture was allowed to stir at -70 °C for 0.5 hrs. The reaction was quenched by the addition of saturated aqueous NH4Cl (30 mL) and extracted with ethyl acetate (30 mL x 2). The organic solutions were combined, washed with brine (10 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 3/1). Methyl 2-bromo-2-(7'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran- 4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate (8.40% yield) was obtained as a yellow oil. LCMS [M+1] = 412.0. 1H NMR (400 MHz, CDCl3) δ = 7.40 (dd, J = 4.2, 8.9 Hz, 1H), 7.07 (dd, J = 8.9, 11.9 Hz, 1H), 4.95 (s, 1H), 4.77 - 4.72 (m, 1H), 4.11 - 4.08 (m, 2H), 3.80 (s, 3H), 3.52 (s, 2H), 2.52 (br d, J = 7.9 Hz, 2H), 2.02 - 1.91 (m, 2H), 1.73 - 1.67 (m, 4H). [000325] Methyl 2-bromo-2-(6'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate was prepared from 4-bromo-6-fluoro-1- (tetrahydro-2H-pyran-4-yl)indoline-2,3-dione following procedures similar to steps 4, 5, 6 and Attorney Docket No. MORF-016WO1 7 above in the synthesis of methyl 2-bromo-2-(7'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetate. 1H NMR (400 MHz, CDCl3) δ = 7.11 (dd, J = 2.3, 10.3 Hz, 1H), 6.89 (dd, J = 2.1, 9.0 Hz, 1H), 4.94 (d, J = 1.4 Hz, 1H), 4.51 (tt, J = 4.4, 12.6 Hz, 1H), 4.13 (d, J = 7.1 Hz, 2H), 3.81 (s, 3H), 3.53 (dt, J = 1.8, 12.0 Hz, 2H), 2.56 - 2.45 (m, 2H), 1.78 (br d, J = 2.3 Hz, 2H), 1.72 - 1.67 (m, 2H), 1.29 - 1.25 (m, 2H). Preparation of 4-bromo-6-fluoro-1-(tetrahydro-2H-pyran-4-yl)indoline-2,3-dione
Figure imgf000126_0001
Step 1: methyl 2-(2-bromo-4,6-difluorophenyl)-2-oxoacetate
Figure imgf000126_0002
[000326] To a solution of 1-bromo-3,5-difluoro-2-iodobenzene (26 g, 81.53 mmol, 1 eq) in toluene (400 mL) was added n-BuLi (2.5 M, 24.46 mL, 0.75 eq) dropwise at -70 °C under an atmosphere of N2. The reaction mixture was allowed to stir at -70 °C for 0.5 hrs. Then to the reaction mixture was added a solution of dimethyl oxalate (19.26 g, 163.07 mmol, 2 eq) in toluene (500 mL) at -70 °C. The reaction mixture was allowed to stir at -70 °C for 1 hr. The reaction was quenched by the addition of aq. NH4Cl (400 mL) and the mixture was extracted with ethyl acetate (100 mL x 2). The organic solutions were combined, washed with brine (200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 2/1). Three batches were carried out in parallel. Methyl 2-(2-bromo-4,6-difluorophenyl)-2- oxoacetate (70.33% yield) was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.25 (td, J = 1.9, 7.8 Hz, 1H), 6.92 (ddd, J = 2.3, 8.4, 9.6 Hz, 1H), 3.96 (s, 3H). Step 2: 4-bromo-6-fluoro-1-(tetrahydro-2H-pyran-4-yl)indoline-2,3-dione
Figure imgf000126_0003
Attorney Docket No. MORF-016WO1 [000327] To a solution of tetrahydro-2H-pyran-4-amine (3.99 g, 39.42 mmol, 1.1 eq) in THF (50 mL) was added n-BuLi (2.5 M, 14.34 mL, 1 eq) at 0 oC under an atmosphere of N2. The reaction was allowed to stir at 0 oC for 0.5 hrs. The reaction mixture was added to a solution of methyl 2-(2-bromo-4,6-difluorophenyl)-2-oxoacetate (10 g, 35.84 mmol, 1 eq) in THF (50 mL) at 0 oC under an atmosphere of N2. The mixture was allowed to stir at 25 oC for 0.5 hrs. The reaction was quenched with aq.2 M HCl (100 mL) and extracted with ethyl acetate (100 mL x2). The organic solutions were combined, washed with brine (50mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was triturated with petroleum ether/ethyl acetate (3/1). 4-bromo-6-fluoro-1-(tetrahydro-2H-pyran-4-yl)indoline- 2,3-dione (42.52% yield) was obtained as a yellow solid. 1H NMR (400 MHz, CDCl3) δ = 7.00 (dd, J = 1.2, 8.6 Hz, 1H), 6.83 (dd, J = 1.2, 8.9 Hz, 1H), 4.36 (tt, J = 4.3, 12.3 Hz, 1H), 4.15 (br dd, J = 4.4, 11.7 Hz, 2H), 3.52 (br t, J = 11.5 Hz, 2H), 2.45 (dq, J = 4.6, 12.5 Hz, 2H), 1.74 (br dd, J = 2.2, 12.5 Hz, 2H) Preparation of methyl 2-bromo-2-((R)-4-methylisochroman-5-yl)acetate
Figure imgf000127_0001
[000328] To a solution of methyl 2-(2-bromophenyl)acetate (50 g, 218.27 mmol, 1 eq) in THF (100 mL) was added LiHMDS (1 M, 240.10 mL, 1.1 eq) dropwise at 0 °C under an atmosphere of N2 and the reaction was allowed to stir at 0 °C for 1 hr. MeI (30.98 g, 218.27 mmol, 13.59 mL, 1 eq) was added dropwise at 0 °C under an atmosphere of N2. The mixture was allowed to stir at 20 °C for 1 hr. The reaction was quenched by the addition of NH4Cl (500 mL) and extracted with ethyl acetate (200 mL x 3). The organic solutions were combined, washed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated under Attorney Docket No. MORF-016WO1 reduced pressure. Methyl 2-(2-bromophenyl)propanoate (60 g, crude) was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.57 (d, J = 8.2 Hz, 1H), 7.35 - 7.27 (m, 2H), 7.16 - 7.10 (m, 1H), 4.24 (q, J = 7.2 Hz, 1H), 3.69 (s, 3H), 1.50 (d, J = 7.2 Hz, 3H) Step 2: 2-(2-bromophenyl)propan-1-ol
Figure imgf000128_0001
[000329] Two reactions were carried out in parallel. To a solution of LiBH4 (8.04 g, 368.86 mmol, 2.99 eq) in THF (100 mL) was added a solution of methyl 2-(2-bromophenyl- )propanoate (30 g, 123.41 mmol, 1 eq) in THF (100 mL) at 0 °C. The mixture was allowed to stir at 20 °C for 12 hrs. The mixture was diluted with H2O (500 mL) and extracted with ethyl acetate (200 mL x 3). The organic solutions were combined, washed with brine (200 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 10/1). 2-(2- bromophenyl)propan-1-ol (37 g, 172.02 mmol, 78.72% yield over 2 steps) as colorless oil. LCMS Rt = 0.869, [M-18+1] = 197.1. 1H NMR (400 MHz, CDCl3) δ = 7.56 (d, J = 7.9 Hz, 1H), 7.32 - 7.27 (m, 1H), 7.26 (d, J = 6.8 Hz, 1H), 7.10 - 7.04 (m, 1H), 3.82 - 3.75 (m, 1H), 3.72 - 3.66 (m, 1H), 3.54 - 3.46 (m, 1H), 1.28 (d, J = 7.0 Hz, 3H). Step 3: 5-bromo-4-methylisochromane
Figure imgf000128_0002
[000330] A solution of of 2-(2-bromophenyl)propan-1-ol (17 g, 79.04 mmol, 1 eq) and (HCHO)n (7.83 g, 86.94 mmol, 1.1 eq) in TFA (100 mL) was allowed to stir at 100 °C for 16 hrs. The reaction mixture was concentrated under reduced pressure. The residue was diluted with H2O (200 mL) and extracted with ethyl acetate (100 mL x 3). The organic solutions were combined, washed with brine (200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The mixture was further purified by prep-HPLC (column: Phenomenex luna C18250*150mm*15um; mobile phase: [water (TFA)-ACN]; B%: 30%-60%, 20min). 5- bromo-4-methylisochromane (44.57% yield) was obtained as a yellow oil. LCMS Rt = 1.031, [M-18+1] = 209.0. 1H NMR (400 MHz, CDCl3) δ = 7.43 (d, J = 7.9 Hz, 1H), 7.05 (t, J = 7.8 Hz, 1H), 6.98 - 6.92 (m, 1H), 4.87 - 4.79 (m, 1H), 4.76 - 4.67 (m, 1H), 4.00 - 3.93 (m, 1H), 3.80 (dd, J = 2.8, 11.3 Hz, 1H), 3.02 - 2.92 (m, 1H), 1.39 (d, J = 6.9 Hz, 3H). Attorney Docket No. MORF-016WO1 Step 4: methyl (R)-2-(4-methylisochroman-5-yl)acetate and methyl (S)-2-(4- methylisochroman-5-yl)acetate
Figure imgf000129_0001
[000331] To a solution of 5-bromo-4-methylisochromane (6 g, 26.42 mmol, 1 eq) and Pd(t- Bu3P)2 (1.35 g, 2.64 mmol, 0.1 eq) in THF (60 mL) was added BrZnCH2COOt-Bu (1.0 M, 60 mL, 2.27 eq) at 20 °C under an atmosphere of N2. The mixture was allowed to stir at 80 °C for 2 hrs. The reaction mixture was diluted with H2O (200 mL) and filtered, then extracted with ethyl acetate (100 mL x 2). The organic solutions were combined, washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was poured into HCl/MeOH (100 mL) at 20 °C. The mixture was allowed to stir at 50 °C for 12 hrs. The reaction mixture was concentrated under reduced pressure. The residue was diluted with H2O (50 mL) and extracted with ethyl acetate (20 mL x 3). The organic solutions were combined, washed with brine (20 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 10/1). The racemate (5 g) was obtained as a yellow oil. The racemate was separated by SFC (column: DAICEL CHIRALPAK AD (250mm*50mm, 10um); mobile phase: [0.1%NH3H2O IPA]; B%: 11%-11%, 1.6min. [000332] Peak 1, arbitrarily assigned as methyl (S)-2-(4-methylisochroman-5-yl)acetate (30.93% yield) was obtained as colorless oil. LCMS [M-18+1] = 203.1. SFC Rt = 1.134. 1H NMR (400 MHz, CDCl3) δ = 7.20 - 7.12 (m, 2H), 6.95 - 6.89 (m, 1H), 4.89 - 4.74 (m, 2H), 3.97 - 3.91 (m, 1H), 3.85 - 3.80 (m, 1H), 3.76 - 3.72 (m, 1H), 3.71 (s, 3H), 3.65 - 3.60 (m, 1H), 2.93 - 2.85 (m, 1H), 1.33 (d, J = 7.0 Hz, 3H). [000333] Peak 2, arbitrarily assigned as methyl (R)-2-(4-methylisochroman-5-yl)acetate (25.78% yield) was obtained as colorless oil. LCMS [M-18+1] = 203.1. SFC Rt = 1.330.1H NMR (400 MHz, CDCl3) δ = 7.18 - 7.11 (m, 2H), 6.94 - 6.89 (m, 1H), 4.89 - 4.73 (m, 2H), 3.97 - 3.91 (m, 1H), 3.87 - 3.79 (m, 1H), 3.76 - 3.72 (m, 1H), 3.71 (s, 3H), 3.66 - 3.59 (m, 1H), 2.94 - 2.84 (m, 1H), 1.33 (d, J = 7.0 Hz, 3H). Step 5: methyl 2-bromo-2-((S)-4-methylisochroman-5-yl)acetate Attorney Docket No. MORF-016WO1
Figure imgf000130_0001
[000334] To a solution of methyl (S)-2-(4-methylisochroman-5-yl)acetate (500.00 mg, 2.27 mmol, 1 eq) in THF (10 mL) was added LDA (2 M, 1.70 mL, 1.5 eq) at -60 °C and the mixture was allowed to stir at -60 °C for 30 min. TMSCl (394.58 mg, 3.63 mmol, 460.96 uL, 1.6 eq) was added at -60 °C and the mixture was allowed to stir at -60 °C for 0.5 hrs. A solution of NBS (484.82 mg, 2.72 mmol, 1.2 eq) in THF (5 mL) was added at -60 °C. The mixture was allowed to stir at-60 °C for 1 hr. The residue was diluted with NH4Cl (20 mL) and extracted with ethyl acetate (10 mL x 3). The organic solutions were combined, washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 20/1). Methyl 2-bromo-2-((S)-4-methylisochroman-5-yl)acetate (29.45% yield) was obtained as a yellow oil. [000335] By a similar procedure starting from arbitrarily assigned methyl (R)-2-(4- methylisochroman-5-yl)acetate was prepared methyl 2-bromo-2-((S)-4-methylisochroman-5- yl)acetate. Preparation of methyl 2-((methylsulfonyl)oxy)-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro- 2H-pyran-4-yl)oxy)phenyl)acetate
Figure imgf000130_0002
Attorney Docket No. MORF-016WO1 Step 1: 4-(3-bromo-2-nitrophenoxy)tetrahydro-2H-pyran
Figure imgf000131_0001
[000336] To a solution of 3-bromo-2-nitrophenol (13 g, 59.63 mmol, 1 eq) in toluene (200 mL) was added DIAD (18.09 g, 89.45 mmol, 17.34 mL, 1.5 eq), tetrahydro-2H-pyran-4-ol (7.31 g, 71.56 mmol, 7.15 mL, 1.2 eq) and PPh3 (18.77 g, 71.56 mmol, 1.2 eq). The mixture was allowed to stir at 100 °C for 2 hrs. The reaction was quenched by the addition of H2O (20 mL) at 20 °C and extracted with ethyl acetate (10 mL x 3). The organic solutions were combined, washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 0/1). 4-(3-bromo-2-nitrophenoxy)tetrahydro-2H-pyran (23 g, 53.29 mmol, 89.37% yield, 70% purity) was obtained as colorless oil. 1H NMR (400 MHz, CDCl3) δ = 7.30 - 7.27 (m, 1H), 7.25 - 7.20 (m, 1H), 7.00 (dd, J = 1.3, 8.3 Hz, 1H), 4.64 (tt, J = 3.5, 7.0 Hz, 1H), 3.90 (ddd, J = 3.5, 7.6, 11.5 Hz, 2H), 3.64 - 3.56 (m, 2H), 2.05 - 1.99 (m, 2H), 1.83 (ddd, J = 3.6, 6.9, 13.5 Hz, 2H). Step 2: 2-bromo-6-((tetrahydro-2H-pyran-4-yl)oxy)aniline
Figure imgf000131_0002
[000337] To a solution of 4-(3-bromo-2-nitrophenoxy)tetrahydro-2H-pyran (20 g, 66.20 mmol, 1 eq) in ethyl acetate (180 mL) and H2O (20 mL) was added AcOH (48.14 g, 801.67 mmol, 45.89 mL, 12.11 eq) at 25°C. The mixture was allowed to stir at 50 °C. Fe (18.48 g, 330.99 mmol, 5 eq) was added at 50 °C. The mixture was allowed to stir at 80 °C for 2 hrs. The reaction was quenched by the addition of aq. NaOH (10 mL) at 20 °C and the mixture was extracted with ethyl acetate (10 mL x 3). The organic solutions were combined, washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 1/0 to 0/1). 2-bromo-6-((tetrahydro-2H-pyran-4-yl)oxy)aniline (18 g, 49.61 mmol, 74.94% yield, 75% purity) was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.06 (dd, J = 0.8, 8.2 Hz, 1H), 6.76 (d, J = 8.0 Hz, 1H), 6.60 - 6.53 (m, 1H), 6.39 (br s, 2H), 4.49 (tt, J = 3.9, 8.0 Attorney Docket No. MORF-016WO1 Hz, 1H), 4.02 - 3.96 (m, 2H), 3.59 (ddd, J = 3.2, 8.6, 11.7 Hz, 2H), 2.08 - 2.04 (m, 2H), 1.83 (tdd, J = 4.2, 8.6, 12.9 Hz, 2H). Step 3: N-(2-bromo-6-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)-4-chlorobutanamide
Figure imgf000132_0001
[000338] To a solution of 2-bromo-6-((tetrahydro-2H-pyran-4-yl)oxy)aniline (9 g, 33.07 mmol, 1 eq) and Na2HPO4 (9.39 g, 66.14 mmol, 9.39 mL, 2 eq) in CHCl3 (90 mL) was added 4-chlorobutanoyl chloride (5.60 g, 39.69 mmol, 4.44 mL, 1.2 eq) at 25 °C and the mixture was allowed to stir at 25 °C for 2 hrs. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. N-(2-bromo-6-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)- 4-chlorobutanamide (12 g, crude) was obtained as a yellow oil.1H NMR (400 MHz, CDCl3) δ = 7.24 (br d, J = 9.5 Hz, 1H), 7.12 (br t, J = 6.4 Hz, 1H), 6.90 (br d, J = 8.1 Hz, 1H), 6.37 (br s, 2H), 4.51 (dt, J = 3.9, 7.6 Hz, 1H), 3.99 - 3.90 (m, 2H), 3.60 - 3.54 (m, 2H), 2.16 - 2.06 (m, 4H), 2.04 - 1.98 (m, 2H), 1.85 - 1.75 (m, 2H). Step 4: 1-(2-bromo-6-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)pyrrolidin-2-one
Figure imgf000132_0002
[000339] To a solution of NaH (1.17 g, 29.20 mmol, 60% purity, 1.1 eq) in DMF (50 mL) was added N-(2-bromo-6-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)-4-chlorobutanamide (10 g, 26.55 mmol, 1 eq) in DMF (50 mL) at 0 °C and the mixture was allowed to stir at 25 °C for 12 hrs. The reaction was quenched by the addition of sat. NH4Cl (50 mL) and the mixture was extracted with ethyl acetate (50 mL x 2). The organic solutions were combined, washed with brine (30 mL), dried over Na2SO4 and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate=1/0 to 0/1). 1-(2-bromo-6-((tetrahydro- 2H-pyran-4-yl)oxy)phenyl)pyrrolidin-2-one (7 g, 16.46 mmol, 62.00% yield, 80% purity) was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.25 - 7.19 (m, 1H), 7.13 (t, J = 8.2 Hz, 1H), 6.89 (d, J = 8.2 Hz, 1H), 4.99 - 4.95 (m, 1H), 4.52 (tt, J = 3.5, 7.0 Hz, 1H), 4.35 (s, 1H), 3.96 - 3.87 (m, 2H), 3.59 (dddd, J = 3.8, 7.5, 11.4, 18.5 Hz, 2H), 2.63 - 2.51 (m, 2H), 2.27 - 2.23 (m, 2H), 2.00 (td, J = 3.4, 6.9 Hz, 2H), 1.82 - 1.75 (m, 2H). Attorney Docket No. MORF-016WO1 Step 5: 1-(2-((tetrahydro-2H-pyran-4-yl)oxy)-6-vinylphenyl)pyrrolidin-2-one
Figure imgf000133_0001
[000340] To a solution of 1-(2-bromo-6-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)pyrrolidin- 2-one (3.5 g, 10.29 mmol, 1 eq) in dioxane (40 mL) and H2O (4 mL) was added K2CO3 (4.27 g, 30.86 mmol, 3 eq), Pd(dppf)Cl2 (1.51 g, 2.06 mmol, 0.2 eq) and trifluoro(vinyl)-λ4-borane, potassium salt (4.13 g, 30.86 mmol, 3 eq). The mixture was allowed to stir at 100 °C for 12 hrs. The reaction was quenched by the addition of H2O (30 mL) at 20 °C and extracted with ethyl acetate (15 mL x 3). The organic solutions were combined, washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 0/1). 1-(2- ((tetrahydro-2H-pyran-4-yl)oxy)-6-vinylphenyl)pyrrolidin-2-one (47.36% yield) was obtained as a brown oil. LCMS [M+1] = 288.1. 1H NMR (400 MHz, CDCl3) δ = 7.26 - 7.20 (m, 2H), 6.87 (d, J = 7.8 Hz, 1H), 6.71 (dd, J = 11.1, 17.6 Hz, 1H), 5.76 (d, J = 17.5 Hz, 1H), 5.34 (d, J = 11.0 Hz, 1H), 4.53 (tt, J = 3.5, 7.0 Hz, 1H), 3.96 - 3.89 (m, 2H), 3.83 - 3.76 (m, 1H), 3.65 - 3.50 (m, 3H), 2.61 - 2.54 (m, 2H), 2.24 (quin, J = 7.5 Hz, 2H), 2.05 - 1.95 (m, 2H), 1.84 - 1.76 (m, 2H). Step 6: 2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4-yl)oxy)benzaldehyde
Figure imgf000133_0002
[000341] To a solution of 1-(2-((tetrahydro-2H-pyran-4-yl)oxy)-6-vinylphenyl)pyrrolidin-2- one (1.4 g, 4.87 mmol, 1 eq) and 2,6-lutidine (1.04 g, 9.74 mmol, 1.13 mL, 2 eq) in THF (20 mL) and H2O (10 mL) was added K2OsO4.2H2O (179.51 mg, 487.21 μmol, 0.1 eq) and NaIO4 (4.17 g, 19.49 mmol, 1.08 mL, 4 eq) at 0 °C. The mixture was allowed to stir at 25°C for 0.5 hrs. The reaction mixture was filtered and the filtrate was diluted with sat. Na2SO3 (20 mL) and extracted with ethyl acetate (10 mL x 3). The organic solutions were combined, washed with brine (15 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 0/1). 2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4-yl)oxy)benzaldehyde (950 mg, 2.63 mmol, 53.92% yield, 80% purity) was obtained as a yellow oil. 1H NMR (400 MHz, Attorney Docket No. MORF-016WO1 CDCl3) δ = 10.03 (s, 1H), 7.54 (dd, J = 1.1, 7.7 Hz, 1H), 7.43 (t, J = 7.9 Hz, 1H), 7.26 - 7.20 (m, 1H), 4.61 - 4.55 (m, 1H), 4.03 - 3.91 (m, 3H), 3.67 - 3.57 (m, 3H), 2.66 - 2.53 (m, 2H), 2.34 - 2.25 (m, 2H), 2.12 - 2.04 (m, 2H), 1.83 (br d, J = 7.6 Hz, 2H). Step 7: 2-hydroxy-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4- yl)oxy)phenyl)acetonitrile
Figure imgf000134_0001
[000342] To a solution of 2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4- yl)oxy)benzaldehyde (950 mg, 3.28 mmol, 1 eq) in DCM (10 mL) was added TMSCN (488.62 mg, 4.93 mmol, 616.16 μL, 1.5 eq) and ZnCl2 (104.81 mg, 328.35 μmol, 0.1 eq). The reaction mixture was allowed to stir at 25 °C for 12 hrs. The reaction mixture was filtered and the filtrate was diluted with H2O (10 mL) and extracted with ethyl acetate (10 mL x 3). The organic solutions were combined, washed with brine (10 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give 2-hydroxy-2-(2-(2-oxopyrrolidin-1-yl)-3- ((tetrahydro-2H-pyran-4-yl)oxy)phenyl)acetonitrile (1.5 g, crude) as a yellow oil. LCMS [M+1] = 389.2. Step 8: methyl 2-hydroxy-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4- yl)oxy)phenyl)acetate
Figure imgf000134_0002
[000343] A solution of 2-hydroxy-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4- yl)oxy)phenyl)acetonitrile (1.3 g, 2.01 mmol, 1 eq) in HCl/MeOH (6 M, 334.59 μL, 1 eq) was allowed to stir at 30 °C for 24 hrs. The reaction mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Phenomenex Luna C18 75*30mm*3um; mobile phase: [H2O (0.1%TFA)-ACN]; gradient: 20%-40% B over 8.0 min). methyl 2-hydroxy-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4- yl)oxy)phenyl)acetate (57.03% yield) was obtained as a yellow oil. LCMS [M+1] = 350.1. 1H NMR (400 MHz, CDCl3) δ = 7.36 (t, J = 8.1 Hz, 1H), 7.08 (d, J = 7.0 Hz, 1H), 6.97 (d, J = 8.2 Attorney Docket No. MORF-016WO1 Hz, 1H), 5.16 (s, 1H), 4.60 - 4.53 (m, 1H), 3.95 - 3.69 (m, 9H), 2.72 - 2.61 (m, 2H), 2.33 - 2.22 (m, 2H), 2.13 - 1.98 (m, 2H), 1.80 (ddd, J = 3.5, 7.3, 13.6 Hz, 2H). Step 9: methyl 2-((methylsulfonyl)oxy)-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H- pyran-4-yl)oxy)phenyl)acetate
Figure imgf000135_0001
[000344] To a solution of methyl 2-hydroxy-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H- pyran-4-yl)oxy)phenyl)acetate (150 mg, 429.34 μmol, 1 eq) in DCM (3 mL) was added TEA (130.33 mg, 1.29 mmol, 179.27 μL, 3 eq) and Ms2O (224.37 mg, 1.29 mmol, 3 eq) at 0 °C. The mixture was allowed to stir at 0 °C for 15 min. The reaction was quenched by the addition of NaHCO3 (aq) (2 mL) at 20 °C and extracted with DCM (2 mL x 3). The organic solutions were combined, washed with brine (3 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. methyl 2-((methylsulfonyl)oxy)-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro- 2H-pyran-4-yl)oxy)phenyl)acetate (170 mg, crude) was obtained as a yellow oil. LCMS [M+1] = 428.1. Preparation of tert-butyl 2-bromo-2-(5-(methoxymethyl)-1-methyl-2-oxo-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetate
Figure imgf000135_0002
Step 1: 7-bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one Attorney Docket No. MORF-016WO1
Figure imgf000136_0001
[000345] Three parallel reactions were carried out. To a mixture of NaH (14.15 g, 353.70 mmol, 60% purity, 5 eq.) in DMF (450 mL) was added a solution of 7-bromoindolin-2-one (15 g, 70.74 mmol, 1 eq.) in DMF (450 mL) at 0 oC under an atmosphere of N2. The reaction was allowed to stir at 0 oC for 1 hr. 1-bromo-2-(2-bromoethoxy)ethane (24.61 g, 106.11 mmol, 13.30 mL, 1.5 eq.) was added at 0 oC. The reaction mixture was allowed to warm to 25 oC and was allowed to stir at 25 oC for 15 hrs. The three parallel reactions were combined. The reaction was quenched by the addition of H2O (3000 mL) and filtered. The filter cake was washed with water (600 mL x 3) and dried in vacuum to give 7-bromo-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-2-one (50 g, 120.46 mmol, 56.76% yield, crude) as a red solid. LCMS [M+1] = 282.1. Step 2: 7-bromo-1-methyl-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one
Figure imgf000136_0002
[000346] Two parallel reactions were carried out. To a solution of 7-bromo-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-2-one (12 g, 42.53 mmol, 1 eq.) in DMF (160 mL) was added NaH (3.40 g, 85.07 mmol, 60% purity, 2 eq.) at 0 oC under an atmosphere of N2. The reaction mixture was allowed to stir at 0 oC under an atmosphere of N2 for 0.5 hrs. MeI (12.07 g, 85.07 mmol, 5.30 mL, 2 eq.) was added dropwise to the reaction mixture at 0 oC. The reaction mixture was allowed to warm to 25 oC and stir for 2 hrs. The two reaction mixtures were combined and quenched by the addition of sat. NH4Cl (500 mL) at 0 oC. The mixture was extracted with ethyl acetate (50 mL x 3). The organic solutions were combined, washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 3/1). 7-bromo-1-methyl-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one (35.72% yield) was obtained as a white solid. LCMS [M+1] = 675.4. 1H NMR (400 MHz, CDCl3) δ = 7.40 (dd, J = 0.8, 8.3 Hz, 1H), 7.23 (dd, J = 0.8, 7.4 Hz, 1H), 6.93 (t, J = 7.8 Hz, 1H), 4.32 - Attorney Docket No. MORF-016WO1 4.26 (m, 2H), 3.93 - 3.88 (m, 2H), 3.60 (s, 3H), 1.95 - 1.88 (m, 2H), 1.76 (br d, J = 13.9 Hz, 2H). Step 3: 7-bromo-5-iodo-1-methyl-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one
Figure imgf000137_0001
[000347] Two parallel reactions were carried out. To a solution of 7-bromo-1-methyl- 2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one (5 g, 16.88 mmol, 1 eq.) in AcOH (50 mL) was added NIS (9.5 g, 42.21 mmol, 2.5 eq.) at 25 oC under an atmosphere of N2. The reaction mixture was heated to 50 oC and allowed to stir for 16 hrs. The two reactions mixtures were combined, quenched by the addition of sat. NaHCO3 (200 mL) and extracted with ethyl acetate (30 mL x 3). The organic solutions were combined, washed with brine (30 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/0 to 90/10). 7-bromo-5-iodo-1- methyl-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one (70.17% yield) was obtained as a white solid. LCMS [M+1] = 421.7. 1H NMR (400 MHz, CDCl3) δ = 7.73 (d, J = 1.5 Hz, 1H), 7.47 (d, J = 1.5 Hz, 1H), 4.29 - 4.23 (m, 2H), 3.91 - 3.86 (m, 2H), 3.56 (s, 3H), 1.93 - 1.86 (m, 2H), 1.76 - 1.71 (m, 2H). Step 4: 7-bromo-1-methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-5- carbaldehyde
Figure imgf000137_0002
[000348] Two parallel reactions were carried out. To a solution of 7-bromo-5-iodo-1- methyl-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one (5 g, 11.85 mmol, 1 eq.) in THF (50 mL) was added i-PrMgBr (1 M, 17.77 mL, 1.5 eq.) dropwise at 0 oC under an atmosphere of N2. The reaction mixture was allowed to stir at 0 oC for 0.5 hrs. To the reaction mixture was added DMF (8.66 g, 118.47 mmol, 9.12 mL, 10 eq.) at 0 oC. The reaction mixture was warmed to 25 oC and allowed to stir at 25 oC for 2 hrs. The two reaction mixtures were Attorney Docket No. MORF-016WO1 combined, quenched by the addition of sat. NH4Cl (200 mL) at 20 oC and extracted with ethyl acetate (50 mL x 3). The organic solutions were combined, washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/0 to 80/20). 7-bromo-1- methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-5-carbaldehyde (78.12% yield) was obtained as a yellow solid. LCMS [M+1] = 323.8. 1H NMR (400 MHz, CDCl3) δ = 9.86 (s, 1H), 7.93 (d, J = 1.3 Hz, 1H), 7.75 (d, J = 1.3 Hz, 1H), 4.27 (t, J = 9.8 Hz, 2H), 3.95 - 3.91 (m, 2H), 3.65 (s, 3H), 1.99 - 1.94 (m, 2H), 1.77 (br d, J = 13.9 Hz, 2H). Step 5: 7-bromo-5-(hydroxymethyl)-1-methyl-2',3',5',6'-tetrahydrospiro[indoline-3,4'- pyran]-2-one
Figure imgf000138_0001
[000349] Two parallel reactions were carried out. To a solution of 7-bromo-1-methyl-2-oxo- 2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-5-carbaldehyde (3 g, 9.25 mmol, 1 eq.) in THF (30 mL) was added NaBH4 (350.12 mg, 9.25 mmol, 1 eq.) at 0 oC under an atmosphere of N2. The reaction mixture was warmed to 25 oC and allowed to stir for 2 hrs. The two reaction mixtures were combined, quenched by the addition of water (250 mL) at 25 oC and extracted with ethyl acetate (50 mL x 3). The organic solutions were combined, washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/0 to 70/30). 7-bromo-5-(hydroxymethyl)-1-methyl-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]- 2-one (82.82% yield) was obtained as a yellow solid. LCMS [M+1] = 325.9. 1H NMR (400 MHz, CDCl3) δ = 7.36 (s, 1H), 7.21 (s, 1H), 4.57 (s, 2H), 4.26 - 4.20 (m, 2H), 3.88 - 3.84 (m, 2H), 3.53 (s, 3H), 1.90 - 1.84 (m, 2H), 1.70 (br d, J = 13.9 Hz, 2H). Step 6: 7-bromo-5-(methoxymethyl)-1-methyl-2',3',5',6'-tetrahydrospiro[indoline-3,4'- pyran]-2-one
Figure imgf000138_0002
Attorney Docket No. MORF-016WO1 [000350] To a solution of 7-bromo-5-(hydroxymethyl)-1-methyl-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-2-one (5 g, 15.33 mmol, 1 eq.) in THF (100 mL) was added NaH (919.64 mg, 22.99 mmol, 60% purity, 1.5 eq.) at 0 oC under an atmosphere of N2. The reaction mixture was allowed to stir at 0 oC for 0.5 hrs. To the reaction mixture was added MeI (3.26 g, 22.99 mmol, 1.43 mL, 1.5 eq.) at 0 oC. The reaction mixture was allowed to stir at 0 oC for 2 hrs. The reaction mixture was quenched by the addition of sat. NH4Cl (200 mL) at 25 oC and extracted with ethyl acetate (50 mL x 3). The organic solutions were combined, washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/0 to 80/20). 7-bromo-5-(methoxymethyl)-1-methyl-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-2-one (92.04% yield) was obtained as a yellow solid. LCMS [M+1] = 340.0. Step 7: tert-butyl 2-(5-(methoxymethyl)-1-methyl-2-oxo-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetate
Figure imgf000139_0001
[000351] To a solution of 7-bromo-5-(methoxymethyl)-1-methyl-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-2-one (4.8 g, 14.11 mmol, 1 eq.) in THF (50 mL) was added Pd(t-Bu3P)3 (721.04 mg, 1.41 mmol, 0.1 eq.) and ZnBrCH2COOt-Bu (1 M, 28.22 mL, 2 eq.) at 25 oC under an atmosphere of N2. The reaction mixture was heated to 80 oC and allowed to stir at 80 oC for 2 hrs. The reaction was quenched by the addition of water (150 mL) at 25 oC and filtered. The filtered cake was washed with ethyl acetate (20 mL x 3) and then with 1 N HCl (500 mL). The filtrate was extracted with ethyl acetate (20 mL x 3). The organic solutions were combined, washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/0 to 80/20). tert-butyl 2-(5- (methoxymethyl)-1-methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetate (84.95% yield) was obtained as a yellow solid. LCMS [M+1] = 376.3. 1HNMR (400 MHz, CDCl3) δ = 7.22 (s, 1H), 7.04 (s, 1H), 4.41 (s, 2H), 4.32 - 4.26 (m, 2H), 3.94 - 3.89 (m, 2H), 3.80 (s, 2H), 3.44 (s, 3H), 3.40 (s, 3H), 1.96 - 1.90 (m, 2H), 1.75 (br d, J = 13.9 Hz, 2H), 1.45 (s, 9H) Attorney Docket No. MORF-016WO1 Step 8: tert-butyl 2-bromo-2-(5-(methoxymethyl)-1-methyl-2-oxo-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetate
Figure imgf000140_0001
[000352] To a solution of tert-butyl 2-(5-(methoxymethyl)-1-methyl-2-oxo-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetate (1 g, 2.66 mmol, 1 eq.) in THF (10 mL) was added LDA (2 M, 1.60 mL, 1.2 eq.) dropwise at -70 oC under an atmosphere of N2. The reaction mixture was allowed to stir at -70 oC for 0.5 hrs. To the reaction mixture was added TMSCl (434.04 mg, 4.00 mmol, 507.05 uL, 1.5 eq.) at -70 oC . The reaction mixture was allowed to stir at -70 oC for 0.5 hrs. To the reaction mixture was added the solution of NBS (711.07 mg, 4.00 mmol, 1.5 eq.) in THF (8 mL) at -70 oC . The reaction mixture was allowed to stir at -70 oC for 1 hr. The reaction was quenched by the addition of sat.NH4Cl (50 mL) at 25 oC and extracted with ethyl acetate (10 mL x 3). The organic solutions were combined, washed with brine (10 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/0 to 75/25). tert-butyl 2-bromo-2-(5-(methoxymethyl)-1-methyl-2-oxo-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetate (24.79% yield) was obtained as yellow oil. LCMS [M+1] = 454.0. 1H NMR (400 MHz, CDCl3) δ = 7.53 (s, 1H), 7.28 (br s, 1H), 6.00 (s, 1H), 4.42 (s, 2H), 4.30 - 4.27 (m, 2H), 3.93 - 3.90 (m, 2H), 3.59 (s, 3H), 3.40 (s, 3H), 1.96 - 1.92 (m, 2H), 1.78 - 1.75 (m, 2H), 1.49 (s, 9H). Preparation of methyl 2-(4-methylchroman-5-yl)acetate
Figure imgf000140_0002
Step 1: methyl (E)-3-(2-bromo-6-fluorophenyl)but-2-enoate Attorney Docket No. MORF-016WO1
Figure imgf000141_0001
[000353] To a solution of methyl 2-(dimethoxyphosphoryl)acetate (15.10 g, 82.94 mmol, 11.95 mL, 1.2 eq) in THF (150 mL) was added t-BuOK (1 M, 82.94 mL, 1.2 eq) at 0 °C. The mixture was allowed to stir at 0 °C for 0.5hrs. 1-(2-bromo-6-fluorophenyl)ethan-1-one (15 g, 69.11 mmol, 1 eq) in THF (150 mL) was added at 0 °C and the mixture was allowed to stir at 0 °C for 1.5 hrs, then at 50 °C for 14 hrs. The reaction was quenched by the addition of H2O(300 mL) and ethyl acetate (50 mL) was added. The organic solution was separated and the aqueous solution was extracted with ethyl acetate (50 mL x 2). The organic solutions were combined, washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 100/1 to 10/1, TLC: Petroleum ether/ethyl acetate = 10/1, Rf = 0.56). methyl (E)-3-(2-bromo-6- fluorophenyl)but-2-enoate (20 g, crude) was obtained as yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.17 - 7.14 (m, 1H), 7.09 - 7.05 (m, 1H), 6.98 - 6.96 (m, 1H), 6.01 (d, J = 1.5 Hz, 1H), 3.66 (s, 3H), 2.47 (d, J = 1.1 Hz, 3H). Step 2: (E)-3-(2-bromo-6-fluorophenyl)but-2-en-1-ol
Figure imgf000141_0002
[000354] Two reactions were carried out in parallel. To a solution of methyl (E)-3-(2- bromo-6-fluorophenyl)but-2-enoate (11 g, 40.28 mmol, 1 eq) in THF (120 mL) at 0 °C, under an atmosphere of nitrogen, was added LiAlH4 (2.5 M, 24.17 mL, 1.5 eq). The reaction mixture was allowed to stir at 20 °C for 2 hrs. To the reaction mixture was added H2O (2.5 mL) and NaOH (15%, 2.5ml). The mixture was further diluted with H2O (500 mL) and extracted with ethyl acetate (100 mL x 3). The organic solutions were combined, washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. (E)-3-(2-bromo-6- fluorophenyl)but-2-en-1-ol (50.65% yield) was obtained as yellow oil. Step 3: 5-bromo-4-methyl-2H-chromene
Figure imgf000141_0003
Attorney Docket No. MORF-016WO1 [000355] To a solution of (E)-3-(2-bromo-6-fluorophenyl)but-2-en-1-ol (15 g, 61.20 mmol, 1 eq) in DMF (180 mL) was added Cs2CO3 (59.82 g, 183.61 mmol, 3 eq) at 20 °C. The mixture was allowed to stir at 80 °C for 16 hrs. The reaction was quenched by the addition of H2O(400 mL) and ethyl acetate (200 mL) was added. The organic solution was separated and the aqueous solution was extracted with ethyl acetate (200 mL x 3). The organic solutions were combined, washed with brine (400 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 100/1 to 10/1). 5-bromo-4-methyl-2H-chromene (19.54% yield) was obtained as yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.20 (dd, J = 1.3, 7.9 Hz, 1H), 6.97 (t, J = 8.0 Hz, 1H), 6.87 (dd, J = 1.3, 8.1 Hz, 1H), 5.82 (ddd, J = 1.5, 3.1, 6.0 Hz, 1H), 4.48 (qd, J = 1.4, 4.5 Hz, 2H), 2.37 (q, J = 1.5 Hz, 3H). Step 4: methyl 2-(4-methyl-2H-chromen-5-yl)acetate
Figure imgf000142_0001
[000356] A suspension of 5-bromo-4-methyl-2H-chromene (200 mg, 888.57 μmol, 1 eq), BrZnCH2COOMe (1 M, 4.44 mL, 5 eq) and Pd(t-Bu3P)2 (22.71 mg, 44.43 μmol, 0.05 eq) in THF (250 mL) was allowed to stir at 70 °C for 2 hrs under an atmosphere of N2. Water (5 mL) was added and the mixture was filtrated. The filtrate was extracted with ethyl acetate (5 mL x 2). The organic solutions were combined, washed with brine (5 mL x 2), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, 25g Sepa Flash ® Silica Flash Column, Eluent of 0~20% Petroleum ethergradient/ Ethyl acetate@ 120 mL/ min). methyl 2-(4-methyl-2H-chromen-5-yl)acetate (85.94% yield) was obtained as yellow oil. LCMS [M+1] = 219.1. 1H NMR (400 MHz, CDCl3) δ = 7.10 (t, J = 7.8 Hz, 1H), 6.87 (dd, J = 1.1, 8.1 Hz, 1H), 6.80 (dd, J = 0.8, 7.6 Hz, 1H), 5.76 (ddd, J = 1.4, 3.2, 5.9 Hz, 1H), 4.48 - 4.44 (m, 2H), 3.87 - 3.85 (m, 2H), 3.73 - 3.70 (m, 3H), 2.16 (d, J = 1.4 Hz, 3H). Step 5: methyl 2-(4-methylchroman-5-yl)acetate
Figure imgf000142_0002
Attorney Docket No. MORF-016WO1 [000357] A solution of methyl 2-(4-methyl-2H-chromen-5-yl)acetate (2 g, 9.16 mmol, 1 eq) and Pd/C (20.00 g, 18.79 mmol, 1.88 mL, 10% purity, 2.05 eq) in MeOH (30 mL) was allowed to stir at 30 °C under H2 (15 psi) for 12 hrs. The mixture was filtered and the filtrate was concentrated under reduced pressure to give methyl 2-(4-methylchroman-5-yl)acetate (1.7 g, 84.22%) as yellow oil. LCMS [M+1] = 221.2. Preparation of 8-bromo-1-methylisochromane
Figure imgf000143_0001
Step 1: 1-(2,6-dibromophenyl)ethan-1-ol
Figure imgf000143_0002
[000358] MeMgBr (3 M, 142.09 mL, 1.5 eq) was added dropwise to a solution of 2,6- dibromobenzaldehyde (75 g, 284.18 mmol, 1 eq) in THF (1000 mL) at 0 °C. The mixture was allowed to stir at 0-10 °C for 2 hrs. The reaction mixture was added dropwise into sat. NH4Cl (1000 mL) at 0 °C under an atmosphere of N2 and the mixture was extracted with ethyl acetate (200 mL x 2). The organic solutions were combined, washed with brine (200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give 1-(2,6-dibromophenyl)ethan- 1-ol (94.97% yield) as yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.55 (d, J = 8.0 Hz, 2H), 6.97 (t, J = 8.0 Hz, 1H), 5.57 (q, J = 6.8 Hz, 1H), 1.64 (d, J = 6.8 Hz, 3H). Step 2: 2-(1-(2,6-dibromophenyl)ethoxy)acetic acid
Figure imgf000143_0003
[000359] To a solution of 1-(2,6-dibromophenyl)ethan-1-ol (36 g, 128.59 mmol, 1 eq) in THF (400 mL)was added NaH (10.29 g, 257.18 mmol, 60% purity, 2 eq) at 0 °C under an atmosphere of N2. The mixture was allowed to stir at 0 °C for 0.5 hrs. BrCH2COOMe (39.34 Attorney Docket No. MORF-016WO1 g, 257.18 mmol, 24.35 mL, 2 eq) was added at 0 oC and the solution was allowed to stir at 20 oC for 1 hr. H2O (200 mL) and NaOH (10.29 g, 257.18 mmol, 2 eq) were added into the reaction mixture and the mixture was allowed to stir at 20 °C for 2 hrs. The mixture was extracted with EtOAc (200 mL x 3). The aqueous solution was adjusted to pH = 3 by the addition of HCl (1M) and extracted with DCM (200 mL x 3). The organic solutions were combined, dried over Na2SO4, filtered and concentrated under reduced pressure to give 2-(1- (2,6-dibromophenyl)ethoxy)acetic acid (98.93% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ = 7.63 (d, J = 8.0 Hz, 2H), 7.09 (t, J = 8.0 Hz, 1H), 5.51 - 5.42 (m, 1H), 3.94 (d, J = 16.5 Hz, 1H), 3.70 (d, J = 16.6 Hz, 1H), 1.60 (d, J = 6.8 Hz, 3H). Step 3: 2-(1-(2,6-dibromophenyl)ethoxy)-N-methoxy-N-methylacetamide
Figure imgf000144_0001
[000360] A mixture of 2-(1-(2,6-dibromophenyl)ethoxy)acetic acid (96 g, 284.03 mmol, 1 eq) and HATU (118.80 g, 312.43 mmol, 1.1 eq) in DCM (1000 mL) was allowed to stir at 20 °C for 1 hr. DIEA (110.13 g, 852.09 mmol, 148.42 mL, 3 eq) and N,O- dimethylhydroxylamine hydrochloride (33.25 g, 340.84 mmol, 1.2 eq) were added to the mixture. The reaction was allowed to stir at 20 °C for 15 hrs. The reaction mixture was quenched by the addition of H2O (1000mL) and extracted with ethyl acetate (200 mL x 3). The organic solutions were combined, washed with brine (200 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 3/1 to 1/1). 2-(1-(2,6- dibromophenyl)ethoxy)-N-methoxy-N-methylacetamide (85.93% yield) was obtained as yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.57 (d, J = 8.1 Hz, 2H), 6.99 (t, J = 7.9 Hz, 1H), 5.45 (q, J = 6.7 Hz, 1H), 4.20 (br d, J = 15.6 Hz, 1H), 3.94 (d, J = 15.8 Hz, 1H), 3.59 (s, 3H), 3.19 (s, 3H), 1.68 (d, J = 6.7 Hz, 3H). Step 4: 8-bromo-1-methylisochroman-4-one
Figure imgf000144_0002
Attorney Docket No. MORF-016WO1 [000361] To a solution of 2-(1-(2,6-dibromophenyl)ethoxy)-N-methoxy-N-methylacetamide (51 g, 133.84 mmol, 1 eq) in THF (300 mL) was added n-BuLi (2.5 M, 53.53 mL, 1 eq) at -70 oC and the solution was allowed to stir at -70 oC for 2 hrs under an atmosphere of N2. The reaction mixture was quenched by the addition of sat. NH4Cl (300 mL) at 0 °C, and extracted with ethyl acetate (50 mL x 3). The organic solutions were combined, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 10/1 to 5/1). 8-bromo-1- methylisochroman-4-one (74.38% yield) was obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ = 8.02 (dd, J = 0.9, 7.8 Hz, 1H), 7.77 (dd, J = 1.2, 7.9 Hz, 1H), 7.30 (t, J = 7.9 Hz, 1H), 5.34 - 5.30 (m, 1H), 4.64 (d, J = 18.3 Hz, 1H), 4.37 (d, J = 18.1 Hz, 1H), 1.67 (d, J = 6.8 Hz, 3H). Step 5: 8-bromo-1-methylisochromane
Figure imgf000145_0001
[000362] To a solution of 8-bromo-1-methylisochroman-4-one (38.5 g, 159.70 mmol, 1 eq) in TFA (300 mL) was added Et3SiH (92.85 g, 798.49 mmol, 127.54 mL, 5 eq) at 20 °C under an atmosphere of N2 and the solution was allowed to stir at 50 oC for 16 hrs. The reaction mixture was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (20 mL) and sat. NaHCO3 (100 mL). The aqueous solution was extracted with ethyl acetate (20 mL x 2). The organic solutions were combined, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 10/1 to 5/1) to give 8-bromo-1-methylisochromane (82.72% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ = 7.39 (dd, J = 0.6, 7.6 Hz, 1H), 7.05 (td, J = 7.2, 14.9 Hz, 2H), 5.06 (q, J = 6.5 Hz, 1H), 4.11 (ddd, J = 4.3, 9.4, 11.5 Hz, 1H), 3.86 (ddd, J = 3.8, 5.9, 11.5 Hz, 1H), 2.99 - 2.90 (m, 1H), 2.78 - 2.72 (m, 1H), 1.59 (d, J = 6.5 Hz, 3H).
Figure imgf000145_0002
Attorney Docket No. MORF-016WO1 Step 1: methyl (S)-2-(1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)isochroman-8-yl)acetate
Figure imgf000146_0001
[000363] To a solution of arbitrarily assigned methyl (S)-2-(1-methylisochroman-8- yl)acetate (1.5 g, 6.81 mmol, 1 eq) in dioxane (20 mL) was added Pin2B2 (3.46 g, 13.62 mmol, 2 eq) and dtbpy (109.67 mg, 408.60 μmol, 0.06 eq) and [Ir(OMe)(cod)]2 (135.42 mg, 204.30 μmol, 0.03 eq) at 20 °C under an atmosphere of N2. The mixture was allowed to stir at 100 °C for 16 hrs. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 10/1 to 5/1) to give methyl (S)-2-(1,6-dimethylisochroman-8-yl)acetate (3 g, crude) as yellow oil. LCMS [M+1] = 235.1. 1H NMR (400 MHz, CDCl3) δ = 7.51 (s, 2H), 5.15 - 5.08 (m, 1H), 4.15 - 4.06 (m, 1H), 3.83 (dd, J = 5.0, 10.9 Hz, 1H), 3.71 - 3.69 (m, 3H), 3.65 - 3.61 (m, 1H), 3.60 - 3.55 (m, 1H), 2.93 (br dd, J = 5.8, 7.8 Hz, 1H), 2.85 - 2.76 (m, 1H), 1.47 (d, J = 6.5 Hz, 3H), 1.34 (s, 12H). Step 2: methyl (S)-2-(1,6-dimethylisochroman-8-yl)acetate
Figure imgf000146_0002
[000364] To a solution of methyl (S)-2-(1,6-dimethylisochroman-8-yl)acetate (3 g, 8.66 mmol, 1 eq) in toluene (50 mL), EtOH (20 mL) and H2O (20 mL) were added Pd(PPh3)4 (500.64 mg, 433.24 μmol, 0.05 eq), K2CO3 (3.59 g, 25.99 mmol, 3 eq) and MeI (6.15 g, 43.32 mmol, 2.70 mL, 5 eq) in turn at 20 °C under an atmosphere of N2. The reaction mixture was heated to 100 °C and allowed to stir at 100 °C for 16 hrs. The reaction was quenched with water (200 mL) at 20 °C and extracted with ethyl acetate (100 mL x 3). The organic solutions were combined, washed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 10/1 to 5/1) to give methyl (S)-2-(1,6-dimethylisochroman-8-yl)acetate (1 g, 3.41 mmol, 39.41% yield, 80% purity) as a yellow oil. LCMS [M+1] = 235.1 1H NMR Attorney Docket No. MORF-016WO1 (400 MHz, CDCl3) δ = 6.93 (br s, 1H), 6.87 (s, 1H), 5.08 (q, J = 6.5 Hz, 1H), 4.13 - 4.05 (m, 1H), 3.81 (td, J = 5.1, 10.8 Hz, 1H), 3.71 (s, 3H), 3.63 - 3.57 (m, 1H), 3.53 - 3.48 (m, 1H), 2.94 - 2.84 (m, 1H), 2.79 - 2.70 (m, 1H), 2.30 (s, 3H), 1.47 (br d, J = 6.5 Hz, 3H). Step 3: methyl 2-bromo-2-((S)-1,6-dimethylisochroman-8-yl)acetate
Figure imgf000147_0001
[000365] To a solution of methyl (S)-2-(1,6-dimethylisochroman-8-yl)acetate (0.5 g, 2.13 mmol, 1 eq) in THF (5 mL) was added LDA (2 M, 3.20 mL, 3 eq) at -60 °C and the mixture was allowed to stir at -60 °C for 30 min. TMSCl (765.10 mg, 7.04 mmol, 893.81 μL, 3.3 eq) was added at -60 °C and the mixture was allowed to stir at -60 °C for 0.5 hrs. A solution of NBS (569.74 mg, 3.20 mmol, 1.5 eq) in THF (5 mL) was added at -60 °C. The mixture was allowed to stir at 60 °C for 1 hr. The reaction was diluted with sat. NH4Cl (50 mL) and extracted with ethyl acetate (20 mL x 3). The organic solutions were combined, washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 10/1 to 5/1) to give methyl 2-bromo-2-((S)-1,6-dimethylisochroman-8-yl)acetate (0.46 g, 734.39 μmol, 34.41% yield, 50% purity) as yellow oil. [000366] By a similar method starting from arbitrarily assigned methyl (R)-2-(1- methylisochroman-8-yl)acetate was prepared arbitrarily assigned methyl 2-bromo-2-((R)-1,6- dimethylisochroman-8-yl)acetate. Preparation of tert-butyl 2-(1-methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]- 7-yl)acetate
Figure imgf000147_0002
Step 1: 7-bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one
Figure imgf000147_0003
Attorney Docket No. MORF-016WO1 [000367] Four parallel reactions were carried out. To a solution of 7-bromoindolin-2-one (5 g, 23.58 mmol, 1 eq) in THF (100 mL) was added LiHMDS (1 M, 117.90 mL, 5 eq) at -70 °C, then the mixture was allowed to stir at -70 °C for 0.5hrs. Then 1-bromo-2-(2- bromoethoxy)ethane (8.20 g, 35.37 mmol, 4.43 mL, 1.5 eq) was added at -70 °C. The reaction was allowed to stir at 25 °C for 16 hrs. The reaction was quenched by the addition of H2O (500 mL) and ethyl acetate (200 mL) was added. The organic solution was separated and the aqueous solution was extracted with ethyl acetate (200 mL x 3). The organic solutions were combined, washed with brine (500 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 100/1 to 3/1). 7-bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'- pyran]-2-one (29.69% yield) was obtained as a yellow solid. 1H NMR (400 MHz, CDCl3) δ = 7.37 (d, J = 8.3 Hz, 1H), 7.29 (s, 1H), 6.97 (t, J = 7.9 Hz, 1H), 4.24 (td, J = 6.2, 11.9 Hz, 2H), 3.92 (td, J = 4.7, 11.8 Hz, 2H), 1.96 - 1.86 (m, 4H). Step 2: 7-bromo-1-methyl-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one
Figure imgf000148_0001
[000368] To a solution of 7-bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one (5.4 g, 19.14 mmol, 1 eq) in DMF (55 mL) was added NaH (765.52 mg, 19.14 mmol, 60% purity, 1 eq) at 0 °C. The mixture was allowed to stir at 0 °C for 30 min and then MeI (5.43 g, 38.28 mmol, 2.38 mL, 2 eq) was added at 0 °C. The mixture was allowed to stir at 20 °C for 16 hrs. The mixture was quenched by the addition of sat. NH4Cl (200 mL) and ethyl acetate (100 mL) was added. The organic and aqueous solutions were separated and the aqueous solution was extracted with ethyl acetate (100 mL x 3). The organic solutions were combined, washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 10/1). 7-bromo-1-methyl-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one (89.97% yield) was obtained as a yellow solid. 1H NMR (400 MHz, CDCl3) δ = 7.39 (dd, J = 1.1, 8.2 Hz, 1H), 7.22 (dd, J = 1.0, 7.4 Hz, 1H), 6.96 - 6.89 (m, 1H), 4.29 (ddd, J = 2.9, 10.4, 11.6 Hz, 2H), 3.90 (td, J = 4.3, 11.8 Hz, 2H), 3.59 (s, 3H), 1.97 - 1.88 (m, 2H), 1.80 - 1.72 (m, 2H). Step 3: tert-butyl 2-(1-methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7- yl)acetate Attorney Docket No. MORF-016WO1
Figure imgf000149_0001
[000369] To a solution of 7-bromo-1-methyl-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]- 2-one (6.5 g, 21.95 mmol, 1 eq) in THF (65 mL) was added BrZnCH2COOt-Bu (1 M, 43.90 mL, 2 eq) and Pd(t-Bu3P)2 (1.12 g, 2.19 mmol, 0.1 eq) at 20 °C. The mixture was allowed to stir at 80 °C for 2 hrs. The mixture was quenched by the addition of H2O and filtered. The filtrate was extracted with ethyl acetate (100 mL x 3). The organic solutions were combined, washed with brine (100 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 100/1to 5/1). tert-butyl 2-(1-methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'- pyran]-7-yl)acetate (89.36% yield) was obtained as a yellow solid.1H NMR (400 MHz, CDCl3) δ = 7.23 (dd, J = 1.4, 7.1 Hz, 1H), 7.09 - 7.01 (m, 2H), 4.38 - 4.21 (m, 2H), 3.92 (td, J = 4.3, 11.7 Hz, 2H), 3.81 (s, 2H), 3.46 (s, 3H), 1.94 (ddd, J = 4.4, 10.0, 14.1 Hz, 2H), 1.77 (br d, J = 13.9 Hz, 2H), 1.45 (s, 9H). Preparation of 4'-bromo-6'-methyl-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'- indolin]-2'-one
Figure imgf000149_0002
Step 1: methyl 2-(2-bromo-6-fluoro-4-methylphenyl)-2-oxoacetate
Figure imgf000149_0003
[000370] To a solution of 1-bromo-3-fluoro-5-methylbenzene (50 g, 264.52 mmol, 1 eq) in THF (500 mL) was added LDA (2 M, 158.71 mL, 1.2 eq) dropwise at -70 °C under an atmosphere of N2. The reaction mixture was allowed to stir at -70 °C for 0.5 hrs. To the Attorney Docket No. MORF-016WO1 reaction mixture was added a solution of dimethyl oxalate (40.61 g, 343.87 mmol, 1.3 eq) in THF (500 mL) at -70 °C under an atmosphere of N2. The reaction mixture was allowed to stir at -70 °C under N2 for 2 hrs. The reaction was quenched by the addition of aq. NH4Cl (500 mL) and extracted with EtOAc (200 mL x 3). The organic solutions were combined, washed with brine (500 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 5/1). Methyl 2-(2-bromo-6-fluoro-4-methylphenyl)-2-oxoacetate (90.71% yield) was obtained as a yellow solid. 1H NMR (400 MHz, CDCl3) δ = 7.28 (s, 1H), 6.95 (d, J = 10.3 Hz, 1H), 3.94 (s, 3H), 2.40 (s, 3H). Step 2: 2-(2-bromo-6-fluoro-4-methylphenyl)-2-oxo-N-(tetrahydro-2H-pyran-4- yl)acetamide
Figure imgf000150_0001
[000371] To a mixture of methyl 2-(2-bromo-6-fluoro-4-methylphenyl)-2-oxoacetate (30 g, 109.06 mmol, 1 eq) in MeOH (300 mL) was added tetrahydro-2H-pyran-4-amine (12.13 g, 119.97 mmol, 1.1 eq) dropwise at 0 °C. The mixture was was allowed to stir at 25 °C for 16 hrs. The reaction mixture was filtered and concentrated under reduced. The crude product was triturated with MeOH at 20 °C for 30 min. 2-(2-bromo-6-fluoro-4-methylphenyl)-2-oxo-N- (tetrahydro-2H-pyran-4-yl)acetamide (71.28% yield) was obtained as a yellow solid. 1H NMR (400 MHz, CDCl3) δ = 7.26-7.21 (m, 1H), 6.93 (d, J = 9.5 Hz, 1H), 6.85 (br d, J = 6.7 Hz, 1H), 4.13-3.97 (m, 3H), 3.51 (dt, J = 2.1, 11.7 Hz, 2H), 2.38 (s, 3H), 2.04-1.94 (m, 2H), 1.70-1.55 (m, 2H). Step 3: 4-bromo-6-methyl-1-(tetrahydro-2H-pyran-4-yl)indoline-2,3-dione
Figure imgf000150_0002
[000372] To a mixture of 2-(2-bromo-6-fluoro-4-methylphenyl)-2-oxo-N-(tetrahydro-2H- pyran-4-yl)acetamide (10 g, 27.76 mmol, 1 eq) in toluene (100 mL) was added dropwise a Attorney Docket No. MORF-016WO1 solution of t-AmylOK (4.56 g, 36.09 mmol, 5.24 mL, 1.3 eq) in toluene (50 mL) at 0 °C. The reaction was allowed to stir at 0 °C for 2 hrs and then quenched by the addition of HCl (1 M, 200 mL). The mixture was extracted with EtOAc (100 mL x 3). The organic solutions were combined, dried over Na2SO4, filtered and concentrated. The crude product was triturated by Petroleum ether : Ethyl acetate (2/1, 50 mL). The mixture was filtered and the filtrate was concentrated to dryness to give 4-bromo-6-methyl-1-(tetrahydro-2H-pyran-4-yl)indoline-2,3- dione (94.44% yield) as a red solid. Step 4: 4-bromo-6-methyl-1-(tetrahydro-2H-pyran-4-yl)indolin-2-one
Figure imgf000151_0001
[000373] To a solution of 4-bromo-6-methyl-1-(tetrahydro-2H-pyran-4-yl)indoline-2,3-dione (24 g, 74.04 mmol, 1 eq) in glycol (250 mL) was added NH2NH2.H2O (51.60 g, 1.03 mol, 50 mL, 13.92 eq) at 25 °C under an atmosphere of N2. The mixture was allowed o stir at 130 °C for 4 hrs. The reaction mixture was concentrated under reduced pressure and quenched by the addition of H2O (300 mL). The mixture was extracted with ethyl acetate (100 mL x 3). The organic solutions were combined, washed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was used directly without further purification. 4-bromo-6-methyl-1-(tetrahydro-2H-pyran-4-yl)indolin-2-one (25 g, crude) was obtained as a yellow solid. LCMS: [M+1] = 312.0. Step 5: 4'-bromo-6'-methyl-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'- indolin]-2'-one
Figure imgf000151_0002
[000374] To a solution of 4-bromo-6-methyl-1-(tetrahydro-2H-pyran-4-yl)indolin-2-one (22.69 g, 73.15 mmol, 1 eq) in DMF (250 mL) was added NaH (14.63 g, 365.75 mmol, 60% purity, 5 eq) at 0 °C under an atompshere of N2. The solution was allowed to stir at 0 °C for Attorney Docket No. MORF-016WO1 0.5 hrs, then 1,2-dibromoethane (68.71 g, 365.75 mmol, 27.59 mL, 5 eq) was added to the solution at 0 °C and the solution was allowed to stir at 20 °C for 2 hrs. The reaction was quenched by the addition of sat. NH4Cl (300 mL) and extracted with EtOAc (100 mL x 3). The organic solutions were combined, washed with brine (200 mL), dried over Na2SO4, filtered and concentrated to give the crude product. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 2/1). 4'-bromo-6'-methyl-1'- (tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-2'-one (60.99% yield) was obtained as a yellow solid. Preparation of methyl 2-bromo-2-((1S,4S)-4,7-dimethyl-5',6'-dihydro-2'H,4'H-
Figure imgf000152_0001
Step 1: 2-(2-bromo-4-methylphenyl)-1-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidotetrahydro- 3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)ethan-1-one
Figure imgf000152_0002
[000375] To a solution of 2-(2-bromo-4-methylphenyl)acetic acid (40 g, 174.62 mmol, 1 eq), (3aR,6S,7aS)-8,8-dimethylhexahydro-3H-3a,6-methanobenzo[c]isothiazole 2,2-dioxide (37.60 g, 174.62 mmol, 1 eq) and TEA (35.34 g, 349.24 mmol, 48.61 mL, 2 eq) in toluene (400 mL) was added PivCl (84.22 g, 698.48 mmol, 85.94 mL, 4 eq) in toluene (20 mL) dropwise at 80°C. The mixture was allowed to stir at 110°C for 16 hrs. The reaction was quenched by the addition of H2O (1 L) at 0oC and extracted with ethyl acetate (300 mL x 3). The organic Attorney Docket No. MORF-016WO1 solutions were combined, washed with brine (300 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 3/1). 2-(2-bromo-4-methylphenyl)-1- ((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)- yl)ethan-1-one (150 g, crude) was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.40 (s, 1H), 7.15 - 7.12 (m, 1H), 7.10 - 7.06 (m, 1H), 4.29 (d, J = 17.3 Hz, 1H), 4.05 (d, J = 17.3 Hz, 1H), 3.92 (dd, J = 4.9, 7.8 Hz, 1H), 3.52 (q, J = 13.8 Hz, 2H), 2.34 - 2.29 (m, 3H), 2.24 - 2.13 (m, 1H), 2.07 - 2.00 (m, 1H), 1.95 - 1.86 (m, 3H), 1.46 - 1.40 (m, 1H), 1.38 - 1.31 (m, 1H), 1.25 - 1.21 (m, 3H), 0.99 (s, 3H). Step 2: (S)-2-(2-bromo-4-methylphenyl)-1-((3aR,6S,7aS)-8,8-dimethyl-2,2- dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)propan-1-one
Figure imgf000153_0001
[000376] Four batches were carried out in parallel. To a solution of 2-(2-bromo-4- methylphenyl)-1-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6- methanobenzo[c]isothiazol-1(4H)-yl)ethan-1-one (38 g, 89.13 mmol, 1 eq) in THF (400 mL) was added LiHMDS (1 M, 98.04 mL, 1.1 eq) under an atmosphere of N2 at -78°C and the mixture was allowed to stir for 30 min. HMPA (79.86 g, 445.63 mmol, 77.98 mL, 5 eq) and MeI (63.25 g, 445.63 mmol, 27.74 mL, 5 eq) were added at -78°C. The reaction was allowed to stir at -78°C for 2 hrs. The reaction was quenched by aq.NH4Cl (800 mL) slowly and extracted with ethyl acetate (300 mL x 3). The organic solutions were combined, washed with brine (300 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate=100/1 to 3/1). (S)-2-(2-bromo-4-methylphenyl)-1-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidotetrahydro- 3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)propan-1-one (120 g, 78.39%) was obtained as a yellow oil.1H NMR (400 MHz, CDCl3) δ = 7.41 (d, J = 1.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.12 - 7.07 (m, 1H), 4.73 (q, J = 7.0 Hz, 1H), 3.91 (dd, J = 5.2, 7.4 Hz, 1H), 3.52 - 3.39 (m, 2H), 2.30 (s, 3H), 2.17 - 2.07 (m, 2H), 1.93 - 1.85 (m, 3H), 1.55 (d, J = 7.0 Hz, 3H), 1.46 - 1.38 (m, 1H), 1.37 - 1.31 (m, 1H), 1.19 (s, 3H), 0.98 (s, 3H). Step 3: (S)-2-(2-bromo-4-methylphenyl)propan-1-ol Attorney Docket No. MORF-016WO1
Figure imgf000154_0001
[000377] Three batches were carried out in parallel. To a solution of (S)-2-(2-bromo-4- methylphenyl)-1-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6- methanobenzo[c]isothiazol-1(4H)-yl)propan-1-one (20 g, 45.41 mmol, 1 eq) in THF (150 mL) was added NaBH4 (3.81 g, 100.65 mmol, 2.22 eq) in H2O (12 mL) at 25°C and the mixture was allowed to stir at 25°C for 16 hrs. The reaction was quenched by the slow addition of ice water (200 mL), adjusted to pH = 6, and extracted with ethyl acetate (200 mL x 2). The organic solutions were combined, washed with brine (300 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The batches were combined and purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 3/1). (S)-2-(2-bromo-4- methylphenyl)propan-1-ol (66 g, crude) was obtained as a yellow oil. Step 4: (S)-2-(2-bromo-4-methylphenyl)propan-1-ol
Figure imgf000154_0002
[000378] To a solution of (S)-2-(2-bromo-4-methylphenyl)propan-1-ol (64 g, 279.34 mmol, 1 eq) in DCM (600 mL) was added DMAP (1.71 g, 13.97 mmol, 0.05 eq), pyridine (38.67 g, 488.84 mmol, 39.46 mL, 1.75 eq) and AcCl (32.89 g, 419.01 mmol, 29.79 mL, 1.5 eq) at 0 oC under an atmosphere of N2 and the solution was allowed to stir at 20 oC for 2 hrs. The reaction was quenched by the addition of H2O (500 mL) at 0 oC and extracted with DCM (500 mL x 3). The organic solutions were combined, washed with brine (600 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 3/1). [(2S)-2-(2-bromo-4- methyl-phenyl) propyl] acetate (66.01% yield) was obtained as a yellow oil. To a solution of [(2S)-2-(2-bromo-4-methyl-phenyl)propyl] acetate (50 g, 184.40 mmol, 1 eq) in H2O (120 mL), THF (600 mL) and MeOH (29.54 g, 922.00 mmol, 37.31 mL, 5 eq) was added KOH (8.28 g, 147.52 mmol, 0.8 eq) at 25oC under an atmosphere of N2 and the solution was allowed to stir at 50oC for 6 hrs. KOH (4.14 g, 73.76 mmol, 0.4 eq) in H2O (20 mL) was added to the mixture at 25°C and the solution was allowed to stir at 50oC for 16 hrs. The mixture was extracted with MTBE (200 mL x 3). The organic solutions were combined, washed with brine Attorney Docket No. MORF-016WO1 (200 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. (S)-2-(2- bromo-4-methylphenyl)propan-1-ol (40 g, 174.59 mmol, 62.50% yield over 2 steps) was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.42 (s, 1H), 7.20 - 7.06 (m, 2H), 3.83 - 3.64 (m, 2H), 3.48 (sxt, J = 6.7 Hz, 1H), 2.31 (s, 3H), 1.28 (d, J = 7.0 Hz, 3H). Step 5: ethyl (4S)-5-bromo-4,7-dimethylisochromane-1-carboxylate
Figure imgf000155_0001
[000379] Two batches were carried out in parallel. To a solution of (S)-2-(2-bromo-4- methylphenyl)propan-1-ol (22.9 g, 99.95 mmol, 1 eq) and ethyl 2,2-diethoxyacetate (52.84 g, 299.85 mmol, 53.64 mL, 3 eq) in DCE (230 mL) was added TiCl4 (75.83 g, 399.80 mmol, 4 eq) at 0oC under an atmosphere of N2 and the reaction was allowed to stir at 50 oC for 16 hrs. The reaction was quenched by the addition of H2O (500 mL) at 0 oC and extracted with DCM (100 mL x 3). The organic solutions were combined, washed with brine (200 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate=100/1 to 3/1). Ethyl (4S)-5- bromo-4,7-dimethylisochromane-1-carboxylate (68 g, crude) was obtained as a yellow oil.1H NMR (400 MHz, CDCl3) δ = 7.34 (s, 1H), 7.12 (s, 1H), 5.31 (s, 1H), 4.30 - 4.23 (m, 2H), 4.06 - 4.01 (m, 1H), 3.80 (dd, J = 2.4, 11.1 Hz, 1H), 2.97 (q, J = 6.6 Hz, 1H), 2.29 (s, 3H), 1.46 - 1.43 (m, 3H), 1.27 (t, J = 7.1 Hz, 3H). Step 6: ethyl (4S)-1-allyl-5-bromo-4,7-dimethylisochromane-1-carboxylate
Figure imgf000155_0002
[000380] Two batches were carried out in parallel. To a solution of ethyl (4S)-5-bromo-4,7- dimethylisochromane-1-carboxylate (34 g, 108.56 mmol, 1 eq) and 3-bromoprop-1-ene (17.07 g, 141.13 mmol, 1.3 eq) in DMF (350 mL) was added Cs2CO3 (70.74 g, 217.12 mmol, 2 eq) at 20°C under an atmosphere of N2. The mixture was allowed to stir at 50 °C for 12 hrs. Water (1 L) was added and the mixture was extracted with ethyl acetate (1 L x 2). The organic solutions were combined, washed with brine (1.5 L x 2), dried over Na2SO4, and concentrated Attorney Docket No. MORF-016WO1 under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 10/1). ethyl (4S)-1-allyl-5-bromo-4,7-dimethylisochromane-1- carboxylate (61.28% yield) was obtained as a yellow oil. Step 7: ((4S)-1-allyl-5-bromo-4,7-dimethylisochroman-1-yl)methanol
Figure imgf000156_0001
[000381] To a solution of ethyl (4S)-1-allyl-5-bromo-4,7-dimethylisochromane-1- carboxylate (21.3 g, 60.30 mmol, 1 eq) in toluene (200 mL) was added DIBAL-H (1 M, 180.89 mL, 3 eq) at 0°C under an atmosphere of N2. The reaction was allowed to stir at 25 °C for 1 hr. The reaction was quenched by the addition of HCl aqueous solution (1 M) to pH = 3 at 0°C. The mixture was extracted with ethyl acetate (300 mL x 2). The organic solutions were combined, washed with brine (300 mL X 3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 1/1). ((4S)-1-allyl-5-bromo-4,7-dimethylisochroman-1-yl)methanol was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.31 (s, 1H), 6.91 (s, 1H), 5.93 - 5.55 (m, 1H), 5.17 - 4.95 (m, 2H), 4.08 - 3.94 (m, 1H), 3.89 - 3.71 (m, 3H), 3.01 - 2.70 (m, 2H), 2.61 - 2.44 (m, 1H), 2.33 - 2.28 (m, 3H), 1.36 (d, J = 6.9 Hz, 3H). Step 8: 3-((4S)-5-bromo-1-(hydroxymethyl)-4,7-dimethylisochroman-1-yl)propan-1-ol
Figure imgf000156_0002
[000382] Two batches were carried out in parallel. To a mixture of ((4S)-1-allyl-5-bromo- 4,7-dimethylisochroman-1-yl)methanol (18.6 g, 59.77 mmol, 1 eq) in THF (100 mL) was added 9-BBN (0.5 M, 358.60 mL, 3 eq) at 20°C under an atmosphere of N2. The reaction mixture was allowed to stir at 20°C for 2 hrs. To the mixture was added NaOH (4 M, 211.10 mL, 14.13 eq) and H2O2 (94.87 g, 836.84 mmol, 80.40 mL, 30% purity, 14.00 eq) at 0°C under an atmosphere of N2. The mixture was allowed to stir at 0°C for 1 hr. The reaction was Attorney Docket No. MORF-016WO1 quenched by the addition of aq.Na2SO3 (300 mL) and extracted with ethyl acetate (300 mL x 2). The organic solutins were combined, washed with brine and dried over Na2SO4. After filtration, the volatile materials were removed under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 0/1). 3- ((4S)-5-bromo-1-(hydroxymethyl)-4,7-dimethylisochroman-1-yl)propan-1-ol (52 g, crude) was obtained as a yellow oil. Step 9: (4S)-5-bromo-4,7-dimethyl-5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran]
Figure imgf000157_0001
[000383] Two batches were carried out in parallel. To a solution of 3-((4S)-5-bromo-1- (hydroxymethyl)-4,7-dimethylisochroman-1-yl)propan-1-ol (24 g, 72.90 mmol, 1 eq) in toluene (240 mL) was added CMBP (35.19 g, 145.80 mmol, 2 eq) at 20 oC under an atmosphere of N2 and the solution was allowed to stir at 120 oC for 2 hrs. The reaction was quenched by the addition of H2O (700 mL) at 0oC and extracted with ethyl acetate (300 mL x 3). The organic solutions were combined, washed with brine (300 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate=100/1 to 1/1). (4S)-5-bromo-4,7- dimethyl-5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran] (23.5 g, crude) was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.30 (s, 1H), 6.91 - 6.86 (m, 1H), 4.08 (br dd, J = 4.4, 11.4 Hz, 1H), 4.00 (dd, J = 2.3, 12.4 Hz, 1H), 3.93 - 3.81 (m, 1H), 3.77 - 3.64 (m, 1H), 3.59 - 3.48 (m, 1H), 3.37 (d, J = 12.5 Hz, 1H), 3.00 - 2.91 (m, 1H), 2.31 (s, 3H), 2.25 - 2.14 (m, 1H), 2.06 - 1.90 (m, 2H), 1.59 - 1.49 (m, 1H), 1.36 (d, J = 6.9 Hz, 3H). Step 10: methyl 2-((1S,4S)-4,7-dimethyl-5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'- pyran]-5-yl)acetate and methyl 2-((1R,4S)-4,7-dimethyl-5',6'-dihydro-2'H,4'H- spiro[isochromane-1,3'-pyran]-5-yl)acetate Attorney Docket No. MORF-016WO1
Figure imgf000158_0001
[000384] Two batches were carried out in parallel. To a solution of (4S)-5-bromo-4,7- dimethyl-5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran] (14.5 g, 46.59 mmol, 1 eq) in THF (140 mL) was added Pd(t-Bu3P)2 (2.38 g, 4.66 mmol, 0.1 eq) and BrZnCH2COOMe (1 M, 69.89 mL, 1.5 eq) at 20oC under an atmosphere of N2 and the reaction was allowed to stir at 80 oC for 2 hrs. The reaction was quenched by the addition of H2O (50 mL), filtered and extracted with ethyl acetate (50 mL x 3). The organic solutions were combined, washed with brine (50 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 3/1) to give a mixture of stereoisomers (56.41% yield). The stereoisomers were separated by SFC (column: ChiralPak IH, 250 * 50 mm, 10 um; mobile phase: [CO2 - IPA]; B%:30%, isocratic elution mode). [000385] Peak 1, arbitrarily assigned as methyl 2-((1S,4S)-4,7-dimethyl-5',6'-dihydro- 2'H,4'H-spiro[isochromane-1,3'-pyran]-5-yl)acetate, was obtained (20.63% yield) as a white solid. SFC Rt1 = 1.394 min. [000386] Peak 2, arbitrarily assigned as methyl 2-((1R,4S)-4,7-dimethyl-5',6'-dihydro- 2'H,4'H-spiro[isochromane-1,3'-pyran]-5-yl)acetate, was obtained (51.88% yield) as a white solid. SFC Rt2 = 2.557 min Step 11: methyl 2-bromo-2-((1R,4S)-4,7-dimethyl-5',6'-dihydro-2'H,4'H- spiro[isochromane-1,3'-pyran]-5-yl)acetate
Figure imgf000158_0002
[000387] To a solution of arbitrarily assigned methyl 2-((1R,4S)-4,7-dimethyl-5',6'-dihydro- 2'H,4'H-spiro[isochromane-1,3'-pyran]-5-yl)acetate (9.3 g, 30.55 mmol, 1 eq) in THF (100 mL) was added LDA (2 M, 45.83 mL, 3 eq) at -70 °C under an atmosphere of N2. After 30 min, Attorney Docket No. MORF-016WO1 TMSCl (9.96 g, 91.66 mmol, 11.63 mL, 3 eq) was added, the mixture was allowed to stir at -70 °Cfor 30 min. Then NBS (16.31 g, 91.66 mmol, 3 eq) in THF (30 mL) was added. The mixture was allowed to stir at -70 °C for 30 min. The reaction was quenched by the addition of saturated aqueous NH4Cl (200 mL) and extracted with ethyl acetate (50 mL x 3). The organic solutions were combined, washed with brine (100 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 3/1). methyl 2-bromo-2-((1R,4S)-4,7-dimethyl-5',6'-dihydro- 2'H,4'H-spiro[isochromane-1,3'-pyran]-5-yl)acetate (95.64% yield) was obtained as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.55 - 7.37 (m, 1H), 6.94 (d, J = 3.0 Hz, 1H), 5.67 (d, J = 11.2 Hz, 1H), 4.10 - 3.98 (m, 2H), 3.96 - 3.76 (m, 5H), 3.57 - 3.49 (m, 1H), 3.40 (dd, J = 9.7, 12.4 Hz, 1H), 2.97 - 2.82 (m, 1H), 2.34 (d, J = 4.6 Hz, 3H), 2.29 - 2.17 (m, 1H), 2.04 - 1.94 (m, 2H), 1.53 (br d, J = 13.5 Hz, 1H), 1.45 - 1.40 (m, 3H).
Figure imgf000159_0001
Step 1: (E)-2-bromo-4-methyl-1-(prop-1-en-1-yl)benzene
Figure imgf000159_0002
[000388] To a solution of 2-bromo-4-methylbenzaldehyde (90.0 g, 452.16 mmol, 1.0 eq.) in THF (900 mL) was added EtMgBr (3.0 M, 301.44 mL, 2.0 eq.) at 0°C. The mixture was allowed to stir under an atmosphere of nitrogen at 0°C for 0.5 hrs and then at 25°C for 1 hr. The reaction was quenched by the addition of sat. aq. NH4Cl (900 mL) and extracted with ethyl acetate (500 mL x 2). The organic solutions were combined, washed with brine (500 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (SiO2, Petroleum ether/Ethyl acetate = 0/100 to 70/30) to give the crude product (80 g) as yellow oil. The crude product (15.0 g, 65.47 mmol, 1 eq.) was Attorney Docket No. MORF-016WO1 dissolved in toluene (150 mL). Then TsOH.H2O (37.4 g, 196.41 mmol, 3.0 eq.) was added at 25oC under an atmosphere of N2. The mixture was heated to 80 oC and allowed to stir at 80°C under an atmosphere of N2 for 12 hrs. The reaction was quenched by the addition of H2O (150 mL) and the mixture was extracted with ethyl acetate (100 mL x 3). The organic solutions were combined, washed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give (E)-2-bromo-4-methyl-1-(prop-1-en-1-yl)benzene (15 g, crude) as yellow oil, which was used for the next step directly without purification. 1 H NMR (400 MHz, CDCl3) δ = 7.37 (d, J = 7.6 Hz, 2H), 7.05 (d, J = 8.1 Hz, 1H), 6.71 (dd, J = 1.4, 15.6 Hz, 1H), 6.15 (dd, J = 6.8, 15.6 Hz, 1H), 2.31 (s, 3H), 1.92 (dd, J = 1.7, 6.7 Hz, 3H). Step 2: 2-(2-bromo-4-methylphenyl)-3-methyloxirane
Figure imgf000160_0001
[000389] To a solution of (E)-2-bromo-4-methyl-1-(prop-1-en-1-yl)benzene (40.0 g, 189.49 mmol, 1.0 eq.) in DCM (400 mL) was added m-CPBA (65.4 g, 322.13 mmol, 85% purity, 1.7 eq.) at 20oC. The mixture was allowed to stir at 20°C for 6 hrs. The reaction was quenched by the addition of sat. aq.Na2SO3 (400 mL) and then DCM (200 mL) was added. The organic solution was separated and the aqueous solution was extracted with DCM (200 mL x 3). The organic solutions were combined, washed with brine (100 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated in vacuum to give a residue, which was purified by silica gel chromatography (SiO2, Petroleum ether/Ethyl acetate = 0/100 to 10/90) to give 2-(2-bromo-4- methylphenyl)-3-methyloxirane (66.23% yield) as yellow oil. Step 3: (2R,3S)-3-(2-bromo-4-methylphenyl)butan-2-ol and (2S,3S)-3-(2-bromo-4- methylphenyl)butan-2-ol
Figure imgf000160_0002
[000390] To a solution of 2-(2-bromo-4-methylphenyl)-3-methyloxirane (36.0 g, 158.52 mmol, 1.0 eq) in DCM (400 mL) was added AlMe3 (1.0 M, 317.04 mL, 2.0 eq) at -70°C under an atmosphere of N2. Then the reaction mixture was allowed to warm to 20°C and stir at 20°C under an atmosphere of N2 for 12 hrs. The mixture was poured into ice water (350 mL) and extracted with DCM (350 mL x 2). The organic solutions were combined, washed with H2O Attorney Docket No. MORF-016WO1 (350 mL x 2) and brine (350 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by silica gel chromatography (SiO2, Petroleum ether/Ethyl acetate = 100/0 to 10/90) to give a mixture of (2R,3S)-3-(2-bromo-4- methylphenyl)butan-2-ol and (2S,3S)-3-(2-bromo-4-methylphenyl)butan-2-ol (36.0 g, crude) as yellow oil. 1H NMR (400 MHz, CDCl3 δ = 7.41 (s, 1H), 7.22 (d, J = 7.9 Hz, 1H), 7.16 - 7.07 (m, 1H), 3.98 (qd, J = 6.1, 12.6 Hz, 1H), 3.38 - 3.24 (m, 1H), 2.31 (s, 3H), 1.26 - 1.21 (m, 6H). Step 4: (3R,4S)-5-bromo-3,4,7-trimethylisochromane
Figure imgf000161_0001
[000391] To a mixture of (2R,3S)-3-(2-bromo-4-methylphenyl)butan-2-ol and (2S,3S)-3-(2- bromo-4-methylphenyl)butan-2-ol (36.0 g, 148.07 mmol, 1.0 eq.) in TFA (360 mL) was added (HCHO)n (40.0 g, 444.19 mmol, 3.0 eq.) at 20°C. The mixture was allowed to stir at 50 °C for 16 hrs. The mixture was diluted by the addition of iced water (300 mL) and adjusted to pH = 7-8 by the addition of sat. aq. NaHCO3 aqueous at 0 oC. The mixture was extracted with ethyl acetate (200 mL x 3). The organic solutions were combined, washed with brine (200 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by prep-HPLC (column: Welch Xtimate C18250 * 100 mm # 10 um; mobile phase: [H2O (0.01%TFA)-ACN]; B%: 60% - 88%, 20.000 min) to give (3R,4S)-5-bromo- 3,4,7-trimethylisochromane (74.45% yield) as yellow oil. 1H NMR (400 MHz, CDCl3) δ = 7.28 (s, 1H), 6.77 (s, 1H), 4.76 - 4.62 (m, 2H), 4.00 (dq, J = 2.3, 6.6 Hz, 1H), 2.77 (dq, J = 2.0, 6.8 Hz, 1H), 2.28 (s, 3H), 1.33 (d, J = 6.9 Hz, 3H), 1.23 (d, J = 6.6 Hz, 3H). Preparation of 5-bromo-7-fluoro-4-methylisochromane
Figure imgf000161_0002
Step 1: 2-(2-bromo-4-fluorophenyl)propanoic acid Attorney Docket No. MORF-016WO1
Figure imgf000162_0001
[000392] To a solution of 2-(2-bromo-4-fluorophenyl)acetic acid (5 g, 21.46 mmol, 1 eq) in THF (100 mL) was added LiHMDS (1 M, 47.20 mL, 2.2 eq) at 0 °C under an atmosphere of N2. The mixture was allowed to stir at 0 °C for 0.5 hrs and then MeI (6.09 g, 42.91 mmol, 2.67 mL, 2 eq) was added at 0 °C. The mixture was allowed to stir and warm to 20°C over 1.5 hrs. The mixture was diluted with NH4Cl solution (200 mL) and extracted with ethyl acetate (100 mL x 3). The organic solutions were combined, washed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 5/1 to 3/1). 2-(2-bromo-4- fluorophenyl)propanoic acid (84.89% yield) was obtained as a yellow solid. 1H NMR (400 MHz, CDCl3) δ = 7.37 - 7.31 (m, 2H), 7.05 (dt, J = 2.6, 8.3 Hz, 1H), 4.25 (q, J = 7.3 Hz, 1H), 1.52 (d, J = 7.3 Hz, 3H). Step 2: 2-(2-bromo-4-fluorophenyl)propan-1-ol
Figure imgf000162_0002
[000393] To a solution of 2-(2-bromo-4-fluorophenyl)propanoic acid (12 g, 48.57 mmol, 1 eq) in THF (140 mL) was added BH3 .THF (1 M, 145.71 mL, 3 eq) at 0 °C under an atmosphere of N2. The mixture was allowed to stir at 20°C for 2 hrs. MeOH (20 mL) was added dropwise at 0 °C followed by 1M aq. HC1 solution (50 mL) and the mixture was allowed to stir for 30 min. The mixture as poured into 10% aq Na2CO3 solution (300 mL) and extracted twice with ethyl acetate (200 mL each). The organic solutions were combined, washed with brine (100 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 100/1 to 10/1). 2-(2-bromo-4- fluorophenyl)propan-1-ol (88.33% yield) was obtained as yellow oil. Step 3: 2-bromo-4-fluoro-1-(1-((2-methoxyethoxy)methoxy)propan-2-yl)benzene
Figure imgf000162_0003
Attorney Docket No. MORF-016WO1 [000394] To a solution of 2-(2-bromo-4-fluorophenyl)propan-1-ol (1 g, 4.29 mmol, 1 eq) in DCM (20 mL) was added DIEA (1.66 g, 12.87 mmol, 2.24 mL, 3 eq) at 0 °C. 1- (chloromethoxy)-2-methoxyethane (1.07 g, 8.58 mmol, 979.72μL, 2 eq) was added at 20 °C under an atmosphere of N2. The mixture was allowed to stir at 20 °C for 16 hrs. The reaction was quenched by the addition of water (50 mL) at 20°C. The mixture was extracted with ethyl acetate (30 mL x 2). The organic solutions were combined, washed with brine (100mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 100/1 to 10/1). 2-bromo-4-fluoro-1-(1-((2-methoxyethoxy)methoxy)propan-2-yl)benzene (87.08% yield) was obtained as yellow oil. 1H NMR (400 MHz, CHLOROFORM-d) δ = 7.33 - 7.29 (m, 1H), 7.27 - 7.24 (m, 1H), 7.05 - 6.98 (m, 1H), 4.70 (s, 2H), 3.76 - 3.70 (m, 1H), 3.64 - 3.58 (m, 3H), 3.55 - 3.50 (m, 3H), 3.39 (s, 3H), 1.27 (d, J = 6.8 Hz, 3H) Step 4: 5-bromo-7-fluoro-4-methylisochromane
Figure imgf000163_0001
[000395] To a solution of 2-bromo-4-fluoro-1-(1-((2-methoxyethoxy)methoxy)propan-2- yl)benzene (5.9 g, 18.37 mmol, 1 eq) in DCM (20 mL) was added TiCl4 (2.13 g, 11.21 mmol, 3 eq) at 0 oC. The mixture was allowed to stir at 40 oC for 16 hrs. The reaction was quenched by the addition of saturated aqueous NaHCO3 (50mL). Ethyl acetate (50 mL) was added to the mixture. The organic solution was separated and the aqueous solution was extracted with ethyl acetate (50 mL x 3). The organic solutions were combined, washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 100/1 to 10/1). 5-Bromo-7-fluoro-4- methylisochromane (71.08% yield) was obtained as brown oil. 1H NMR (400 MHz, CDCl3) δ = 7.20 (dd, J = 1.9, 8.1 Hz, 1H), 6.69 (br d, J = 7.1 Hz, 1H), 4.82 - 4.76 (m, 1H), 4.70 - 4.63 (m, 1H), 3.97 (d, J = 11.2 Hz, 1H), 3.76 (dd, J = 2.3, 11.2 Hz, 1H), 2.97 - 2.87 (m, 1H), 1.35 (d, J = 6.8 Hz, 3H). Attorney Docket No. MORF-016WO1 Final Compounds General Example of Alkylation and Hydrolysis: Preparation of 2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((R)-1-
Figure imgf000164_0001
Step 1 (arbitrary stereochemistry): methyl 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((R)-1-methylisochroman-8-yl)acetate
Figure imgf000164_0002
[000396] To a solution of (1S,3S)-N-methyl-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentan-1-amine (200 mg, 659.11 μmol, 1 eq) in MeCN (4 mL) was added DIEA (255.55 mg, 1.98 mmol, 344.41 μL, 3 eq) and methyl 2-bromo-2-((R)-1- methylisochroman-8-yl)acetate (197.18 mg, 659.11 μmol, 1 eq) at 25°C under N2. The mixture was stirred at 80 °C for 12 hrs. LCMS showed (1S,3S)-N-methyl-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentan-1-amine was consumed completely and one main peak with desired mass was detected. The reaction mixture was quenched by addition H2O (20 mL) at 20 °C, and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 1/0 to 0/1). Methyl 2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((R)-1-methylisochroman-8- yl)acetate (78.52% yield) was obtained as a yellow oil. LCMS: [M+1] = 528.1. Attorney Docket No. MORF-016WO1 Step 1 (absolute stereochemistry): methyl 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((S)-1-methylisochroman-8-yl)acetate
Figure imgf000165_0001
[000397] To a solution of (1S,3S)-N-methyl-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentan-1-amine (200 mg, 659.11 μmol, 1 eq) in MeCN (4 mL) was added DIEA (255.55 mg, 1.98 mmol, 344.41 μL, 3 eq) and methyl 2-bromo-2-((R)-1- methylisochroman-8-yl)acetate (197.18 mg, 659.11 μmol, 1 eq) at 25°C under N2. The mixture was stirred at 80 °C for 12 hrs. LCMS showed (1S,3S)-N-methyl-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentan-1-amine was consumed completely and one main peak with desired mass was detected. The reaction mixture was quenched by addition H2O (20 mL) at 20 °C, and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/ethyl acetate = 1/0 to 0/1). Methyl 2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((S)-1-methylisochroman-8- yl)acetate (78.52% yield) was obtained as a yellow oil. LCMS: [M+1] = 528.1. Step 2 (arbitrary stereochemistry): 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((R)-1-methylisochroman-8-yl)acetic acid (Compounds 300 and 299)
Figure imgf000165_0002
299 [000398] To a solution of methyl 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((R)-1-methylisochroman-8-yl)acetate (250 mg, 479.21 μmol, 1 eq) in DCM (3 mL) in dioxane (4 mL) and H2O (4 mL) was added LiOH.H2O (60.32 mg, 1.44 mmol, 3 eq) at 25°C. The mixture was stirred at 35°C for 12 hrs. Attorney Docket No. MORF-016WO1 LCMS (Rt = 1.193 min, [M+1] = 508.3, 96.78%) showed methyl 2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((R)-1- methylisochroman-8-yl)acetate was consumed completely and one main peak with desired mass was detected. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [NH4HCO3-ACN]; gradient: 25%-55% B over 8.0 min). The residue was separated by SFC (column: REGIS (s, s) WHELK-O1 (250mm*30mm, 5um); mobile phase: [CO2-MeOH (0.1%NH3H2O)]; B%:50%, isocratic elution mode) to give two peaks. Step 2 (absolute stereochemistry): 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((S)-1-methylisochroman-8-yl)acetic acid (Compounds 300* and 299*)
Figure imgf000166_0001
[000399] To a solution of methyl 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((S)-1-methylisochroman-8-yl)acetate (250 mg, 479.21 μmol, 1 eq) in DCM (3 mL) in dioxane (4 mL) and H2O (4 mL) was added LiOH.H2O (60.32 mg, 1.44 mmol, 3 eq) at 25°C. The mixture was stirred at 35°C for 12 hrs. LCMS (Rt = 1.193 min, [M+1] = 508.3, 96.78%) showed methyl 2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((S)-1- methylisochroman-8-yl)acetate was consumed completely and one main peak with desired mass was detected. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [NH4HCO3-ACN]; gradient: 25%-55% B over 8.0 min). The residue was separated by SFC (column: REGIS (s, s) WHELK-O1 (250mm*30mm, 5um); mobile phase: [CO2-MeOH (0.1%NH3H2O)]; B%:50%, isocratic elution mode) to give two peaks. Attorney Docket No. MORF-016WO1 [000400] Compound 300 (peak 1), arbitrarily assigned as (S)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((R)-1- methylisochroman-8-yl)acetic acid, (81.45% yield) was obtained as a white solid. LCMS: [M+1] = 508.3. 1H NMR (400 MHz, CD3OD) δ = 7.62 (d, J = 7.4 Hz, 1H), 7.23 - 7.12 (m, 3H), 6.37 (d, J = 7.3 Hz, 1H), 5.27 (q, J = 6.5 Hz, 1H), 4.58 (s, 1H), 4.16 (ddd, J = 4.6, 9.0, 11.5 Hz, 1H), 3.96 (br s, 1H), 3.89 - 3.75 (m, 2H), 3.38 (td, J = 5.8, 8.9 Hz, 4H), 3.32 - 3.31 (m, 1H), 2.97 - 2.88 (m, 1H), 2.84 - 2.76 (m, 1H), 2.71 (t, J = 6.3 Hz, 2H), 2.59 - 2.49 (m, 2H), 2.47 (s, 3H), 2.10 (br dd, J = 7.3, 13.4 Hz, 1H), 2.01 - 1.90 (m, 2H), 1.90 - 1.81 (m, 4H), 1.71 (d, J = 6.7 Hz, 3H), 1.66 - 1.58 (m, 2H), 1.56 - 1.48 (m, 2H). [000401] Compound 299 (peak 2), arbitrarily assigned as (R)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((R)-1- methylisochroman-8-yl)acetic acid, (13.66% yield) was obtained as a white solid. LCMS: [M+1] = 508.3. 1H NMR (400 MHz, CD3OD) δ = 7.55 (d, J = 7.9 Hz, 1H), 7.26 - 7.19 (m, 2H), 7.12 (br d, J = 7.3 Hz, 1H), 6.40 (d, J = 7.3 Hz, 1H), 5.59 - 5.51 (m, 1H), 4.55 (s, 1H), 4.18 - 4.05 (m, 2H), 3.96 (br s, 1H), 3.84 - 3.79 (m, 1H), 3.43 (br t, J = 6.1 Hz, 2H), 3.38 (br d, J = 5.4 Hz, 2H), 2.97 - 2.90 (m, 1H), 2.83 - 2.76 (m, 1H), 2.72 (br t, J = 6.3 Hz, 2H), 2.68 - 2.60 (m, 1H), 2.56 - 2.51 (m, 1H), 2.40 (s, 3H), 2.20 - 2.12 (m, 1H), 2.09 - 1.99 (m, 2H), 1.91 - 1.81 (m, 4H), 1.78 - 1.64 (m, 4H), 1.60 (d, J = 6.6 Hz, 3H), 1.58 - 1.56 (m, 1H). [000402] When the General Method of Alkylation and Hydrolysis was carried out, the stereochemistry of the starting materials was arbitrarily assigned. Someone skilled in the art will recognize that if the stereochemistry of the starting materials are later determined to be different, the stereochemistry of intermediates and final products may also be determined to be different than those drawn in the scheme. In this example, further analysis led to the reassignment of 299 as (R)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)-2-((S)-1-methylisochroman-8-yl)acetic acid (Compound 299*), and of 300 as (S)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)-2-((S)-1-methylisochroman-8-yl)acetic acid (Compound 300*).
Figure imgf000167_0001
Attorney Docket No. MORF-016WO1 [000403] Additional Compounds were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents and using appropriate purification and separation conditions: Preparation of 2-(1-(tert-butyl)-6-fluoro-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol- 4-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl- )amino)acetic acid (Compounds 102 and 101)
Figure imgf000168_0001
[000404] Isomers of 2-(1-(tert-butyl)-6-fluoro-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)-amino)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by reversed-phase HPLC (column: Phenomenex Gemini - NX 80 * 40 mm * 3 um; mobile phase: [H2O (10 mM NH4HCO3) - ACN]; gradient: 25% - 45% B over 8.0 min) and separated by SFC (column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 um); mobile phase: [CO2 – IPA (0.1% NH3H2O)]; B%: 45%, isocratic elution mode. [000405] Compound 102 (peak 1), arbitrarily assigned (S)-2-(1-(tert-butyl)-6-fluoro-3- methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (87.5 mg, 148.96 umol, 32.09% yield, 99.03% purity) was obtained as a white solid. LCMS: [M+1] = 582.4. 1H NMR (400 MHz, METHANOL-d4) δ = 7.37 - 7.31 (m, 2H), 7.29 (dd, J = 2.4, 11.1 Hz, 1H), 6.46 (d, J = 7.4 Hz, 1H), 5.09 (s, 1H), 3.99 - 3.94 (m, 1H), 3.86 (br s, 1H), 3.78 (s, 3H), 3.48 - 3.41 (m, 4H), 2.75 (t, J = 6.2 Hz, 2H), 2.73 - 2.66 (m, 1H), 2.63 - 2.55 (m, 1H), 2.39 (s, 3H), 2.28 (br dd, J = 6.3, 12.7 Hz, 1H), 2.04 - 1.94 (m, 2H), 1.93 - 1.88 (m, 2H), 1.85 - 1.78 (m, 1H), 1.78 (s, 9H), 1.71 - 1.61 (m, 4H), 1.61 - 1.51 (m, 2H). [000406] Compound 101 (peak 2), arbitrarily assigned (R)-2-(1-(tert-butyl)-6-fluoro-3- methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (83.5 mg, 140.94 Attorney Docket No. MORF-016WO1 umol, 30.37% yieid, 98.18% purity) was obtained as a white solid. LCMS: [M+1] = 582.4. 1H NMR (400 MHz, METHANOL-d4) δ = 7.37 - 7.29 (m, 2H), 7.26 (dd, J = 2.5, 10.9 Hz, 1H), 6.43 (d, J = 7.3 Hz, 1H), 5.07 (s, 1H), 4.13 - 3.98 (m, 1H), 3.97 - 3.92 (m, 1H), 3.77 - 3.75 (m, 3H), 3.43 - 3.35 (m, 4H), 2.76 - 2.72 (m, 2H), 2.72 - 2.65 (m, 1H), 2.58 - 2.51 (m, 1H), 2.45 - 2.34 (m, 3H), 2.15 - 2.06 (m, 1H), 2.03 - 1.95 (m, 2H), 1.88 (dd, J = 5.2, 6.4 Hz, 2H), 1.82 - 1.78 (m, 1H), 1.77 (s, 9H), 1.76 - 1.63 (m, 4H), 1.61 - 1.55 (m, 2H). Preparation of 2-((R)-6-fluoro-1-methylisochroman-8-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (Compounds 152 and 151)
Figure imgf000169_0001
[000407] Isomers of 2-((R)-6-fluoro-1-methylisochroman-8-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC (column: Phenomenex luna C18100 * 40 mm * 5 um; mobile phase: [H2O (0.2% FA)-ACN]; gradient: 10%-45% B over 8.0 min) and separated by SFC (column: DAICEL CHIRALPAK AD (250 mm * 30 mm, 10 um); mobile phase: [CO2-EtOH (0.1% NH3H2O)]; B%: 30%, isocratic elution mode). [000408] Compound 152 (peak 1), arbitrarily assigned as (S)-2-((R)-6-fluoro-1- methylisochroman-8-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid (122.7 mg, 233.42 μmol, 68.17% yield, 100% purity) was obtained as a white solid. LCMS: [M+1] = 526.3. 1H NMR (400 MHz, METHANOL-d4) δ = 7.46 (dd, J = 2.7, 10.3 Hz, 1H), 7.26 (d, J = 7.4 Hz, 1H), 6.91 (dd, J = 2.4, 8.8 Hz, 1H), 6.41 (d, J = 7.4 Hz, 1H), 5.30 (q, J = 6.5 Hz, 1H), 4.54 (d, J = 1.0 Hz, 1H), 4.15 (ddd, J = 4.6, 9.2, 11.5 Hz, 1H), 3.96 (br s, 1H), 3.79 (ddd, J = 3.8, 6.2, 11.5 Hz, 2H), 3.45 - 3.36 (m, 4H), 3.00 - 2.89 (m, 1H), 2.85 - 2.76 (m, 1H), 2.73 (t, J = 6.3 Hz, 2H), 2.67 - 2.59 (m, 1H), 2.57 - 2.48 (m, 1H), 2.38 (s, 3H), 2.18 (br dd, J = 6.9, 13.3 Hz, 1H), 2.00 - 1.86 (m, 4H), 1.81 - 1.70 (m, 3H), 1.67 (d, J = 6.6 Hz, 4H), 1.65 - 1.48 (m, 3H). [000409] Compound 151 (peak 2), arbitrarily assigned as (R)-2-((R)-6-fluoro-1- methylisochroman-8-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- Attorney Docket No. MORF-016WO1 yl)butoxy)cyclopentyl)amino)acetic acid (25.2 mg, 46.19 μmol, 13.49% yield, 96.342% purity) was obtained as a white solid. LCMS: [M+1] = 526.3. 1H NMR (400 MHz, METHANOL-d4) δ = 7.41 (dd, J = 2.6, 10.5 Hz, 1H), 7.34 (d, J = 7.3 Hz, 1H), 6.84 (dd, J = 2.4, 8.8 Hz, 1H), 6.44 (d, J = 7.4 Hz, 1H), 5.55 (q, J = 6.5 Hz, 1H), 4.48 (s, 1H), 4.16 - 4.02 (m, 2H), 3.93 (br s, 1H), 3.81 (ddd, J = 3.8, 6.3, 11.4 Hz, 1H), 3.49 - 3.43 (m, 2H), 3.40 - 3.36 (m, 2H), 2.99 - 2.90 (m, 1H), 2.82 - 2.71 (m, 4H), 2.59 - 2.52 (m, 1H), 2.28 (s, 3H), 2.15 (br dd, J = 6.1, 12.7 Hz, 1H), 2.04 - 1.93 (m, 2H), 1.91 - 1.86 (m, 2H), 1.80 - 1.65 (m, 5H), 1.60 (d, J = 6.5 Hz, 5H). [000410] When the General Method of Alkylation and Hydrolysis was carried out, the stereochemistry of the starting materials was arbitrarily assigned. Someone skilled in the art will recognize that if the stereochemistry of the starting materials are later determined to be different, the stereochemistry of intermediates and final products may also be determined to be different than those drawn in the scheme. In this example, further analysis led to the reassignment of 151 (R)-2-((S)-6-fluoro-1-methylisochroman-8-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (Compound 151*), and of 152 as (S)-2-((S)-6-fluoro-1-methylisochroman-8-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (Compound 152*).
Figure imgf000170_0001
Preparation of 2-(1-(1-methoxy-2-methylpropan-2-yl)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid (Compounds 292 and 291)
Figure imgf000170_0002
[000411] Isomers of 2-(1-(1-methoxy-2-methylpropan-2-yl)-3-methyl-2-oxo-2,3-dihydro- 1H-benzo[d]imidazol-4-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- Attorney Docket No. MORF-016WO1 yl)butoxy)cyclopentyl)amino)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [NH4HCO3- ACN]; gradient: 25%-65% B over 8.0 min)and separated by SFC (column: REGIS (s, s) WHELK-O1 (250 mm * 30 mm, 5 um); mobile phase: [CO2-EtOH (0.1% NH3H2O)]; B%:50%, isocratic elution mode). [000412] Compound 292 (peak 1), arbitrarily assigned (S)-2-(1-(1-methoxy-2- methylpropan-2-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-2- (methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid (58.92% yield) was obtained as a white solid. LCMS: [M+1] = 594.2. 1H NMR (400 MHz, METHANOL-d4) δ = 7.51 (d, J = 8.3 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 7.4 Hz, 1H), 7.03 (t, J = 8.1 Hz, 1H), 6.41 (d, J = 7.3 Hz, 1H), 5.16 (s, 1H), 3.96 (br s, 1H), 3.93 - 3.82 (m, 3H), 3.80 (s, 3H), 3.40 (s, 4H), 3.29 (s, 3H), 2.73 (t, J = 6.3 Hz, 2H), 2.63 - 2.52 (m, 2H), 2.50 (s, 3H), 2.21 (br dd, J = 6.8, 12.9 Hz, 1H), 2.01 - 1.93 (m, 2H), 1.92 - 1.82 (m, 3H), 1.77 (d, J = 3.6 Hz, 7H), 1.73 - 1.63 (m, 3H), 1.58 - 1.50 (m, 2H). [000413] Compound 291 (peak 2), arbitrarily assigned (R)-2-(1-(1-methoxy-2- methylpropan-2-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-2- (methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid (53.78% yield) was obtained as a white solid. LCMS: [M+1] = 594.2. 1H NMR NMR (400 MHz, METHANOL-d4) δ = 7.52 (d, J = 7.6 Hz, 1H), 7.42 (d, J = 7.4 Hz, 1H), 7.23 (d, J = 7.4 Hz, 1H), 7.06 (t, J = 8.1 Hz, 1H), 6.38 (d, J = 7.3 Hz, 1H), 5.14 (s, 1H), 4.04 - 3.97 (m, 1H), 3.94 (br d, J = 2.0 Hz, 1H), 3.90 - 3.83 (m, 2H), 3.78 (s, 3H), 3.40 - 3.32 (m, 4H), 3.29 (s, 3H), 2.71 (t, J = 6.2 Hz, 2H), 2.61 - 2.51 (m, 2H), 2.48 (s, 3H), 2.07 - 1.97 (m, 3H), 1.90 - 1.81 (m, 4H), 1.77 (d, J = 3.5 Hz, 6H), 1.73 - 1.61 (m, 3H), 1.56 - 1.49 (m, 2H). Attorney Docket No. MORF-016WO1 Preparation of 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)-2-(4-methyl-5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'- pyran]-5-yl)acetic acid (Compounds 112 and 111)
Figure imgf000172_0001
[000414] Isomers of 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)-2-((1S,4S)-4-methyl-5',6'-dihydro-2'H,4'H-spiro[isochromane- 1,3'-pyran]-5-yl)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents and purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150*40mm*10um; mobile phase: [H2O (10mM NH4HCO3)-ACN]; gradient: 10%-50% B over 8.0 min). [000415] Compound 112 (peak 1), arbitrarily assigned as (S)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((1S,4S)-4-methyl- 5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran]-5-yl)acetic acid (189.6 mg, 325.38 μmol, 45.85% yield, 99.15% purity) was obtained as a white solid. LCMS: [M+1] = 578.4. 1H NMR (400 MHz, METHANOL-d4) δ = 7.66 (dd, J = 1.5, 7.4 Hz, 1H), 7.31-7.24 (m, 2H), 7.19 (d, J = 7.4 Hz, 1H), 6.38 (d, J = 7.3 Hz, 1H), 4.76 (s, 1H), 4.02-3.90 (m, 5H), 3.80 (d, J = 11.4 Hz, 1H), 3.63-3.55 (m, 1H), 3.47 (d, J = 12.4 Hz, 1H), 3.39 (dt, J = 3.2, 5.7 Hz, 4H), 3.04-2.96 (m, 1H), 2.71 (t, J = 6.3 Hz, 2H), 2.53 (q, J = 7.3 Hz, 2H), 2.49-2.42 (m, 3H), 2.24-2.09 (m, 3H), 2.05-1.92 (m, 2H), 1.92-1.83 (m, 5H), 1.73-1.68 (m, 1H), 1.67-1.59 (m, 2H), 1.56-1.50 (m, 6H). [000416] Compound 111 (peak 2), arbitrarily assigned as (R)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((1S,4S)-4-methyl- 5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran]-5-yl)acetic acid (40.1 mg, 67.52 μmol, 9.51% yield, 97.28% purity), was obtained as a white solid. LCMS: [M+1] = 578.4. 1H NMR (400 MHz, METHANOL-d4) δ = 7.59 (dd, J = 3.3, 5.9 Hz, 1H), 7.28-7.25 (m, 2H), 7.22 (d, J = 7.4 Hz, 1H), 6.39 (d, J = 7.4 Hz, 1H), 4.72 (s, 1H), 4.16-4.09 (m, 1H), 3.99-3.93 (m, 4H), 3.78 (d, J = 11.3 Hz, 1H), 3.62-3.56 (m, 1H), 3.48 (d, J = 12.4 Hz, 1H), 3.44-3.40 (m, 2H), 3.37 (s, 2H), 2.71 (t, J = 6.3 Hz, 2H), 2.64-2.58 (m, 1H), 2.56-2.51 (m, 1H), 2.41 (br s, 3H), 2.20-2.14 Attorney Docket No. MORF-016WO1 (m, 2H), 2.13-2.05 (m, 2H), 2.04-1.98 (m, 1H), 1.93-1.84 (m, 5H), 1.75-1.65 (m, 3H), 1.60- 1.49 (m, 4H), 1.41 (d, J = 6.9 Hz, 3H). [000417] When the General Method of Alkylation and Hydrolysis was carried out, the stereochemistry of the starting materials was arbitrarily assigned. Someone skilled in the art will recognize that if the stereochemistry of the starting materials are later determined to be different, the stereochemistry of intermediates and final products may also be determined to be different than those drawn in the scheme. In this example, further analysis led to the reassignment of 111 as (R)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)-2-((1R,4S)-4-methyl-5',6'-dihydro-2'H,4'H-spiro[isochromane- 1,3'-pyran]-5-yl)acetic acid (Compound 111*), and of 112 as (S)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((1R,4S)-4-methyl- 5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran]-5-yl)acetic acid (Compound 112*).
Figure imgf000173_0001
Preparation of 2-(6'-methoxy-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'- indolin]-4'-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-
Figure imgf000173_0002
[000418] Isomers of 2-(6'-methoxy-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane- 1,3'-indolin]-4'-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [H2O (10 mM Attorney Docket No. MORF-016WO1 NH4HCO3)-ACN]; gradient: 25%-55% B over 8.0 min) and separated by SFC (column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 um); mobile phase: [CO2-IPA (0.1% NH3H2O)]; B%:50%, isocratic elution mode). [000419] Compound 60 (peak 1), arbitrarily assigned as (S)-2-(6'-methoxy-2'-oxo-1'- (tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (42.63% yield) was obtained as a white solid. LCMS: [M+1] = 633.4. 1H NMR (400 MHz, METHANOL-d4) δ = 7.27 (d, J = 7.3 Hz, 1H), 7.08 (d, J = 2.1 Hz, 1H), 6.83 (d, J = 2.3 Hz, 1H), 6.41 (d, J = 7.4 Hz, 1H), 4.39 (tt, J = 4.1, 12.1 Hz, 1H), 4.06 (dd, J = 4.3, 11.4 Hz, 2H), 4.00 - 3.89 (m, 3H), 3.84 (s, 3H), 3.59 - 3.51 (m, 2H), 3.40 (q, J = 6.3 Hz, 4H), 2.72 (t, J = 6.2 Hz, 2H), 2.65 - 2.47 (m, 5H), 2.36 (s, 3H), 2.11 (br dd, J = 6.7, 12.9 Hz, 1H), 2.05 - 1.86 (m, 5H), 1.78 - 1.62 (m, 7H), 1.59 - 1.51 (m, 4H). [000420] Compound 59 (peak 2), arbitrarily assigned as (R)-2-(6'-methoxy-2'-oxo-1'- (tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (39.30% yield) was obtained as a white solid. LCMS: [M+1] = 633.4. 1H NMR (400 MHz, METHANOL-d4) δ = 7.27 (d, J = 7.4 Hz, 1H), 7.03 (d, J = 2.1 Hz, 1H), 6.83 (d, J = 2.1 Hz, 1H), 6.40 (d, J = 7.4 Hz, 1H), 4.39 (tt, J = 4.2, 12.1 Hz, 1H), 4.09 - 4.01 (m, 3H), 3.94 (br s, 1H), 3.90 (s, 1H), 3.84 (s, 3H), 3.56 (br t, J = 11.6 Hz, 2H), 3.42 - 3.35 (m, 4H), 2.72 (t, J = 6.3 Hz, 2H), 2.66 - 2.44 (m, 5H), 2.35 (s, 3H), 2.10 (br dd, J = 6.3, 12.7 Hz, 1H), 2.02 - 1.92 (m, 3H), 1.87 (br dd, J = 5.1, 5.9 Hz, 2H), 1.82 - 1.68 (m, 4H), 1.67 - 1.55 (m, 7H). Preparation of 2-((S)-6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]- 8-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid (Compounds 96 and 95)
Figure imgf000174_0001
[000421] Isomers of 2-((S)-6-fluoro-1-methyl-2',3',5',6'-tetrahydrospiro[isochromane-4,4'- pyran]-8-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)-amino)acetic acid were prepared according to the General Example of Attorney Docket No. MORF-016WO1 Alkylation and Hydrolysis, substituting the appropriate reagents and purified by prep-HPLC (TFA condition; column: 3_Phenomenex Luna C1875*30mm*3um;mobile phase: [H2O(0.1% TFA)-ACN];gradient:10%-30% B over 10.0 min). [000422] Compound 96 (peak 1), arbitrarily assigned as (S)-2-((S)-6-fluoro-1-methyl- 2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]-8-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (44.7% yield) was obtained as a white solid. LCMS: [M+1] = 596.3. 1H 1H NMR (400 MHz, MeOD-d4) δ = 7.57 (d, J = 7.3 Hz, 1H), 7.44 (d, J = 9.8 Hz, 2H), 6.58 (d, J = 7.4 Hz, 1H), 5.23 (q, J = 6.5 Hz, 1H), 4.95 - 4.89 (m, 1H), 4.18 - 4.13 (m, 1H), 4.08 - 4.04 (m, 1H), 4.02 (br s, 1H), 3.90 - 3.81 (m, 2H), 3.79 - 3.70 (m, 1H), 3.62 (br t, J = 11.5 Hz, 1H), 3.51 - 3.47 (m, 2H), 3.47 - 3.36 (m, 2H), 3.31 (td, J = 1.6, 3.2 Hz, 3H), 2.81 (t, J = 6.1 Hz, 2H), 2.79 - 2.61 (m, 3H), 2.58 (br d, J = 1.6 Hz, 2H), 2.31 - 2.31 (m, 1H), 2.31 - 2.22 (m, 1H), 2.21 - 1.85 (m, 8H), 1.81 (br s, 1H), 1.68 - 1.51 (m, 4H) [000423] Compound 95 (peak 2), arbitrarily assigned as (R)-2-((S)-6-fluoro-1-methyl- 2',3',5',6'-tetrahydrospiro[isochromane-4,4'-pyran]-8-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (9.1% yield) was obtained as a white solid. LCMS: [M+1] = 596.3. 1H NMR (400 MHz, MeOD-d4) δ = 7.53 (d, J = 7.4 Hz, 1H), 7.41 (dd, J = 2.5, 10.3 Hz, 1H), 7.32 (dd, J = 2.5, 9.4 Hz, 1H), 6.57 (d, J = 7.3 Hz, 1H), 5.47 (d, J = 6.6 Hz, 1H), 4.83 (s, 1H), 4.59 - 4.40 (m, 1H), 4.25 (d, J = 12.3 Hz, 1H), 4.04 (br t, J = 4.5 Hz, 1H), 3.99 (d, J = 12.3 Hz, 1H), 3.90 - 3.84 (m, 2H), 3.83 - 3.74 (m, 1H), 3.69 - 3.60 (m, 1H), 3.59 - 3.54 (m, 1H), 3.53 - 3.47 (m, 1H), 3.41 (br dd, J = 3.9, 6.1 Hz, 2H), 2.91 - 2.81 (m, 1H), 2.78 (br t, J = 6.1 Hz, 2H), 2.69 - 2.58 (m, 1H), 2.58 - 2.47 (m, 3H), 2.40 (br dd, J = 5.7, 11.9 Hz, 1H), 2.35 - 2.26 (m, 1H), 2.35 - 2.16 (m, 2H), 1.85 - 1.85 (m, 1H), 1.93 - 1.84 (m, 1H), 1.84 - 1.83 (m, 1H), 1.92 - 1.83 (m, 3H), 1.82 (br s, 1H), 1.80 (br s, 1H), 1.70 (br s, 1H), 1.58 (br d, J = 13.8 Hz, 1H). Attorney Docket No. MORF-016WO1 Preparation of 2-(3,6-dimethyl-1-(1-methylcyclopropyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid (Compounds 274 and 273)
Figure imgf000176_0001
[000424] Isomers of 2-(3,6-dimethyl-1-(1-methylcyclopropyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-4-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC (column: Phenomenex luna C18100*40mm*3 um;mobile phase: [H2O(0.1%TFA)- ACN];gradient:1%-30% B over 8.0 min) and separated by SFC (column: REGIS (s,s) WHELK-O1 (250 mm*30 mm, 5 um);mobile phase: [CO2-IPA(0.1% NH3H2O)];B%:50%, isocratic elution mode). [000425] Compound 274 (peak 1), arbitrarily assigned as (S)-2-(3,6-dimethyl-1-(1- methylcyclopropyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (46.20% yield) was obtained as a white solid. LCMS: [M+1] = 576.3. 1H NMR (400 MHz, METHANOL-d4) δ = 7.29 (s, 1H), 7.25 (d, J = 7.3 Hz, 1H), 7.15 (s, 1H), 6.40 (d, J = 7.3 Hz, 1H), 5.06 (s, 1H), 4.04 - 3.92 (m, 2H), 3.76 (s, 3H), 3.40 (t, J = 5.9 Hz, 4H), 2.73 (t, J = 6.2 Hz, 2H), 2.64 - 2.54 (m, 2H), 2.49 (s, 3H), 2.40 (s, 3H), 2.20 (br dd, J = 7.2, 13.1 Hz, 1H), 1.97 (dt, J = 5.7, 11.9 Hz, 2H), 1.91 - 1.86 (m, 2H), 1.84 - 1.74 (m, 2H), 1.72 - 1.62 (m, 3H), 1.58 - 1.52 (m, 2H), 1.45 (s, 3H), 1.12 - 1.05 (m, 2H), 1.04 - 0.98 (m, 2H). [000426] Compound 273 (peak 2), arbitrarily assigned as (R)-2-(3,6-dimethyl-1-(1- methylcyclopropyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (53.10% yield) was obtained as a white solid. LCMS: [M+1] = 576.2. 1H NMR (400 MHz, METHANOL-d4) δ = 7.32 - 7.22 (m, 2H), 7.17 (d, J = 0.6 Hz, 1H), 6.41 (d, J = 7.3 Hz, 1H), 5.06 (s, 1H), 4.20 - 4.04 (m, 1H), 3.96 (br s, 1H), 3.74 (s, 3H), 3.45 - 3.34 (m, 4H), 2.72 (t, J = 6.2 Hz, 2H), 2.68 - Attorney Docket No. MORF-016WO1 2.61 (m, 1H), 2.56 - 2.47 (m, 3H), 2.41 (s, 3H), 2.12 - 1.95 (m, 3H), 1.91 - 1.80 (m, 4H), 1.79 - 1.69 (m, 2H), 1.69 - 1.47 (m, 4H), 1.45 (s, 3H), 1.12 - 1.06 (m, 2H), 1.05 - 0.99 (m, 2H). Preparation of 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)-2-(6'-methyl-1'-((2R,4R)-2-methyltetrahydro-2H-pyran-4-yl)-
Figure imgf000177_0001
[000427] Isomers of 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)-2-(6'-methyl-1'-((2R,4R)-2-methyltetrahydro-2H-pyran-4-yl)-2'- oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents and purified by prep-HPLC (column: Phenomenex Luna C1875*30 mm*3 um; mobile phase: [H2O (0.1%TFA)-ACN]; gradient: 20%-40% B over 8.0 min). [000428] Compound 70 (peak 1), arbitrarily assigned as (S)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-(6'-methyl-1'- ((2R,4R)-2-methyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'- yl)acetic acid (42.39% yield), was obtained as a white solid. LCMS: [M+1] = 631.3. 1H NMR (400 MHz, METHANOL-d4) δ = 7.56 (d, J = 7.3 Hz, 1H), 7.23 (d, J = 4.5 Hz, 2H), 6.58 (d, J = 7.3 Hz, 1H), 4.47 (tt, J = 4.0, 12.2 Hz, 1H), 4.28 - 4.16 (m, 1H), 4.16 - 4.00 (m, 3H), 3.66 - 3.57 (m, 2H), 3.56 - 3.32 (m, 5H), 2.80 (br t, J = 6.2 Hz, 2H), 2.76 - 2.64 (m, 2H), 2.53 (dt, J = 4.8, 12.5 Hz, 3H), 2.44 (s, 3H), 2.38 - 2.31 (m, 1H), 2.27 - 2.02 (m, 4H), 1.99 - 1.89 (m, 5H), 1.84 - 1.70 (m, 5H), 1.69 - 1.56 (m, 4H), 1.24 (d, J = 6.1 Hz, 3H). [000429] Compound 69 (peak 2), arbitrarily assigned as (R)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-(6'-methyl-1'- ((2R,4R)-2-methyltetrahydro-2H-pyran-4-yl)-2'-oxospiro[cyclopropane-1,3'-indolin]-4'- yl)acetic acid (28.91% yield), was obtained as a white solid. LCMS: [M+1] = 631.3. 1H NMR (400 MHz, METHANOL-d4) δ = 7.53 (d, J = 7.3 Hz, 1H), 7.22 (s, 1H), 7.15 (s, 1H), 6.57 (d, J = 7.3 Hz, 1H), 4.56 - 4.34 (m, 2H), 4.22 - 4.12 (m, 1H), 4.11 - 4.02 (m, 2H), 3.67 - 3.59 (m, Attorney Docket No. MORF-016WO1 2H), 3.57 - 3.46 (m, 2H), 3.44 - 3.38 (m, 2H), 2.79 (br t, J = 6.2 Hz, 3H), 2.70 - 2.56 (m, 2H), 2.55 - 2.47 (m, 3H), 2.44 (s, 3H), 2.37 - 2.26 (m, 2H), 2.22 (br d, J = 11.3 Hz, 1H), 2.16 - 2.04 (m, 2H), 1.96 - 1.80 (m, 7H), 1.77 - 1.63 (m, 7H), 1.24 (d, J = 6.1 Hz, 3H). Preparation of 2-(1-(tert-butyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-2- (methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid (Compounds 344 and 343)
Figure imgf000178_0001
[000430] Isomers of 2-(1-(tert-butyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4- yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC (column: Phenomenex Luna C1875 * 30 mm * 3 um; mobile phase: [TFA-ACN]; B%: 5%- 35%, 8.00 min) and separated by SFC (column: DAICEL CHIRALPAK IG (250mm*30mm,10um);mobile phase: [0.1%NH3H2O ETOH];B%: 50%-50%,15min). [000431] Compound 344 (peak 1), arbitrarily assigned as (S)-2-(1-(tert-butyl)-3-methyl-2- oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (0.056 g, 99.34 μmol, 16.20%)), was obtained as a white solid. LCMS: [M+1] = 564.4. 1H NMR (400 MHz, METHANOL-d4) δ = 7.54 (br dd, J = 2.2, 8.2 Hz, 1H), 7.43 (br dd, J = 2.1, 7.9 Hz, 1H), 7.26 (br d, J = 7.1 Hz, 1H), 7.04 (dt, J = 2.8, 8.1 Hz, 1H), 6.41 (br dd, J = 2.7, 7.3 Hz, 1H), 5.18 - 5.13 (m, 1H), 3.96 (br s, 2H), 3.82 - 3.76 (m, 3H), 3.40 (br d, J = 2.6 Hz, 3H), 2.73 (br s, 2H), 2.65 - 2.52 (m, 3H), 2.50 (br d, J = 2.5 Hz, 3H), 2.24 - 2.18 (m, 1H), 1.89 (br s, 6H), 1.80 - 1.75 (m, 9H), 1.72 - 1.63 (m, 3H), 1.54 (br s, 2H). [000432] Compound 343 (peak 2), arbitrarily assigned as (R)-2-(1-(tert-butyl)-3-methyl-2- oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (0.060 g, 10.64 μmol, 17.36%)), was obtained as a white solid. LCMS: [M+1] = 564.4. 1H NMR (400 MHz, METHANOL-d4) δ = 7.56 (d, J = 7.9 Hz, 1H), 7.42 (d, J = 7.9 Hz, 1H), 7.23 (d, J = 7.3 Hz, 1H), 7.08 (t, J = 8.1 Hz, Attorney Docket No. MORF-016WO1 1H), 6.38 (d, J = 7.3 Hz, 1H), 5.14 (s, 1H), 4.03 - 3.93 (m, 2H), 3.77 (s, 3H), 3.39 - 3.35 (m, 3H), 2.72 (t, J = 6.3 Hz, 2H), 2.67 - 2.52 (m, 3H), 2.49 (br s, 3H), 2.06 - 1.94 (m, 4H), 1.89 - 1.85 (m, 3H), 1.78 (s, 9H), 1.72 - 1.62 (m, 3H), 1.56 - 1.50 (m, 2H). Preparation of Isomers of 2-((3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-(1'-((R)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2'-
Figure imgf000179_0001
[000433] Isomers of 2-((3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-(1'-((R)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2'- oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep- HPLC (column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [H2O (10mM NH4HCO3)-ACN]; gradient: 20%-70% B over 8.0 min). The residue was further separated by SFC (column: DAICEL CHIRALPAK) to afford pure 353 (51.4 mg) and mixture of 354 & 63 & 64 (200 mg). The mixture of 354 & 63 & 64 (200 mg) was further separated by SFC (column: DAICEL CHIRALCEL OX (250 mm * 30 mm, 10 um); mobile phase: [CO2- EtOH: CAN = 1:1 (0.1% NH3H2O)]; B%:55%, isocratic elution mode) to afford pure 354 (34.25 mg crude) and a mixture of 63 & 64 (120 mg). The isolated 354 was further purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [H2O (10mM NH4HCO3)-ACN]; gradient: 25%-75% B over 8.0 min) to afford 354 (25.2 mg). The mixture of 63 & 64 (120 mg) was further separated by SFC (column: DAICEL CHIRALCEL OX (250 mm * 30 mm, 10 um); mobile phase: [CO2-EtOH: CAN = 1:1 (0.1% NH3H2O)]; B%:55%, isocratic elution mode) to afford 63 (33.1 mg) & 64. 64 was further purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150 * 40 mm * 10um; Attorney Docket No. MORF-016WO1 mobile phase: [H2O (10mM NH4HCO3)-ACN]; gradient: 25%-75% B over 8.0 min) to afford 64 (24.1 mg). [000434] Compound 353 (peak 1, 450 mg, 682.99 μmol, 11.28%), arbitrarily assigned as (R)-2-(((1R,4S)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-(1'-((R)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2'- oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 659.4, 98.79%; SFC Rt = 1.317, 92.58%; 1H NMR (400 MHz, METHANOL-d4) δ = 7.41 (d, J = 8.0 Hz, 1H), 7.31 (t, J = 7.9 Hz, 1H), 7.24 (d, J = 7.4 Hz, 2H), 6.40 (d, J = 7.3 Hz, 1H), 4.64 (ddd, J = 4.4, 8.3, 12.6 Hz, 1H), 4.17 - 4.06 (m, 1H), 3.88 - 3.83 (m, 3H), 3.43 - 3.36 (m, 4H), 2.72 (t, J = 6.3 Hz, 2H), 2.59 (s, 1H), 2.58 - 2.50 (m, 3H), 2.41 - 2.34 (m, 4H), 2.20 - 2.13 (m, 1H), 2.07 - 2.02 (m, 1H), 1.98 (br s, 1H), 1.90 - 1.85 (m, 2H), 1.76 - 1.56 (m, 11H), 1.37 (s, 3H), 1.28 (s, 3H), 1.09 (s, 3H), 0.94 (s, 3H). [000435] Compound 354 (peak 2, 25.3 mg, 36.58 μmol, 5.47%), arbitrarily assigned as (S)- 2-(((1R,4S)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-(1'-((R)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2'- oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 659.4, 97.69%; SFC Rt = 4.937, 98.42%; 1H NMR (400 MHz, CD3OD) δ = 7.42 - 7.37 (m, 1H), 7.35 - 7.26 (m, 3H), 6.43 (d, J = 7.3 Hz, 1H), 4.70 - 4.62 (m, 1H), 4.28 - 4.16 (m, 1H), 3.91 (s, 1H), 3.86 (br d, J = 8.0 Hz, 2H), 3.51 - 3.35 (m, 6H), 2.75 - 2.65 (m, 3H), 2.58 - 2.50 (m, 3H), 2.42 - 2.38 (m, 3H), 2.20 - 2.13 (m, 1H), 2.05 - 1.98 (m, 2H), 1.90 - 1.85 (m, 2H), 1.80 - 1.73 (m, 2H), 1.70 - 1.59 (m, 8H), 1.37 (s, 3H), 1.28 (s, 3H), 1.10 (s, 3H), 0.97 (s, 3H). [000436] Compound 64 (peak 3, 24.1 mg, 36.58 μmol, 5.26%), arbitrarily assigned (S)-2- (((1S,4R)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-(1'-((R)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2'- oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 659.4, 98.19%; SFC Rt = 1.653, 100%; 1 H NMR (400 MHz, CD3OD) δ = 7.42 (dd, J = 1.1, 7.7 Hz, 1H), 7.31 - 7.23 (m, 3H), 6.41 (d, J = 7.3 Hz, 1H), 4.69 - 4.60 (m, 1H), 4.05 - 3.95 (m, 2H), 3.89 - 3.83 (m, 2H), 3.52 - 3.47 (m, 1H), 3.43 - 3.37 (m, 4H), 2.72 (t, J = 6.2 Hz, 2H), 2.64 - 2.50 (m, 4H), 2.41 (s, 3H), 2.38 (s, 1H), 2.17 - 2.07 (m, 2H), 2.05 - 1.99 (m, 1H), 1.91 - 1.85 (m, 2H), 1.75 - 1.55 (m, 10H), 1.37 (s, 3H), 1.28 (s, 3H), 1.08 (s, 3H), 0.93 (s, 3H). Attorney Docket No. MORF-016WO1 [000437] Compound 63 (peak 4, 33.1 mg, 48.83 μmol, 7.15%), arbitrarily assigned as (R)- 2-(((1S,4R)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-(1'-((R)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2'- oxospiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 659.4, 97.19%; SFC Rt = 2.288, 97.72%; 1 H NMR (400 MHz, CD3OD) δ = 7.42 (d, J = 7.4 Hz, 1H), 7.32 - 7.24 (m, 3H), 6.42 (d, J = 7.3 Hz, 1H), 4.64 (ddd, J = 4.1, 8.5, 12.5 Hz, 1H), 4.07 - 3.98 (m, 1H), 3.96 (s, 1H), 3.88 - 3.84 (m, 2H), 3.49 (br d, J = 5.9 Hz, 1H), 3.43 - 3.37 (m, 4H), 2.72 (t, J = 6.3 Hz, 2H), 2.64 - 2.52 (m, 4H), 2.41 (s, 3H), 2.39 - 2.33 (m, 1H), 2.16 - 2.07 (m, 2H), 2.05 - 1.99 (m, 1H), 1.91 - 1.85 (m, 2H), 1.73 - 1.54 (m, 10H), 1.37 (s, 3H), 1.28 (s, 3H), 1.08 (s, 3H), 0.93 (s, 3H). Preparation of 2-(1-(tert-butyl)-3,7-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)- 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-
Figure imgf000181_0001
[000438] Isomers of 2-(1-(tert-butyl)-3,7-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol- 4-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC (column: Waters Xbridge BEH C 18100 * 30 mm * 10 um; mobile phase: [H2O (10 mM NH4HCO3)-ACN]; gradient: 20%-50% B over 8.0 min). The racemate was further separated by SFC (column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 um); mobile phase: [CO2- EtOH (0.1% NH3H2O)]; B%:50%, isocratic elution mode). [000439] Compound 357 (peak 1), arbitrarily assigned as (S)-2-(1-(tert-butyl)-3,7- dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid, was obtained as a white solid (20.49% yield). LCMS [M+1] = 578.2, 99%; SFC Rt = 0.833, 100.00%; 1H NMR (400 MHz, CD3OD) δ = 7.36 (d, J = 8.4 Hz, 1H), 7.24 (d, J = 7.3 Hz, 1H), 6.92 (d, J = 8.4 Hz, 1H), 6.40 (d, J = 7.4 Hz, 1H), 5.15 (s, 1H), 4.04 - 3.83 (m, 2H), 3.75 (s, 3H), 3.42 - 3.37 (m, 4H), 2.73 (t, J = 6.3 Hz, 2H), 2.64 (s, 3H), 2.55 (br dd, J = 6.6, 8.4 Hz, 2H), 2.51 (s, 3H), 2.19 Attorney Docket No. MORF-016WO1 (br dd, J = 6.8, 13.2 Hz, 1H), 2.00 - 1.80 (m, 5H), 1.74 (s, 9H), 1.73 - 1.57 (m, 4H), 1.57 - 1.48 (m, 2H). [000440] Compound 358 (peak 2), arbitrarily assigned as (R)-2-(1-(tert-butyl)-3,7-dimethyl- 2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid, was obtained as a white solid (49 mg, 83.11 umol, 20.91%). LCMS [M+1] = 578.2, 98%; SFC Rt = 1.287, 100.00%; 1H NMR (400 MHz, CD3OD) δ = 7.35 (d, J = 8.4 Hz, 1H), 7.21 (d, J = 7.4 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.37 (d, J = 7.3 Hz, 1H), 5.13 (s, 1H), 3.95 (br s, 2H), 3.74 (s, 3H), 3.41 - 3.33 (m, 4H), 2.71 (t, J = 6.2 Hz, 2H), 2.64 (s, 3H), 2.62 - 2.41 (m, 5H), 2.07 - 1.92 (m, 3H), 1.91 - 1.81 (m, 4H), 1.74 (s, 9H), 1.71 - 1.55 (m, 3H), 1.55 - 1.45 (m, 2H). Preparation of 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4-
Figure imgf000182_0001
[000441] Isomers of 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)-2-(2-(2-oxopyrrolidin-1-yl)-3-((tetrahydro-2H-pyran-4- yl)oxy)phenyl)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150*40mm*10um; mobile phase: [H2O (10mM NH4HCO3)-ACN]; gradient:20%-50% B over 8.0 min ) to give two peaks. Then peak 2 was purified by prep- HPLC (column: Phenomenex Luna C1875*30mm*3um; mobile phase: [H2O (0.1%TFA)- ACN]; gradient: 15%-35% B over 8.0 min). [000442] Compound 359 (peak 1), arbitrarily assigned as (S)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-(2-(2-oxopyrrolidin-1- yl)-3-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)acetic acid, was obtained as a white solid (60.4 mg, 94.38 μmol, 39.94%). LCMS [M+1] = 621.4, 97.20%; SFC Rt = 1.246 min, 95.40%; 1H NMR (400 MHz, CD3OD) δ = 7.42 - 7.36 (m, 1H), 7.32 - 7.27 (m, 1H), 7.18 - 7.13 (m, 2H), Attorney Docket No. MORF-016WO1 6.37 (d, J = 7.4 Hz, 1H), 4.67 (tt, J = 3.6, 7.2 Hz, 1H), 4.52 (d, J = 5.4 Hz, 1H), 3.97 (br d, J = 3.2 Hz, 2H), 3.95 - 3.84 (m, 3H), 3.84 - 3.76 (m, 1H), 3.68 - 3.56 (m, 2H), 3.42 - 3.36 (m, 4H), 2.70 (t, J = 6.3 Hz, 2H), 2.58 (td, J = 4.1, 8.4 Hz, 2H), 2.55 - 2.50 (m, 2H), 2.47 (s, 3H), 2.41 - 2.32 (m, 1H), 2.31 - 2.25 (m, 1H), 2.16 (br s, 1H), 2.12 - 2.04 (m, 2H), 2.02 - 1.94 (m, 2H), 1.92 - 1.82 (m, 3H), 1.80 - 1.70 (m, 4H), 1.69 - 1.63 (m, 2H), 1.58 - 1.51 (m, 2H). [000443] Compound 360 (peak 2), arbitrarily assigned as (R)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-(2-(2-oxopyrrolidin-1- yl)-3-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)acetic acid, was obtained as a white solid (5.5 mg, 8.68 μmol, 3.67%). LCMS [M+1] = 621.4, 97.89%; SFC Rt = 1.242 min, 98.43%; 1H NMR (400 MHz, CD3OD) δ = 7.64 (d, J = 7.9 Hz, 1H), 7.59 (d, J = 7.4 Hz, 1H), 7.53 (d, J = 7.7 Hz, 1H), 7.45 - 7.37 (m, 1H), 6.62 (d, J = 7.4 Hz, 1H), 5.49 (q, J = 6.2 Hz, 1H), 4.97 (br s, 1H), 4.90 (br s, 1H), 4.21 (d, J = 12.0 Hz, 1H), 4.06 (br d, J = 12.4 Hz, 1H), 3.98 - 3.90 (m, 1H), 3.73 (br dd, J = 3.5, 12.6 Hz, 1H), 3.69 - 3.60 (m, 1H), 3.58 (br t, J = 5.9 Hz, 3H), 3.50 (br d, J = 5.6 Hz, 2H), 2.82 (t, J = 6.2 Hz, 2H), 2.73 (t, J = 7.6 Hz, 2H), 2.57 (br s, 2H), 2.11 (d, J = 14.3 Hz, 1H), 1.98 - 1.93 (m, 2H), 1.87 - 1.71 (m, 7H), 1.68 - 1.61 (m, 6H), 1.57 - 1.47 (m, 2H), 1.29 (d, J = 14.8 Hz, 6H), 1.15 - 1.07 (m, 4H), 0.96 (br s, 3H). Preparation of Isomers of 2-((3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4-methylisochroman-5-yl)acetic acid (Compounds 279, 280, 355 and 356)
Figure imgf000183_0001
[000444] Isomers of 2-((3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4-methylisochroman-5-yl)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC (column: Waters Xbridge BEH C18250 * 50 mm * 10 um; mobile phase: [H2O (10mM NH4HCO3)-ACN]; gradient: 20% - 60% B over 10.0 min) to give a white solid (74.11% yield). This solid was further separated by chiral SFC Attorney Docket No. MORF-016WO1 (column: Daicel ChiralPak IG (250 * 30 mm, 10 um); mobile phase: [CO2-IPA (0.1% NH3H2O)]; B%: 50%, isocratic elution mode) to give peak 1, a mixture of peak 2 & peak 3, and peak 4. The mixture of peak 2 & peak 3 was further separated by SFC (column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 um); mobile phase: [CO2-MeOH (0.1%NH3H2O)]; B%: 50%, isocratic elution mode). [000445] Compound 355 (peak 1), arbitrarily assigned as (R)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methylisochroman-5-yl)acetic acid, was obtained as a white solid (54.2 mg, 92.69 umol, 6.18%). LCMS [M+1] = 536.4, 91.62%; 1H NMR (400 MHz, CD3OD) δ = 7.54 (d, J = 7.8 Hz, 1H), 7.25 - 7.15 (m, 2H), 7.01 (d, J = 7.5 Hz, 1H), 6.39 (d, J = 7.3 Hz, 1H), 4.82 (br s, 1H), 4.76 (s, 1H), 4.66 (s, 1H), 4.14 (br t, J = 8.6 Hz, 1H), 3.94 (d, J = 11.1 Hz, 1H), 3.79 (dd, J = 2.0, 11.1 Hz, 1H), 3.54 - 3.46 (m, 2H), 3.40 - 3.35 (m, 3H), 2.71 (br t, J = 6.1 Hz, 2H), 2.56 (br dd, J = 8.4, 16.0 Hz, 3H), 2.46 (s, 3H), 2.26 - 2.17 (m, 1H), 2.12 - 2.05 (m, 1H), 1.91 - 1.85 (m, 3H), 1.78 - 1.67 (m, 3H), 1.61 - 1.56 (m, 2H), 1.41 (d, J = 7.0 Hz, 3H), 1.11 (s, 3H), 0.96 (s, 3H).; SFC Rt = 0.411, de = 100.00%. [000446] Compound 280 (peak 2), arbitrarily assigned as (S)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methylisochroman-5-yl)acetic acid, was obtained as a white solid (138.4 mg, 258.35 umol, 15.78%). LCMS [M+1] = 536.2, 100.00%; 1H NMR (400 MHz, CD3OD) δ = 7.53 (d, J = 7.8 Hz, 1H), 7.26 - 7.17 (m, 2H), 7.02 (d, J = 7.6 Hz, 1H), 6.39 (d, J = 7.3 Hz, 1H), 4.82 (s, 1H), 4.78 - 4.72 (m, 1H), 4.65 (s, 1H), 4.24 (br t, J = 8.4 Hz, 1H), 3.94 (d, J = 11.0 Hz, 1H), 3.79 (dd, J = 2.1, 11.1 Hz, 1H), 3.54 - 3.41 (m, 3H), 3.40 - 3.33 (m, 3H), 2.71 (t, J = 6.3 Hz, 2H), 2.62 - 2.51 (m, 2H), 2.47 (s, 3H), 2.30 (td, J = 7.0, 14.1 Hz, 1H), 2.12 - 2.03 (m, 1H), 1.94 - 1.84 (m, 3H), 1.76 - 1.65 (m, 3H), 1.63 - 1.56 (m, 2H), 1.38 (d, J = 7.0 Hz, 3H), 1.12 (s, 3H), 0.96 (s, 3H).; SFC Rt = 0.564, de = 100%. [000447] Compound 279 (peak 3), arbitrarily assigned as (S)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methylisochroman-5-yl)acetic acid, was obtained as a white solid (28.7 mg, 53.57 umol, 3.27%). LCMS [M+1] = 536.2, 100%; 1H NMR (400 MHz, CD3OD) δ = 7.62 (d, J = 7.6 Hz, 1H), 7.25 - 7.13 (m, 2H), 7.05 (d, J = 7.5 Hz, 1H), 6.37 (d, J = 7.4 Hz, 1H), 4.85 - 4.79 (m, 1H), 4.76 - 4.71 (m, 1H), 4.68 (s, 1H), 3.98 (d, J = 11.0 Hz, 2H), 3.82 (dd, J = 2.3, 11.2 Hz, 1H), 3.52 - 3.42 (m, 2H), 3.41 - 3.35 (m, 3H), 3.00 (q, J = 6.6 Hz, 1H), 2.71 (t, J = 6.3 Hz, 2H), Attorney Docket No. MORF-016WO1 2.57 - 2.43 (m, 5H), 2.22 (td, J = 7.2, 14.0 Hz, 1H), 2.02 - 1.93 (m, 1H), 1.91 - 1.85 (m, 2H), 1.79 - 1.70 (m, 2H), 1.70 - 1.62 (m, 2H), 1.62 - 1.53 (m, 2H), 1.51 (d, J = 6.9 Hz, 3H), 1.09 (s, 3H), 0.90 (s, 3H).; SFC Rt = 0.759, de = 100%. [000448] Compound 356 (peak 4), arbitrarily assigned as (R)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methylisochroman-5-yl)acetic acid, was obtained as a white solid (180.3 mg, 336.56 umol, 20.56%). LCMS [M+1] = 536.2, 100%; 1H NMR (400 MHz, CD3OD) δ = 7.60 (d, J = 7.8 Hz, 1H), 7.24 (t, J = 7.7 Hz, 1H), 7.18 (d, J = 7.3 Hz, 1H), 7.06 (d, J = 7.5 Hz, 1H), 6.38 (d, J = 7.3 Hz, 1H), 4.82 (s, 1H), 4.76 - 4.71 (m, 1H), 4.67 (s, 1H), 4.09 (br s, 1H), 3.96 (d, J = 11.1 Hz, 1H), 3.81 (dd, J = 2.1, 11.1 Hz, 1H), 3.50 - 3.36 (m, 5H), 2.99 - 2.90 (m, 1H), 2.71 (t, J = 6.2 Hz, 2H), 2.59 - 2.51 (m, 2H), 2.51 - 2.38 (m, 3H), 2.27 (td, J = 7.0, 14.1 Hz, 1H), 1.94 (br d, J = 5.6 Hz, 1H), 1.91 - 1.83 (m, 3H), 1.74 - 1.63 (m, 3H), 1.61 - 1.54 (m, 2H), 1.51 (d, J = 6.9 Hz, 3H), 1.11 (s, 3H), 0.92 (s, 3H).; SFC Rt = 1.109, de = 94.74%. Preparation of 2-(6'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'- indolin]-4'-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid (Compounds 365 and 366)
Figure imgf000185_0001
[000449] Isomers of 2-(6'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane- 1,3'-indolin]-4'-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC (column: Phenomenex Luna C1875*30mm*3um; mobile phase: [H2O (0.1%TFA)-ACN]; gradient: 20%-40% B over 8.0 min). [000450] Compound 365 (peak 1), arbitrarily assigned as (S)-2-(6'-fluoro-2'-oxo-1'- (tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid, was obtained as a white solid. LCMS [M+1] = 621.3, 99.72%; SFC Rt = 0.687 min, 98.74%; 1H NMR (400 MHz, CD3OD) δ = 7.55 (d, J = 7.4 Hz, 1H), 7.25 (dd, J = 2.1, 9.3 Hz, 1H), 7.18 (br d, J = 10.4 Attorney Docket No. MORF-016WO1 Hz, 1H), 6.58 (d, J = 7.4 Hz, 1H), 4.40 (tt, J = 4.1, 12.1 Hz, 1H), 4.24 - 4.13 (m, 2H), 4.10 - 4.04 (m, 3H), 3.56 (br t, J = 11.4 Hz, 2H), 3.51 - 3.46 (m, 3H), 3.44 - 3.39 (m, 1H), 2.80 (t, J = 6.2 Hz, 2H), 2.70 (dt, J = 7.3, 14.9 Hz, 2H), 2.64 - 2.52 (m, 5H), 2.43 - 2.36 (m, 1H), 2.20 - 2.10 (m, 2H), 2.09 - 2.02 (m, 1H), 1.99 - 1.91 (m, 5H), 1.84 - 1.76 (m, 2H), 1.74 - 1.66 (m, 5H), 1.62 - 1.55 (m, 2H). [000451] Compound 366 (peak 2), arbitrarily assigned as (R)-2-(6'-fluoro-2'-oxo-1'- (tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid, was obtained as a white solid. LCMS [M+1] = 621.3, 100.00%; SFC Rt = 2.002 min, 95.10%; 1H NMR (400 MHz, CD3OD) δ = 7.53 (d, J = 7.4 Hz, 1H), 7.25 (dd, J = 2.2, 9.3 Hz, 1H), 7.09 (dd, J = 2.1, 10.3 Hz, 1H), 6.57 (d, J = 7.3 Hz, 1H), 4.49 - 4.35 (m, 2H), 4.16 (s, 1H), 4.11 - 4.03 (m, 3H), 3.57 (br t, J = 11.5 Hz, 2H), 3.50 (br dd, J = 5.4, 10.9 Hz, 2H), 3.42 (br t, J = 5.6 Hz, 2H), 2.79 (br t, J = 6.1 Hz, 3H), 2.70 - 2.57 (m, 3H), 2.55 (br s, 3H), 2.39 - 2.26 (m, 2H), 2.20 - 2.06 (m, 2H), 1.94 - 1.89 (m, 4H), 1.85 (br d, J = 7.4 Hz, 2H), 1.81 - 1.72 (m, 2H), 1.71 - 1.58 (m, 6H). Preparation of 2-(7'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'- indolin]-4'-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid(Compounds 367 and 368)
Figure imgf000186_0001
[000452] Isomers of 2-(7'-fluoro-2'-oxo-1'-(tetrahydro-2H-pyran-4-yl)spiro[cyclopropane- 1,3'-indolin]-4'-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents and purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [H2O (10 mM NH4HCO3) - ACN]; gradient: 25% - 55% B over 8.0 min). The product was further separated by SFC (column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 um); mobile phase: [CO2 – EtOH (0.1%NH3H2O)]; B%: 50%, isocratic elution mode. [000453] Compound 367 (peak 1), arbitrarily assigned as (S)-2-(7'-fluoro-2'-oxo-1'- (tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)-2-(methyl((1S,3S)-3-(4- Attorney Docket No. MORF-016WO1 (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid, was obtained. LCMS [M+1] = 621.4, 99.53%; SFC Rt = 1.896 min, 100%; 1H NMR (400 MHz, CD3OD) δ = 7.51 (dd, J = 4.5, 8.9 Hz, 1H), 7.34 (d, J = 7.4 Hz, 1H), 7.10 (dd, J = 8.9, 12.3 Hz, 1H), 6.45 (d, J = 7.3 Hz, 1H), 4.78 - 4.72 (m, 1H), 4.07 (br dd, J = 4.4, 11.5 Hz, 2H), 3.97 (s, 2H), 3.90 - 3.77 (m, 1H), 3.52 (br t, J = 12.0 Hz, 2H), 3.46 - 3.39 (m, 4H), 2.74 (br t, J = 6.3 Hz, 2H), 2.72 - 2.62 (m, 2H), 2.61 - 2.50 (m, 3H), 2.28 (s, 4H), 2.17 (br dd, J = 6.4, 12.5 Hz, 1H), 2.01 - 1.93 (m, 2H), 1.92 - 1.86 (m, 2H), 1.77 - 1.65 (m, 9H), 1.60 - 1.54 (m, 2H). [000454] Compound 368 (peak 2), arbitrarily assigned as (R)-2-(7'-fluoro-2'-oxo-1'- (tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid, was obtained LCMS [M+1] = 621.4, 95.62%; SFC Rt = 2.174 min, 94.92%; 1H NMR (400 MHz, CD3OD) δ = 7.46 (dd, J = 4.4, 8.9 Hz, 1H), 7.31 (br d, J = 7.0 Hz, 1H), 7.12 (dd, J = 9.0, 12.3 Hz, 1H), 6.43 (d, J = 7.4 Hz, 1H), 4.79 - 4.70 (m, 1H), 4.07 (br dd, J = 4.3, 11.4 Hz, 2H), 4.02 (br d, J = 5.8 Hz, 1H), 3.93 (br s, 1H), 3.89 (s, 1H), 3.52 (br t, J = 11.9 Hz, 2H), 3.44 - 3.36 (m, 4H), 2.75 - 2.72 (m, 2H), 2.64 (br dd, J = 4.1, 9.0 Hz, 2H), 2.59 - 2.49 (m, 3H), 2.30 - 2.14 (m, 4H), 2.13 - 2.06 (m, 1H), 2.02 - 1.90 (m, 2H), 1.89 - 1.84 (m, 2H), 1.79 - 1.64 (m, 9H), 1.62 - 1.57 (m, 2H) Preparation of 2-(((1S,4R)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4-methyl-2',3',5',6'- tetrahydrospiro[isochromane-1,4'-pyran]-5-yl)acetic acid and 2-(((1R,4S)-3,3-dimethyl-4- (42-Preparation of Isomers of ((3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4-methyl-2',3',5',6'- tetrahydrospiro[isochromane-1,4'-pyran]-5-yl)acetic acid (Compounds 209, 210, 361 and 362)
Figure imgf000187_0001
Attorney Docket No. MORF-016WO1 [000455] Isomers of 2-((3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4-methyl-2',3',5',6'-tetrahydrospiro[isochromane- 1,4'-pyran]-5-yl)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC (column: Phenomenex Luna C1875*30mm*3um; mobile phase: [H2O (0.1%TFA)-ACN]; gradient: 20%-50% B over 8.0 min). The resulting solid was further purified by SFC (column: DAICEL CHIRALPAK IG (250mm*30mm, 10um); mobile phase: [CO2-IPA (0.1%NH3H2O)]; B%:55%, isocratic elution mode). [000456] Compound 361 (peak 1), arbitrarily assigned as (R)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]-5-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 606.3, 90%; SFC Rt = 0.960, 100%; 1H NMR (400 MHz, CD3OD) δ = 7.56 (br d, J = 7.3 Hz, 1H), 7.27 - 7.22 (m, 2H), 7.18 (br d, J = 7.3 Hz, 1H), 6.39 (d, J = 7.3 Hz, 1H), 4.67 (br s, 1H), 3.95 (br s, 2H), 3.89 - 3.84 (m, 2H), 3.79 (br s, 1H), 3.54 - 3.51 (m, 1H), 3.46 (br dd, J = 5.3, 11.3 Hz, 2H), 3.40 - 3.35 (m, 4H), 2.71 (br s, 2H), 2.56 (br d, J = 7.9 Hz, 2H), 2.43 (s, 3H), 2.24 - 2.19 (m, 2H), 2.10 - 2.03 (m, 2H), 1.93 - 1.87 (m, 5H), 1.73 - 1.67 (m, 3H), 1.61 - 1.57 (m, 3H), 1.41 (d, J = 6.9 Hz, 3H), 1.10 (s, 3H), 0.96 (s, 3H). [000457] Compound 210 (peak 2), arbitrarily assigned as (R)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]-5-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 606.3, 98.3%; SFC Rt = 0.960, 100%; 1H NMR (400 MHz, CD3OD) δ = 7.54 (br d, J = 6.5 Hz, 1H), 7.32 - 7.27 (m, 1H), 7.27 - 7.24 (m, 1H), 7.20 (br d, J = 7.3 Hz, 1H), 6.39 (d, J = 7.3 Hz, 1H), 4.67 (s, 1H), 3.96 - 3.89 (m, 2H), 3.84 (br dd, J = 3.8, 13.2 Hz, 2H), 3.80 (br s, 1H), 3.52 - 3.41 (m, 4H), 3.40 - 3.35 (m, 3H), 2.71 (br t, J = 6.1 Hz, 2H), 2.60 - 2.53 (m, 2H), 2.45 (br s, 3H), 2.26 (br dd, J = 5.8, 18.4 Hz, 2H), 2.11 - 2.05 (m, 1H), 1.94 - 1.86 (m, 5H), 1.70 (br dd, J = 9.8, 12.7 Hz, 3H), 1.64 - 1.56 (m, 4H), 1.39 (d, J = 6.9 Hz, 3H), 1.12 (s, 3H), 0.97 (s, 3H). [000458] Compound 209 (peak 3), arbitrarily assigned as (S)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]-5-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 606.3, 95.4%; SFC Rt = 0.960, 100%; 1H NMR (400 MHz, CD3OD) δ = 7.64 - 7.61 (m, 1H), 7.27 (d, J = 4.4 Hz, 2H), 7.17 (d, J = 7.4 Hz, 1H), 6.37 (d, J = Attorney Docket No. MORF-016WO1 7.3 Hz, 1H), 4.71 (s, 1H), 3.91 (br d, J = 9.0 Hz, 2H), 3.84 (br s, 2H), 3.80 - 3.77 (m, 1H), 3.49 - 3.41 (m, 3H), 3.41 - 3.36 (m, 4H), 2.98 (br d, J = 6.8 Hz, 2H), 2.71 (br t, J = 6.2 Hz, 2H), 2.56 - 2.52 (m, 2H), 2.50 (br s, 3H), 2.21 (br dd, J = 5.2, 12.7 Hz, 2H), 1.92 - 1.86 (m, 5H), 1.72 (br d, J = 8.1 Hz, 2H), 1.65 (br d, J = 8.0 Hz, 3H), 1.52 (br d, J = 6.9 Hz, 3H), 1.08 (s, 3H), 0.89 (s, 3H). [000459] Compound 362 (peak 4), arbitrarily assigned as (S)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methyl-2',3',5',6'-tetrahydrospiro[isochromane-1,4'-pyran]-5-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 606.3, 100%; SFC Rt = 1.149, 95.7%; 1H NMR (400 MHz, CD3OD) δ = 7.57 - 7.51 (m, 2H), 7.42 - 7.37 (m, 2H), 6.59 (d, J = 7.4 Hz, 1H), 4.77 - 4.26 (m, 1H), 4.00 - 3.87 (m, 3H), 3.87 - 3.74 (m, 4H), 3.56 - 3.49 (m, 2H), 3.48 - 3.43 (m, 3H), 2.92 (br d, J = 6.3 Hz, 1H), 2.80 (br t, J = 6.1 Hz, 3H), 2.76 - 2.54 (m, 2H), 2.44 - 2.35 (m, 1H), 2.26 (dt, J = 5.3, 12.9 Hz, 3H), 1.98 - 1.89 (m, 5H), 1.89 - 1.73 (m, 3H), 1.72 - 1.62 (m, 4H), 1.51 (d, J = 6.9 Hz, 3H), 1.13 (s, 3H), 1.01 (br s, 3H). Preparation of (R)-2-((1S,4S)-4,7-dimethyl-5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'- pyran]-5-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid and (S)-2-((1S,4S)-4,7-dimethyl-5',6'-dihydro- 2'H,4'H-spiro[isochromane-1,3'-pyran]-5-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (Compounds 1 and 2)
Figure imgf000189_0001
[000460] Isomers of arbitrarily assigned 2-((1S,4S)-4,7-dimethyl-5',6'-dihydro-2'H,4'H- spiro[isochromane-1,3'-pyran]-5-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, and were purified by prep-HPLC (column: Phenomenex luna C18250 * 150 mm *15 um; mobile phase: [H2O (0.1%TFA) - ACN]; gradient: 5% - 35% B over 20.0 min). [000461] Compound 2 (peak 1), arbitrarily assigned as (S)-2-((1S,4S)-4,7-dimethyl-5',6'- dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran]-5-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8- Attorney Docket No. MORF-016WO1 tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (98.30% purity), was obtained as a white solid. [000462] Compound 1 (peak 2), arbitrarily assigned as (R)-2-((1S,4S)-4,7-dimethyl-5',6'- dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran]-5-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid, was obtained as a yellow solid. [000463] When synthesis was carried out, the stereochemistry of the starting materials was arbitrarily assigned. Someone skilled in the art will recognize that if the stereochemistry of the starting materials are later determined to be different, the stereochemistry of intermediates and final products may also be determined to be different than those drawn in the scheme. In this example, further analysis led to the reassignment of 2 as (S)-2-((1R,4S)-4,7-dimethyl-5',6'- dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran]-5-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (Compound 2*), and of 1 as (R)-2-((1R,4S)-4,7-dimethyl-5',6'-dihydro-2'H,4'H-spiro[isochromane-1,3'-pyran]-5-yl)-2- (methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid (Compound 1*).
Figure imgf000190_0001
Preparation of (R)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)-2-(6'-methyl-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid and (S)-2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-(6'-methyl-2'-oxo-1'- Attorney Docket No. MORF-016WO1 (tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid (Compounds 155 and 156)
Figure imgf000191_0001
[000464] Isomers of arbitrarily assigned 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-(6'-methyl-2'-oxo-1'-(tetrahydro-2H-pyran-4- yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, and were purified by prep-HPLC (column: Phenomenex luna C18250*150mm*15um; mobile phase: [H2O (0.2%FA)-ACN]; gradient: 26%-55% B over 20.0 min). The products were separated by SFC (column: DAICEL CHIRALPAK IK (250 mm * 25 mm, 10 um); mobile phase: [CO2 – EtOH (0.1%NH3H2O)]; B%:60%, isocratic elution mode). [000465] Compound 156 (peak 1), arbitrarily assigned as (S)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-(6'-methyl-2'-oxo-1'- (tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid was obtained as a white solid. [000466] Compound 155 (peak 2) was arbitrarily assigned as (R)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-(6'-methyl-2'-oxo-1'- (tetrahydro-2H-pyran-4-yl)spiro[cyclopropane-1,3'-indolin]-4'-yl)acetic acid. Preparation of (S)-2-((R)-7-fluoro-4-methylisochroman-5-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid and (R)-2- Attorney Docket No. MORF-016WO1 ((R)-7-fluoro-4-methylisochroman-5-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (Compounds 387 and 388)
Figure imgf000192_0001
[000467] Compounds 387 and 388 were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [H2O (10 mM NH4HCO3)-ACN]; gradient: 20%-50% B over 8.0 min) and separated by SFC (column: ChiralPak IH, 250 * 30 mm, 10um; mobile phase: [CO2-IPA (0.1%NH3H2O)]; B%:28%, isocratic elution mode).. [000468] Compound 387 (peak 1), arbitrarily assigned as (S)-2-((R)-7-fluoro-4- methylisochroman-5-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid, was obtained (17 mg, 30.81 μmol) as a white solid. LCMS [M+1]= 526.3. 1H NMR (400 MHz, CD3OD) δ = 7.44 (dd, J = 2.2, 10.3 Hz, 1H), 7.31 (br d, J = 7.5 Hz, 1H), 6.79 - 6.65 (m, 1H), 6.44 (d, J = 7.3 Hz, 1H), 4.81 (s, 1H), 4.74 - 4.69 (m, 1H), 4.63 (s, 1H), 4.01 - 3.90 (m, 3H), 3.79 - 3.73 (m, 1H), 3.56 - 3.36 (m, 5H), 2.75 - 2.68 (m, 3H), 2.58 - 2.51 (m, 1H), 2.33 (s, 3H), 2.22 (br d, J = 6.2 Hz, 1H), 1.97 (br d, J = 3.7 Hz, 2H), 1.91 - 1.85 (m, 2H), 1.79 - 1.65 (m, 5H), 1.61 - 1.55 (m, 2H), 1.38 (d, J = 7.0 Hz, 3H). [000469] Compound 388 (peak 2), arbitrarily assigned as (R)-2-((R)-7-fluoro-4- methylisochroman-5-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid, was obtained (64.9 mg, 123.47 μmol) as a white solid. LCMS [M+1]= 526.3. 1H NMR (400 MHz, CD3OD) δ = 7.41 (dd, J = 2.6, 10.1 Hz, 1H), 7.22 (d, J = 7.3 Hz, 1H), 6.81 (dd, J = 2.4, 8.5 Hz, 1H), 6.39 (d, J = 7.2 Hz, 1H), 4.81 (s, 1H), 4.70 (br d, J = 12.3 Hz, 2H), 3.94 (br d, J = 10.6 Hz, 3H), 3.77 (dd, J = 2.0, 11.2 Hz, 1H), 3.42 - 3.35 (m, 4H), 3.07 - 2.92 (m, 1H), 2.72 (t, J = 6.2 Hz, 2H), 2.65 - 2.50 (m, 2H), 2.49 - 2.26 (m, 3H), 2.09 - 1.94 (m, 3H), 1.93 - 1.85 (m, 3H), 1.84 - 1.77 (m, 1H), 1.74 - 1.60 (m, 3H), 1.55 (br s, 2H), 1.49 (d, J = 6.8 Hz, 3H). Preparation of (S)-2-((S)-7-fluoro-4-methylisochroman-5-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid and (R)-2- Attorney Docket No. MORF-016WO1 ((S)-7-fluoro-4-methylisochroman-5-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (Compounds 389 and 390)
Figure imgf000193_0001
[000470] Compounds 389 and 390 were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC (column: DAICEL CHIRALCEL OZ 250 * 25 mm I.D.10 um; mobile phase: [CO2-MeOH (0.1%NH3H2O)]; B%:55%, isocratic elution mode) and separated by SFC (column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [H2O (10mM NH4HCO3)- ACN]; gradient: 20%-50% B over 8.0 min). [000471] Compound 389 (peak 1), arbitrarily assigned as (S)-2-((S)-7-fluoro-4- methylisochroman-5-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid, was obtained (74.3 mg, 135.70 μmol) as a white solid. LCMS [M+1]= 526.3. 1H NMR (400 MHz, CD3OD) δ = 7.47 (dd, J = 2.6, 10.4 Hz, 1H), 7.25 (d, J = 7.3 Hz, 1H), 6.81 (dd, J = 2.5, 8.6 Hz, 1H), 6.41 (d, J = 7.4 Hz, 1H), 4.81 (s, 2H), 4.68 (s, 2H), 3.98 (br s, 1H), 3.96 - 3.93 (m, 1H), 3.92 - 3.82 (m, 1H), 3.78 (dd, J = 2.3, 11.2 Hz, 1H), 3.45 - 3.38 (m, 4H), 3.05 (br d, J = 6.8 Hz, 1H), 2.74 (t, J = 6.2 Hz, 2H), 2.65 - 2.51 (m, 2H), 2.42 (s, 3H), 2.21 (br dd, J = 7.1, 13.2 Hz, 1H), 1.94 (br d, J = 3.1 Hz, 2H), 1.90 (br dd, J = 5.2, 6.1 Hz, 2H), 1.82 - 1.78 (m, 1H), 1.75 - 1.68 (m, 2H), 1.60 - 1.52 (m, 2H), 1.48 (d, J = 7.0 Hz, 3H), 1.16 (d, J = 6.1 Hz, 1H). [000472] Compound 390 (peak 2), arbitrarily assigned as (R)-2-((S)-7-fluoro-4- methylisochroman-5-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid, was obtained (20.7 mg, 37.73 μmol) as a white solid. LCMS [M+1]= 526.3. 1H NMR (400 MHz, CD3OD) δ = 7.40 (dd, J = 2.6, 10.3 Hz, 1H), 7.30 (d, J = 7.3 Hz, 1H), 6.78 - 6.69 (m, 1H), 6.43 (d, J = 7.4 Hz, 1H), 4.74 (s, 2H), 4.69 - 4.58 (m, 2H), 4.16 - 4.06 (m, 1H), 3.97 - 3.92 (m, 2H), 3.78 (dd, J = 2.2, 11.1 Hz, 1H), 3.45 (dt, J = 2.3, 5.8 Hz, 2H), 3.40 - 3.36 (m, 3H), 2.73 (br t, J = 6.2 Hz, 3H), 2.59 - 2.53 (m, 1H), 2.17 (br dd, J = 6.9, 11.8 Hz, 1H), 2.03 - 1.96 (m, 2H), 1.93 - 1.84 (m, 3H), 1.83 - 1.68 (m, 5H), 1.62 - 1.57 (m, 2H), 1.38 (d, J = 7.0 Hz, 3H), 1.29 (s, 1H). Attorney Docket No. MORF-016WO1 Preparation of (S)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)-2-((S)-4-methylisochroman-5-yl)acetic acid and (R)-2- (methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2- ((S)-4-methylisochroman-5-yl)acetic acid (Compounds 391 and 392)
Figure imgf000194_0001
[000473] Compounds 391 and 392 were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by prep-HPLC (column: Waters Xbridge BEH C18100 * 30 mm * 10 um; mobile phase: [water (NH4HCO3)- ACN]; B%: 25%-50%, 8 min) and separated by SFC (column: (s, s) WHELK-O1 (250 mm * 30 mm, 5 um); mobile phase: [0.1% NH3H2O IPA]; B%: 50%-50%, 8 min). [000474] Compound 391 (peak 1), arbitrarily assigned as (S)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((S)-4- methylisochroman-5-yl)acetic acid, was obtained (165.1 mg, 323.96 umol) as a white solid. LCMS [M+1] = 508.3. 1H NMR (400 MHz, CD3OD) δ = 7.63 (d, J = 7.8 Hz, 1H), 7.24 - 7.17 (m, 2H), 7.04 (d, J = 7.5 Hz, 1H), 6.37 (d, J = 7.4 Hz, 1H), 4.81 (s, 1H), 4.75 - 4.69 (m, 2H), 3.96 (br d, J = 11.4 Hz, 3H), 3.80 (dd, J = 2.4, 11.1 Hz, 1H), 3.41 - 3.36 (m, 4H), 3.00 (br d, J = 7.0 Hz, 1H), 2.71 (t, J = 6.3 Hz, 2H), 2.57 - 2.45 (m, 5H), 2.13 (br dd, J = 7.4, 13.3 Hz, 1H), 2.00 - 1.81 (m, 6H), 1.74 - 1.59 (m, 3H), 1.56 - 1.49 (m, 5H). [000475] Compound 392 (peak 2), arbitrarily assigned as (R)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((S)-4- methylisochroman-5-yl)acetic acid, was obtained (48.2 mg, 94.53 umol) as a white solid. LCMS [M+1] = 508.3. 1H NMR (400 MHz, CD3OD) δ = 7.55 (d, J = 7.6 Hz, 1H), 7.26 - 7.18 (m, 2H), 7.01 (d, J = 7.5 Hz, 1H), 6.39 (d, J = 7.3 Hz, 1H), 4.82 (s, 1H), 4.77 - 4.71 (m, 2H), 4.19 - 4.08 (m, 1H), 4.01 - 3.93 (m, 2H), 3.80 (dd, J = 2.3, 11.1 Hz, 1H), 3.44 - 3.35 (m, 5H), 2.71 (t, J = 6.3 Hz, 2H), 2.63 - 2.43 (m, 5H), 2.19 (br dd, J = 6.9, 13.3 Hz, 1H), 2.10 - 1.80 (m, 6H), 1.76 - 1.62 (m, 3H), 1.59 - 1.51 (m, 2H), 1.39 (d, J = 6.9 Hz, 3H). Preparation of (S)-2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)- 3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid and Attorney Docket No. MORF-016WO1 (R)-2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (Compounds 381 and 382)
Figure imgf000195_0001
Step 1: (S)-2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid
Figure imgf000195_0002
[000476] To a solution of tert-butyl 2-bromo-2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H- indazol-7-yl)acetate (0.25 g, 604.88 μmol, 1 eq) and (1S,3S)-N-methyl-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentan-1-amine (183.55 mg, 604.88 μmol, 1 eq) in MeCN (2 mL) was added DIEA (312.71 mg, 2.42 mmol, 421.44 μL, 4 eq) and 4A MS (0.1 g, 604.88 μmol, 1 eq) at 20°C. The mixture was allowed to stir at 50°C for 2hrs. The reaction was quenched by the addition of H2O (30 mL), and the mixture was extracted with ethyl acetate (10 mLx3). The organic solutions were combined, washed with brine (20 mLx3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=4/3 to 0/1) to give (S)-2-(5-(2- methoxyethoxy)-1,3-dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro- Attorney Docket No. MORF-016WO1 1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (0.4 g, 545.43 μmol, 90.17% yield, 86.7% purity) as yellow oil. LCMS [M+1] = 636.4. Step 2: 2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid
Figure imgf000196_0001
[000477] To a solution of (S)-2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H-indazol-7-yl)-2- (methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid (0.4 g, 629.09 μmol, 1 eq) in DCM (3 mL) was added TFA (1.54 g, 13.46 mmol, 1 mL, 21.40 eq) at 20°C. The mixture was allowed to stir at 35°C for 16 hr sand then concentrated under reduced pressure to remove solvent. The mixture was purified by pre-HPLC (column: Phenomenex Luna C1875*30mm*3um; mobile phase: [H2O (0.1%TFA)-ACN]; gradient: 10%-40% B over 8.0 min) to give 2-(5-(2-methoxyethoxy)-1,3- dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid (82.26% yield) as a white solid. LCMS: [M+1] = 580.35. Step 3: (S)-2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid and (R)- 2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (Compounds 381 and 382)
Figure imgf000196_0002
Attorney Docket No. MORF-016WO1 [000478] 2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (0.3 g, 517.48 umol) was separated by SFC (column: ChiralPak IH, 250*30mm, 10um; mobile phase: [CO2- EtOH (0.1% NH3H2O)]; B%:27%, isocratic elution mode). [000479] 381 (Peak 1), arbitrarily assigned as (S)-2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H- indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid, was obtained as a white solid (68 mg, 117.30 μmol). LCMS [M+1] = 580.3.1H NMR (400 MHz, CD3OD) δ = 7.51 (d, J = 2.3 Hz, 1H), 7.36 (br d, J = 7.3 Hz, 1H), 7.10 (d, J = 2.3 Hz, 1H), 6.46 (d, J = 7.4 Hz, 1H), 5.15 (s, 1H), 4.35 (s, 3H), 4.16 (br d, J = 4.5 Hz, 2H), 3.96 (br s, 1H), 3.77 (dd, J = 3.8, 5.3 Hz, 3H), 3.45 (br d, J = 2.4 Hz, 3H), 3.43 (s, 3H), 2.76 (br t, J = 6.1 Hz, 2H), 2.62 - 2.56 (m, 1H), 2.48 (s, 3H), 2.41 (s, 3H), 2.39 - 2.34 (m, 1H), 2.06 - 1.99 (m, 1H), 1.99 - 1.86 (m, 4H), 1.83 - 1.77 (m, 1H), 1.73 - 1.54 (m, 7H). [000480] 382 (Peak 2), arbitrarily assigned as (R)-2-(5-(2-methoxyethoxy)-1,3-dimethyl-1H- indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid, was obrained as a white solid (67.7 mg, 116.78 μmol). LCMS [M+1] = 580.3. 1H NMR (400 MHz, CD3OD) δ = 7.40 (d, J = 2.3 Hz, 1H), 7.18 (d, J = 7.3 Hz, 1H), 7.01 (d, J = 2.3 Hz, 1H), 6.30 (d, J = 7.3 Hz, 1H), 5.00 (s, 1H), 4.23 (s, 3H), 4.07 - 4.01 (m, 2H), 3.95 - 3.86 (m, 1H), 3.82 (br s, 1H), 3.66 (dd, J = 3.8, 5.3 Hz, 2H), 3.32 (s, 3H), 3.29 - 3.24 (m, 3H), 2.62 (br t, J = 6.1 Hz, 2H), 2.58 - 2.50 (m, 1H), 2.46 - 2.40 (m, 1H), 2.37 (s, 3H), 2.34 (br s, 3H), 2.00 - 1.86 (m, 3H), 1.83 - 1.76 (m, 2H), 1.75 - 1.61 (m, 3H), 1.61 - 1.46 (m, 3H), 1.45 - 1.37 (m, 2H). Preparation of (S)-2-(1,3-dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid and (R)-2-(1,3- dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid (Compounds 379 and 380)
Figure imgf000197_0001
379 380 Attorney Docket No. MORF-016WO1 [000481] Compounds 379 and 380 were prepared starting from the appropriate starting material using procedures similar to those described for the preparation of compounds 381 and 382. The final compounds were purified by by prep-HPLC (column: Phenomenex Luna C 18 75 * 30 mm * 3 um; mobile phase: [H2O (0.1%TFA)-ACN]; gradient: 1%-25% B over 8.0 min) to give two peaks. Peak 1 was further purified by prep-HPLC (column: REGIS(s, s) WHELK-O1 (250 mm * 30 mm, 5 um); mobile phase: [CO2-EtOH (0.1% NH3H2O)]; B%: 50%, isocratic elution mode). Peak 2 was further purified by prep-HPLC (column: REGIS (s, s) WHELK-O1 (250 mm * 30 mm, 5 um); mobile phase: [CO2- EtOH (0.1% NH3H2O)]; B%:50%, isocratic elution mode). [000482] Peak 1, Compound 379, arbitrarily assigned as (S)-2-(1,3-dimethyl-1H-indazol-7- yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)- amino)acetic acid (16.33% yield), was obtained as a white solid. LCMS: [M+1] = 506.3. 1H NMR (400 MHz, CD3OD) δ = 7.76 (d, J = 7.3 Hz, 1H), 7.68 (d, J = 7.9 Hz, 1H), 7.33 (d, J = 7.4 Hz, 1H), 7.13 (t, J = 7.6 Hz, 1H), 6.45 (d, J = 7.3 Hz, 1H), 5.23 (s, 1H), 4.40 (s, 3H), 3.97 (br s, 1H), 3.89 - 3.80 (m, 1H), 3.49 - 3.38 (m, 6H), 2.75 (br t, J = 6.3 Hz, 2H), 2.71 - 2.65 (m, 1H), 2.61 - 2.55 (m, 1H), 2.52 (s, 3H), 2.44 (s, 3H), 2.33 (br dd, J = 6.5, 12.9 Hz, 1H), 2.04 - 1.98 (m, 1H), 1.93 - 1.89 (m, 2H), 1.80 - 1.73 (m, 2H), 1.68 - 1.63 (m, 2H), 1.61 - 1.54 (m, 2H). [000483] Peak 2, Compound 380, arbitrarily assigned as (R)-2-(1,3-dimethyl-1H-indazol-7- yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)- amino)acetic acid (23.9 mg, 47.27 umol, 15.93%), was obtained as a white solid. LCMS: [M+1] = 506.3. 1H NMR (400 MHz, CD3OD) δ = 7.78 - 7.73 (m, 1H), 7.70 (br d, J = 8.1 Hz, 1H), 7.27 (br d, J = 7.3 Hz, 1H), 7.17 (br t, J = 7.5 Hz, 1H), 6.40 (br d, J = 7.1 Hz, 1H), 5.20 (br s, 1H), 4.38 (s, 3H), 4.05 - 3.98 (m, 1H), 3.93 (br s, 1H), 3.44 - 3.34 (m, 6H), 2.73 (br t, J = 6.1 Hz, 2H), 2.69 - 2.55 (m, 2H), 2.51 (s, 3H), 2.46 (br s, 3H), 2.07 - 2.00 (m, 2H), 1.90 - 1.78 (m, 4H), 1.70 - 1.62 (m, 2H), 1.56 - 1.45 (m, 2H). Preparation of (S)-2-(5-methoxy-1,3-dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid and (R)-2- (5-methoxy-1,3-dimethyl-1H-indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)amino)acetic acid (Compounds 383 and 384) Attorney Docket No. MORF-016WO1
Figure imgf000199_0001
Compounds 383 and 384 were prepared starting from the appropriate starting material using procedures similar to those described for the preparation of compounds 381 and 382. The final compounds were purified by prep-HPLC column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [H2O (0.05% NH3H2O + 10 mM NH4HCO3)-ACN]; gradient: 10%-40% B over 8.0 min) by prep-HPLC column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [H2O (0.05% NH3H2O + 10 mM NH4HCO3)-ACN]; gradient: 10%-40% B over 8.0 min). [000484] Peak 1, Compound 383, arbitrarily assigned as (S)-2-(5-methoxy-1,3-dimethyl-1H- indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid, was obtained (63.8 mg, 119.10 μmol) as a white solid. LCMS [M+1] = 536.2. 1H NMR (400 MHz, CD3OD) δ = 7.47 (d, J = 2.1 Hz, 1H), 7.29 (d, J = 7.3 Hz, 1H), 7.08 (d, J = 2.3 Hz, 1H), 6.41 (d, J = 7.3 Hz, 1H), 5.10 (s, 1H), 4.33 (s, 3H), 4.01 (br dd, J = 3.0, 7.4 Hz, 1H), 3.92 (br s, 1H), 3.84 (s, 3H), 3.39 - 3.35 (m, 3H), 2.72 (t, J = 6.2 Hz, 2H), 2.66 - 2.60 (m, 1H), 2.56 - 2.51 (m, 1H), 2.48 (s, 3H), 2.43 (br s, 3H), 2.12 - 1.96 (m, 3H), 1.96 - 1.80 (m, 3H), 1.79 - 1.58 (m, 5H), 1.56 - 1.48 (m, 2H). [000485] Peak 2, Compound 384, arbitrarily assigned as (R)-2-(5-methoxy-1,3-dimethyl-1H- indazol-7-yl)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)acetic acid, was obtained (65.1 mg, 121.53 μmol) as a white solid. LCMS [M+1] = 536.3. 1H NMR (400 MHz, CD3OD) δ = 7.49 (d, J = 2.3 Hz, 1H), 7.37 (d, J = 7.2 Hz, 1H), 7.08 (d, J = 2.3 Hz, 1H), 6.48 (d, J = 7.3 Hz, 1H), 5.16 (s, 1H), 4.37 (s, 3H), 3.98 (br s, 1H), 3.84 (s, 3H), 3.81 - 3.84 (m, 1H), 3.48 - 3.44 (m, 3H), 2.80 - 2.74 (m, 2H), 2.72 (br dd, J = 5.5, 9.4 Hz, 1H), 2.63 - 2.53 (m, 1H), 2.50 (s, 3H), 2.43 (s, 3H), 2.39 - 2.32 (m, 1H), 2.09 - 2.01 (m, 1H), 1.99 - 1.90 (m, 3H), 1.87 - 1.70 (m, 3H), 1.68 - 1.56 (m, 5H). Preparation of (R)-2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)amino)-2-((3R,4S)-3,4,7-trimethylisochroman-5-yl)acetic acid and (S)- Attorney Docket No. MORF-016WO1 2-(methyl((1S,3S)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)- 2-((3R,4S)-3,4,7-trimethylisochroman-5-yl)acetic acid (Compounds 385 and 386)
Figure imgf000200_0001
[000486] Compounds 385 and 386 were prepared starting from the appropriate starting material using procedures similar to those described for the preparation of compounds 381 and 382. The final compounds were purified by prep-HPLC (column: Phenomenex Luna 80 * 30 mm * 3 um; mobile phase: [water (TFA)-ACN]; B%: 5%-35%, 8 min) and separated by SFC (column: Daicel Chiral Pak IG (250 * 30 mm, 10 um); mobile phase: [CO2-MeOH (0.1%NH3H2O)]; 45%% B isocratic elution mode). [000487] Peak 1, Compound 385, arbitrarily assigned as (R)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((3R,4S)-3,4,7- trimethylisochroman-5-yl)acetic acid, was obtained (43.5 mg, 80.50 μmol) as a white solid. LCMS [M+1] = 536.3. 1H NMR (400 MHz, CD3OD) δ = 7.42 (s, 1H), 7.18 (d, J = 7.3 Hz, 1H), 6.82 (s, 1H), 6.37 (d, J = 7.4 Hz, 1H), 4.71 (d, J = 3.8 Hz, 2H), 4.60 (s, 1H), 4.08 - 4.00 (m, 2H), 3.99 - 3.95 (m, 1H), 3.41 - 3.35 (m, 4H), 3.22 (br d, J = 6.8 Hz, 1H), 2.70 (t, J = 6.3 Hz, 2H), 2.57 - 2.48 (m, 2H), 2.47 - 2.42 (m, 3H), 2.29 (s, 3H), 2.14 - 1.92 (m, 4H), 1.91 - 1.75 (m, 4H), 1.69 - 1.63 (m, 2H), 1.58 - 1.52 (m, 2H), 1.33 (d, J = 7.0 Hz, 3H), 1.16 (d, J = 6.6 Hz, 3H). [000488] Peak 2, Compound 386, arbitrarily assigned as (S)-2-(methyl((1S,3S)-3-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)amino)-2-((3R,4S)-3,4,7- trimethylisochroman-5-yl)acetic acid, was obtained (108.5 mg, 202.11 μmol) as a white solid. LCMS [M+1] = 536.3.1H NMR (400 MHz, CD3OD) δ = 7.50 (s, 1H), 7.17 (d, J = 7.3 Hz, 1H), 6.88 (s, 1H), 6.36 (d, J = 7.3 Hz, 1H), 4.71 - 4.66 (m, 3H), 4.04 - 3.96 (m, 2H), 3.88 (br s, 1H), 3.41 - 3.35 (m, 4H), 2.81 (q, J = 6.6 Hz, 1H), 2.71 (t, J = 6.3 Hz, 2H), 2.54 - 2.45 (m, 5H), 2.28 (s, 3H), 2.11 - 1.97 (m, 2H), 1.94 - 1.84 (m, 5H), 1.74 - 1.67 (m, 1H), 1.64 - 1.57 (m, 2H), 1.55 - 1.49 (m, 2H), 1.45 (d, J = 7.0 Hz, 3H), 1.20 (d, J = 6.6 Hz, 3H). Attorney Docket No. MORF-016WO1 Preparation of tert-butyl 2-(((1S,4R)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin- 2-yl)butoxy)cyclopentyl)(methyl)amino)-2-(5-(methoxymethyl)-1-methyl-2-oxo-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetate and tert-butyl 2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-(5-
Figure imgf000201_0001
[000489] Isomers of were prepared according to Step 1 of the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents, purified by flash silica gel chromatography (Biotage®; 4 g SepaFlash® Silica Flash Column, Eluent of 0 ~ 10% MEOH/Ethyl acetate gradient @ 20 mL/min). The residue was separated by SFC (column: REGIS (s, s) WHELK-O1 (250 mm * 30 mm, 5 um); mobile phase: [CO2 - MeOH (0.1%NH3H2O)]; B%: 50%, isocratic elution mode). [000490] Peak 1, arbitrarily assigned as tert-butyl 2-(((1S,4R)-3,3-dimethyl-4-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-(5-(methoxymethyl)-1- methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetate, was obtained as yellow oil. [000491] Peak 2, arbitrarily assigned as tert-butyl 2-(((1R,4S)-3,3-dimethyl-4-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-(5-(methoxymethyl)-1- methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetate, was obtained as a yellow oil. Preparation of as (S)-2-(((1S,4R)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-(5-(methoxymethyl)-1-methyl-2-oxo-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetic acid and (R)-2-(((1S,4R)-3,3-dimethyl-4-(4- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-(5- Attorney Docket No. MORF-016WO1 (methoxymethyl)-1-methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetic acid (Compounds 248 and 363) +
Figure imgf000202_0001
363 [000492] To a solution of tert-butyl 2-(((1S,4R)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-(5-(methoxymethyl)-1-methyl-2-oxo- 2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetate (200 mg, 283.71 μmol, 1 eq) in DCM (3 mL) was added TFA (1.54 g, 13.46 mmol, 1 mL, 47.45 eq) at 25 oC. The reaction mixture was allowed to stir at 25 oC for 16 hrs. The reaction mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Phenomenex luna C18 100 * 40 mm * 5 um; mobile phase: [H2O (0.2% FA) - ACN]; gradient: 15% - 40% B over 8.0 min). The product was separated by SFC (column: DAICEL CHIRALCEL OD (250 mm * 30 mm, 10 um); mobile phase: [CO2 - IPA (0.1% NH3H2O)]; B%: 50%, isocratic elution mode. SFC: Rt1 = 1.365 min, 56.20% Rt2 = 1.737 min, 38.79%) to give two peaks. [000493] Compound 248 (peak 1), arbitrarily assigned as (S)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-(5- (methoxymethyl)-1-methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetic acid, was obtained as a white solid (25.85% yield). LCMS [M+1] = 649.4. SFC Rt = 1.328 min. 1H NMR (400 MHz, CD3OD) δ = 7.60 (s, 1H), 7.48 - 7.36 (m, 1H), 7.35 - 7.22 (m, 1H), 6.43 (d, J = 7.3 Hz, 1H), 5.10 (s, 1H), 4.43 (s, 2H), 4.30 - 4.15 (m, 3H), 3.89 (dt, J = 3.9, 7.6 Hz, 2H), 3.62 (s, 3H), 3.49 - 3.38 (m, 5H), 3.37 (s, 3H), 2.73 (t, J = 6.2 Hz, 2H), 2.67 - 2.61 (m, 1H), 2.60 - 2.54 (m, 1H), 2.51 (br s, 3H), 2.24 - 2.17 (m, 1H), 2.04 - 1.82 (m, 6H), 1.75 - 1.67 (m, 4H), 1.66 - 1.51 (m, 3H), 1.09 (s, 3H), 0.95 (s, 3H). [000494] Compound 363 (peak 2), arbitrarily assigned as (R)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-(5- (methoxymethyl)-1-methyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetic Attorney Docket No. MORF-016WO1 acid, was obtained as a white solid (18.55% yield). LCMS [M+1] = 649.4. SFC Rt = 1.675 min. 1H NMR (400 MHz, CD3OD) δ = 7.51 (s, 1H), 7.34 - 7.25 (m, 1H), 7.15 (d, J = 7.3 Hz, 1H), 6.31 (d, J = 7.3 Hz, 1H), 4.99 (s, 1H), 4.32 (s, 2H), 4.20 - 4.10 (m, 2H), 3.85 - 3.75 (m, 3H), 3.55 (s, 3H), 3.39 - 3.35 (m, 1H), 3.30 (t, J = 5.6 Hz, 4H), 3.26 (s, 3H), 2.63 (t, J = 6.2 Hz, 2H), 2.52 - 2.41 (m, 5H), 2.08 - 2.00 (m, 1H), 1.97 - 1.91 (m, 1H), 1.86 - 1.76 (m, 4H), 1.66 - 1.54 (m, 6H), 1.49 - 1.41 (m, 2H), 0.97 (s, 3H), 0.77 (s, 3H). Preparation of 2-(((1R,4S)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-(5-(methoxymethyl)-1-methyl-2-oxo-2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-7-yl)acetic acid (Compounds 364)
Figure imgf000203_0001
[000495] Compounds 364 were prepared starting from the appropriate starting material using a procedure similar to that described for the preparation of compounds 248 and 363 and purified by prep-HPLC (column: Phenomenex luna C18100 * 40 mm * 5 um; mobile phase: [H2O (0.2% FA) - ACN]; gradient: 25% - 55% B over 8.0 min. Compounds 364 were obtained as a white solid. LCMS [M+1] = 649.4. 1H NMR (400 MHz, CD3OD) δ = 7.61 (d, J = 12.8 Hz, 1H), 7.43 (dd, J = 1.3, 9.8 Hz, 1H), 7.35 (dd, J = 7.3, 15.6 Hz, 1H), 6.47 (t, J = 7.4 Hz, 1H), 5.15 (d, J = 6.0 Hz, 1H), 4.44 (d, J = 4.5 Hz, 2H), 4.25 (dq, J = 2.6, 11.1 Hz, 2H), 3.94 - 3.86 (m, 2H), 3.64 (d, J = 14.3 Hz, 3H), 3.52 - 3.44 (m, 2H), 3.44 - 3.40 (m, 3H), 3.38 (d, J = 4.1 Hz, 3H), 2.75 (br t, J = 6.1 Hz, 2H), 2.72 - 2.62 (m, 1H), 2.59 (s, 2H), 2.52 (br s, 1H), 2.23 - 2.05 (m, 2H), 1.97 - 1.86 (m, 4H), 1.76 - 1.58 (m, 7H), 1.30 (d, J = 6.5 Hz, 3H), 1.12 - 1.07 (m, 3H), 0.99 (s, 1H), 0.90 (s, 1H). Attorney Docket No. MORF-016WO1
Figure imgf000204_0001
[000496] Isomers of (RS)-2-(((1RS,4SR)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1-methylisochroman-8-yl)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents. The intermediates after alkylation were purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/0 to 0/1) and then separated by SFC (column: DAICEL CHIRALPAK IG (250mm*30mm, 10um); mobile phase: [CO2- EtOH (0.1%NH3 H2O)]; B%:40%, isocratic elution mode) to give 2 product mixtures. Each product mixture following SFC separation was separately subjected to hydrolysis and purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150*40mm*10um; mobile phase: [H2O (10mM NH4HCO3)-ACN]; gradient: 30%-60% B over 8.0 min) to give two product mixtures. [000497] The product of hydrolysis of SFC peak 1, arbitrarily assigned as (S)-2- (((1RS,4SR)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1-methylisochroman-8-yl)acetic acid, was Attorney Docket No. MORF-016WO1 purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150*40mm*10um; mobile phase: [H2O (10mM NH4HCO3)-ACN]; gradient: 30%-60% B over 8.0 min) and separated by SFC (column: REGIS (s, s) WHELK-O1 (250mm*30mm, 5um); mobile phase: [CO2-EtOH (0.1%NH3H2O)]; B%:50%, isocratic elution mode) to give two compounds. [000498] Compound 369 (peak 1), arbitrarily assigned as (S)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1- methylisochroman-8-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 536.3. SFC Rt = 1.753 min. 1H NMR (400 MHz, CD3OD) δ = 7.60 (d, J = 7.6 Hz, 1H), 7.27 - 7.20 (m, 1H), 7.16 (dd, J = 3.6, 7.3 Hz, 2H), 6.37 (d, J = 7.3 Hz, 1H), 5.22 (q, J = 6.6 Hz, 1H), 4.50 (s, 1H), 4.17 (ddd, J = 4.8, 9.1, 11.4 Hz, 1H), 4.03 - 3.85 (m, 1H), 3.81 (ddd, J = 4.1, 6.1, 11.4 Hz, 1H), 3.50 - 3.36 (m, 5H), 2.99 - 2.88 (m, 1H), 2.85 - 2.77 (m, 1H), 2.71 (t, J = 6.3 Hz, 2H), 2.58 - 2.35 (m, 5H), 2.25 (td, J = 7.0, 14.1 Hz, 1H), 1.95 - 1.84 (m, 3H), 1.80 (br dd, J = 8.8, 12.9 Hz, 1H), 1.73 - 1.63 (m, 6H), 1.59 - 1.51 (m, 2H), 1.09 (s, 3H), 0.89 (s, 3H). [000499] Compound 227 (peak 2), arbitrarily assigned as (S)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1- methylisochroman-8-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 536.3. SFC Rt = 1.955 min. 1H NMR (400 MHz, CD3OD) δ = 7.63 (d, J = 7.4 Hz, 1H), 7.28 - 7.16 (m, 3H), 6.39 (d, J = 7.4 Hz, 1H), 5.29 (q, J = 6.5 Hz, 1H), 4.55 (s, 1H), 4.19 (ddd, J = 4.7, 8.8, 11.5 Hz, 1H), 3.99 - 3.86 (m, 1H), 3.86 - 3.80 (m, 1H), 3.53 - 3.39 (m, 5H), 3.01 - 2.91 (m, 1H), 2.88 - 2.80 (m, 1H), 2.73 (t, J = 6.2 Hz, 2H), 2.59 - 2.46 (m, 5H), 2.20 (td, J = 7.1, 14.1 Hz, 1H), 2.01 - 1.93 (m, 1H), 1.93 - 1.88 (m, 2H), 1.77 - 1.63 (m, 7H), 1.62 - 1.54 (m, 2H), 1.10 (s, 3H), 0.89 (s, 3H). [000500] The product of hydrolysis of SFC peak 2, arbitrarily assigned as (R)-2- (((1RS,4SR)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1-methylisochroman-8-yl)acetic acid, was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150*40mm*10um; mobile phase: [H2O (10mM NH4HCO3)-ACN]; gradient: 30%-60% B over 8.0 min) and separated by SFC (column: REGIS (s, s) WHELK-O1 (250mm*30mm, 5um); mobile phase: [CO2-EtOH (0.1%NH3H2O)]; B%:50%, isocratic elution mode) to give two compounds. [000501] Compound 370 (peak 1), arbitrarily assigned as (R)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1- methylisochroman-8-yl)acetic acid, was obtained as white solid. LCMS [M+1] = 536.3. SFC Rt Attorney Docket No. MORF-016WO1 = 1.489 min.1H NMR (400 MHz, CD3OD) δ = 7.54 (d, J = 7.6 Hz, 1H), 7.29 - 7.17 (m, 2H), 7.16 - 7.08 (m, 1H), 6.41 (d, J = 7.3 Hz, 1H), 5.52 (q, J = 6.4 Hz, 1H), 4.53 (s, 1H), 4.19 - 4.04 (m, 2H), 3.85 - 3.76 (m, 1H), 3.57 - 3.50 (m, 1H), 3.47 - 3.37 (m, 4H), 2.99 - 2.90 (m, 1H), 2.85 - 2.77 (m, 1H), 2.72 (t, J = 6.2 Hz, 2H), 2.67 - 2.54 (m, 2H), 2.43 (s, 3H), 2.22 - 2.10 (m, 2H), 1.88 (td, J = 5.9, 11.3 Hz, 3H), 1.78 - 1.67 (m, 3H), 1.64 - 1.57 (m, 5H), 1.09 (s, 3H), 0.97 (s, 3H). [000502] Compound 226 (peak 2), arbitrarily assigned as (R)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1- methylisochroman-8-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 536.3. SFC Rt = 1.792 min. 1H NMR (400 MHz, CD3OD) δ = 7.52 (br d, J = 7.5 Hz, 1H), 7.25 - 7.17 (m, 2H), 7.13 (br d, J = 7.4 Hz, 1H), 6.40 (d, J = 7.4 Hz, 1H), 5.53 (q, J = 6.5 Hz, 1H), 4.49 (s, 1H), 4.24 - 4.09 (m, 2H), 3.86 - 3.76 (m, 1H), 3.55 - 3.48 (m, 1H), 3.46 - 3.40 (m, 2H), 3.39 - 3.35 (m, 2H), 2.99 - 2.89 (m, 1H), 2.79 (td, J = 4.1, 16.5 Hz, 1H), 2.71 (br t, J = 6.1 Hz, 2H), 2.65 - 2.52 (m, 2H), 2.44 (s, 3H), 2.24 (td, J = 7.1, 13.9 Hz, 1H), 2.06 (br d, J = 4.5 Hz, 1H), 1.92 - 1.84 (m, 3H), 1.79 - 1.65 (m, 3H), 1.63 - 1.56 (m, 5H), 1.11 (s, 3H), 0.96 (s, 3H).
Figure imgf000206_0001
Attorney Docket No. MORF-016WO1 [000503] Isomers of (RS)-2-(((1SR,4RS)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4-methylchroman-5-yl)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents. The intermediates after alkylation were purified by SFC (column: REGIS(S, S) WHELK-O1 (250 mm*25 mm, 10 um); mobile phase: [CO2-IPA (0.1%NH3H2O)]; B%:43%, isocratic elution mode to give 2 product mixtures. Each product following SFC separation was separately subjected to hydrolysis and purified by prep-HPLC (column: Waters Xbridge BEH C18100*30 mm*10 um; mobile phase: [H2O (10mM NH4HCO3)-ACN]; gradient: 30%-60% B over 8.0 min) to give two products. [000504] The product of hydrolysis of alkylation SFC peak 1, arbitrarily assigned as (R)-2- (((1RS,4SR)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4-methylchroman-5-yl)acetic acid, was purified by by SFC (column: REGIS (s,s) WHELK-O1 (250 mm*30 mm, 5 um); mobile phase: [CO2- IPA(0.1%NH3H2O)]; B%:50%, isocratic elution mode) to give two compounds. [000505] Compound 224 (peak 1), arbitrarily assigned as (R)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methylchroman-5-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 536.3. SFC Rt = 0.998 min. 1H NMR (400 MHz, CD3OD) δ = 7.25 (br d, J = 7.8 Hz, 1H), 7.17 (br d, J = 7.3 Hz, 1H), 7.10 (br t, J = 7.9 Hz, 1H), 6.80 (br d, J = 8.0 Hz, 1H), 6.38 (d, J = 7.3 Hz, 1H), 4.68 (s, 1H), 4.26 (br d, J = 8.0 Hz, 2H), 4.10 - 3.90 (m, 1H), 3.49 - 3.42 (m, 2H), 3.41 - 3.37 (m, 3H), 3.19 (br s, 1H), 2.71 (br t, J = 6.1 Hz, 2H), 2.59 - 2.46 (m, 5H), 2.26 - 2.18 (m, 1H), 2.12 - 1.97 (m, 2H), 1.90 - 1.84 (m, 3H), 1.78 - 1.71 (m, 2H), 1.70 - 1.63 (m, 2H), 1.59 - 1.53 (m, 2H), 1.49 (br d, J = 7.0 Hz, 3H), 1.10 (s, 3H), 0.90 (s, 3H). [000506] Compound 371 (peak 2), arbitrarily assigned as (R)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methylchroman-5-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 536.3. SFC Rt = 1.506 min. 1H NMR (400 MHz, CD3OD) δ = 7.24 (br d, J = 7.6 Hz, 1H), 7.18 - 7.07 (m, 2H), 6.80 (br d, J = 8.0 Hz, 1H), 6.37 (d, J = 7.4 Hz, 1H), 4.66 (s, 1H), 4.25 (br d, J = 8.1 Hz, 2H), 4.17 - 3.89 (m, 1H), 3.48 - 3.42 (m, 2H), 3.41 - 3.34 (m, 3H), 3.14 (br s, 1H), 2.70 (br t, J = 6.1 Hz, 2H), 2.56 - 2.43 (m, 4H), 2.34 - 2.26 (m, 1H), 2.11 - 2.03 (m, 1H), 1.94 - 1.77 (m, 5H), 1.74 - 1.64 (m, 3H), 1.60 - 1.53 (m, 2H), 1.48 (br d, J = 7.0 Hz, 3H), 1.37 - 1.26 (m, 1H), 1.11 (s, 3H), 0.91 (br s, 3H) Attorney Docket No. MORF-016WO1 [000507] The product of hydrolysis of alkylation SFC peak 2, arbitrarily assigned as (S)-2- (((1RS,4SR)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4-methylchroman-5-yl)acetic acid, was purified by prep-HPLC (column: Waters Xbridge BEH C18100*30 mm*10 um; mobile phase: [H2O (10mM NH4HCO3)-ACN]; gradient: 30%-60% B over 8.0 min) and separated by SFC (column: REGIS (s,s) WHELK-O1 (250 mm*30 mm, 5 um); mobile phase: [CO2- IPA(0.1%NH3H2O)]; B%:50%, isocratic elution mode) to give two compounds. [000508] Compound 223 (peak 1), arbitrarily assigned as (S)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methylchroman-5-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 536.3. SFC Rt = 1.821 min. 1H NMR (400 MHz, CD3OD) δ = 7.20 - 7.13 (m, 2H), 7.13 - 7.06 (m, 1H), 6.83 - 6.72 (m, 1H), 6.38 (d, J = 7.3 Hz, 1H), 4.67 (s, 1H), 4.26 (br d, J = 8.0 Hz, 2H), 4.22 - 4.12 (m, 1H), 3.59 - 3.47 (m, 3H), 3.45 - 3.40 (m, 1H), 3.40 - 3.36 (m, 2H), 2.72 - 2.68 (m, 2H), 2.58 - 2.52 (m, 2H), 2.50 (s, 3H), 2.24 (td, J = 6.8, 13.8 Hz, 1H), 2.12 - 2.02 (m, 2H), 1.96 - 1.82 (m, 4H), 1.76 - 1.62 (m, 3H), 1.61 - 1.54 (m, 2H), 1.37 (d, J = 7.0 Hz, 3H), 1.11 (s, 3H), 0.96 (s, 3H). [000509] Compound 372 (peak 2), arbitrarily assigned as (S)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-4- methylchroman-5-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 536.3. SFC Rt = 2.183 min. 1H NMR (400 MHz, CD3OD) δ = 7.20 - 7.09 (m, 3H), 6.76 (d, J = 7.9 Hz, 1H), 6.38 (d, J = 7.3 Hz, 1H), 4.64 (s, 1H), 4.28 - 4.20 (m, 3H), 3.55 - 3.41 (m, 4H), 3.39 - 3.36 (m, 2H), 2.70 (br t, J = 6.1 Hz, 2H), 2.59 - 2.52 (m, 2H), 2.49 (br s, 3H), 2.31 (td, J = 6.9, 14.0 Hz, 1H), 2.12 - 2.03 (m, 2H), 1.93 - 1.85 (m, 3H), 1.81 (br d, J = 13.8 Hz, 1H), 1.75 - 1.67 (m, 3H), 1.61 - 1.56 (m, 2H), 1.34 (br d, J = 7.0 Hz, 3H), 1.12 (s, 3H), 0.96 (s, 3H).
Figure imgf000208_0001
Attorney Docket No. MORF-016WO1
Figure imgf000209_0001
[000510] Isomers of (RS)-2-(((1RS,4SR)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((R)-4-methylchroman-5-yl)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents. The intermediates after alkylation were purified by by column chromatography (SiO2, 12g Sepa Flash ® Silica Flash Column, Eluent of 0~80% Petroleum ethergradient/ Ethyl acetate@ 120 mL/min) and then separated by SFC (column: DAICEL CHIRALPAK IC (250 mm * 30 mm, 10 um); mobile phase: [CO2-IPA (0.1%NH3H2O)]; B%:60%, isocratic elution mode) to give 2 product mixtures. Each product following SFC separation was separately subjected to hydrolysis to give two products. [000511] The product of hydrolysis of alkylation SFC peak 1, arbitrarily assigned as (S)-2- (((1RS,4SR)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((R)-4-methylchroman-5-yl)acetic acid, was purified by by prep-HPLC (column: Waters Xbridge Prep OBD C18150 * 40 mm * 10 um; mobile phase: [H2O (10mM NH4HCO3)-ACN]; gradient: 35%-65% B over 8.0 min) and separated by SFC (column: DAICEL CHIRALPAK IG (250mm*30mm, 10um); mobile phase: [CO2-MeOH (0.1%NH3H2O)]; B%:40%, isocratic elution mode) to give two compounds. [000512] Compound 373 (peak 1,), arbitrarily assigned as (S)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((R)-4- methylchroman-5-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 536.3. SFC Attorney Docket No. MORF-016WO1 Rt1 = 1.224 min. 1H NMR (400 MHz, CD3OD) δ = 7.31 - 7.20 (m, 1H), 7.17 - 7.09 (m, 2H), 6.80 (d, J = 8.0 Hz, 1H), 6.37 (d, J = 7.3 Hz, 1H), 4.66 (s, 1H), 4.28 - 4.22 (m, 2H), 4.05 (br d, J = 6.1 Hz, 1H), 3.48 - 3.35 (m, 5H), 3.14 (br d, J = 1.5 Hz, 1H), 2.70 (t, J = 6.3 Hz, 2H), 2.63 - 2.34 (m, 5H), 2.29 (td, J = 7.0, 14.1 Hz, 1H), 2.12 - 2.03 (m, 1H), 1.98 - 1.77 (m, 5H), 1.74 - 1.63 (m, 3H), 1.60 - 1.53 (m, 2H), 1.48 (d, J = 7.0 Hz, 3H), 1.11 (s, 3H), 0.91 (br s, 3H). [000513] Compound 213 (peak 2,), arbitrarily assigned as (S)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((R)-4- methylchroman-5-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 536.3. SFC Rt1 = 1.642 min. 1H NMR (400 MHz, CD3OD) δ = 7.26 (d, J = 7.6 Hz, 1H), 7.20 (d, J = 7.3 Hz, 1H), 7.11 (t, J = 7.9 Hz, 1H), 6.80 (d, J = 8.0 Hz, 1H), 6.39 (d, J = 7.3 Hz, 1H), 4.69 (s, 1H), 4.29 - 4.24 (m, 2H), 4.03 (br s, 1H), 3.53 - 3.47 (m, 1H), 3.44 (br d, J = 6.5 Hz, 1H), 3.42 - 3.36 (m, 3H), 3.22 - 3.14 (m, 1H), 2.71 (t, J = 6.3 Hz, 2H), 2.59 - 2.45 (m, 5H), 2.27 - 2.18 (m, 1H), 2.13 - 2.06 (m, 1H), 2.03 - 1.96 (m, 1H), 1.92 - 1.85 (m, 3H), 1.78 - 1.72 (m, 2H), 1.71 - 1.64 (m, 2H), 1.60 - 1.53 (m, 2H), 1.49 (d, J = 7.0 Hz, 3H), 1.10 (s, 3H), 0.91 (s, 3H). [000514] The product of hydrolysis of alkylation SFC peak 2, arbitrarily assigned as (R)-2- (((1RS,4SR)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((R)-4-methylchroman-5-yl)acetic acid, was purified by prep-HPLC (column: Waters Xbridge BEH C18100 * 30 mm * 10 um; mobile phase: [H2O (10mM NH4HCO3)-ACN]; gradient: 30%-60% B over 8.0 min) and separated by SFC (column: REGIS (s,s) WHELK-O1 (250 mm * 30 mm, 5 um);mobile phase: [CO2- IPA(0.1%NH3H2O)];B%:50%, isocratic elution mode) to give two compounds. [000515] Compound 374 (peak 1,), arbitrarily assigned as (R)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((R)-4- methylchroman-5-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 536.3. SFC Rt1 = 1.658 min. 1H NMR (400 MHz, CD3OD) δ = 7.17 (br d, J = 8.0 Hz, 2H), 7.12 - 7.07 (m, 1H), 6.76 (d, J = 8.3 Hz, 1H), 6.38 (d, J = 7.4 Hz, 1H), 4.67 (s, 1H), 4.28 - 4.23 (m, 2H), 4.20 - 4.12 (m, 1H), 3.59 - 3.51 (m, 2H), 3.50 - 3.47 (m, 1H), 3.45 - 3.40 (m, 1H), 3.39 - 3.36 (m, 2H), 2.70 (t, J = 6.2 Hz, 2H), 2.58 - 2.52 (m, 2H), 2.50 (s, 3H), 2.28 - 2.21 (m, 1H), 2.12 - 2.04 (m, 2H), 1.93 - 1.82 (m, 4H), 1.76 - 1.65 (m, 3H), 1.61 - 1.56 (m, 2H), 1.37 (d, J = 7.0 Hz, 3H), 1.11 (s, 3H), 0.96 (s, 3H). [000516] Compound 225 (peak 2), arbitrarily assigned as (R)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((R)-4- Attorney Docket No. MORF-016WO1 methylchroman-5-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 536.3. SFC Rt1 = 2.091 min. 1H NMR (400 MHz, CD3OD) δ = 7.22 - 7.16 (m, 2H), 7.13 (d, J = 8.0 Hz, 1H), 6.77 (d, J = 8.0 Hz, 1H), 6.39 (d, J = 7.4 Hz, 1H), 4.64 (s, 1H), 4.28 (s, 2H), 4.22 (br d, J = 2.6 Hz, 1H), 3.59 - 3.52 (m, 2H), 3.51 - 3.48 (m, 1H), 3.46 - 3.42 (m, 1H), 3.41 - 3.38 (m, 2H), 2.72 (t, J = 6.3 Hz, 2H), 2.57 (br d, J = 7.9 Hz, 2H), 2.53 - 2.46 (m, 3H), 2.36 - 2.29 (m, 1H), 2.12 - 2.04 (m, 2H), 1.95 - 1.83 (m, 4H), 1.76 - 1.69 (m, 3H), 1.63 - 1.57 (m, 2H), 1.36 (d, J = 7.0 Hz, 3H), 1.14 (s, 3H), 0.97 (s, 3H). Preparation of Compounds 124, 125, 375 and 376
Figure imgf000211_0001
[000517] Isomers of 2-(((1RS,4SR)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin- 2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1,6-dimethylisochroman-8-yl)acetic acid were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents. The intermediates after alkylation were purified by column chromatography (SiO2, petroleum ether/ethyl acetate = 1/1 to 0/1) and then separated by SFC (column: DAICEL CHIRALPAK IG (250mm*30mm, 10um); mobile phase: [CO2-MeOH (0.1%NH3H2O)]; B%:45%, isocratic elution mode) to give 2 product mixtures. Each product mixture following SFC separation of the alkylation products was separately subjected to Attorney Docket No. MORF-016WO1 hydrolysis and purified by by prep-HPLC (column: Phenomenex Luna C1875*30mm*3um; mobile phase: [H2O (0.1%TFA)-ACN]; gradient: 20%-45% B over 8.0 min). [000518] The product of hydrolysis of alkylation SFC peak 1, arbitrarily assigned as 2- (((1S,4R)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1,6-dimethylisochroman-8-yl)acetic acid, was separated by SFC (column: DAICEL CHIRALPAK IG (250mm*30mm,10um);mobile phase: [CO2-MeOH(0.1%NH3H2O)];B%:45%, isocratic elution mode) to give two compounds. [000519] Compound 125 (peak 1), arbitrarily assigned as (R)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1,6- dimethylisochroman-8-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 550.4. SFC Rt = 1.552. 1H NMR (400 MHz, CD3OD) δ = 7.43 (s, 1H), 7.16 (d, J = 7.3 Hz, 1H), 7.00 (s, 1H), 6.37 (d, J = 7.3 Hz, 1H), 5.16 (q, J = 6.5 Hz, 1H), 4.47 (s, 1H), 4.14 (ddd, J = 4.6, 9.0, 11.5 Hz, 1H), 4.09 - 3.83 (m, 1H), 3.82 - 3.76 (m, 1H), 3.49 - 3.40 (m, 2H), 3.40 - 3.35 (m, 3H), 2.94 - 2.85 (m, 1H), 2.81 - 2.74 (m, 1H), 2.71 (t, J = 6.3 Hz, 2H), 2.51 (dt, J = 7.0, 13.1 Hz, 4H), 2.29 (s, 3H), 2.27 - 2.22 (m, 1H), 2.00 - 1.90 (m, 1H), 1.90 - 1.85 (m, 2H), 1.85 - 1.78 (m, 1H), 1.73 - 1.57 (m, 7H), 1.57 - 1.48 (m, 2H), 1.10 (s, 3H), 0.90 (s, 3H). [000520] Compound 124 (peak 2), arbitrarily assigned as (S)-2-(((1S,4R)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1,6- dimethylisochroman-8-yl)acetic acid, was further purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150*40mm*10um;mobile phase: [H2O(10mM NH4HCO3)- ACN];gradient:30%-60% B over 8.0 min) and was obtained as a white solid. LCMS [M+1] = 550.4. SFC Rt = 1.776. 1H NMR (400 MHz, CD3OD) δ = 7.44 (s, 1H), 7.16 (d, J = 7.4 Hz, 1H), 7.00 (s, 1H), 6.37 (d, J = 7.4 Hz, 1H), 5.21 (q, J = 6.7 Hz, 1H), 4.49 (s, 1H), 4.15 (ddd, J = 4.6, 8.8, 11.5 Hz, 1H), 3.90 (br dd, J = 2.3, 4.4 Hz, 1H), 3.82 - 3.76 (m, 1H), 3.48 - 3.41 (m, 2H), 3.40 - 3.36 (m, 3H), 2.93 - 2.85 (m, 1H), 2.80 - 2.74 (m, 1H), 2.70 (t, J = 6.3 Hz, 2H), 2.57 - 2.46 (m, 5H), 2.28 (s, 3H), 2.19 (td, J = 6.8, 13.9 Hz, 1H), 1.99 - 1.91 (m, 1H), 1.90 - 1.85 (m, 2H), 1.73 (br d, J = 9.4 Hz, 2H), 1.68 (d, J = 6.6 Hz, 5H), 1.58 - 1.52 (m, 2H), 1.09 (s, 3H), 0.87 (s, 3H). [000521] The product of hydrolysis of alkylation SFC peak 2, arbitrarily assigned as 2- (((1R,4S)-3,3-dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1,6-dimethylisochroman-8-yl)acetic acid, was Attorney Docket No. MORF-016WO1 separated by SFC (column: REGIS (s,s) WHELK-O1 (250mm*30mm,5um);mobile phase: [CO2-MeOH(0.1%NH3H2O)];B%:50%, isocratic elution mode) to give two compounds. [000522] Compound 375 (peak 1), arbitrarily assigned as (S)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1,6- dimethylisochroman-8-yl)acetic acid, was further purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150*40mm*10um;mobile phase: [H2O(10mM NH4HCO3)- ACN];gradient:35%-65% B over 8.0 min) and was obtained as a white solid. LCMS [M+1] = 550.4. SFC Rt = 1.611. 1H NMR (400 MHz, CD3OD) δ = 7.36 (s, 1H), 7.21 (d, J = 7.3 Hz, 1H), 6.96 (s, 1H), 6.40 (d, J = 7.4 Hz, 1H), 5.47 (q, J = 6.3 Hz, 1H), 4.50 (s, 1H), 4.16 - 4.07 (m, 2H), 3.81 - 3.75 (m, 1H), 3.55 - 3.50 (m, 1H), 3.48 - 3.41 (m, 2H), 3.40 - 3.33 (m, 3H), 2.92 - 2.84 (m, 1H), 2.78 - 2.69 (m, 3H), 2.62 - 2.53 (m, 2H), 2.45 (s, 3H), 2.29 (s, 3H), 2.19 - 2.08 (m, 2H), 1.92 - 1.85 (m, 3H), 1.76 - 1.68 (m, 3H), 1.59 (d, J = 6.5 Hz, 4H), 1.10 (s, 3H), 0.96 (s, 3H). [000523] Compound 376 (peak 2), arbitrarily assigned as (R)-2-(((1R,4S)-3,3-dimethyl-4- (4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)-2-((S)-1,6- dimethylisochroman-8-yl)acetic acid, was obtained as a white solid. LCMS [M+1] = 550.4. SFC Rt = 2.044. 1H NMR (400 MHz, CD3OD) δ = 7.36 (s, 1H), 7.21 (d, J = 7.3 Hz, 1H), 6.96 (s, 1H), 6.40 (d, J = 7.3 Hz, 1H), 5.47 (q, J = 6.5 Hz, 1H), 4.45 (s, 1H), 4.23 - 4.14 (m, 1H), 4.10 (ddd, J = 4.6, 9.2, 11.4 Hz, 1H), 3.82 - 3.76 (m, 1H), 3.53 - 3.48 (m, 1H), 3.46 - 3.41 (m, 2H), 3.39 - 3.35 (m, 2H), 2.94 - 2.85 (m, 1H), 2.78 - 2.69 (m, 3H), 2.61 (br d, J = 8.3 Hz, 1H), 2.58 - 2.52 (m, 1H), 2.44 (s, 3H), 2.29 (s, 3H), 2.27 - 2.21 (m, 1H), 2.10 - 2.01 (m, 1H), 1.91 - 1.84 (m, 3H), 1.79 - 1.72 (m, 1H), 1.71 - 1.65 (m, 2H), 1.60 (br d, J = 7.3 Hz, 1H), 1.56 (d, J = 6.6 Hz, 3H), 1.11 (s, 3H), 0.96 (s, 3H).
Figure imgf000213_0001
Attorney Docket No. MORF-016WO1
Figure imgf000214_0001
[000524] Compounds 265, 266, 377 and 378 were prepared according to the General Example of Alkylation and Hydrolysis, substituting the appropriate reagents as shown. The intermediates after alkylation were separated by SFC (column: REGIS(S,S)WHELK- O1(250mm*25mm,10um); mobile phase: [CO2-IPA(0.1% NH3 H2O)]; B%: 62%, isocratic elution mode) to give 2 product mixtures. Each product following SFC separation was separately subjected to hydrolysis and purified by by prep-HPLC (column: Phenomenex Luna C1875*30mm*3um;mobile phase: [H2O(0.1%TFA)-ACN]; gradient:10%-40% B over 8.0 min) to give two product mixtures. [000525] The products of hydrolysis of alkylation SFC peak 1, arbitrarily assigned as (R)-2- (1,5-dimethyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)-2-(((1RS,4SR)-3,3- dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)acetic acid, were separated by SFC (column: DAICEL CHIRALCEL OD (250mm*30mm,10um); mobile phase: [CO2-EtOH(0.1%NH3H2O)]; B%:50%, isocratic elution mode) to give two compounds. [000526] Compound 266 (peak 1), arbitrarily assigned as (R)-2-(1,5-dimethyl-2-oxo- 2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)-2-(((1S,4R)-3,3-dimethyl-4-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)acetic acid, was obtained as a white solid. LCMS [M+1]= 619.4. SFC Rt = 1.222min.1 H NMR (400 MHz, CD3OD) δ = 7.43 (s, 1H), 7.31 - 7.10 (m, 2H), 6.41 (d, J = 7.4 Hz, 1H), 5.06 (s, 1H), 4.37 - 4.10 (m, 3H), Attorney Docket No. MORF-016WO1 3.92 - 3.83 (m, 2H), 3.60 (s, 3H), 3.45 - 3.35 (m, 5H), 2.73 (t, J = 6.3 Hz, 2H), 2.63 - 2.50 (m, 4H), 2.34 (s, 3H), 2.27 - 2.18 (m, 1H), 1.95 - 1.86 (m, 4H), 1.84 - 1.77 (m, 1H), 1.74 - 1.62 (m, 5H), 1.57 (br d, J = 6.0 Hz, 2H), 1.09 (s, 3H), 0.94 (s, 3H). [000527] Compound 377 (peak 2), arbitrarily assigned as (R)-2-(1,5-dimethyl-2-oxo- 2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)-2-(((1R,4S)-3,3-dimethyl-4-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)acetic acid, was obtained as a white solid. LCMS [M+1] = 619.4. SFC Rt = 1.748min. 1 H NMR (400 MHz, CD3OD) δ = 7.43 (s, 1H), 7.28 - 7.12 (m, 2H), 6.39 (d, J = 7.4 Hz, 1H), 5.04 (s, 1H), 4.28 - 4.19 (m, 2H), 3.89 (br dd, J = 5.5, 11.3 Hz, 3H), 3.62 (s, 3H), 3.51 - 3.45 (m, 2H), 3.42 - 3.38 (m, 4H), 3.15 - 3.10 (m, 1H), 2.72 (t, J = 6.2 Hz, 2H), 2.59 - 2.55 (m, 3H), 2.32 (s, 3H), 2.22 - 2.13 (m, 1H), 2.05 - 1.96 (m, 1H), 1.92 - 1.87 (m, 3H), 1.70 - 1.63 (m, 5H), 1.59 - 1.52 (m, 2H), 1.07 (s, 3H), 0.86 (s, 3H). [000528] The products of hydrolysis of SFC peak 2, arbitrarily assigned as (S)-2-(1,5- dimethyl-2-oxo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)-2-(((1RS,4SR)-3,3- dimethyl-4-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- yl)butoxy)cyclopentyl)(methyl)amino)acetic acid, were separated by SFC (column: DAICEL CHIRALPAK AD (250mm*30mm,10um);mobile phase: [CO2-EtOH(0.1% NH3H2O)];B%:15%, isocratic elution mode) to give two compounds. [000529] Compound 378 (peak 1), arbitrarily assigned as (S)-2-(1,5-dimethyl-2-oxo- 2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)-2-(((1R,4S)-3,3-dimethyl-4-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)acetic acid, was obtained as a white solid. LCMS [M+1] = 619.4. SFC Rt = 1.126min. 1H NMR (400 MHz, CD3OD) δ = 7.43 (s, 1H), 7.31 - 7.10 (m, 2H), 6.41 (d, J = 7.4 Hz, 1H), 5.06 (s, 1H), 4.37 - 4.10 (m, 3H), 3.92 - 3.83 (m, 2H), 3.60 (s, 3H), 3.45 - 3.35 (m, 5H), 2.73 (t, J = 6.3 Hz, 2H), 2.63 - 2.50 (m, 4H), 2.34 (s, 3H), 2.27 - 2.18 (m, 1H), 1.95 - 1.86 (m, 4H), 1.84 - 1.77 (m, 1H), 1.74 - 1.62 (m, 5H), 1.57 (br d, J = 6.0 Hz, 2H), 1.09 (s, 3H), 0.94 (s, 3H). [000530] Compound 265 (peak 2), arbitrarily assigned as (S)-2-(1,5-dimethyl-2-oxo- 2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-7-yl)-2-(((1S,4R)-3,3-dimethyl-4-(4-(5,6,7,8- tetrahydro-1,8-naphthyridin-2-yl)butoxy)cyclopentyl)(methyl)amino)acetic acid, was obtained as a white solid. LCMS [M+1] = 619.3. SFC Rt = 1.173min. 1H NMR (400 MHz, CD3OD) δ = 7.43 (s, 1H), 7.28 - 7.12 (m, 2H), 6.39 (d, J = 7.4 Hz, 1H), 5.04 (s, 1H), 4.28 - 4.19 (m, 2H), 3.89 (br dd, J = 5.5, 11.3 Hz, 3H), 3.62 (s, 3H), 3.51 - 3.45 (m, 2H), 3.42 - 3.38 (m, 4H), 3.15 - Attorney Docket No. MORF-016WO1 3.10 (m, 1H), 2.72 (t, J = 6.2 Hz, 2H), 2.59 - 2.55 (m, 3H), 2.32 (s, 3H), 2.22 - 2.13 (m, 1H), 2.05 - 1.96 (m, 1H), 1.92 - 1.87 (m, 3H), 1.70 - 1.63 (m, 5H), 1.59 - 1.52 (m, 2H), 1.07 (s, 3H), 0.86 (s, 3H). [000531] Additional compounds of the invention were prepared using synthetic routes similar to those described above, substituting the appropriate reagents, purification and separation conditions. Assay Conditions [000532] Fluorescence Polarization (FP) assays with the fluorescein-labeled, disulfide- cyclized peptide ACRGDGWCG. In the assay, 6.5 nM of integrin a5b1 was incubated with the test compound in 2 mM manganese chloride, 0.1 mM calcium chloride, 20 mM HEPES buffer at pH 7.3, 150 mM sodium chloride, 0.01% Triton X-100, 2% DMSO, and 3 nM of the fluorescein-labeled peptide. The assays were run in 384-well plates. The integrin protein was pre-incubated with the test compounds for 15 minutes at 22⁰C before the fluorescein-labeled peptide was added. After the fluorescein-labeled peptide was added, the assay was incubated at 22⁰C for 1 hour and fluorescence polarization was measured. IC50 values were determined by nonlinear regression, 4-parameter curve fitting. [000533] IC50 values of Tables 1 and 2 as determined by the fluorescence polarization assay are categorized as: A: < 5 nM; B: 5-500 nM; and C: >500 nM. Table 1. Potency Data Table
Figure imgf000216_0001
Attorney Docket No. MORF-016WO1
Figure imgf000217_0001
Attorney Docket No. MORF-016WO1
Figure imgf000218_0001
Attorney Docket No. MORF-016WO1
Figure imgf000219_0001
Table 2. Potency Data Table
Figure imgf000219_0002
[000534] From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope Attorney Docket No. MORF-016WO1 thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. [000535] All references, patents or applications, U.S. or foreign, cited in the application are hereby incorporated by reference as if written herein in their entireties. Where any inconsistencies arise, material literally disclosed herein controls. [000536] From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. [000537] All references, patents or applications, U.S. or foreign, cited in the application are hereby incorporated by reference as if written herein in their entireties. Where any inconsistencies arise, material literally disclosed herein controls. Enumerated Embodiments Embodiment 1: In one aspect, the invention features a compound of Formula (I), or a pharmaceutically acceptable salt thereof:
Figure imgf000220_0001
wherein:
Figure imgf000220_0002
a 3- to 15-member heterocyclyl ring structure optionally substituted with halogen, C1-6 alkyl, C1-6alkyloxy, a 3-8 member heterocyclyl ring structure, an aryl, or a 5- to 6- member heteroaryl, wherein the C1-6 alkyl, the C1-6alkyloxy, the 3-8 member heterocyclyl ring structure, the aryl, or the 5- to 6-member heteroaryl are optionally substituted with one or more halogen, C1-4alkyloxy, or C1-6 alkyl optionally substituted with one or more halogen; a is 1, 2, 3, 4, 5, 6, 7 or 8; and Ra is C1-6 alkyl. Attorney Docket No. MORF-016WO1 Embodiment 2: The compound of Embodiment 1, wherein the compound is a compound of Formula (I-A), or a pharmaceutically acceptable salt thereof.
Figure imgf000221_0001
Embodiment 3: The compound of any one of Embodiments 1-2, wherein
Figure imgf000221_0002
phenyl or a 6-member heteroaryl. Embodiment 4: The compound of Embodiment 3, wherein
Figure imgf000221_0003
R1 is C1-4 alkoxy; and R2 is C1-4 alkyl optionally substituted with one or more halogen; or R1 and R2 together form a fused 5- to 8-member heterocycloalkyl ring, a fused 5- to 6-member heteroaryl ring, a fused 7- to 15-member spirocyclic heterocycloalkyl ring system, wherein the fused ring is optionally substituted with halogen, C1-4 alkyl, C3-6 cycloalkyl, or a 4- to 8-member heterocycloalkyl ring, wherein the C1-4 alkyl, the C3-6 cycloalkyl, or the 4- to 8-member heterocycloalkyl ring is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen; R3 is C1-4 alkyl optionally substituted with one or more halogen; Embodiment 5: The compound of Embodiment 4, wherein R1 is methoxy; R2 is fluoro; and R3 is C1-4 alkyl optionally substituted with one or more fluoro. Embodiment 6: The compound of Embodiment 4, wherein
Figure imgf000221_0004
Attorney Docket No. MORF-016WO1
Figure imgf000222_0001
wherein R4 and R14 are each independently H, halogen or C1-4 alkyl optionally substituted with one or more halogen; X1 is CR5aR5b or NR5c R5a is H or a C1-4 alkyl optionally substituted with one or more halogen, and R5b is a C1-4 alkyl or a C3-6 cycloalkyl, wherein the C1-4 alkyl or the C3-6 cycloalkyl is optionally substituted with one or more halogen; or R5a and R5b together form a spirocyclic 3- to 8-member heterocycloalkyl or a spirocyclic C3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl optionally substituted with one or more halogen, a 4- to 6-member spirocyclic heterocycloalkyl or a C3-6 spirocyclic cycloalkyl optionally substituted with C1-4 alkyl optionally substituted with one or more halogen; R5c is a C1-4 alkyl or a C3-6 cycloalkyl, wherein the C1-4 alkyl or the C3-6 cycloalkyl is optionally substituted with one or more halogen; X2 is CR6aR6b, -CH2CR6aR6b, C=O, O or NR6c; R6a and R6b are each independently H, a C1-4 alkyl, a 5- to 6-member heteroaryl, a 6-member aryl, a C3-7 cycloalky, or a 4- to 7-member heterocycloalkyl, wherein the C1-4 alkyl, the 5- to 6-member heteroaryl, the 6-member aryl, the C3-8 cycloalky, or the 4- to 7-member heterocycloalkyl is each optionally substituted with one or more halogen or C1-4 alkyl; R6c is C1-4 alkyl optionally substituted with one or more halogen X3 is a direct bond, CR7aR7b, O or NR7c; R7a and R7b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen; Attorney Docket No. MORF-016WO1 R7c is a C1-4 alkyl optionally substituted with one or more halogen; X4 is CR8aR8b or NR8c R8a is H and R8b is halogen or a C1-4 alkyl optionally substituted with one or more halogen; R8a and R8b together form a spirocyclic 3- to 8-member heterocycloalkyl or a C3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl optionally substituted with one or more halogen, a 4- to 8-member spirocyclic heterocycloalkyl or a C3-7 spirocyclic cycloalkyl optionally substituted with C1-4 alkyl optionally substituted with one or more halogen; and R8c is H, C1-4 alkyl, a 4- to 8-member heterocycloalkyl, or a C3-6 cycloalkyl, wherein the C1-4 alkyl, the 4- to 8-member heterocycloalkyl, or the C3-6 cycloalkyl is optionally substituted with one or more halogen; provided that no two of both X2 and X3 .comprise O or N heteroatoms and no two of X3 and X4. comprise O or N heteroatoms. Embodiment 7: The compound of Embodiment 6, wherein R14 is H; and X1 is CR5aR5b and R5a is H, and R5b is methyl or cyclopropyl. Embodiment 8: The compound of any one of Embodiments 6-7, wherein R4 is H, fluoro, or methyl; X1 is CR5aR5b and R5a is H, and R5b is methyl; X2 is O and X3 is CR7aR7b and R7a and R7b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen; or X3 is O and X2 is CR6aR7b and R6a and R6b are each independently H; and X4 is CR8aR8b and R8a and R8b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen, or R8a and R8b together form a 4- to 7-member heterocycloalkyl ring or a C3-7 cycloalkyl ring, wherein the 4- to 7-member heterocycloalkyl or the C3-7 cycloalkyl is optionally substituted with halogen, C1-4 alkyl optionally substituted with one or more Attorney Docket No. MORF-016WO1 halogen, a 4- to 7-member spirocyclic heterocycloalkyl, or a C3-7 spirocyclic cycloalkyl, optionally substituted with C1-4 alkyl optionally substituted with one or more halogen. Embodiment 9: The comopound of Embodiment 6, wherein
Figure imgf000224_0001
wherein R10a and R10b are each independently H, halogen, or a C1-4 alkyl optionally substituted with one or more halogen; or R10a and R10b together form a spirocyclic C3-6 cycloalkyl or a spirocyclic 6-member heterocycloalkyl; R11a and R11b are each independently H, halogen or a C1-4 alkyl optionally substituted with one or more halogen; R12a and R12b are each independently H, halogen or a C1-4 alkyl optionally substituted with one or more halogen; R13a is methy, ethyl, or cyclopropyl; R13b is H; R14 is H, halogen, or a C1-4 alkyl optionally substituted with one or more halogen. Embodiment 10: The compound of Embodiment 9, wherein R10a and R10b are each independently H or methyl; R11a and R11b are each independently H, methyl, or ethyl; R12a and R12b are each independently H or methyl; R13a is methyl, ethyl, or cyclopropyl; R13b is H; R14 is H, fluoro, or methyl. Attorney Docket No. MORF-016WO1 Embodiment 11: The compound of Embodiment 10, wherein R4 is H or fluoro; R13a is methyl, ethyl, or cyclopropyl; and R14 is H. Embodiment 12: The compound of Embodiment 6, wherein X2 is NR6c and R6c is C1-4 alkyl. Embodiment 13: The compound of Embodiment 6, wherein
Figure imgf000225_0001
wherein R13a is H or methyl, and R4 is H, F, or methyl. Embodiment 14: The compound of Embodiment 6, wherein
Figure imgf000225_0002
Figure imgf000225_0003
Embodiment 15: The compound of Embodiment 14, wherein R10a, R10b, and R11a are each H or methyl. Embodiment 16: The compound of Embodiment 14, wherein R11b is H, methyl, or ethyl. Embodiment 17: The compound of Embodiment 6, wherein
Figure imgf000225_0004
Figure imgf000225_0005
, wherein R4 is H, halogen, or methyl optionally substituted with one or more halogen; and Attorney Docket No. MORF-016WO1 R9a and R9b are each independently H, halogen, or methyl optionally substituted with one or more halogen. Embodiment 18: The compound of Embodiment 17, wherein R4 is H, fluoro, or methyl; and R9a and R9b are each independently H, fluoro, chloro, or methyl optionally substituted with one or more fluoro. Embodiment 19: The compound of Embodiment 4, wherein
Figure imgf000226_0001
Figure imgf000226_0002
R20 is H, halogen, a C1-4 alkyl or a C1-4 alkoxy, wherein the C1-4 alkyl and the C1-4 alkoxy are each optionally substituted with one or more halogen; X5 is CR25aR25b or NR25c R25a and R25b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or alkoxy; or R25a and R25b together form a C3-6 cycloalkyl ring or a 4- to 6-member heterocyclyl ring, each optionally substituted with halogen, C1-4 alkyl, a spirocyclic C3-6 cycloalkyl, or a spirocyclic 4- to 6-member heterocyclyl ring, wherein the C1-4 alkyl, the spirocyclic C3-6 cycloalkyl or the spirocyclic 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen or C1-4 alkyl; R25c is C1-4 alkyl, a 5-6 member heteroaryl, or a C6 aryl, wherein the C1-4 alkyl, the 5-6 member heteroaryl, or the C6 aryl is optionally substituted with one or more halogen or C1-4 alkoxy; X6 is CR26aR26b or C=O; R26a and R26b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkyl; X7 is CR27aR27b or NR27c; Attorney Docket No. MORF-016WO1 R27a and R27b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or alkoxy; R27a and R27b together form a C3-6 cycloalkyl ring or a 4- to 6-member heterocyclyl ring, wherein the C3-6 cycloalkyl ring or the 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen, one or more C1-4 alkyl, a spirocyclic C3-6 cycloalkyl or a spirocyclic 4 to 6 member heterocyclyl ring, wherein the C1-4 alkyl, the spirocyclic C3-6 cycloalkyl, or the spirocyclic 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen or C1-4 alkyl; and R27c is H, a C1-4 alkyl, a C3-6 cycloalkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, a 5-6 member heteroaryl, or a C6 aryl, wherein the C1-4 alkyl, the C3-6 cycloalkyl, the 4- to 6-member heterocycloalkyl, the 5- to 11-member spirocyclic heterocycloalkyl, the 5-6 member heteroaryl, or the C6 aryl is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen; provided that only one of X5 and X7.comprise a N heteroatom. Embodiment 20: The compound of Embodiment 19, wherein R20 is H, halogen, a C1-4 alkyl, or a C1-4 alkoxy, wherein the C1-4 alkyl and the C1-4 alkoxy is optionally substituted with one or more halogen; X5 is CR25aR25b R25a and R25b are each independently methyl; or R25a and R25b together form a cyclopropyl; X6 is C=O; R26a and R26b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkyl; X7 is NR27c; and R27c is a C1-4 alkyl, a C3-6 cycloalkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, a 5-6 member heteroaryl, or a C6 aryl, wherein the C1-4 alkyl, the C3-6 cycloalkyl, the 4- to 6-member heterocycloalkyl, the 5- to 11-member spirocyclic heterocycloalkyl, the 5-6 member heteroaryl, or the C6 aryl is Attorney Docket No. MORF-016WO1 optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen; Embodiment 21: The compound of Embodiment 20, wherein R27c is a C1-4 alkyl. Embodiment 22: The compound of Embodiment 20, wherein R27c is a 5-member heteroaryl. Embodiment 23: The compound of Embodiment 20, wherein R27c is a C3-6 cycloalkyl optionally substituted with one or more halogen or a C1-4 alkyl optionally substituted with one or more halogen. Embodiment 24: The compound of Embodiment 20, wherein R27c is a C1-4 alkyl, a 4- to 7- member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, wherein the C1-4 alkyl, the 4- to 7-member heterocycloalkyl, and the 5- to 11-member spirocyclic heterocycloalkyl is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen. Embodiment 25: The compound of Embodiment 24, wherein
Figure imgf000228_0001
Figure imgf000228_0002
wherein R20 is H, fluoro, methyl, ethyl, methoxy, -CH2-O-CH3, or -CF3. Embodiment 26: The compound of Embodiment 25, wherein R27c is a tetrahydropyan optionally substituted by one or more methyl or fluoro. Embodiment 27: The compound of Embodiment 25, wherein
Figure imgf000228_0003
Figure imgf000228_0004
, wherein R32a, R32b, R33a and R33b are each independently H, methyl, or fluoro; or Attorney Docket No. MORF-016WO1 one of R32a and R32b or R33a and R33b together form a spirocyclic C3-6 cycloalkyl or a spirocyclic 3- to 6-member heterocyclic ring. Embodiment 28: The compound of Embodiment 25, wherein R27c is
Figure imgf000229_0001
. Embodiment 29: The compound of Embodiment 19, wherein
Figure imgf000229_0002
Figure imgf000229_0003
R30a, R30b, R31a, and R31b are each independently H, fluoro, or methyl; R20 is H, fluoro, methyl, ethyl, methoxy, -CH2-O-CH3, or -CF3; and R27c is methyl. Embodiment 30: The compound of Embodiment 25, wherein R27c is a C1-4 alkyl. Embodiment 31: The compound of Embodiment 19, wherein
Figure imgf000229_0004
Embodiment 32: The compound of Embodiment 4, wherein
Figure imgf000229_0005
Attorney Docket No. MORF-016WO1
Figure imgf000230_0001
wherein R20 is H, halogen, a C1-4 alkoxy optionally substituted with C1-4 alkoxy, a C1-4 alkyl optionally substituted with a 4- to 6-member heterocyclyl or one or more halogen. Embodiment 33: The compound of Embodiment 32, wherein R25c is a C1-4 alkyl; and R27c is a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkoxy, a C3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C3-6 cycloalkyl or the 4- to 6-member heterocycloalkyl is optionally substituted with a C1-4 alkyl optionally substituted with one or more halogen. Embodiment 34: The compound of Embodiment 32, wherein R27c is a C1-4 alkyl; and R25c is a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkoxy, a C3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C3-6 cycloalkyl or the 4- to 6-member heterocycloalkyl is optionally substituted with a C1-4 alkyl optionally substituted with one or more halogen. Embodiment 35: The compound of any one of Embodiments 32-34, wherein R20 is H or methyl. Embodiment 36: The compound of Embodiment 19, wherein
Figure imgf000230_0002
Figure imgf000230_0003
Attorney Docket No. MORF-016WO1 R20 is H, halogen, a C1-4 alkoxy optionally substituted with C1-4 alkoxy, C1-4 alkyl optionally substituted with a 4- to 6-member heterocyclyl or one or more halogen; R25c is a C1-4 alkyl; and R27c is a 4- to 6-member heterocyclyl or a C3-6 cycloalkyl, wherein the 4- to 6- member heterocyclyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl. Embodiment 37: A compound of the chemical formula
Figure imgf000231_0001
pharmaceutically acceptable salt thereof. Embodiment 38: A compound of the chemical formula
Figure imgf000231_0002
pharmaceutically acceptable salt thereof. Embodiment 39: A compound of the chemical formula
Figure imgf000231_0003
pharmaceutically acceptable salt thereof. Embodiment 40: A compound of the chemical formula
Figure imgf000231_0004
pharmaceutically acceptable salt thereof. Attorney Docket No. MORF-016WO1 Embodiment 41: A compound selected from the group consisting of the compounds in Figure 1, or a pharmaceutically acceptable salt thereof. Equivalents and Scope [000538] The invention is not to be limited in scope by the specific embodiments disclosed in the examples that are intended as illustrations of a few aspects of the invention and any embodiments that are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims. A number of references have been cited, the entire disclosures of which are incorporated herein by reference for all purposes.

Claims

Attorney Docket No. MORF-016WO1 CLAIMS 1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:
Figure imgf000233_0001
wherein:
Figure imgf000233_0002
a 6- to 12-member aryl ring structure or a 3- to 19-member heterocyclyl ring structure, wherein
Figure imgf000233_0003
is optionally substituted with halogen, C1-6 alkyl, C1-6alkyloxy, a 3-8 member heterocyclyl ring structure, an aryl, or a 5- to 6-member heteroaryl, wherein the C1-6 alkyl, the C1-6alkyloxy, the 3-8 member heterocyclyl ring structure, the aryl, or the 5- to 6- member heteroaryl are optionally substituted with one or more halogen, C1-4alkyloxy, or C1-6 alkyl optionally substituted with one or more halogen; a is 1, 2, 3, 4, 5, 6, 7 or 8; and Ra is C1-6 alkyl. 2. The compound of claim 1, wherein the compound is a compound of Formula (I-A), or a pharmaceutically acceptable salt thereof.
Figure imgf000233_0004
(IA). 3. The compound of any one of claims 1-2, wherein
Figure imgf000233_0005
phenyl or a 6-member heteroaryl. Attorney Docket No. MORF-016WO1 The compound of any one of claims 1-3, wherein
Figure imgf000234_0001
wherein R1 is C1-4 alkoxy; and R2 is C1-4 alkyl optionally substituted with one or more halogen; or
Figure imgf000234_0002
a 9- to 19-member heterocyclyl when R1 and R2 are taken together to form a fused 5- to 8-member heterocycloalkyl ring, a fused 5- to 6-member heteroaryl ring, a fused 7- to 15-member spirocyclic heterocycloalkyl ring system, wherein the fused ring is optionally substituted with halogen, C1-4 alkyl, C3-6 cycloalkyl, or a 4- to 8-member heterocycloalkyl ring, wherein the C1-4 alkyl, the C3-6 cycloalkyl, or the 4- to 8-member heterocycloalkyl ring is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen; and R3 is C1-4 alkyl optionally substituted with one or more halogen. 5. The compound of claim 4, wherein R1 is methoxy; R2 is fluoro; and R3 is C1-4 alkyl optionally substituted with one or more fluoro. one of claims 1-3, wherein
Figure imgf000234_0003
Figure imgf000234_0004
, wherein R4 and R14 are each independently H, halogen or C1-4 alkyl optionally substituted with one or more halogen; Attorney Docket No. MORF-016WO1 X1 is CR5aR5b or NR5c R5a is H or a C1-4 alkyl optionally substituted with one or more halogen, and R5b is a C1-4 alkyl or a C3-6 cycloalkyl, wherein the C1-4 alkyl or the C3-6 cycloalkyl is optionally substituted with one or more halogen; or R5a and R5b together form a spirocyclic 3- to 8-member heterocycloalkyl or a spirocyclic C3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl optionally substituted with one or more halogen, a 4- to 6-member spirocyclic heterocycloalkyl or a C3-6 spirocyclic cycloalkyl optionally substituted with C1-4 alkyl optionally substituted with one or more halogen; R5c is a C1-4 alkyl or a C3-6 cycloalkyl, wherein the C1-4 alkyl or the C3-6 cycloalkyl is optionally substituted with one or more halogen; X2 is CR6aR6b, -CH2CR6aR6b, C=O, O or NR6c; R6a and R6b are each independently H, a C1-4 alkyl, a 5- to 6-member heteroaryl, a 6-member aryl, a C3-7 cycloalky, or a 4- to 7-member heterocycloalkyl, wherein the C1-4 alkyl, the 5- to 6-member heteroaryl, the 6-member aryl, the C3-8 cycloalky, or the 4- to 7-member heterocycloalkyl is each optionally substituted with one or more halogen or C1-4 alkyl; R6c is C1-4 alkyl optionally substituted with one or more halogen X3 is a direct bond, CR7aR7b, O or NR7c; R7a and R7b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen; R7c is a C1-4 alkyl optionally substituted with one or more halogen; X4 is CR8aR8b or NR8c R8a is H and R8b is halogen or a C1-4 alkyl optionally substituted with one or more halogen; R8a and R8b together form a spirocyclic 3- to 8-member heterocycloalkyl or a C3-6 cycloalkyl, wherein the 3- to 8-member heterocycloalkyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl optionally substituted with one or more halogen, a Attorney Docket No. MORF-016WO1 4- to 8-member spirocyclic heterocycloalkyl or a C3-7 spirocyclic cycloalkyl optionally substituted with C1-4 alkyl optionally substituted with one or more halogen; and R8c is H, C1-4 alkyl, a 4- to 8-member heterocycloalkyl, or a C3-6 cycloalkyl, wherein the C1-4 alkyl, the 4- to 8-member heterocycloalkyl, or the C3-6 cycloalkyl is optionally substituted with one or more halogen; provided that no two of both X2 and X3 .comprise O or N heteroatoms and no two of X3 and X4. comprise O or N heteroatoms. 7. The compound of claim 6, wherein R14 is H; and X1 is CR5aR5b and R5a is H, and R5b is methyl or cyclopropyl. 8. The compound of any one of claims 6-7, wherein R4 is H, fluoro, or methyl; X1 is CR5aR5b and R5a is H, and R5b is methyl; X2 is O and X3 is CR7aR7b and R7a and R7b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen; or X3 is O and X2 is CR6aR7b and R6a and R6b are each independently H; and X4 is CR8aR8b and R8a and R8b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen, or R8a and R8b together form a 4- to 7-member heterocycloalkyl ring or a C3-7 cycloalkyl ring, wherein the 4- to 7-member heterocycloalkyl or the C3-7 cycloalkyl is optionally substituted with halogen, C1-4 alkyl optionally substituted with one or more halogen, a 4- to 7-member spirocyclic heterocycloalkyl, or a C3-7 spirocyclic cycloalkyl, optionally substituted with C1-4 alkyl optionally substituted with one or more halogen. 9. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein
Figure imgf000236_0001
Attorney Docket No. MORF-016WO1
Figure imgf000237_0001
wherein R10a and R10b are each independently H, halogen, or a C1-4 alkyl optionally substituted with one or more halogen; or R10a and R10b together form a spirocyclic C3-6 cycloalkyl or a spirocyclic 6-member heterocycloalkyl; R11a and R11b are each independently H, halogen or a C1-4 alkyl optionally substituted with one or more halogen; R12a and R12b are each independently H, halogen or a C1-4 alkyl optionally substituted with one or more halogen; R13a is methy, ethyl, or cyclopropyl; R13b is H; R14 is H, halogen, or a C1-4 alkyl optionally substituted with one or more halogen. 10. The compound of claim 9, wherein R10a and R10b are each independently H or methyl; R11a and R11b are each independently H, methyl, or ethyl; R12a and R12b are each independently H or methyl; R13a is methyl, ethyl, or cyclopropyl; R13b is H; R14 is H, fluoro, or methyl. 11. The compound of claim 10, wherein R4 is H or fluoro; Attorney Docket No. MORF-016WO1 R13a is methyl, ethyl, or cyclopropyl; and R14 is H. 12. The compound of claim 6, wherein X2 is NR6c and R6c is C1-4 alkyl. 13. The compound of claim 6, wherein
Figure imgf000238_0001
wherein R13a is H or methyl, and R4 is H, F, or methyl. 14. The compound of claim 6, wherein
Figure imgf000238_0002
Figure imgf000238_0003
15. The compound of claim 14, wherein R10a, R10b, and R11a are each H or methyl. 16. The compound of claim 14, wherein R11b is H, methyl, or ethyl. 17. The compound of claim 6, wherein
Figure imgf000238_0004
Figure imgf000238_0005
, wherein R4 is H, halogen, or methyl optionally substituted with one or more halogen; and R9a and R9b are each independently H, halogen, or methyl optionally substituted with one or more halogen. Attorney Docket No. MORF-016WO1 18. The compound of claim 17, wherein R4 is H, fluoro, or methyl; and R9a and R9b are each independently H, fluoro, chloro, or methyl optionally substituted with one or more fluoro. 19. The compound of any one of claims 1-4, wherein
Figure imgf000239_0001
Figure imgf000239_0002
R20 is H, halogen, a C1-4 alkyl or a C1-4 alkoxy, wherein the C1-4 alkyl and the C1-4 alkoxy are each optionally substituted with one or more halogen; X5 is CR25aR25b or NR25c R25a and R25b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or alkoxy; or R25a and R25b together form a C3-6 cycloalkyl ring or a 4- to 6-member heterocyclyl ring, each optionally substituted with halogen, C1-4 alkyl, a spirocyclic C3-6 cycloalkyl, or a spirocyclic 4- to 6-member heterocyclyl ring, wherein the C1-4 alkyl, the spirocyclic C3-6 cycloalkyl or the spirocyclic 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen or C1-4 alkyl; R25c is C1-4 alkyl, a 5-6 member heteroaryl, or a C6 aryl, wherein the C1-4 alkyl, the 5-6 member heteroaryl, or the C6 aryl is optionally substituted with one or more halogen or C1-4 alkoxy; X6 is CR26aR26b or C=O; R26a and R26b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkyl; X7 is CR27aR27b or NR27c; R27a and R27b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or alkoxy; Attorney Docket No. MORF-016WO1 R27a and R27b together form a C3-6 cycloalkyl ring or a 4- to 6-member heterocyclyl ring, wherein the C3-6 cycloalkyl ring or the 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen, one or more C1-4 alkyl, a spirocyclic C3-6 cycloalkyl or a spirocyclic 4 to 6 member heterocyclyl ring, wherein the C1-4 alkyl, the spirocyclic C3-6 cycloalkyl, or the spirocyclic 4- to 6-member heterocyclyl ring is optionally substituted with one or more halogen or C1-4 alkyl; and R27c is H, a C1-4 alkyl, a C3-6 cycloalkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, a 5-6 member heteroaryl, or a C6 aryl, wherein the C1-4 alkyl, the C3-6 cycloalkyl, the 4- to 6-member heterocycloalkyl, the 5- to 11-member spirocyclic heterocycloalkyl, the 5-6 member heteroaryl, or the C6 aryl is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen; provided that only one of X5 and X7.comprise a N heteroatom. 20. The compound of claim 19, wherein R20 is H, halogen, a C1-4 alkyl, or a C1-4 alkoxy, wherein the C1-4 alkyl and the C1-4 alkoxy is optionally substituted with one or more halogen; X5 is CR25aR25b R25a and R25b are each independently methyl; or R25a and R25b together form a cyclopropyl; X6 is C=O; R26a and R26b are each independently H or a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkyl; X7 is NR27c; and R27c is a C1-4 alkyl, a C3-6 cycloalkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, a 5-6 member heteroaryl, or a C6 aryl, wherein the C1-4 alkyl, the C3-6 cycloalkyl, the 4- to 6-member heterocycloalkyl, the 5- to 11-member spirocyclic heterocycloalkyl, the 5-6 member heteroaryl, or the C6 aryl is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen; 21. The compound of claim 20, wherein R27c is a C1-4 alkyl. Attorney Docket No. MORF-016WO1 22. The compound of claim 20, wherein R27c is a 5-member heteroaryl. 23. The compound of claim 20, wherein R27c is a C3-6 cycloalkyl optionally substituted with one or more halogen or a C1-4 alkyl optionally substituted with one or more halogen. 24. The compound of claim 20, wherein R27c is a C1-4 alkyl, a 4- to 7-member heterocycloalkyl, or a 5- to 11-member spirocyclic heterocycloalkyl, wherein the C1-4 alkyl, the 4- to 7-member heterocycloalkyl, and the 5- to 11-member spirocyclic heterocycloalkyl is optionally substituted with one or more halogen or C1-4 alkyl optionally substituted with one or more halogen. 25. The compound of claim 24, wherein
Figure imgf000241_0001
Figure imgf000241_0002
wherein R20 is H, fluoro, methyl, ethyl, methoxy, -CH2-O-CH3, or -CF3. 26. The compound of claim 25, wherein R27c is a tetrahydropyan optionally substituted by one or more methyl or fluoro. 27. The compound of claim 25, wherein
Figure imgf000241_0003
wherein R32a, R32b, R33a and R33b are each independently H, methyl, or fluoro; or one of R32a and R32b or R33a and R33b together form a spirocyclic C3-6 cycloalkyl or a spirocyclic 3- to 6-member heterocyclic ring. 28. The compound of claim 25, wherein R27c is
Figure imgf000241_0004
29. The compound of claim 19, wherein
Figure imgf000241_0005
Attorney Docket No. MORF-016WO1
Figure imgf000242_0001
wherein R30a, R30b, R31a, and R31b are each independently H, fluoro, or methyl; R20 is H, fluoro, methyl, ethyl, methoxy, -CH2-O-CH3, or -CF3; and R27c is methyl. 30. The compound of claim 25, wherein R27c is a C1-4 alkyl. 31. The compound of claim 19, wherein
Figure imgf000242_0002
32. The compound of any one of claims 1-4, wherein
Figure imgf000242_0003
Figure imgf000242_0004
wherein Attorney Docket No. MORF-016WO1 R20 is H, halogen, a C1-4 alkoxy optionally substituted with C1-4 alkoxy, a C1-4 alkyl optionally substituted with a 4- to 6-member heterocyclyl or one or more halogen. 33. The compound of claim 32, wherein R25c is a C1-4 alkyl; and R27c is a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkoxy, a C3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C3-6 cycloalkyl or the 4- to 6-member heterocycloalkyl is optionally substituted with a C1-4 alkyl optionally substituted with one or more halogen. 34. The compound of claim 32, wherein R27c is a C1-4 alkyl; and R25c is a C1-4 alkyl optionally substituted with one or more halogen or C1-4 alkoxy, a C3-6 cycloalkyl or a 4- to 6-member heterocycloalkyl, wherein the C3-6 cycloalkyl or the 4- to 6-member heterocycloalkyl is optionally substituted with a C1-4 alkyl optionally substituted with one or more halogen. 35. The compound of any one of claims 32-34, wherein R20 is H or methyl. 36. The compound of claim 19, wherein
Figure imgf000243_0001
Figure imgf000243_0002
wherein R20 is H, halogen, a C1-4 alkoxy optionally substituted with C1-4 alkoxy, C1-4 alkyl optionally substituted with a 4- to 6-member heterocyclyl or one or more halogen; R25c is a C1-4 alkyl; and R27c is a 4- to 6-member heterocyclyl or a C3-6 cycloalkyl, wherein the 4- to 6- member heterocyclyl or the C3-6 cycloalkyl is optionally substituted with C1-4 alkyl. Attorney Docket No. MORF-016WO1 37. A compound of the chemical formula
Figure imgf000244_0001
pharmaceutically acceptable salt thereof. 38. A compound of the chemical formula
Figure imgf000244_0002
pharmaceutically acceptable salt thereof. 39. A compound of the chemical formula
Figure imgf000244_0003
, or a pharmaceutically acceptable salt thereof. 40. A compound of the chemical formula
Figure imgf000244_0004
, or a pharmaceutically acceptable salt thereof. 41. A compound of the chemical formula
Figure imgf000244_0005
pharmaceutically acceptable salt thereof. Attorney Docket No. MORF-016WO1 42. A compound of the chemical formula
Figure imgf000245_0001
, or a pharmaceutically acceptable salt thereof. 43. A compound of the chemical formula
Figure imgf000245_0002
, or a pharmaceutically acceptable salt thereof. 44. A compound of the chemical formula
Figure imgf000245_0003
a pharmaceutically acceptable salt thereof. 45. A compound of the chemical formula
Figure imgf000245_0004
, or a pharmaceutically acceptable salt thereof. Attorney Docket No. MORF-016WO1
Figure imgf000246_0001
46. A compound of the chemical , or a pharmaceutically acceptable salt thereof.
Figure imgf000246_0002
47. A compound of the chemical formula , or a pharmaceutically acceptable salt thereof. 48. A compound of the chemical formula
Figure imgf000246_0003
, or a pharmaceutically acceptable salt thereof. 49. A compound of the chemical formula
Figure imgf000246_0004
a pharmaceutically acceptable salt thereof. 50. A compound of the chemical formula
Figure imgf000246_0005
, or a pharmaceutically acceptable salt thereof. Attorney Docket No. MORF-016WO1 51. A compound selected from the group consisting of the compounds in Figure 1, or a pharmaceutically acceptable salt thereof. 52. A compound selected from the group consisting of the compounds in Table 3, or a pharmaceutically acceptable salt thereof.
PCT/US2024/047672 2023-09-21 2024-09-20 INHIBITING HUMAN INTEGRIN α5β1 Pending WO2025064802A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363584383P 2023-09-21 2023-09-21
US63/584,383 2023-09-21
US202463687186P 2024-08-26 2024-08-26
US63/687,186 2024-08-26

Publications (1)

Publication Number Publication Date
WO2025064802A1 true WO2025064802A1 (en) 2025-03-27

Family

ID=93015092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/047672 Pending WO2025064802A1 (en) 2023-09-21 2024-09-20 INHIBITING HUMAN INTEGRIN α5β1

Country Status (2)

Country Link
TW (1) TW202513065A (en)
WO (1) WO2025064802A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089353A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as alpha v integrin inhibitors
WO2021175196A1 (en) * 2020-03-06 2021-09-10 清药同创(北京)药物研发中心有限公司 Pyrrolidine integrin modulator and use thereof
US20230219949A1 (en) * 2018-08-29 2023-07-13 Bryce A. Harrison Inhibitors of (alpha-v)(beta-6) integrin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089353A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as alpha v integrin inhibitors
US20230219949A1 (en) * 2018-08-29 2023-07-13 Bryce A. Harrison Inhibitors of (alpha-v)(beta-6) integrin
WO2021175196A1 (en) * 2020-03-06 2021-09-10 清药同创(北京)药物研发中心有限公司 Pyrrolidine integrin modulator and use thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
"Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING CO., pages: 172 - 178,949-982
BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104
BUNDEGAARD, H: "Design of Prodrugs", 1985, ELESEVIER, pages: 1 - 9,21-24
CHUNG ET AL., CHEST, vol. 138, no. 6, 2010, pages 1383 - 1394
HIGUCHI, T. ET AL.: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
ZAIMAN ET AL., AM. J. RESPIR. CELL MOL. BIOL., vol. 33, 2005, pages 425 - 31

Also Published As

Publication number Publication date
TW202513065A (en) 2025-04-01

Similar Documents

Publication Publication Date Title
US20230219949A1 (en) Inhibitors of (alpha-v)(beta-6) integrin
US11702424B2 (en) Bicyclic-fused heteroaryl or aryl compounds
KR102889907B1 (en) PCSK9 inhibitors and methods of using the same
US20230219947A1 (en) INHIBITORS OF AV ß6 INTEGRIN
TWI527798B (en) Substituted isoquinoline derivatives
JP2019052180A (en) Compounds that inhibit MCL-1 protein
CN112805001A (en) Inhibition of alpha v beta 6 integrins
KR102700471B1 (en) Pyrrolopyrazine derivatives as alpha V integrin inhibitors
EP3589285A1 (en) Inhibitors of (alpha-v)(beta-6) integrin
KR20150036142A (en) Spiro - fused piperidine derivatives for use as inhibitors of the renal outer medullary potassium channel
US20230242524A1 (en) Inhibitors of (alpha-v)(beta-6) integrin
JP2024525368A (en) Azetidinylpyrimidines and uses thereof
AU2017359773A1 (en) Dihydropyrimidine compound and preparation method and use thereof
JP2021530474A (en) 7-Amino-5-thio-thiazolo [4,5-D] Pyrimidine phosphate and phosphonate derivatives and their use in therapeutic conditions associated with elevated levels of CX3CR1 and / or CX3CL1
WO2025064802A1 (en) INHIBITING HUMAN INTEGRIN α5β1
WO2025106644A1 (en) Heterocyclic compounds as inhibitors of alpha-v beta-1 integrin
WO2025024329A2 (en) Compounds, compositions, and methods
EA050655B1 (en) SUBSTITUTED BICYCLIC COMPOUNDS SUITABLE FOR USE AS TLR9 INHIBITORS
KR20250172693A (en) Pcsk9 inhibitors and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24786937

Country of ref document: EP

Kind code of ref document: A1